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Abstract 
Introduction  
The HPTN 071 (PopART) trial is a community randomised trial in Zambia and South Africa, examining 
the impact of combination prevention, including treatment as prevention using Universal Test and 
Treat (UTT), on community level HIV-incidence. This PhD evaluates the factors associated with 
uptake of the key interventions, during the first year of the trial. 
Methods 
Two systematic reviews were conducted on home-based HIV testing and counselling (HB-HTC), and 
the cascade-of-care following community-based HTC, respectively. In addition, two case-control (CC) 
studies were nested within PopART, to examine factors associated with the uptake of the door-to-
door home-based universal testing (CC study 1), and universal treatment (CC study 2) interventions. 
Results 
Our results suggest that HB-HTC in sub-Saharan Africa is widely accepted – uptake among those 
offered HB-HTC was 83% in a systematic review and meta-analysis of studies (2000-2012). The 
second systematic review found considerable variability in measures used to report linkage-to-care 
and ART initiation and in outcomes reported, even for similar time periods following HIV-detection 
(studies between 2006-2016).  
CC1 found no differences between acceptors and non-acceptors of HB-HTC by demographic and 
behavioural characteristics. CC2 identified that the more lifetime sexual partners participants 
reported, the more likely they were to achieve timely linkage and ART initiation (TLA). Negative 
perceptions about clinic infra-structure were associated with failure to achieve TLA.  
Both CC studies found that favourable views about the Community HIV-care Providers was 
associated with uptake of interventions, while neither stigma nor unfavourable views about clinic 
staff were associated with uptake. 
Conclusion 
This PhD contributes to knowledge on the cascade-of-care and UTT. It suggests that PopART 
interventions are acceptable across population sub-groups, providing optimism for achieving 
universal coverage using the PopART model to implement UTT. If individuals with high-risk sexual 
behaviour embrace interventions as we observed, there is great promise for treatment as 
prevention. 
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Outline of Chapter 
This chapter describes the structure of the thesis and introduces the background to the PhD. It 
summarises the HIV epidemic in sub-Saharan Africa, and explains Treatment as Prevention and the 
concept of Universal Test and Treat (UTT). It also describes in summary the design of the HPTN 071 
(PopART) trial within which the PhD primary research is nested and goes on to outline the rationale 
of the components of the PhD. 
1.1  Structure of the PhD thesis 
The purpose of this PhD is to evaluate the factors associated with uptake of the key steps in the 
cascade of care in the UTT model provided by the PopART trial. To that end, two nested case-control 
(CC) studies were done to examine the factors associated with the uptake of the door-to-door home-
based universal testing (CC study 1), and universal treatment (CC study 2) interventions. In order to 
inform and place the respective studies in context, two systematic reviews were conducted on HB-
HTC and the cascade of care following community-based HIV detection, respectively.  
This first chapter lays out the context of research done for the PhD as described above. In chapter 2 
of this “paper-style” PhD thesis document, the methods of the primary research conducted are 
described in greater detail than could be presented in the manuscripts of the studies which were 
submitted for publication. In chapter 3, the published manuscript of the systematic review on HB-
HTC which helped inform the first case-control study is presented. Chapter 4 presents the 
manuscript which has been submitted for publication on CC study 1 which examines the factors 
associated with uptake of HB-HTC during the first year of the PopART intervention. The manuscript 
of the second systematic review which was undertaken to examine the cascade of care following 
HTC done in the community is presented in chapter 5. Chapter 6 presents the second case-control 
study on the factors associated with timely linkage to ART during the first year of PopART. Finally, 
Chapter 7 discusses the findings of the PhD, examines the strengths and limitations and reflects on 
the potential implications of the research conducted. 
1.2.1 HIV epidemic in sub-Saharan Africa 
Great progress has been made globally in the response to the HIV epidemic in recent years, not least 
in the Eastern and Southern African region. (1) With an estimated 10.3 million people on 
antiretroviral treatment (ART) in the region, this represents 54% of the 19 million people living with 
HIV on ART – more than twice what coverage was in 2010. This has helped reduce the number of 
deaths due to HIV to 470,000 in 2015 from 760,000 in 2010. The result is an increase in the number 
of people living with HIV. Despite the positive developments there are other more sobering data to 
consider. HIV incidence has remained essentially static at 2.1 million per year globally and has 
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reduced by just 4% since 2010 to just below 1 million new infections in 2015 in the Eastern and 
Southern Africa region. 
The importance of preventing new infections is obvious at the individual level. At a public-health 
level HIV prevention helps reduce the burden on struggling health systems especially across sub-
Saharan Africa - in terms of reduction in HIV related co-morbidities and the cost of long-term ART 
provision for what would otherwise be ever increasing numbers of people living with HIV. There is a 
global commitment to end the AIDS epidemic by 2030 and UNAIDS recommends a Fast-Track 
approach which involves front-loading investment over the next five years “to overcome within 15 
years one of the greatest public health challenges in this generation”. (1) There is therefore an 
urgent need to deliver on HIV prevention goals. It is acknowledged that a combination of prevention 
methods is needed in order to achieve steep reductions in HIV incidence (2-4). 
1.2.2 Treatment as prevention  
HIV-infected individuals require ART to remain healthy in the longer term. The optimal timing of ART 
initiation has been a subject of on-going research and convincing evidence now exists for the 
benefits of early initiation.(5, 6) The TEMPRANO trial showed a reduction by 44% of serious illness 
and death when ART was initiated at a CD4-count >500/cc3 and the START trial observed a 57% 
reduction in death, AIDS and serious non-AIDS events in those in the intervention arm which 
received immediate ART (median CD4-count of 651/cc3) vs those randomised to ART at CD4-count 
<350/cc3. The evidence in favour of starting treatment earlier for the HIV-infected individual’s own 
health has meant that the latest World Health Organization (WHO) guidelines now recommend  
initiation of ART for all those living with HIV irrespective of CD4-count.(7)  
The achievements in prevention of transmission from mother to child (PMTCT) have provided the 
proof needed that treatment can be used to prevent transmission and have led to the prospect of 
elimination of infant HIV-infection. (8-11) The biological rationale for using treatment to prevent 
sexual transmission was provided by observational data in studies which showed that when HIV-
infected individuals had plasma viral loads of <400 HIV RNA copies/ml, no transmission to sexual 
partners occurred (12-14).  
“Treatment as prevention”, the concept of using treatment for HIV-infected individuals to achieve 
viral suppression so that the risk of transmission to uninfected sexual partners is negligible, 
therefore arose. The HIV Prevention Trials Network (HPTN) 052 randomised controlled trial, which 
examined this concept within clinical trial settings, showed at final analysis a 93% reduction in linked 
HIV transmissions from HIV-infected to uninfected partners when the former were treated early 
(ART initiated between CD4 counts >350 cells/mm3 and <550 cells/mm3) compared to late (CD4 
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counts <250 cells/mm3).(15)  There were 3 linked transmission events in the early treatment arm 
compared to 43 in the late treatment arm, and there were no linked transmission events observed if 
the HIV-positive partner was stably suppressed on ART. Similarly, results from the PARTNER Study 
found no evidence of linked transmission between couples — a zero rate of HIV transmission if the  
HIV-positive partner had a suppressed viral load (< 200 copies/ml) on ART.(16)  
Mathematical modelling studies have also suggested that dramatic reductions in the incidence of 
HIV at a population level can be achieved using antiretroviral treatment as prevention. (17-19) While 
conclusions of some of these studies have been questioned (20), the interest in exploring the 
treatment as prevention strategy at scale has not diminished (7, 21). 
A large population-based prospective cohort of HIV uninfected individuals in South Africa provided 
ecological evidence that the risk of HIV acquisition is inversely proportional to local ART 
coverage.(22) Nonetheless, research on the public health benefit of using treatment as prevention 
remains an urgent priority, not least to determine the feasibility of delivery at large scale.  
1.2.3 Universal test and treat 
‘Universal test and treat’ (UTT) aims to maximize the effects of treatment as prevention by delivering 
universal voluntary HIV testing throughout the community, with effective linkage-to-care for 
immediate offer of ART irrespective of immune-status.(23) The universal testing component which 
actively provides HIV-testing to increase knowledge of HIV status at a large scale, combined with 
active referral for timely care and treatment means that UTT goes beyond just “immediate 
treatment” for those presenting for HIV care.  
The community-wide identification of HIV-infected individuals is regarded as one of the corner-
stones of effective early treatment and is a pre-requisite for successful treatment as prevention at a 
public-health level.(24, 25) Following diagnosis, HIV-infected individuals require timely linkage-to-
care for clinical assessment with minimal delay. Under existing treatment guidelines in many 
countries which have not yet adapted to changes in WHO guidelines of treatment for all HIV-
infected, upon successful linkage, maintenance in “pre-ART” care is generally required. “Pre-ART” 
care is for those who are not yet eligible for ART, until ART initiation criteria are met and treatment 
can be commenced.(26) As any HIV-infected individual who links into care will be immediately 
eligible for ART within a UTT approach, the “pre-ART” care step is effectively removed, or minimised 
to a very short period of time (only to allow for the preparatory processes for ART initiation which 
may include CD4 count, liver and kidney function testing for clinical evaluation purposes, ART 
preparedness counselling etc).  
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Emerging evidence suggests that once those living with HIV reach care, acceptability of ART initiation 
at any CD4-count is high. (27, 28) The challenge seems to lie in linkage-to-care.(27, 28) In the context 
of UTT individuals must successfully achieve timely linkage-to-ART (TLA) in order for optimal benefit 
of “immediate ART”. Most individuals in a UTT context will be diagnosed in community settings, and 
linkage to care requires reaching the clinic and registering for care, in contrast with health facility 
diagnosed patients who are usually already at the location where HIV care will be provided, thus 
making registration for care much easier. Successful TLA requires individuals who may be 
asymptomatic and who had not considered themselves at risk of HIV to link-to-care without delay, as 
well as initiate ART as soon as possible. The latter requires efficient functioning of health-systems as 
well as willingness on the part of people living with HIV (PLWH). 
Ending the AIDS epidemic, defined as a reduction of HIV incidence to ~200,000 by 2030, so that HIV 
is no longer a major public health threat is a goal which has been set by UNAIDS with global 
consensus. It has been stated that “it will be impossible to end the epidemic without bringing HIV 
treatment to all who need it”.(29)  With this ambitious goal in sight, the 90-90-90 targets were 
released in 2014. The targets are that by 2020 - 90% of all people living with HIV will know their HIV 
status; 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy 
and; 90% of all people receiving antiretroviral therapy will have viral suppression. In combination, 
achieving these three targets would lead to 73% of PLWH being virally suppressed, and 
mathematical models suggest this would enable the ending of the AIDS epidemic by 2030.(29) 
While these targets provide much needed motivation to improve, current realities in most of sub-
Saharan Africa are not quite achieving them. Lack of services and /or services which are inaccessible 
or too inconvenient for users (in relation to competing priorities of daily life) have been identified as 
key failings in the cascade.(30-32) Lack of awareness about the benefits of knowledge of HIV status 
and early linkage-to-care, especially in individuals who are asymptomatic has been found to be 
another major gap.(31, 33, 34) The on-going requirement in many settings to meet eligibility criteria 
before starting ART is also an obstacle.(34, 35) Negative perceptions of PLWH, of HIV services and of 
ART have been shown to act as further barriers in the cascade. (30, 36)  
1.2.4 Treatment as prevention community randomised trials1 
The ANRS 12249 TasP trial team announced sobering results from their trial in rural South Africa, of 
the impact of UTT on HIV-incidence. They found no reduction in HIV-incidence when comparing a 
                                                          
1 The designs of the trials described here are as they were originally planned. Following the change in WHO 
guidelines in 2015 to offer ART to all HIV-positive individuals, all the trials changed practice accordingly, 
including in control arms which previously offered ART according to CD4-count criteria recommended in 
national guidelines. 
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UTT arm with 6 monthly HB-HTC and referral for care at trial clinics which provided immediate ART 
vs an arm with 6 monthly HB-HTC and referral for care at trial clinics which provided ART according 
to national guidelines (initially <350/cc3, transitioning to <500/cc3). (37) While they observed high 
acceptability of HB-HTC and high proportions with viral suppression on ART at 3 months (in both 
study arms), linkage-to-care proved to be the weak link in the cascade. Rather than the desired 90-
90-90 target, what was achieved was 92-49-93 in the intervention arm and 93-46-94 in the control 
arm, resulting in no difference in HIV incidence between the study arms. In addition, rather than the 
target 73% of PLWH virally suppressed, 43% were virally suppressed in the UTT arm. These results 
provide important lessons for other UTT initiatives although at this stage we must be cautious when 
generalising beyond the rural South African setting of the trial. The TasP trial was also only 
examining the impact of immediate treatment vs treatment with eligibility criteria. Other UTT trials 
are examining other aspects of the treatment cascade such as the added benefit of universal testing 
vs current standards of HIV test provision, or emphasis on patient-centred services to enhance 
linkage-to-care – in addition to the impact of immediate treatment. 
The SEARCH study has reported much more optimistic interim results from process data of the initial 
phase of their community randomised trial in Uganda and Kenya.(38) This study is delivering a multi-
disease community based campaign combined with a streamlined service delivery model designed 
to reduce structural barriers, improve patient-clinician relationships, and enhance patient 
knowledge and attitudes about HIV. After two years of implementation, the SEARCH team report 
that 81% of PLWH were virally suppressed having exceeded UNAIDS targets by achieving 97-93-90 at 
each of the key steps.  
The Botswana Combination Prevention Project (BCPP) is another UTT trial which is exploring the 
impact of combination prevention including home-based and mobile HIV testing and counselling; 
point-of-care CD4 testing; linkage to care support; expanded ART (for CD4 351–500 cells/mm3 or 
CD4 >500 with HIV-1 RNA≥10,000 copies/mL, in addition to local criteria); and enhanced male 
circumcision services, on HIV incidence at a population level. (39) Results from a baseline population 
survey indicate that 70% of PLWH were virally suppressed (83-87-97 for each of the target steps). 
The HPTN 071 (PopART) trial (Population Impact of Antiretroviral Treatment to Reduce 
Transmission) is the largest HIV prevention trial to date. (40) It is examining the impact of delivering 
UTT in Zambia and South Africa. Results have been published after one year of implementing the full 
trial intervention of door-to-door testing and treatment for all PLWH in Zambia, on the first two 
UNAIDS targets. (27) These indicate that among PLWH an estimated 78% of men and 87% of women 
were aware of their HIV positive status and approximately three-quarters of them were on ART after 
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one year. The primary research of this PhD is nested within PopART and it is therefore described in 
greater detail below. 
1.3 Summary of HPTN 071 (PopART) Trial 
The HPTN 071 (PopART) trial is a 3-arm community randomised trial which is testing the hypothesis 
that a combination prevention package including UTT can substantially reduce HIV incidence at a 
population level.(40) PopART is being conducted in 21 communities in Zambia and South Africa and 
commenced in November 2013 (see Figure 1.1 and Appendix 1). The trial applies a combination 
prevention approach which combines UTT with other proven HIV prevention methods. This includes 
wide-scale promotion of voluntary medical male circumcision (VMMC), which has been shown to 
reduce acquisition of HIV-infection in men by 60% in trials in sub-Saharan Africa (SSA) (41-43), as 
well as prevention of mother-to-child transmission (PMCT), and behavioural elements including 
condom promotion.  
The 21 trial communities were grouped into seven matched triplets (four in Zambia and three in 
South Africa) based on geographical proximity, implementing partners for HIV services and 
estimated adult HIV prevalence. Allocation of the communities into three study arms was carried out 
using a process of restricted randomisation to ensure overall balance across study arms on cluster 
size, ART uptake at baseline and HIV prevalence.  
Seven communities (four in Zambia and three in South Africa) in the main intervention arm (Arm A) 
have been receiving the full PopART package described above from the start of the trial. Seven Arm 
B communities were receiving the same package but with ART eligibility according to national 
guidelines (these changed from CD4 counts of <350 to <500/mm3). These two intervention arm 
communities were designed to be compared with the standard of care arm (Arm C) communities 
which were receiving not only ART according to national guidelines, but also testing and linkage-to-
care as was standard at the time. The trial schema shown in Figure 1.1 summarises the intervention 
arms based on the original design of the trial. 
Following the change to WHO guidelines in 2015 all PopART communities, including those in Arms B 
and C, have switched to ART eligibility for all PLWH, in keeping with best practice and ethical 
principles. Arms A and B are therefore now receiving the same package, while Arm C remains 
different in terms of testing, linkage-to-care and promotion of other prevention services. 
Mathematical modelling suggests that the impact of intervening on HIV testing and linkage-to-care is 
likely to see a significant impact on HIV-incidence, over and above the impact of switching to ART 
eligibility for all without increasing knowledge of HIV status and/or enhancing linkage-to-care of 
those tested HIV-positive. (19) 
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The cornerstone of the PopART intervention is the service provide by the Community HIV-care 
Providers (CHiPs) which is summarised in Figure 1.2. This cadre of staff are members of the 
community who were hired and trained by PopART to work in their communities to provide the 
services available to the intervention communities. In summary, a team of CHiPs are responsible for 
delivering services to a zone within a community of approximately 500 households. Each team 
ideally consists of a man and a woman who speak the prevalent local languages. CHiPs use handheld 
electronic devices to record intervention data which in turn are used to aid service delivery e.g. for 
following-up PLWH who have been referred for HIV care etc.  
The CHiPs attempt to conduct annual visits to all households to seek verbal consent before collecting 
information on household members (name, sex and age details). Individuals who consent are 
offered the intervention i.e. the offer of HIV-testing and promotion of HIV prevention services and 
have basic health information recorded (past HIV test history, ART history etc.) onto a database. For 
individuals who self-report HIV-infection or who agree to test and are diagnosed HIV-positive, a 
written referral is made to link to the local government health centre (Figure 1.2). Men who are not 
already circumcised are advised to attend VMMC services. Patients with symptoms of TB or sexually 
transmitted infections are also referred accordingly (including collection of sputum samples for 
potential TB patients).  
All HIV-infected individuals who are not stable on ART are followed-up to try to ensure linkage-to-
care and provide support for ART. Individuals who were not previously encountered at home are 
also sought out through repeat home-visits to offer the intervention and try to ensure universal 
coverage of the intervention. All treatment services are provided at local government health 
facilities which were strengthened prior to trial preparation (to ensure supply chains etc.) but 
otherwise largely operate within the usual infrastructure of the local health system. 
The primary outcome of HIV incidence will be measured in a Population Cohort (N=42,000) formed 
by 2,000 randomly selected adults from each community. This longitudinal cohort is being surveyed 
annually over 3 years and the primary outcome of HIV incidence over 36 months will be measured. A 
number of secondary outcomes are being measured to evaluate trial process measures and the 
impact, safety, cost and cost-effectiveness of the intervention.(40) Mathematical modelling is being 
done using trial data to project the longer term effects of the intervention. Qualitative research is 
embedded within the trial and case-control studies have been undertaken to examine factors 
associated with uptake of key interventions. 
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Figure 1.1 PopART Trial Schema 
3 arm cluster-randomised trial with 21 communities 
Full PopART
intervention 
including
immediate ART 
irrespective of CD4 
count
Standard of care at 
current service 
provision levels 
including 
ART initiation 
according to current 
national guidelines
ART initiation 
according to current 
national guidelines
7 communities 
per arm (N=21)
Arm A Arm B Arm C
PopART intervention 
except
PopART intervention package
 Annual rounds of  Home Based Voluntary HIV Testing by Community HIV-care Providers (CHiPs)
 Health promotion, Active Referral and/or Retention in Care support by CHiPs for the following:
• Voluntary Medical Male Circumcision (VMMC) for HIV negative men
• Prevention of Mother to Child Transmission (PMCT) for HIV positive women
• HIV treatment and care for all HIV positive individuals
• Promotion of sexual health and TB services
• Condom provision
 ART irrespective of CD4-count or immune-status provided at the local health centre in Arm A 
~ 2,000 random sample 
from each community :
Population Cohort 
N = 42,000
Primary outcome:
HIV incidence at 36 months
12 in Zambia
9 in S. Africa
 
Figure 1.2 Schematic Overview of Household Visit 
Health centre
(HIV & ART, 
PMCT, TB, STI 
management)
VMMC facility
1. HB-HTC
2. Referral of HIV-positive individuals 
not currently on ART
3. Referral for and promotion of other 
relevant services
4. Follow-up 
on referral
5. Support for: 
- Retention in care
- Adherence 
to treatment
Intervention activities carried out by CHiPs in Arm A and B 
1. HB-HTC for household members who  accept CHiP intervention 
2. Referral letter for timely linkage and ART initiation
3. Additional referral for other relevant prevention or treatment service (VMMC, ANC+PMCT,  STI, TB ) and distribution of condoms
4. Follow-up on referral
5. Support for retention in care – scheduled and tailored visits to patients to offer counselling, encourage adherence and attendance at 
health centre if medical attention is indicated  
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1.4 Key research components of PhD 
1.4.1 Systematic review on home-based HIV testing and counselling 
When the PhD was started in 2012, knowledge of HIV status in sub-Saharan Africa was low. The 
acceptability of home-based HIV counselling and testing (HB-HTC) as an approach to delivering wide-
scale HIV testing held promise, but was not fully established. There was uncertainty about HB-HTC 
and concern that it may be poorly accepted or even harmful, partly owing to the stigma and 
discrimination around HIV/AIDS. During the period under study (2000-2012) testing was sometimes 
offered at the household but clients were required to attend the clinic to have post-test counselling 
to receive HIV results. We therefore explored both the proportion of acceptance of HB-HTC and of 
results received among those offered it. We also explored any potential social harm caused by HB-
HTC and sought to summarise information on cost-effectiveness. (25) Studies from SSA which 
reported the proportion of individuals who accepted HIV testing, and who received results, out of 
those offered were included and meta-analysis performed to estimate acceptability of HB-HTC. The 
manuscript of this study is presented in Chapter 3. 
1.4.2 Factors associated with the uptake of Home-Based Voluntary HIV 
Testing and Counselling during the first annual round of the PopART 
intervention - Case-control study 1 
1.4.2.1 Rationale for Case-control study 1 
HB-HTC is the key HIV testing intervention in PopART. It is provided in addition to other local efforts 
to increase knowledge of HIV status in the intervention communities.  
While there are descriptive studies of acceptors of testing and HB-HTC, there is little analytical 
evidence specifically on non-acceptors of HB-HTC and their reasons to decline. There continue to be 
gaps in understanding of the structural, health systems and individual characteristics which affect 
the uptake of HB-HTC based on existing literature.  Studies have demonstrated high acceptability of 
HB-HTC, but most of this evidence comes from conditions where ART eligibility criteria apply.(45, 46) 
It is important to identify the factors which influence the non-uptake and uptake of HB-HTC within 
the context of a UTT intervention as delivered in PopART. Research conducted on the uptake of HB-
HTC during the first annual round of CHiPs HB-HTC could help to inform future rounds of HB-HTC in 
PopART.  Mathematical modelling for the PopART trial suggests that the acceptability of HB-HTC is 
one of the important determinants of the size of the impact of the PopART intervention on HIV 
incidence (19). Exploring in detail the reasons that underpinned the achieved coverage of the 
intervention is critical to inform policy makers on the generalizability of the findings and help inform 
the future design and implementation of HB-HTC in sub-Saharan Africa. This case-control study 
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characterises in detail the factors associated with, and reported reasons for acceptance or non-
acceptance of the HB-HTC component of the UTT strategy.  
1.4.2.2 Study hypotheses 
We hypothesised that there would be several factors including demographics, socio-economic 
circumstances, health and psychological status, alcohol and drug use, sexual behaviour, previous HIV 
testing, stigma and other related factors which would be different between non-acceptors and 
acceptors of HB-HTC in the first annual round of HB-HTC in PopART. Cases and controls were asked 
questions, to explore reasons for not testing and motivation to test, respectively. The questionnaire 
themes were tailored to provide a description of the case and control population (demographics, 
socio-economic circumstances etc.), as well as to identify if certain behaviours are more frequently 
associated with non-uptake of interventions. For instance, is the individual’s satisfaction with their 
experience of the CHiPs team associated with uptake or non-uptake of testing with CHiPs? Such a 
finding would inform future training and conduct of the teams in order to improve uptake. Another 
example is that if an association is found between experience of intimate partner violence and non-
uptake, this might inform us that associations between experience of violence and acceptance of 
health services (e.g. due to lack of autonomy to accept services for fear of consequences) require 
further investigation. Associations between various factors and uptake or non-uptake of CHiPs HB-
HTC will be established, some of which may be modifiable to improve delivery of services. 
This study is presented in Chapter 4. 
1.4.3 Cascade of care following community-based HTC 
A second systematic review was done to examine the effectiveness of community-based HIV-testing 
services (HTS), including home and mobile-based HIV-testing services (HB-/M-HTS), in improving 
care in SSA. While community-based approaches of testing have become established as effective 
means to increase knowledge of HIV status on a large scale, it was less clear whether they had an 
impact on enhancing access to timely HIV care. These approaches detect infected individuals earlier 
in the course of infection but individuals who feel well may not be ready to access care at health 
facilities even when provided with a diagnosis. While community-HTS reduces barriers for testing, 
the challenges associated with health facilities remain and individuals identified by community-HTS 
may be less likely and/or take longer to link-to-care. Studies from SSA between 2006-2016 which 
reported the proportion of individuals who link-to-care and/or initiate ART after detection of HIV 
through community-based testing were examined to determine the impact on uptake of the 
subsequent steps in the cascade of care. The manuscript of this study which has been submitted for 
publication is presented in Chapter 5. 
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1.4.4 Factors associated with timely initiation of immediate ART during the 
first annual round of the PopART trial - Case-control study 2 
1.4.4.1 Rationale for Case-control Study 2 
As “immediate treatment” is the linchpin of the PopART UTT intervention, understanding any 
barriers to wide-scale uptake will be crucial to understanding the trial findings. Although WHO 
guidelines now recommend ART irrespective of CD4-count for all PLWH, the provision of “immediate 
ART” for all HIV positive individuals represents largely uncharted territory.(7) As described in section 
1.3, the UTT approach first seeks to test everyone in the community (universal testing) and refer 
them for care in the health-facility. This has to be followed by “timely-linkage-to-ART” (TLA) 
involving the 2 key steps of timely linkage-to-care (LTC) and ART initiation. A key challenge of TLA in 
UTT is that it seeks to achieve TLA among individuals who were detected with HIV in the community 
as part of universal testing, who may be asymptomatic and/or may not otherwise have sought HIV 
testing. Treatment readiness among such newly diagnosed individuals may be a challenge. 
Qualitative data from in-depth interviews on initiation of ART before eligibility criteria are met 
suggest acceptability is high but much more data is needed. (47) Barriers have also been identified, 
including anxiety about life-long commitment and side effects of treatment, risks of drug resistance, 
fear of unwanted disclosure, perceived incompatibility with alcohol and resources required to obtain 
refills of drugs/continue in long-term care.(47) The loss from care of patients registered for care but 
not meeting ART eligibility criteria is now also well documented.(34, 35) The UTT approach removes 
the barrier imposed by the requirement to meet eligibility criteria. 
Uptake of treatment in UTT would have to be wide-spread across sub-sets of the population with 
different socio-demographic and behavioural characteristics, for reduction of community-level HIV-
incidence. The full impact of UTT on prevention would not be seen if sub-sets of the population were 
excluded or not engaging with the universal treatment intervention.  
A case-control study was undertaken to identify the characteristics of those who do/do not link-to-
care and start ART within 6 months of referral by the CHiPs upon detection of HIV (through HIV 
testing or self-report) in PopART during the first year of the intervention, and explored reasons for 
achieving TLA. The study seeks to address not only the treatment irrespective of immune-status or 
CD4 count aspect of UTT, but also the need to link-to-care, and for initiation of ART without delay, if 
the community level reduction in HIV incidence goal is to be achieved.  
1.4.4.2 Study hypotheses 
We hypothesised that there will be several factors including demographics, socio-economic 
circumstances, health and psychological status, alcohol and drug use, sexual behaviour, previous HIV 
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testing, stigma, perceptions about health services and other related factors which are different 
between achievers and non-achievers of TLA during the first year of the CHiP intervention in PopART 
Arm A.  As in Case-control study 1, cases and controls were asked questions, to explore reasons for 
TLA and barriers against achieving TLA. The questionnaire themes were tailored to provide a 
description of the case and control population (demographics, socio-economic circumstances etc.), 
as well as to identify if certain behaviours are more frequently associated with non-uptake of 
interventions. For instance, is alcohol use negatively associated with TLA? Such a finding would help 
inform health providers that alcohol reduction services may be important to help towards enhancing 
TLA and universal treatment. Another example is that if an association is found between high risk 
sexual behaviour and non-uptake, it would inform us that a key population is not participating in the 
trial intervention and not benefiting from immediate treatment for prevention. This could have 
implications for onward HIV transmission in the communities, despite high uptake in the community 
overall.  
This study is presented in Chapter 6. 
1.5 Contribution to research 
Both of the systematic reviews which were conducted for the PhD were conceived and led by me 
with oversight from Richard Hayes as my supervisor. I led on conceptualising the research questions, 
formulating search criteria and was the first reviewer on both papers. The systematic review and 
meta-analysis on HB-HTC was a collaboration with Nathan Ford and Rafael van den Burgh, who led 
on the meta-analysis component of the study and acted as second reviewer, respectively. The 
systematic review on the cascade of care following HB-HTC was a collaboration with Bernadette 
Hensen and Olivia Varsaneux, who jointly undertook the role of second independent reviewer for 
different components of the review (see Chapter 5). As first author, I co-ordinated the reviews, 
wrote the first drafts and led on revisions of subsequent drafts, including responding to journal 
reviewer comments on study manuscripts.  
Although the case-control studies were nested within PopART and were subject to the regulatory 
requirements of the wider trial, the leadership of the studies was always my responsibility. The 
studies were identified as components which would contribute to my PhD from the beginning, when 
the PopART trial protocol was being written, and I was a member of the protocol writing team. With 
oversight from my supervisor who is Principal Investigator of the wider trial, I designed the case-
control studies (including the questionnaires), wrote all study specific protocols and applied for 
regulatory approvals. Once approval was obtained, with senior input from in-country Principal 
Investigators (Helen Ayles, Zambia and Nulda Beyers, South Africa), I was responsible for staffing the 
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studies (conducting pre-employment interviews and training of field research assistants together 
with in-country management staff); collaborating with in-country data managers on programming of 
questionnaires and other aspects of data collection; and leading the initial data collection with field 
research managers and research assistants. I was in weekly contact with field research managers 
about challenges encountered by the teams, to offer support and guidance. I was responsible for the 
“real-time” monitoring of the electronic questionnaire data which was collected in the field and sent 
to me weekly/fortnightly. I performed the necessary data cleaning and carried out all statistical 
analyses, with advice from my supervisor and Sian Floyd (senior statistician on PopART). As with the 
systematic reviews, I wrote the first drafts and led on revisions of subsequent drafts of the study 
manuscripts.   
1.6 Summary  
In summary, the aim of this PhD is to improve understanding of the factors associated with the 
uptake of key interventions in UTT as delivered by the PopART trial. Two systematic reviews were 
done to inform and contextualise the primary research consisting of two case-control studies which 
were nested within the trial. The studies were done to enhance the understanding of factors 
associated with engagement in key steps in the cascade of HIV care during the first year of 
implementation of the trial. The findings will have immediate implications for the on-going 
implementation of activities at later stages of PopART. These studies will help to identify if 
individuals who do not engage in the interventions are also more likely to acquire/transmit HIV and 
affect the primary outcome of the trial (HIV incidence). This could provide data to inform 
mathematical models. Finally, it is hoped that this research will have longer term consequences for 
translating trial interventions into future policy and implementation.  
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Chapter 2: Case-control study methods 
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Outline of chapter 
As described, two case-control studies were conducted as part of the PhD to evaluate the 2 key 
elements of the UTT model – universal testing and universal treatment. This chapter describes the 
methods used in the design, implementation and analysis of those studies.  
2.1. Factors associated with the uptake and non-uptake of Home-Based 
Voluntary HIV Testing and Counselling during the first annual round of the 
PopART intervention - Case-Control study 1 (CC1) 
2.1.1 CC1 objectives 
i. To identify differences between non-acceptors and acceptors of HB-HTC during the first annual 
round of HB-HTC in PopART.  
ii. To identify reasons for non-acceptance of HB-HTC during the first annual round of HB-HTC in 
PopART. 
Achieving the above objectives could help to modify aspects of delivery of the HB-HTC intervention 
that may be associated with non-acceptance.  
2.1.2 CC1 Study design  
A case-control study was planned to study the factors associated with uptake of HB-HTC in PopART 
(Arms A and B) – Case-control Study 1. Given the evidence that HB-HTC is likely to receive high 
acceptance, non-acceptance was expected to be a relatively infrequent event. A case-control design 
was chosen because it is suited to explore infrequent outcomes and multiple exposures in an 
efficient manner.  
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2.1.3 CC1 Study setting 
Figure 2.1 List and location of the 21 PopART trial communities 
ZAMBIA
Dambwa
Maramba
Chawama
Kanyama
Shampande
Chipata
Ngungu
Makululu
Ndeke
Chimwemwe
Chifubu
Chipulukusu
S AFRICA
Delft South
Ikhwezi
Bloekombos
Dalevale
Wellington
Cloetesville
Luvuyo
Kuyasa
Town II
Source: HPTN 071 (PopART) Trial Protocol Version 1.0  
The 21 communities involved in PopART are shown above (12 in Zambia and 9 in South Africa). They 
vary in size from 21,386 to 166,251 total population size (an average of 57,828 or 66,864 in Zambia 
and 45,780 in South Africa) and adult HIV prevalence estimates range from 13-26%. They are all 
urban or peri-urban sites. The source population for CC1 was the populations of all 14 communities 
in Zambia and South Africa allocated to Arms A and B in PopART. 
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2.1.4 Inclusion and exclusion criteria of CC1 study participants 
Inclusion Criteria Case-Control Study 1
• At least 18 years of age
• Able and willing to provide informed consent 
• Resident in the cluster during the first round of testing
• Visited by a CHiP team and offered testing during the first 
round of home-based testing
Exclusion Criteria Case-Control Study 1
• Individuals belonging to the Population Cohort of the 
trial or other case-control studies
• Individuals known to be HIV-infected after testing 
elsewhere. 
 
As shown above, community members who were at least 18 years old and able and willing to 
provide informed consent were eligible for inclusion in Case-control study 1. Their residence in the 
community during the first PopART annual round was recorded in the CHiPs electronic register along 
with whether face-to-face contact was made during delivery of the intervention. Acceptance of the 
intervention involved consent to basic data being collected and receiving health information 
provided by the CHiPs. Community members may have chosen to accept the intervention but not 
accepted HB-HTC. To be included in the case-control study, the individual must have accepted the 
CHiP intervention (in order to be offered HB-HTC). Those who also accepted HB-HTC were eligible to 
be controls and those who did not accept the HB-HTC component of the intervention were potential 
cases. 
Members of the PC were excluded to minimise the Hawthorne effect on the main trial research 
cohort. Community members who self-reported as already known to be HIV-infected were also 
excluded (as they were not routinely offered HIV testing - previously known HIV-positive status was 
recorded in the electronic register). No proof of HIV-positive status (among those self-reporting) was 
sought as it was thought quite unlikely that individuals would claim to be HIV-positive just to avoid 
study participation. 
Inclusion and exclusion criteria were determined from information in the CHiP database in the first 
instance (e.g.. residence in the cluster during the first annual round or self-report of HIV positive 
status) and completed by the CC RAs at the time of approach for study participation, for information 
which was not available from the CHiP database (e.g.. ability/willingness to provide informed 
consent or prior inclusion into the Population Cohort).   
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2.1.5 Factors which may influence non-uptake/uptake of HB-HTC 
Shown in Figure 2.2 are the factors which were expected to influence the non-uptake and uptake of 
HB-HTC which were explored by the standardised questionnaires in the study. It was expected that 
some associations would be causal while other factors would co-exist and have a causal factor in 
common. Several factors may be inter-related or have a confounding effect on other associations. 
These elements were important to explore in order to improve understanding of non-engagement 
with the HB-HTC intervention and the resultant impact of the PopART package on HIV incidence 
reduction.
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Figure 2.2 Factors which may influence non-uptake/uptake of HB-HTC 
TO TEST
OR 
NOT TO TEST?
Sexual behavioural factors
• Age at 1st sex
• Lifetime partners (no.)
• Partners characterisitcs - last 12m 
• Transactional sex / concurrency
• Condom use
K/A: PopART
• Knowledge of and 
attitudes to study goals
Peer influences
• whether HH members tested
• whether sexual partner & spouse tested
• whether friends tested
Physical health 
• History of illness requiring 
consultation / hospitalisation
• Health care utilisation – traditional 
vs western etc 
Mental health
• Depression related
Pregnancy / ANC history in women
Circumcision history in men
HIV testing
• Previous test information 
• Reasons favouring testing with CHiP
• Reasons against testing with CHiP
Stigma and discrimination
• Fear of infection
• Social judgement
• Anticipated stigma
• Experienced stigma
• Perceived stigma
Alcohol and drug use
• AUDIT questions
• Non-prescription drug use  
• Association with sex
Economic activity and food security 
• Housing / toilets
• Water / energy (cooking fuel etc)
• Household income
• Household assets
Violence
• Physical
• Sexual
• Psychological
Experience with CHiP team
• confidentiality/ respect/ professionalism
Sociodemographic factors
• Age
• Gender 
• Marital status
• Parenthood status
• Country of origin / migrant status
• Religion
• Educational achievement
• Occupation
• Absence from community (travel)
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2.1.6 CC1 Study procedures 
2.1.6.1 Selection of cases 
Definition of cases in Case-control study 1: a random sample of non-acceptors of HB-HTC offered by 
CHiPs in Arms A and B of the PopART trial during the first annual round of the intervention. Non-
acceptance was defined as such after the end of the CHiP annual round of initial visits to offer the 
intervention. By design this meant that community members who were absent from the household 
when a CHiP team visited and those who declined to be interviewed by the CHiP (both after 
repeated attempts), were excluded. This was a necessary compromise for feasibility of study 
conduct and allow direct comparison between those who accepted and those who declined - both 
after being offered HB-HTC.   
It is also acknowledged that between the CHiPs home-visit and the time of the study, some 
individuals may have had an HIV test (by other means of testing), who had declined HB-HTC when 
offered by CHiPs during the annual round. However, provided a community-member met the afore-
mentioned inclusion and exclusion criteria, and non-acceptance of the HIV test was recorded in the 
CHiP EDC register at the time of random selection, the individual was eligible to be a case in the 
study.  
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Figure 2.3 Selection of cases – at the end of the first annual round of HB-HTC 
N
randomly selected and placed on list for CHiPs to 
approach sequentially
CHiPs attempt to ask for permission 
from N
potential cases 
RA attempt contact with N-a
potential cases
Decline visit by RA or unable to locate individuals
(“a” eg 40% unsuccessful)
N-a-b ≈ number asked for full written informed consent 
Step 2
Step 3
Step 4
RANDOM subset out of all non-acceptors per community 
from electronic register after the first annual round
Step 1
Decline study participation / ineligible 
or unable to locate individuals
(“b” eg 30% unsuccessful)
 
As shown in Figure 2.3 above, approximately 400 cases (200 men and 200 women) were to be 
included in the study (see Section 2.5 on Sample size calculations) – amounting to approximately 30 
cases per community (7 Arm A and 7 Arm B communities). The following describes the planned 
recruitment strategy. Chapter 4 presents the actual numbers recruited into CC1. 
 The CHiP Electronic Data Capture (EDC) register of individuals in PopART Arm A and B communities 
provided the starting point for selection of non-acceptors of HB-HTC (amongst those offered HB-HTC 
during the first year of the trial intervention). From all non-acceptors in the register, a higher 
number than was required for inclusion in the study was randomly selected (N = 70 per community). 
This larger number allowed for failures to locate individuals and/or refusals to participate in the 
study. It was estimated as the number needed after back calculation from the final number needed 
(30 cases and 30 controls per community), as described below. The ID numbers of 70 randomly 
selected non-acceptors were placed in a random order, on a sequential list of potential subjects as 
shown in Step 1 above.  
In Step 2, CHiPs visited each of the non-acceptors on the list for the CC study. They sought to obtain 
verbal permission from individuals for their details to be passed on to the Case-control study 
Research Assistants (RAs). It was anticipated that a number of individuals would not be located 
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when the CHiPs returned to request permission or would decline permission for details to be passed 
on to an RA for any further discussion regarding study participation (“a” – estimated to be 
approximately 40% based on experience from the Population Cohort enrolment process). The 
permission requested by the CHiPs was to enable them to pass on the individual’s name, gender, 
age/date of birth and address - to facilitate approach of the client by a study RA. Note, no 
information about HB-HTC acceptance/ non-acceptance or any details gathered during the CHiP 
intervention were conveyed to the RAs, and clients were explicitly informed of this by the CHiPs. 
Shown in Appendix 2 is the Information sheet and verbal consent document used by the CHiPs in 
Zambia (with an alternative country-specific version used for SA). 
In Step 3, the study RAs attempted to approach the individuals who had given verbal permission (“N-
a” who agreed when asked by CHiPs). Again at this stage it was anticipated that some individuals 
would not be located or they may decline (“b” – estimated to be approximately 30%). This 
proportion was smaller than “a” as these were individuals who had already agreed when asked by 
the CHiPs at Step 2 (just a short time earlier).  In Step 4, all clients who had agreed to study 
participation (N-a-b i.e. ~30 individuals) were provided with detailed study information and written 
informed consent for study participation was requested.  
Note, all N-a-b individuals were to be included in the study if they consented, even if the number 
was higher than the required ~30 participants per community as defined by the sample size 
calculations. If the number who consented was much less than required, then the steps described 
above would be repeated, with a fresh random sample of participants selected from the CHiP 
register. On this occasion N, a and b would be estimated based on the actual response rates at the 
initial stage, separately for men and women, with the aim of reaching the required sample size in 
total. The process outlined above was to be undertaken with a view to minimising selection bias, 
which may otherwise occur if a more convenient sampling approach was taken. We wanted to 
ensure the sample of non-acceptors was as representative of the overall pool of non-acceptors as 
possible. The study was planned to take place at the end of the first annual round of HB-HTC. 
The above description outlines how cases were selected. The same process was undertaken for 
controls, simultaneously. When CHiPs approached non-acceptors for study participation, they may 
on that occasion have re-offered HB-HTC – for service delivery purposes and in keeping with their 
ethical duty to clients. Even if an individual now took up HB-HTC, his/her uptake status at the time of 
random selection was used to define case vs control status.  In addition, the research team was kept 
blind to the acceptance/non-acceptance status of potential participants when they approached 
them for informed consent.  
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2.1.6.2 Selection of controls 
The purpose of having controls in this study was to have a representative sample of individuals who 
accepted HB-HTC for comparison with those who did not accept.  
Controls in Case-control study 1 were defined as a subset of acceptors of HB-HTC which was offered 
by Community HIV-care providers (CHiPs) in Arms A and B of the PopART trial in the first annual 
round of HB-HTC. Acceptance was defined as such if HB-HTC was accepted before the end of the 
CHiP annual round. 
The inclusion and exclusion criteria were the same as for cases. The controls for Case-control study 1 
were selected through a similar process as described for the cases, simultaneously with the case 
selection process and beginning with the approach by CHiPs of a random subset of individuals who 
accepted HB-HTC, aiming for inclusion in the study of ~30 controls per community. The ratio of cases 
to controls would be approximately 1:1, and among each of cases and controls the ratio of men to 
women would be approximately 1:1 because the random sample would be selected stratified on 
gender. They would also be frequency matched on the communities in which they resided. All the 
ratios would be approximate dependent on what proportion of the N initially selected eventually 
accepted study participation among cases vs controls, men vs women and by community, with the 
goal of achieving the required total number in the study of ~400 cases and ~400 controls as guided 
by the sample size estimates. Chapters 4 and 6 present the actual numbers recruited into the CC1 
and CC2, respectively. 
2.1.7 CC1 Study questionnaire 
Research assistants conducted participant interviews for Case-control study 1 at approximately the 
end of the first annual round of HB-HTC in PopART. Standardised questionnaires which explored 
potential factors which may be associated with non-uptake / uptake of HB-HTC in PopART were 
administered by the RAs (Figure 2.2). Written informed consent was obtained and questionnaires 
administered during an interview lasting 1-1.5 hour total duration, at the household or a preferred 
location of the participant. Shown in Appendix 3 is the Information and sheet and informed consent 
form for South Africa (with an alternative country-specific version used for Zambia) and Appendix 4 
displays the CC1 study questionnaire. Data were captured using electronic capture devices.  
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2.2. Factors associated with timely initiation of immediate ART during the 
first annual round of the PopART trial - Case-Control study 2 (CC2) 
2.2.1 CC2 Study objectives 
i. To identify differences between those who do and do not achieve timely linkage-to-care and ART 
initiation in Arm A during the first year of the PopART intervention. 
ii. To identify reasons for failure to achieve timely linkage-to-care and ART initiation in Arm A during 
the first year of the PopART intervention. 
Achieving the above objectives could help to ensure the PopART intervention succeeds in achieving 
UTT. 
2.2.2 CC2 Study design 
A case-control study was planned to study the factors associated with timely linkage and uptake of 
immediate ART in PopART (Arm A) during the first year of the trial – Case-control Study 2. As in CC1, 
this design was chosen because it is suited to explore infrequent outcomes and multiple exposures 
in an efficient manner. As it turned out failure to initiate ART in a timely manner was not infrequent. 
The choice of design was still relevant however as it enabled to the examination of multiple 
exposures. The source population for this study was the population of all 7 sites allocated to Arm A 
in PopART, in Zambia and South Africa. 
2.2.3 CC2 Study setting 
CC2 was conducted in 7 PopART Arm A communities in Zambia and South Africa, (4 in Zambia and 3 
in South Africa) where immediate ART was provided from the launch of the trial (Figure 1.1). Arm B 
and C communities were providing treatment according to national guidelines with eligibility criteria 
and were therefore not included in this study. 
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2.2.4 Inclusion and exclusion criteria of CC2 study participants 
Inclusion Criteria Case-Control Study 2
• At least 18 years of age
• Able and willing to provide informed consent 
• Resident in the cluster during the first round of testing
• Tested HIV-infected in CHiP home-based testing, or HIV-
infected and disclosed that they were previously 
diagnosed as HIV-infected to CHiP team
Exclusion Criteria Case-Control Study 2
• Individuals belonging to the Population Cohort or other 
case-control studies
• HIV-infected individuals already on ART when initially 
seen by the CHiPs
  
As shown above, community members who were at least 18 years old and able and willing to 
provide informed consent were eligible for inclusion in Case-control study 2. Residence in the 
community during the first PopART annual round was recorded in the CHiPs electronic register. The 
individual had to have been visited by a CHiP team, consented to the CHiP intervention, and 
identified as HIV-positive – either upon testing positive from CHiP HB-HTC or self-report of being 
HIV-positive but not on treatment. Such individuals would then have been referred to the health-
facility for HIV care and immediate ART. 
As for CC1, members of the PC were excluded to minimise the Hawthorne effect on the main trial 
research cohort. Participants of CC1 were also excluded to minimise research fatigue and because 
there were overlaps in the CC1 and CC2 questionnaire which could have led to reporting bias. 
Community members who self-reported as already known to be on ART when initially seen by the 
CHiPs were also excluded.  
Inclusion and exclusion criteria were determined from information in the CHiP database in the first 
instance (e.g. HIV-positive status or information that client already on ART) and completed by the CC 
RAs at the time of approach for study participation, for information which was not available from the 
CHiP database (e.g.. ability/willingness to provide informed consent or prior participation in CC1). 
2.2.5 Factors which may influence non-uptake/uptake of immediate ART 
Shown in Figure 2.4 are the factors which were expected to influence TLA which were explored by 
the standardised questionnaires in the study. The evidence on factors associated with TLA are 
important to identify in the context of PopART to discover both what is and what is not associated 
with non-uptake. It was expected that some associations would be causal while others would co-
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exist and have a causal factor in common. Several factors may be inter-related or confound other 
associations. These elements were important to explore in order to improve understanding of non-
engagement with the immediate ART intervention and the resultant impact of the PopART package 
on HIV incidence reduction. 
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Figure 2.4 Factors which may influence non-uptake/uptake of immediate ART 
Sexual behavioural factors
• Age at 1st sex
• Lifetime partners (no.)
• Partners characterisitcs - last 12m 
• Transactional sex / concurrency
• Condom use
K/A: PopART
• Knowledge of and 
attitudes to study goals
Peer influences
• whether sexual partner & spouse 
/ other HH members / friends on ART
Physical health 
• History of illness requiring 
consultation / hospitalisation
• Health care utilisation – traditional 
vs western etc 
Mental health
• Depression related
Pregnancy / ANC history in women
Circumcision history in men
Stigma and discrimination
• Fear of infection
• Social judgement
• Anticipated stigma
• Experienced stigma
• Perceived stigma
Alcohol and drug use
• AUDIT questions
• Non-prescription drug use  
• Association with sex
Economic activity and food security 
• Housing / toilets
• Water / energy (cooking fuel etc)
• Household income
• Household assets
Violence
• Physical
• Sexual
• Psychological
Experience with CHiP team
• confidentiality/ respect/ professionalism
Sociodemographic factors
• Age
• Gender 
• Marital status
• Parenthood status
• Country of origin / migrant status
• Religion
• Educational achievement
• Occupation
• Absence from community (travel)
TO START
OR 
NOT TO 
START
ART?
ART related
• HIV health-care seeking behaviour before and after 
CHiP referral
• ART before and after CHiP referral
• Reasons for and against starting ART
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2.2.6 CC2 Study procedures 
2.2.6.1 Selection of cases 
Cases in Case-control study 2 were defined as a subset of randomly selected individuals who did not 
link-to-care and initiate ART within 6 months of HIV positive status being recorded in the CHiPs 
electronic register in Arm A, during the first year of PopART (see Figure 2.5).  
A timeline of 6 months was used to define “immediate” ART. This was revised from an earlier cut-off 
of 3 months when it was observed in the intervention process data that too few PLWH had initiated 
within this time. The majority of those who initiated ART (in the first year) had done so by six-
months and this time-point was chosen instead. In order to achieve HIV incidence reduction with 
UTT in PopART, timely linkage and ART initiation is the goal. As such, provided an HIV positive 
community-member met the afore-mentioned inclusion and exclusion criteria, and was recorded in 
the CHiP electronic register as not having initiated ART within 6 months, the individual was eligible 
to be a case in the study, just as if ART was not initiated at all. Whether or not TLA had been 
achieved was determined at follow-up visits which were routinely done by CHiPs for PLWH who had 
been referred for TLA. Outcomes were recorded in the CHiP register. Individuals who were not 
contactable at follow-up to obtain information on ART initiation status were therefore not included 
as potential candidates for the study (Figure 2.5). 
Figure 2.5 Identification of individuals who did and did not achieve TLA  
CHiP* attempts to offer 
intervention
Agree to participate in intervention 
CHiPs identify HIV infected 
and refer (if not already on ART)
Enumerated as HH member but not found 
at CHiP visit or avoid/ refuse CHiP interview
By CHiP test or 
self-report HIV 
+ve
Referral for HIV care and ART
Follow-up visits to check 
If not found at follow-up 
- ineligible for study 
Linked into care Not linked into care
TLA ≤ 6 months
Potential cases
TLA > 6 months ART not started
When >6 months since HIV+ve recorded in register – TLA can be defined
Potential controls
*CHiP=Community HIV-care Provider  
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Shown in Figure 2.6 below was the process of selection of cases, after they had been identified as 
eligible for random selection from the CHiP electronic register i.e. as potential cases. 
 Figure 2.6 Selection of cases 
N
randomly selected and placed on list for CHiPs to 
approach sequentially
CHiPs attempt to ask for permission 
from N
potential cases 
RA attempt contact with N-a
potential cases
Decline visit by RA or unable to locate individuals
(“a” eg 40% unsuccessful)
N-a-b ≈ number asked for full written informed consent 
Step 2
Step 3
Step 4
RANDOM subset out of all non-acceptors per community 
from electronic register after the first annual round
Step 1
Decline study participation / ineligible 
or unable to locate individuals
(“b” eg 30% unsuccessful)
 
As shown in Figure 2.5, approximately 400 cases (200 men and 200 women) were to be included in 
the study (see Section 2.5 on Sample size calculations) – amounting to approximately 60 cases per 
community (7 Arm A communities). The following describes the planned recruitment strategy. 
Chapter 6 presents the actual numbers recruited into CC2. 
The CHiP electronic register of individuals in PopART Arm A communities provided the starting point 
for selection of those who had not achieved TLA (amongst those referred by CHiPs) during the first 
year of the intervention. A higher number than was required for inclusion in the study was randomly 
selected (N = 140 per community). It was estimated as the number needed after back calculation 
from the final number needed (60 cases and 60 controls per community), as described below. This 
larger number allowed for failures to locate individuals and/or refusals to participate in the study. 
The ID numbers of 140 randomly selected potential cases were placed in a random order, on a 
sequential list of potential subjects as shown in Step 1 above.  
In Step 2, CHiPs visited each of those who had not achieved TLA on the list. They sought to obtain 
verbal permission from individuals for their details to be passed on to the case-control study 
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Research Assistants (RAs). It was anticipated that a number of individuals would not be located 
when the CHiPs returned to request permission or would decline permission for details to be passed 
on to an RA for any further discussion regarding study participation (“a“ – was estimated to be 
approximately 40% based on the experience of enrolment into the Population Cohort and CC1). The 
permission sought by the CHiPs was to enable them to pass on the individual’s name, gender, age 
and address - to facilitate approach of the client by a study RA. No information about ART initiation 
or any details gathered during the CHiP intervention were conveyed except the fact that the 
individual had been referred for HIV care, and clients were explicitly informed of this when 
permission was requested. 
As in CC1 in Step 3, the study RAs attempted to approach the individuals who had given verbal 
permission (“N-a” individuals who agreed when asked by CHiPs). At this stage it was anticipated that 
some individuals (who previously assented to CHiPs) would not be located or may decline study 
participation at this stage (“b” – estimated to be approximately 30% further unsuccessful attempts). 
This proportion was smaller than “a” as these were individuals who had already agreed when asked 
by the CHiPs at Step 2 (just a short time earlier). In Step 4, all clients who had agreed to study 
participation (“N-a-b” ≈ 60 individuals) were provided with detailed study information and written 
informed consent for study participation was requested.  
Note, all “N-a-b” individuals were to be included in the study if they consented, even if the number 
was much higher than the required ~60 participants per community as defined by the sample size 
calculations. If the number who consented was much less than required, then the steps described 
above were to be repeated, with a fresh random sample of participants selected from the CHiP 
register. On this occasion N, a and b would be estimated based on the actual response rates at the 
initial stage, separately for men and women, with the aim of reaching the required sample size in 
total. The process outlined above was to be undertaken with a view to minimising selection bias, 
which would otherwise occur if a more convenient sampling approach was taken. This was to ensure 
the sample of non-acceptors was as representative of the overall pool of non-initiators as possible. 
The study was to take place at the end of the first CHiP annual round and be restricted to community 
members who had at least 6 months to start ART since referral by a CHiP.  
The above description outlines how cases were selected, but the same process was undertaken for 
controls, simultaneously. When CHiPs approached non-acceptors for study participation, they may 
on that occasion have re-referred participants who had not yet started treatment – for service 
delivery purposes and in keeping with their ethical duty to clients. Even if an individual now went on 
to start ART, his/her ART` initiation status at the time of random selection was used to define case vs 
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control status.  In addition, the research team were kept blind to the ART status of potential 
participants when they approached them for informed consent.   
2.2.6.2 Selection of controls 
The purpose of having controls in this study was to have a representative sample of individuals who 
achieved TLA for comparison with those who did not.  
Controls in Case-control study 2 were defined as a subset of individuals who linked-to-care and 
initiated ART within 6 months of HIV test positive status being recorded in the CHiP electronic 
register in Arm A, after a year of the PopART intervention. 
The inclusion and exclusion criteria were the same as for cases. The controls for Case-control study 2 
were selected through a similar process as described for the cases, simultaneously with the case 
selection process and beginning with the approach by CHiPs of a random subset of individuals who 
linked-to-care and initiated ART within 6 months, aiming for inclusion in the study of ~60 controls 
per community. The ratio of cases to controls was to be approximately 1:1, and among each of cases 
and controls the ratio of men to women would be approximately 1:1 because the random sample 
would be selected stratified on gender, and they would be frequency matched on the communities 
in which they resided.  All the ratios would be approximate dependent on what proportion of the N 
initially selected eventually accepted study participation among cases vs controls, men vs women 
and by community, with the goal of achieving the required total number in the study of ~400 cases 
and ~400 controls as guided by the sample size estimates. 
2.2.7 CC2 Study questionnaire 
Research assistants conducted participant interviews for Case-control study 2 at approximately the 
end of the first annual round. Standardised questionnaires which explored potential factors which 
may be associated with achieving/not achieving TLA (Figure 2.4) were administered by the RAs. 
Written informed consent was obtained and questionnaires administered during an interview lasting 
1-1.5 hour total duration, at the household or a preferred location of the participant. Shown in 
Appendix 5 is the Information sheet and informed consent form for South Africa (with an alternative 
country-specific version used for Zambia) and Appendix 6 displays the CC1 study questionnaire. Data 
were captured using electronic capture devices.  
2.3. Recruitment, training and field preparation for case-control studies 
Prior to the launch of the CC studies new staff were recruited. One team per community were 
recruited. A team consisted of two RAs, one woman and one man if possible, who spoke the most 
prevalent language of the community they worked in or so that each RA spoke one local language 
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each (e.g. in some South African communities it was important that there was one Xhosa and one 
Afrikaans speaking RA). All RAs were also fluent in written and spoken English which was the 
language of the questionnaires. In addition to the RAs, a study manager was appointed in each 
country (from existing staff in SA and newly recruited in Zambia) to monitor the quality of day to day 
study progress, liaise with other colleagues in-country (e.g. CHiP teams, senior supervisory staff, data 
management colleagues etc.) and to provide feedback to the in-country PI and to me as study PI. 
Immediately prior to launch of the respective study in each country, trainings for the RAs were 
conducted which involved providing background for questionnaire themes, role-play and practice in 
administering questionnaires, and training on the use of electronic devices. Pilots were carried out 
with volunteer community members and minor changes made to the questionnaire / programming 
of electronic device, as needed. All staff underwent Good Clinical Practice and Human Subjects 
Protection training in line with the respective country’s requirements. 
The CHiPs teams in all Arm A and Arm B communities where the studies were to be conducted were 
also visited by the in-country CC study manger and me as study PI. The CC studies were introduced 
and CHiPs’ role in requesting permission from their clients for contact details to be shared with the 
CC RAs was described. 
2.4. Data management of case-control studies 
2.4.1 Routine data management 
All data about participants from both CC1 and CC2 were stored after removing identifying 
information so that data could not be readily traced back to individual community members. In-
country data management was done in each respective country by local data managers. Data were 
sent to me as the study PI at regular intervals for monitoring and feedback to in-country research 
teams. 
2.4.2 Data irregularities in South African CC1 data 
During routine data monitoring I noted irregularities in the data which led to internal investigations 
being carried out in cooperation with the in-country study team. The findings indicated strong 
evidence of data fabrication in two communities (19 and 16) and limited evidence of data fabrication 
in one further community (14) - in South Africa. There was no clear evidence of data fabrication in 
the three remaining communities (13, 18 and 20) in South Africa, or in Zambia. These findings were 
supported by subsequent external investigations. Corrective and preventive actions were instituted, 
relating to human resource management, field work implementation and management including re-
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training on research integrity. The study team formulated a plan to verify data and retain data that 
could be verified. 
In summary, the CC1 Data Verification plan was to discard all data from Community 19 in South 
Africa and to omit this community from the study (due to the scale of data fabrication there). In the 
other five communities, we carried out a rigorous verification exercise for each participant and 
retained data if the identity of the participant and the responses provided in the study were verified.  
The CC1 Data Verification plan was approved by both the South African and LSHTM ethics 
committees and the process was undertaken in early March 2016. Shown in Appendix 5-8 are the 
key reports relating to this adverse event and the Data Verification plan.1 
2.5. Sample size calculations for case-control studies 
An iterative process was undertaken to achieve an estimate of the most appropriate sample size 
required to provide balance between adequate power to detect meaningful differences between 
cases and controls (for any given prevalence of a given exposure in the population) and feasibility of 
conducting the study.  For example, to examine whether a characteristic which had an approximate 
prevalence of 10% among controls and an odds ratio of 2.25 when comparing the odds of exposure 
in cases and controls, a sample size of approximately 200 was required to have 80% power (with a 
5% significance level and 1:1 case: control ratio). However, an odds ratio as high as 2.25 may not be 
present for many exposures and more subtle differences between cases and controls was allowed 
for. If an odds ratio of 1.7 was assumed instead (with 10% prevalence of an exposure among 
controls), then in order to achieve 80% power almost 600 cases and controls would be required. 
However, with the same odds ratio (OR: 1.7), same study power (80%) and prevalence of 20% 
among the controls instead, 300 cases and controls would be required.  
Shown in the table below are assumptions for a sample size of 400 cases and 400 controls 
(approximately 30 cases and 30 controls per community, in the 14 communities of Arms A and B for 
Case-control study 1; and 60 cases and 60 controls per community in the 7 communities of Arm A for 
Case-control study 2). This sample size was appropriate to adequately balance power, importance (in 
relation to prevalence of an exposure among the controls) and feasibility.   
                                                          
1 Due to the length of the reports these are inserted as hyperlinks which are available digitally only. 
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Table 2.1 Study power with sample size of 400 cases and controls for a range of exposure 
prevalence and odds ratio estimates  
Prevalence of exposure in 
controls 
Odds ratio for not accepting testing or starting 
treatment (depending on the study), comparing 
individuals with an exposure to those without  
Power (%) 
10% 1.75 71% 
15% 1.75 85% 
20% 1.75 91% 
10% 2.0 90% 
15% 2.0 97% 
20% 2.0 99% 
 
Assuming that the percentage of controls exposed to a particular risk factor was 10%, or 15%, or 
20%, and that the odds ratio comparing exposed with unexposed individuals was 1.75, the 
corresponding study power to show an effect of the risk factor was 71%, 85%, and 91% respectively. 
With an odds ratio of 2, the corresponding figures for study power were 90%, 97%, and 99% 
respectively. When the proportion of controls exposed to a particular risk factor was 15% or more, 
the sample size was sufficient for stratified analyses, such as separate analyses by trial arm or 
country. When examining associations for men and women separately with 200 cases and 200 
controls for each gender, if 15% and 20% of controls respectively were exposed to the risk factor, 
study power was 75% and 83% respectively, if the odds ratio comparing exposed with unexposed 
individuals was 2. 
2.6. Data exploration and statistical analysis  
2.6.1 Exploring the study population 
The first step in understanding the study population was to explore the distribution of characteristics 
in the data-set – starting with the age, gender and other basic demographics and going on to 
tabulate all the variables to see the proportions in the study population with various characteristics. 
Variables were categorised as needed – based on what was logical e.g. grouping “strongly agree” 
with “agree” where numbers were too few to allow separate analysis or according to the 
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distribution of the data so that there were approximately equal proportions in each category. Note 
that the categories were created independently of case/control status. 
This was followed by cross-tabulation of the variables (in above categories if relevant) with 
case/control status to provide understanding of the distribution of the variables by case/control 
status. The cross-tabulations were also performed stratified by country and by gender to add to 
understanding of the study population.  
 2.6.2 Logistic regression analysis 
Stata 14 was used to perform logistic regression modelling to estimate odd ratios of the association 
between exposure variables and uptake of testing / TLA for CC1 and CC2, respectively. As the 
controls were frequency matched to cases by community and gender, all models included (and thus 
controlled for) community and gender. The estimated odds ratios adjusted for community and 
gender for each exposure of interest separately were examined (univariable analysis). Variables 
which were about demographic and behavioural characteristics were considered fundamental 
features which may have a confounding effect on associations with other variables and considered 
for addition to a multivariable model, while those which represented participant views or opinions 
were not. Variables which showed statistical evidence of association with case/control status on a 
Likelihood ratio test (p ≤ 0.05) were examined to consider adding them to a multivariable logistic 
regression model. Age was added as an a-priori potential confounding factor. 
Each variable (demographic or behavioural characteristic) which had statistical evidence of an 
association with case/control status was added along with age category, to the “crude” models (with 
community and gender included). A multivariable logistic regression model was then constructed, 
including all the variables (demographic or behavioural characteristics) with statistical evidence of 
association with case/control status (i.e. after adjustment for age, community and gender), to 
examine the adjusted odds ratios of each exposure variable in the study. 
As mentioned above, Likelihood ratio testing (LRT) was done - comparing two models with and 
without a given exposure variable to examine the statistical evidence for association between the 
exposure variable and case/control status. A p-value of ≤ 0.05 was chosen as the threshold for 
evidence of association. Statistical evidence for effect medication of associations by gender and 
country were also explored using LRTs for variables which may have plausibly differed in association 
with the outcome, by gender or country, respectively. Models with interaction terms of a given 
exposure variable and gender or country as appropriate, were compared with models without 
interaction terms. A p-value of ˂0.05 was chosen as the threshold for evidence of interaction. 
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For variables with 3 or more response categories which had a possibility of a dose-response 
relationship, tests for trends were performed.  
2.7. Safety monitoring and social harm reporting  
2.7.1 Safety monitoring 
Safety issues were not anticipated for these studies.  
2.7.2 Social harm reporting 
The HPTN defines social harms as any untoward social occurrence that happens to a participant as a 
result of their participation in the study, with examples including loss of employment, harassment by 
neighbours, shunned by family, rejection by partner, etc.  Social harms were monitored during Case-
control studies 1 and 2. Research assistants were trained to identify and report any direct negative 
social consequences of participation in the studies. If the study management team judged an 
individual social harm to be serious or unexpected, they would have worked together with 
appropriate bodies (in-country investigator, community advisory board, sponsor, IRB, etc.) to 
determine if a response was indicated, and if so, what it should have been.   
2.8. Human subjects and ethical considerations 
2.8.1 Risk-benefit assessment 
As described above, only individuals who gave permission for approach by RAs had their information 
passed on to the RAs, by the CHiPs who obtained verbal assent for this. This information included 
the individual’s name, gender, age and address - to facilitate approach of the client by a study RA. No 
information about HB-HTC acceptance/ non-acceptance or any details gathered during the CHiP 
intervention were conveyed for Case-control study 1. In Case-control study 2, no information about 
whether TLA was achieved by a given participant was given to RAs. We did however have to include 
the fact that the client was PLWH and was referred for TLA. Community members were explicitly 
informed of this by the CHiPs, when they asked for verbal permission. 
Written informed consent was obtained by RAs before questionnaires were administered. The 
importance of confidentiality and sensitivity in administering the questionnaires were of highest 
priority in training and study preparation. All analyses were conducted after identifying information 
was removed from the data, and data were not traceable to individual participants. Provided these 
precautions were adhered to there were no major risks anticipated with participating in these 
studies. 
The direct benefit from study participation were relatively minor, but consenting individuals did 
benefit from representing their communities and providing feedback about the PopART testing and 
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treatment intervention. There will be community-level benefits from the research – both to 
communities from which research participants originate and beyond. All research findings 
(aggregated and anonymised) will be shared with local and national health authorities to enhance 
understanding of barriers and facilitators of service uptake and where relevant to contribute 
towards improvements in service provision. 
Participants were not paid or compensated for participation as there were concerns that it could 
bias the study sample or responses given. PopART leadership were also reluctant to set a precedent 
which required incentivisation for research participation. 
2.8.2 Ethical review 
The studies were approved by the relevant in-country and international ethical review boards (ethics 
committees of the University of Zambia, Stellenbosch University and the London School of Hygiene 
and Tropical Medicine), as part of the main PopART trial. The following study materials were 
submitted to the necessary ethics and regulatory authorities prior to study commencement: 
i. Study Protocol Summary Document 
ii. Verbal Permission Request Sheet (for use by CHiPs) 
iii. Study Information and Informed Consent Form (for use by study RAs) 
2.9 Funding   
The funding for these studies is included in the main PopART / HPTN 071 trial budget1 and no 
additional costs were incurred. 
2.10 Timeline 
The PopART trial commenced in some communities in Zambia in November 2013, but got underway 
in earnest in January 2014; while in South Africa some activities began in January and full roll-out in 
all communities was achieved in March 2014. After completion of the annual round, CC1 started in 
Zambia in February 2015 and in April in South Africa. CC2 commenced after an additional 6 months 
to allow for all those referred at the end of the annual round to link-to-care and initiate ART. In 
addition, as the same field RAs who were conducting CC1 were also responsible for CC2, the former 
study had to be completed before CC2 was able to finally start in October 2015. All CC study 
                                                          
1 HPTN 071 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) under 
Cooperative Agreements UM1-AI068619, UM1-AI068617, and UM1-AI068613, with funding from the 
U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Additional funding is provided through 
NIAID, the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), 
and the International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda 
Gates Foundation.  
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activities were completed by mid-2016 (including the additional activities involving data verification 
in South Africa related to the data fabrication issue). 
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Chapter 3: Home-based voluntary HIV testing in sub-Saharan Africa: a 
systematic review and meta-analysis 
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Outline of chapter 
To contribute to the wider aim of the PhD to evaluate the factors associated with uptake of the key 
steps in the cascade of care provided by the PopART trial, a detailed understanding of the 
acceptability of HB-HTC was sought. A systematic review and meta-analysis of evidence was 
conducted. As this was carried out at the start of the PhD in 2012, the data examined were largely 
from the decade prior. At the time of writing this thesis document, more has been published on HB-
HTC but conclusions about the acceptability of HB-HTC have not changed. As such, it was not 
considered productive for this systematic review to be updated. The study was published in PLoS 
Medicine and the manuscript is presented below. 
Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N (2012) Uptake of Home-Based Voluntary HIV 
Testing in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. PLoS Med 9(12): e1001351. 
https://doi.org/10.1371/journal.pmed.1001351 
3.1 Abstract 
Introduction: Improving access to HIV testing is recognized as a key priority in scaling up HIV 
treatment and prevention services. Home-based testing (HBT) as an approach to delivering wide-
scale HIV testing is explored in this study.  
Methods and Findings:  A systematic review and random effects meta-analysis of published studies 
reporting on uptake of HBT in sub-Saharan Africa since 2000 were conducted to assess the 
proportion of individuals accepting HBT and receiving their test result. Three electronic databases 
were searched. 
Our initial search yielded 1199 articles, 114 were reviewed as full-text articles and 19 publications 
involving 21 studies (N=524,787 offered HBT) were included for final review. The studies came from 
5 countries: Uganda, Malawi, Kenya, South Africa and Zambia.  
The proportion of people who accepted HBT (N=474,516) ranged from 58.1% to 100%, with a pooled 
proportion of 83.8% (95%CI: 80.9-86.6%). Heterogeneity was high (20.13). Sixteen studies reported 
on the number of people who received the result of HBT (N=432,835). The proportion of individuals 
receiving their results out of all those offered testing ranged from 24.9% to 99.7% with a pooled 
proportion of 77.4% (95%CI:74.0-80.7%), (2 0.12).  HIV prevalence ranged from 2.9%-36.5%. New 
diagnosis of HIV following HBT ranged from 40-79% of those testing positive. Forty-eight percent of 
those offered testing were men and they were just as likely to accept HBT as women (pooled odds 
ratio 0.84 (95%CI: 0.56-1.26) (20.33). The proportion of individuals previously tested for HIV among 
those offered a test ranged from 5-66%. 
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No evidence was reported of negative consequences of HBT.  
Conclusion: Home based voluntary counselling and testing has the potential to dramatically increase 
awareness of HIV status in previously undiagnosed men and women in sub-Saharan Africa. HBT is a 
gateway to accessing care early and the benefits for individual and public health, both for treatment 
and prevention, make it an invaluable tool in the fight against HIV. 
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3.2 Introduction 
Testing for HIV is the first step in the cascade of care for HIV-positive individuals who need 
treatment. Knowledge of HIV status is also an important part of HIV prevention, for both HIV-
negative and HIV-positive individuals, and innovative means to increase uptake of testing has 
recently been identified as an international policy priority (1-4).  Despite some progress, knowledge 
of HIV status remains low in sub-Saharan Africa (SSA) where HIV prevalence is highest(5). National 
population surveys in six sub-Saharan African countries found that amongst participants living with 
HIV there was a wide range in respondents’ awareness of their status (from 30% in Kenya to 70% in 
Congo)(5). Men were less aware of their status than women (in countries with available data)(5). 
Home-based voluntary counselling and testing (HBT) has recently been suggested as an effective 
way to identify HIV-infected people earlier in the stage of their disease and so enrol people into care 
and treatment in a timely manner(6, 7).  However, there is uncertainty about HBT and concern that 
it may be poorly accepted or even harmful, partly owing to the enduring climate of stigma and 
discrimination around HIV/AIDS in many settings (8, 9). 
We carried out a systematic review and meta-analysis of the available evidence for acceptability of 
HBT in SSA, and assessed a number of potential determinants of uptake and programme success.  
3.3 Methods 
We conducted this systematic review and meta-analysis according to the criteria set out by the 
Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group(10) and devised a pre-
defined search protocol. The specific objectives of the study were to summarise the following 
proportions: “accepted” (or uptake), defined as accepted and had HIV test performed at home as a 
proportion of all individuals offered HBT; “received”, defined as obtained result of home-based HIV 
test as a proportion of all individuals who accepted; and “overall” defined as the proportion of 
patients who received a test result among all those offered VCT (including refusals). We also planned 
sub-group analyses as outlined below.  
Search strategy 
We aimed to summarize studies that described uptake of HIV testing provided at home in SSA. We 
screened studies published between January 2000 (the onset of programmes providing antiretroviral 
therapy in SSA) and 31st March 2012. The following study designs were permitted: randomised 
controlled trials, observational cohort studies, cross-sectional surveys, and programme evaluations. 
Any study that described an intervention to provide HIV testing at home and reported proportions 
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accepting HIV testing out of all individuals offered a home based HIV test was included. Where 
acceptance of testing was reported, it was assumed that testing was performed unless stated 
otherwise.   
To avoid duplication we excluded reports that pooled data from previously published studies, and 
where there was substantial overlap of study subjects we included the study with the most complete 
information. No language or age restriction was applied. To identify studies for this systematic 
review we searched Pubmed, Embase and Global Health electronic databases and manually 
searched the bibliographies of relevant articles. We only included peer-reviewed journal articles; 
conference abstracts were excluded. Anticipating overlap between studies reporting HBT and other 
community-based strategies, we developed a broad compound search strategy that combined terms 
for “HIV” and “voluntary counselling and testing”; “home based”, “mobile”, “community”, 
“workplace”, “couples” and “self”. We then combined these terms with individual names of 
countries in SSA (Supporting Information 3.1). Finally, we excluded all studies that did not report 
home-based delivery of HIV testing. 
Eligibility of abstracts and journal articles was determined by one investigator (KS) and verified by a 
second researcher (RVdB). Two investigators (KS, RVdB) then independently extracted data on study 
characteristics and outcomes using a standardised form. Any disagreements regarding eligibility or 
outcome data were verified by a third investigator (NF). The rigour of study processes and research 
methods was examined using pre-defined criteria but studies were not excluded for quality reasons.  
Data synthesis and analysis 
We calculated the proportion of people who accepted HIV testing at home and  the proportion who 
received their test result, out of those i) who were offered and ii) who accepted testing. The variance 
of raw proportions was stabilised using a Freeman-Tukey type arcsine square-root transformation 
and proportions were then pooled using a DerSimonian-Laird random-effects model (11-13). Pooled 
odds ratios were calculated for proportions stratified by gender using the same method. We report 
the I2 statistic to assess the proportion of variability due to between-study heterogeneity (but this 
estimate is known to increase as the number of subjects contributing to the meta-analysis 
increases(13)).  We therefore also report 2 as a measure of between-study variance (reported on 
the arcsine square-root scale). We explored potential sources of heterogeneity through univariate 
subgroup analysis to determine the potential influence of the following covariates: HIV prevalence 
(<10% vs ≥10%), study period (<2005 vs ≥2005), incentives provided, sensitization campaigns done, 
and study setting (urban vs rural). We further explored the potential influence of type of test (point-
of-care testing with immediate result and whether oral specimens were used).  Finally, subgroup 
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analyses were done to assess the potential influence of the proportion of individuals in the study 
who had previously tested (arbitrarily divided into 2 categories, <30% vs ≥30%), and targeted HBT of 
household members of index HIV-positive individuals. All analyses were conducted using Stata 
version 12.0 (Stata Corp, College station, Texas).  
3.4 Results 
Characteristics of included studies 
Our initial search yielded 1199 articles, of which 114 were reviewed as full-text articles and 19 were 
included in the final review (Figure 3.1) after excluding four studies with clearly overlapping study 
populations(14-17). Two publications presented data of 2 sub-studies: the first article included data 
from two surveys done in two separate time periods(18); the second article reported different sub-
sets of individuals (residents and migrants)(19).  As such, we present data and results of analyses 
based on these 21 studies from the 19 articles. The studies were from 5 countries:  Uganda(20-27), 
Malawi(18, 28-31), Kenya(32, 33), South Africa(19, 34) and Zambia(35), and carried out between 
1999 and 2010. Most studies focused on adults (defined variously as aged ≥18years or, more 
commonly ≥15years) while 7 studies also included children(20, 22, 24, 25, 27, 32, 34). Regional HIV 
prevalence (reported by the authors for the study areas or obtained from UNAIDS contemporaneous 
national data) ranged from 4.4-22% (Table-1).  
Testing was generally provided by counsellors; one study included laboratory assistants in the 
testing teams (24) and two utilised nurses (23,34). One study employed self-testing with counsellor 
supervision(28). HIV prevalence amongst those tested ranged from 2.9% to 36.5%. One study 
reported giving advice for repeat testing after 3 months to people testing HIV negative(18). Two 
other studies reported HIV prevention counselling for negative individuals (23,32). Ten studies 
reported some means of linkage to care, mostly advising HIV-positive patients to seek care at the 
nearest health facility(18, 20, 22-24, 28, 31-33, 36).  One study presented data on the proportion of 
individuals linked into care upon testing HIV-positive, with 97 %( N=11,033) initiated on co-
trimoxazole prophylaxis (24).  Two studies presented information on the clinical condition of 
individuals found to be HIV-positive (22,24). Following HBT a higher proportion of HIV-positive 
individuals had CD4 counts above treatment initiation thresholds (>200 cells/mm3) than below 
(22,24). 
Table-2 summarises the factors that potentially influence the rigour of the studies and shows that 
there was wide variation in standards of implementation and research.  
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Proportion of individuals accepting testing and receiving results 
A total of 524,787 people were offered HBT across the 21 studies which ranged in size from 216(28) 
to 282,857(24) people. Twelve studies disaggregated data by gender with 180,942 men and 198,042 
women, offered testing overall (19-25,28-3035). The proportion of men who were offered testing (in 
the studies which reported on gender) ranged from 26% to 49%, with an overall proportion of 48%.  
Across all 21 studies the proportion of people who accepted HBT ranged from 58.1%(95%CI:57.5-
58.8%) to 100%(95%CI:100-100%) , with a pooled proportion of 83.8%(95%CI:80.9 -86.6%) accepting 
to be tested (N=474,516) (Figure 3.2). Heterogeneity was high (20.13).  Overall, men were just as 
likely as women to accept testing: 78.5% (95%CI 78.3-78.7%) of men (N=140,459) and 82.4% (95%CI 
82.3-82.5%) of women (N=163,238). The pooled odds ratio of men accepting HBT was 0.84 (95%CI: 
0.56–1.26%) that of women (2 0.33). Studies which offered targeted HBT to household members of 
index HIV-positive individuals achieved higher proportions of acceptance than the other studies: 
96.0% (95%CI:92.2-99.8%) vs 81.7% (95%CI:77.9-85.4%) (p<0.001).  
Sixteen studies reported on the number of people who received the result of HBT (N=432,835)(18, 
20-24, 26-30, 32, 33, 35, 36). The proportion receiving a result out of those who accepted testing 
ranged from 36.8% (95%CI:33.9-39.7%) (26) to 100% (95%CI:100-100%) (32) with a pooled 
proportion of 99.1% (95%CI:98.9-99.1%) receiving their result (2 0.12) (Supplementary Figure 3.1). 
The proportion of individuals receiving their results overall (out of all those offered testing) ranged 
from 24.9% (95%CI: 22.8-27.1%) to 99.7% (95%CI: 99.7-99.8%) with a pooled proportion of 77.4% 
(95%CI: 74.0-80.7%) (2 0.12) (Figure 3.3).  
Eleven studies (N=456,283) reported on the number of individuals offered testing who had already 
been previously tested (N=78,527)(18, 21-25, 28-30, 32, 36); 3 studies reported on the number 
tested within the last 12 months(18, 23, 26). However, authors did not report the definition of 
‘previously tested’ and whether it included all those who had had a test or was limited to those who 
received their result and became aware of their HIV status. The proportion of individuals previously 
tested ranged from 5-66% overall (11 studies); 22-50% were previously tested within the last 12 
months (3 studies). Studies in which <30% of people had previously been tested (5 studies, 
N=436,618) (22, 24, 25, 29, 32) were more likely to report a higher frequency of test acceptance 
compared to studies in which ≥30% of people had been previously tested (6 studies, N=19665)(18, 
21, 23, 28, 30, 36) (92.1%(95%CI:87.6-96.7%) vs 83.8%(95% CI 77.7-89.9%), p=0.03).  
One study (Kimaiyo et al) explicitly reported excluding individuals already known to be HIV-positive 
(32).  Angotti et al reported that 68%(11/72) of known HIV-positive individuals accepted HBT vs 
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90%(1430/1588) amongst individuals who were HIV-negative when they previously tested(18). 
Choko et al invited participants to partake in oral self-testing even if they knew they were HIV-
positive(28) (19/175 who had previously tested). Amongst individuals previously tested for HIV who 
accepted HBT in the study by Matovu et al 10% (N=350/3362) were already known to be sero-
positive. Of those testing HIV-positive through HBT, 40-79% had not previously been diagnosed (5 
studies)(14, 23, 25, 28, 32) (the information for the study by Matovu et al was obtained from a 
second publication in 2005(14)). 
Supplementary Table-1 summarises the individual level factors associated with uptake of testing and 
shows a wide variation in findings across the studies which reported on this(20, 21, 23, 24, 29, 30). 
Potential harm and cost considerations 
Eight of the articles we examined acknowledged the potential for harm from testing for HIV(20, 22, 
24, 26, 27, 30, 33, 34) and none reported any. Four of these described no adverse events and 
suggested that HBT could serve to normalise HIV testing by its uniform and non-discriminatory 
deployment regardless of risk factors or health status(20, 22, 24, 26). Wolff et al presented 
qualitative research findings that fear of stigmatisation and emotional vulnerability associated with 
receiving results from public facilities were the most common explanations for the relative 
popularity  of HBT(26). A further three articles noted that concerns about stigma and fears about 
confidentiality could account for non-participation in HBT (30,3334); uptake in these studies was 71-
98%. Another study commented that confidentiality may be enhanced with HBT(27). Two studies 
(both from Uganda) reported on the costs of HBT and demonstrated that the cost of testing per 
client was less than $9USD (22,24).  
Heterogeneity 
Statistical heterogeneity as measured by I2 was high. However, over three quarters of the studies 
(16/21 studies; N=483,472) reported an acceptance rate above 75%. Subgroup analyses to examine 
heterogeneity did not find any differences in HBT uptake and receipt of results according to study 
period, study setting, or whether or not sensitization campaigns were reported as being done (Figure 
3.4). The provision of incentives appeared to result in higher test uptake and immediate provision of 
results increased the frequency of receiving the test result. Studies in which <30% of individuals had 
been previously tested or those in sites where local HIV prevalence was <10% also had higher uptake 
of testing (Figure 3.4).There was also a tendency towards a greater frequency of test acceptance 
when immediate provision of results was available (87.6% (95%CI: 83.8-91.3%) vs 79.2% (95%CI: 
70.9-87.8%), p=0.07). 
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3.5 Discussion 
This systematic review and meta-analysis of 19 papers based on 21 studies of HBT across 5 countries 
in SSA demonstrates that voluntary counselling and testing for HIV at home is highly acceptable with 
an average 84% of people accepting testing and 99% of those accepting testing receiving their result. 
Over three quarters of everyone who was offered a test accepted to be tested and received their 
result (77% in 16 studies reporting on this). The proportion of previously undiagnosed HIV was high 
(40-79% of those diagnosed HIV-positive), emphasising the value of HBT. 
A study from Malawi of clinic based HIV counselling and testing showed that just 13.3% of 18,021 
clinic attendances (8.5% amongst men) included HIV counselling and testing. This meta-analysis 
indicates that HBT is an important addition to other approaches such as stand-alone testing, 
community and work-place testing, as well as provider initiated testing that could dramatically 
improve awareness of HIV status in SSA.  
Delayed presentation for HIV treatment services is recognised as an important cause of morbidity 
and mortality from HIV despite major progress in increasing access to antiretrovirals (37). Both 
studies which reported on clinical status of patients diagnosed HIV-positive upon HBT, found that a 
higher proportion of them had CD4 counts above treatment initiation thresholds (for the study 
period) than below this threshold. This has implications for earlier treatment and better prognosis 
(7,38), as well as higher impact for treatment as prevention endeavours (39,40). A recent pilot study 
in South Africa found a reduction in mean community viral load six months after the introduction of 
a HBT campaign(41). 
While women are disproportionately affected by HIV in SSA(5), men have long been known to 
under-utilise HIV services and present later for care than women, and consequently have worse 
outcomes on treatment(42-44). In the studies reviewed here, an overall proportion of 48% of those 
offered testing were men. This compares favourably with facility-based testing where testing of 
males attending the clinic may be as low as 9%(44). In our meta-analysis of HBT men were just as 
likely as women to be offered a test, and to accept testing, giving promise to greatly improving 
awareness of HIV status for both sexes. Studies which provided results at a distant site even if 
testing was conducted at home were associated with lower proportions of people receiving results 
out of those who accepted testing, emphasising the benefits of HBT including immediate result 
provision in raising awareness of HIV status. 
While the results of subgroup analyses need to be interpreted with caution, they suggest that the 
running of pre-test sensitization campaigns may be of little benefit in terms of uptake of HBT. 
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However, these are essentially “ecological” comparisons which may be confounded by many other 
differences between the study populations examined. Also, the number of studies where incentives 
were given was very small (Table 1), and strong conclusions cannot be drawn. Nevertheless, the fact 
that most of the studies demonstrated similar proportions of uptake of HBT perhaps argues against 
a strong effect. The finding that studies with a lower proportion of individuals previously tested for 
HIV (<30%) had a higher frequency of test uptake points to the value of HBT as an effective approach 
to engage those not previously aware of their HIV status in testing. Targeted HBT of index HIV-
positive clients’ household members may be an effective way to achieve higher acceptance in 
settings where more general HBT is not feasible. 
 Uptake of HBT may be influenced by availability of treatment, as indicated by the fact that the study 
with the lowest overall success (only 25% of people offered a test received their result) was done at 
a time when antiretroviral treatment was not available in the communities studied(26) (although 
overall there was no effect of “study period”). However, there may be other confounding factors 
involved and this study was based on a small sample size; in sensitivity analysis, excluding it from the 
analysis did not change the overall result (data not shown). Three other studies were notable for 
having <70% receipt of results amongst those who accepted HBT (Supplementary Figure 3.1). Two of 
these studies did not provide immediate result after testing (18,21), while the third (20) offered the 
option of receiving results later.  
Human rights protections should be an integral part of any testing campaign and every effort should 
be made to avoid physical, social and psychological harm to individuals (8,9). However, the high level 
of uptake we have found overall seems to indicate acceptability of HBT in the communities studied. 
There are several strengths and limitations to this review. We used a broad search strategy that 
allowed us to capture a relatively large number of studies, resulting in a large overall sample size and 
giving increased confidence in the pooled estimates. There was high statistical heterogeneity, as 
expected for pooled proportions in observational studies. We limited our search to studies 
conducted in SSA over the last decade in order to improve comparability, and used a random-effects 
model to pool data. We undertook a number of sensitivity and subgroup analyses to explore 
potential sources of heterogeneity. Another limitation was that, as a trade-off to using a broad 
search strategy, our search was limited to just 3 databases, and published articles in peer-reviewed 
journals. We therefore cannot rule out the possibility that we may have missed some studies, or the 
possibility of publication bias leading to the non-publication of studies with lower uptake.  
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Our findings indicate a number of directions for future research. In particular, the suggestion that 
the conduct of sensitization campaigns have little or no impact on uptake of HBT and receipt of 
results has important implications for programme cost and efficiency, and deserves further 
evaluation. Other key areas for further research include linkage to care following HBT and repeated 
HBT for ongoing knowledge of HIV status. Sustainability and cost considerations (short and long-
term) are important to help guide policy and further work on cost-effectiveness is required. 
In conclusion, home based voluntary counselling and testing has the potential to dramatically 
increase awareness of HIV status in previously undiagnosed men and women in sub-Saharan Africa. 
HBT is a gateway to accessing care early and the benefits for individual and public health, both for 
treatment and prevention, make it an invaluable tool in the fight against HIV. 
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Table 3.1: Characteristics of included studies 
 
Author, 
Publication 
Year 
Country, 
setting 
Period 
of study 
N 
offered 
testing 
Purpose of 
study 
HIV 
prevalencea 
Age 
eligibity of 
participants 
Testing 
provider 
Community 
sensitization 
described 
Incentives 
provided 
Sampling method 
and tests used 
Previously 
tested %  
Angotti (1), 
 2009 
Malawi,  
3 rural 
districts 2004 3659 
Longitudinal HIV 
prevalence 
study 4.4-7.9% 15-49y 
Locally 
trained VCT 
counselors Yes No 
Oral swab 
(Orasure)(2004)                                
Not 
specified 
Angotti (2), 
 2009 As above 2006 3459 As above As above As above As above As above As above 
FP RDTsb 
(Determine & 
UniGold) (2006) 66%  
Choko, 
 2011 
Malawi,  
urban 
district 2010 216 
Feasibility of 
(supervised) oral 
self testing 11% 22-32y 
Self 
administered 
(supervision 
from VCT 
counselor) No No 
Oral swab 
(Oraquick) 
followed by FP 
RDTs (Determine 
and UniGold) 63% 
Helleringer, 
2009 
Malawi, 
rural 
district  2006 751 Uptake of HBT 11% 18-35y 
Trained 
health 
counsellors Yes 
Yes  
Bar of soap 
FP RDTs 
 (Determine and 
UniGold) 21% 
Kimaiyo, 
 2010 
Kenya, 
2 rural 
districts 2007-9 101167 
Feasibility and 
acceptability of 
HBT 6.3% 
>13y and 
eligible 
childrenc 
Counsellors 
trained for 
purpose Yes No 
FP RDTs 
 (Determine and 
Bioline) 26%d 
Kranzer, 
 2008 
Malawi, 
rural 
district 2005-6 2047 
Factors 
associated with 
HBT refusal 11.4% 18-59y 
Trained local 
VCT 
counselors No No 
Venous blood 
sampling for 
ELISAe & particle 
agglutination 
testing in 
laboratory 36% 
Lugada, 
 2010 
Uganda, 
5 rural 
districts 2005-7 4798 
Uptake of HBT 
vs clinic based 
testing in 
household 
members of 
HIV-positive 
index patient 5.6% Any 
Trained lay 
field workers No No 
FP RDTs 
(Determine 
screening, 
Unigold 
confirmation) 
Not 
specified 
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Maheswaran, 
2012 
South 
Africa, rural 
district 2009 1726 
Uptake of HBT 
and community 
mobile HIV 
testing and 
factors 
associated with 
HBT vs mobile 
testing 22% ≥15y 
HIV 
Counsellors No No Not specifiedf 40%   
Matovu, 
 2002 
Uganda, 
rural 
district 
1999-
2000 11709 
Uptake of HBT 
and effects on 
sexual risk 
behavior and 
HIV acquisition 5.6% 15-49y Counsellors No No 
Venous blood 
sampling for 
ELISA(x2) testing 
in laboratory  
 
55%  
Menzies, 
 2009 
Uganda, 
setting not 
specified 2003-5 49470 
Comparison of 4 
testing 
approaches: 
door-to-door 
HBT, household 
member HBT (of  
index patient) – 
please clarify 
wording for this 
one, stand 
alone, hospital 
based VCT 5.6% Any Not specified Yes No 
FP RDTs 
(screening test 
followed by 
confirmation if 
HIV-positive; 
tests not 
specified) 10% 
Michelo, 
 2006 
Zambia, 
one rural, 
one urban 
district 2003 5445 
HIV prevalence 
survey 20.4% 15-59y Not specified No No 
Bionor saliva test 
+ “serum test” for 
saliva positive or 
second saliva test 
Not 
specified 
Molesworth, 
2010 
Malawi, 
rural 
district 2007-8 16894 
To assess the 
performance of 
HIV RDTs in a 
HIV prevalence 
survey 11.6% ≥15y 
Non-
laboratory 
basic health 
personnel Yes No 
Venous blood 
sampling for RDTs 
(Determine & 
Unigold in 
parallel pre-May 
2008, serially 
post -May 2008) 
Not 
specified 
Negin, 
 2009 
Kenya,  
rural 
province 2008 2033 
Feasibility, 
acceptability 
and cost of HBT 7.8% 15-49y 
Lay 
counsellors Yes No 
FP RDTs 
 (Determine and 
Bioline) 
Not 
specified 
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Sekandig, 
 2011 
Uganda, 
urban 
district 2009 508 
Uptake of HBT 
and factors 
associated with 
HBT 6.5% ≥15y 
Trained 
nurse 
counsellors No No 
FP RDTs 
(Determine 
screening, 
Statpak 
confirmation) 61% 
Shisana, 
 2004 
South 
Africa, 
nationwide 2002 9963 
HIV prevalence 
survey 26.5% ≥2y Nurses No 
Yes 
Money 
provided to 
head of 
household 
FP onto filter 
paper; ELISA (x2) 
testing in 
laboratory  
Not 
specified 
Tumwesigye, 
2010 
Uganda, 
rural 
district 2004-7 282857 
Acceptability 
and uptake of 
HBT 5.4% 
>14y & 
eligibleh 
children 
>18m 
Counsellor 
and 
laboratory 
assistant 
teams Yes 
Yes 
HIV-positive 
provided with 
condoms, 
insecticide 
treated 
bednets & 
home water 
treatment 
equipment 
FP RDTs 
(Determine 
screening, 
Statpak 
confirmation) 9% 
Welz (1), 
 2007 
South 
Africa, 
rural 
district 2003-4 19867 
HIV prevalence 
survey 
(residents) 27.9% 
Women 15-
49y Men 
15-54y 
Trained 
fieldworkers No No 
FP onto filter 
paper; ELISA (x2) 
testing in 
laboratory  
Not 
specified 
Welz (2), 
 2007 As above 
As 
above 916 
HIV prevalence 
survey (subset 
of migrants in 
the community) As above As above As above No No As above 
Not 
specified 
Were, 
2003 
Uganda, 
rural 
district 
Not 
specified 2373 
Uptake of VCT 
HBT 4.1% Any Not specified No No 
Venous sampling, 
tests not 
specified 
Not 
specified 
Were, 
 2006 
Uganda, 
2 rural 2003-4 3338 
Acceptability of 
HBT and HIV 
prevalence 
among 
household 
members of 
HIV-positive 
index patient 4.1% Any Counsellors No No 
FP onto filter 
paper; ELISA (x2) 
testing in 
laboratory; 
For children 
<24m - HIV DNA 
measurement on 
dried blood spot 4.9% 
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Wolffi, 
2005 
Uganda, 
rural (15 
villages) 2001 1591 
Uptake of HIV 
results from HIV 
prevalence 
survey 7.9% ≥15y Counsellors No No 
Venous blood 
sampling for 
ELISA (x2) testing 
in laboratory 
Not 
specified 
a data from study area or UNAIDS national data (adult prevalence) if shown in italics b FP RDT = finger prick rapid diagnostic test c eligible if <13y and mother HIV +ve, mother unknown HIV +ve living status, 
mother dead d 35,815/137,268 encountered in the area e Emzyme Immunosorbent Assays  f Stated only  as following national guidelines for testing g Excluded non-English and non-
Lugandan speakers  h eligible if mother deceased or HIV-positive  i study done in period before antiretrovirals were available  
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Table 3.2:  Assessment of Study Rigour 
 
 Study Process Quality Indicators 
Research Method Quality 
Indicators 
Author,  
Publication 
Year 
Pre-test 
counseling 
donea 
Consent 
provided 
Test offered 
based on 
giving results 
Confirmatory 
laboratory 
testing done  
Discordant 
results 
addresseda 
Repeat 
sampling if 
discordant  
Repeat visits if 
absenteeism 
Specific advice if 
HIV result negative 
Linkage to 
care for HIV 
infected 
Sampling 
strategy 
described 
Selective 
outcome 
reporting 
Angotti, 
2009 Yes Yes Yes No 
Not 
specified No No 
Yes, retest in 3 
months time Yes Yes No 
Choko, 
2011 Yes Yes No No Yes Yes No No Yes Yes No 
Helleringer, 
2009 Yes Yes No No 
Not 
specified Yes Yes No No Yes No 
Kimaiyo,  
2010 Yes Yes Yes No Yes Yes Yes 
Yes, behaviour 
change  &“ABC’s” of 
HIV prevention Yes No No 
Kranzer, 
2008 Yes Yes Yes Yes Yes Yes Yes No No Yes No 
Lugada, 
 2010 Yes Yes Yes No Yes Yes Yes No Yes Yes No 
Maheswaran, 
2012 Yes Yes Yes No 
Not 
specified No No No Yes No No 
Matovu, 
2002 Yes Yes No Yes Yes Yes Yes No No No No 
Menzies, 
2009 Yes Yes Yes Yes 
Not 
specified Yes No No Yes No No 
Michelo, 
2006 Yes Yes Yes Yes Yes Yes No No No Yes No 
Molesworth, 
2010 Yes Yes Yes Yes Yes Yes No No Yes Yes No 
Negin, 
2009 Yes Yes Yes No Yes Yes No No Yes No No 
Sekandi, 
2011 Yes Yes Yes No Yes Yes No 
Yes, HIV prevention 
counseling Yes Yes No 
Shisana, 
2004 
Not 
specified Yes No Yes 
Not 
specified Yes Yes No No Yes No 
Tumwesigye, Yes Yes Yes Yes Yes Yes No No Yes No No 
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2010 
Welz, 
2007 
Not 
specified Yes Yes Yes 
Not 
specified Yes Yes No No Yes No 
Were, 
2003 Yes Yes No No 
Not 
specified No Yes No No No No 
Were, 
2006 
Not 
specified Yes Yes Yes Yes Yes No No No No No 
Wolff, 
2005 
Not 
specified Yes No Yes  Yes Yes No No No Yes No 
a Where no information is available  – ‘not specified’ is indicated for these variables as we considered it possible that these activities were done but not reported in the paper b Some studies offered testing and 
results were not promised eg. available only if client sought the result separately or entirely blinded testing was done for anonymous population HIV prevalence estimation   
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Figure 3.1: Flow diagram of study selection process 
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Figure 3.2: Proportion accepting HBT 
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Figure 3.3: Proportion achieving knowledge of HIV status overall 
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Figure 3.4: Subgroup analyses 
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Supplementary Table 3.1:  Studies reporting predictors of uptake of HBT 
 
Author, Publication year Positive association with HBT uptake Negative association with HBT uptake No statistically significant association (aOR) Comments 
Helleringer,  
2009 
Income bottom quartile;  
Symptomatic STI in last 3m 
Age>25y;  
Having concurrent  partnership at time of HBT 
Gender;  
Marital status; 
 Schooling;  
Religion;  
Residence mainland;  
No. of sexual partners past  3y;  
Ever tested prior to study  
Kranzer,  
2008a 
Female (Odds Ratio not given); 
Never married;  
Farmer profession;  
Older (>45y) head of HHb;  
>7% HIV prevalence in cluster  
Female counsellors approaching male clients;  
Wife of head of HHb man who's not tested OR 
Wife of head of HHb man who's not part of study 
OR head of  HHb is non-husband;   
<1km from main road  Age 
Men less  likely to be 
found at home 
Lugada,  
2010 
Female; 
Age: <14 or >35y when compared with 15-24 
Index HIV-positive client CD4 >200 (compared to 
<50) 
Index client education level;  
No. of persons in HH b  
Matovu,  
2002 
Currently married or 
Divorced/widowed/separated compared to 
never married 
Primary/post primary education compared to no 
education; 
 Prior self-reported VCT or no prior VCT 
compared to prior VCT in the programme;  
HIV +ve vs HIV-ve;  
Condom use  vs no condom use in past  6m 
Age;  
Gender;  
Self-perception of HIV risk;  
No. of sexual partners  
Sekandi, 2011 
Male; 
Age ≥35y compared to 15-24y; 
Previously married; 
Previous HIV testing in last 12m Not Applicable 
Age 25-34y: 
Religion; 
Education level; 
Previous HIV testing > 12m prior  
Tumwesigye, 2010 Female  Not Applicable Not Applicable 
Females  more likely to be 
found at home  
a Study actually reports refusal of HBT  b Household 
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Supplementary Figure 3.1: Proportion receiving result of HBT 
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Supporting Information 3.1: Search terms and Prisma Checklist 
Search terms 31/3/12 
1. HIV 
HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR 
hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immune deficiency 
virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR 
((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR 
acquired immunodeficiency syndrome[tw] OR acquired immunodeficiency syndrome[tw] OR 
acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])) 
OR ”sexually transmitted diseases, viral“[MESH:NoExp] 
2. Home based  
 
Home-based or home based or homebased OR door to door OR door-to-door OR home care services OR homecare services 
OR homecare OR home care OR home-care OR home access OR home OR in-home OR domicile 
 
3. Community 
  
Community OR community based OR community-based OR mobile  
 
4. Work place 
 
Work place OR work-place OR workplace OR work OR occupation* 
 
5. VCT  
 
Voluntary Counselling or voluntary Counselling or voluntary Testing or hiv testing or Vct or hbvct or hct 
 
6. Africa 
sub-Saharan Africa  OR south Africa  OR Africa South of the Sahara OR Lesotho  OR Swaziland  OR 
Namibia  OR Botswana  OR Zimbabwe  OR Mozambique  OR  Malawi  OR Zambia  OR Angola  OR 
Tanzania  OR Rwanda  OR Burundi  OR Democratic republic of Congo  OR Republic of Congo  OR 
Uganda  OR Kenya  OR Ethiopia  OR Somalia  OR Sudan  OR Central African republic  OR Cameroon  
OR Gabon  OR Guinea  OR Chad  OR Nigeria  OR Niger  OR Togo  OR Benin  OR Ghana  OR Burkina 
Faso  OR Cote d'ivoire   OR Ivory coast  OR Liberia  OR sierra Leone  OR Senegal  OR Gambia 
 
7. (1 AND 5) AND (2 OR 3 OR 4)  
8. (1 AND 5) AND (2 OR 3 OR 4) AND 6  
9. Limit 8 to 01/01/2000 to 31/12/2012  
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PRISMA Checklist 
 
  # Checklist item Reported on page # 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. M1 
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number. 
M2 
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known.  M3 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
M3-4 
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
M3-4 
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale. 
M3-4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
M3-4 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated. 
M3-4 
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  # Checklist item Reported on page # 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
M3-4 
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators. 
M3-4 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made. 
M3-4 
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in 
any data synthesis. 
M3-4 
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).  M3-4 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis. 
M3-4 
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).   
M3-4 
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified. 
M4-5 
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram. 
M5-7, F1 
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations. 
M5-7, F6-7 
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see 
Item 12). 
M5-7, F8 
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  # Checklist item Reported on page # 
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group and (b) effect estimates and confidence intervals, ideally with a 
forest plot. 
M5-7, F2-3, F5 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency. 
M5-7, F2-3, F5 
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). M5-7, F8 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]). 
M5-7, F4 
DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., health care providers, users, and policy makers). 
M8-10 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., 
incomplete retrieval of identified research, reporting bias). 
M8-10 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications 
for future research. 
M8-10 
FUNDING 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review. 
M10 
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Chapter 4: Is home-based HIV testing universally acceptable? Findings from 
a case-control study nested within the HPTN 071 (PopART) trial  
85 
 
Outline of chapter 
The first of two case-control studies for this PhD was done to examine the factors associated with 
the uptake of HB-HTC during the first year of PopART. Presented below is the manuscript for this 
study which is currently under review with the Journal of Acquired Immune Deficiency Syndrome. 
4.1 Abstract 
Introduction 
The HPTN 071 (PopART) trial is examining the impact of a package including universal testing and 
treatment on community-level HIV-incidence in Zambia and South Africa. We conducted a nested 
case-control study to examine factors associated with acceptance of home-based HIV testing and 
counselling (HB-HTC) delivered by Community HIV-care Providers (CHiPs) in PopART intervention 
communities.   
Methods 
Of 295,447 individuals who were offered testing, random samples of individuals who declined HB-
HTC (cases) and accepted HB-HTC (controls), stratified by gender and community, were selected. 
Odds ratios comparing cases and controls were estimated using multi-variable logistic regression. 
Results 
Data from 642 participants (313 cases, 329 controls) were analysed. There were no differences 
between cases and controls by demographic or behavioural characteristics including age, marital or 
socio-economic position. Participants who felt they could be open with CHiPs (AOR:0.46, 
95%CI:0.30-0.71, p<0.001); self-reported as not previously tested (AOR:0.64; 95%CI:0.43-0.95, 
p=0.03); considered HTC at home to be convenient (AOR:0.38, 95%CI:0.27-0.54, p=0.001); knowing 
others who had accepted HB-HTC from the CHiPs (AOR:0.49, 95%CI:0.31-0.77, p=0.002); or were 
motivated to get treatment without delay (AOR:0.60, 95%CI:0.43-0.85, p=0.004), were less likely to 
decline the offer of HB-HCT. Those who self-reported high-risk sexual behaviour were also less likely 
to decline HB-HCT (AOR: 0.61, 95% CI: 0.39-0.93, p=0.02). Having stigmatising attitudes about HB-
HTC was not an important barrier to HB-HCT uptake. Among men, those who reported fear of HIV 
were more likely to decline HB-HCT (AOR: 2.68, 95%CI: 1.33-5.38, p=0.005). 
Discussion and Conclusion 
This study, nested within the largest HIV prevention trial to date, provides valuable insights into the 
acceptability of HB-HTC. Acceptance was associated with lack of previous HIV-testing, positive 
attitudes about HIV-services/treatment and high sexual-risk perception. Among those contacted, 
HB-HCT was acceptable across a range of demographic and behavioural characteristics suggesting 
HB-HCT was “universally” acceptable. 
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4.2 Introduction 
Great advances have been made in controlling the HIV epidemic over time and especially so in the 
last decade. HIV-incidence worldwide has declined as have HIV related deaths.(1) The number of 
people receiving anti-retroviral treatment (ART) has increased to 17 million and coverage has 
reached unprecedented levels even in high-prevalence countries.(2) To gain further ground, a fast-
track strategy is called for to achieve UNAIDS’ 90-90-90 targets - with benefits for individual health 
and prevention of transmission.(3-7) The feasibility of treatment as prevention for public health 
benefit, whereby a sufficiently high proportion of those infected with HIV know their status, start 
ART and become virally suppressed so that transmission and HIV-incidence may be reduced to a very 
low level is currently being tested by a number of studies.(8-12)  The HPTN 071/ Population Effects 
of Antiretroviral Therapy to Reduce HIV Transmission (PopART) trial is being conducted in 21 
communities in Zambia and South Africa (with an average population of >50,000 
individuals/community) to examine the impact of Universal Testing and Treatment (UTT) on 
community-level HIV-incidence.(10, 13)  
Despite the progress so far, unless uptake of testing is extensive and inclusive in terms of 
acceptability to all subsets of the population, the full potential of UTT will not be realised. Home-
based HIV-testing and counselling (HB-HTC) has the potential to increase awareness of HIV status in 
previously undiagnosed individuals in sub-Saharan Africa.(14-17) In theory, offering free HIV-testing 
services to individuals in their homes provides an opportunity to test with minimal cost (time, effort 
or financial) to the individual, thereby reducing a number of barriers associated with facility-based 
HIV-testing.  On the other hand, concerns around testing in the household setting and about the 
value of offering it when individuals feel healthy, may be deterrents to uptake and inhibit universal 
acceptability.  
The PopART intervention includes door-to-door HB-HTC with the aim of achieving universal testing. 
A case-control (CC) study on a randomly selected subset of those who had accepted (controls) and 
those who had declined HB-HTC (cases) when offered by Community HIV-care Providers (CHiPs) was 
carried out, to examine the acceptability of the PopART HB-HTC intervention during the first year of 
delivery. In addition to exploring demographic, lifestyle, health and behavioural characteristics, we 
explored differences in perceptions between cases and controls about factors that may affect 
uptake of HB-HTC. We examined participants’ perceptions of HIV services; advantages and 
disadvantages of accepting HB-HTC for them as individuals and enquired about stigmatising 
attitudes which may affect uptake. By comparing non-acceptors (cases) and acceptors (controls) of 
HB-HTC, we hoped to identify any differences and any excluded subsets of the population so that 
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recommendations could be made to help enable universal knowledge of HIV status be achieved 
through HB-HTC. 
4.3 Methods 
The design of the HPTN 071 (PopART) trial has been described previously.(10) Key elements of the 
trial are shown in Figure 4.1. Working in pairs, the CHiPs (who were community-members employed 
to work in their communities) were assigned to zones with approximately 500 households to which 
they delivered the intervention, including HB-HCT. During the first year of the PopART intervention 
194,795 individuals in Zambia (88,860 men/105,935 women) and 100,652 in South Africa (44,172 
men/56,480 women) were offered HB-HTC by CHiPs in the 14 intervention communities. Of them, 
126,208 individuals in Zambia (55,568 men/70,640 women) and 92,375 (40,519 men/51,856 
women) in South Africa, accepted testing. Individuals who self-reported HIV-positive status were not 
routinely offered testing (and are not included in the above figures). 
The nested case-control study was done in all the intervention (Arms A and B) communities - 8 in 
Zambia and 6 in South Africa. The study objectives were to identify differences between non-
acceptors (cases) and acceptors (controls) of HB-HTC in the first annual round of HB-HTC in PopART; 
and to identify reasons for non-acceptance of HB-HTC.  
While delivering the PopART intervention, CHiPs captured the details of all individuals who 
consented to the intervention offered by CHiPs, irrespective of whether or not they accepted HB-
HTC, on an electronic register.(10) From the electronic register random samples of non-acceptors 
(cases) and acceptors (controls) of HB-HTC were selected, with a ratio of 1 case:1 control, an equal 
number of men and women, and an equal number from each community, to have adequate 
representation of individuals from all the PopART intervention communities and from both genders. 
An initial random sample in excess of the number needed to be recruited was selected, in 
anticipation of difficulties in finding participants – due to mobility of community members with 
frequent change of address.  
To be eligible for the case-control study, participants had to be ≥18 years old, able and willing to 
provide informed consent and have participated in the first year of the PopART intervention. 
Belonging to the Population Cohort of the PopART trial (see Figure 4.1) or another PopART case-
control study, and already being known to be HIV-infected at the time of the initial CHiP visit were 
exclusion criteria. HB-HTC acceptance/non-acceptance was defined based on whether a community 
member had accepted/not-accepted HB-HTC offered by CHiPs at the time of random selection in 
January (Zambia) and March (South Africa) 2015 – representing one year since the start of the 
intervention in each country, respectively.   
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Verbal permission to allow research staff to approach participants was obtained by the CHiP staff 
who had provided the intervention to individual community members. Written informed consent for 
study participation was then obtained by study research assistants (RAs). RAs conducted surveys 
using standardised questionnaires administered electronically. Questionnaire themes were informed 
by current evidence in the literature or anecdotal local information on factors that may influence 
uptake of HIV-testing. RAs were kept unaware of participants’ case or control status. In the 
questionnaire, the question about whether the individual had accepted or declined HB-HTC was 
asked at the end of the interview to minimise interviewer bias. 
While monitoring data as part of routine quality assurance, the study team uncovered some 
irregularities in data collection in South Africa. In-depth internal and independent investigations 
followed, with oversight from the relevant ethical and regulatory bodies responsible for the study. 
Consequently, data from one community were not used due to concerns about substantive data 
irregularities, while in the remaining 5 communities in South Africa a rigorous data-verification 
process was undertaken to ensure data integrity. Only participants who could be re-contacted and 
whose data were verified as genuine were retained. The verification process involved confirming the 
identity of the participant and checking that responses to selected key questions matched responses 
given during the initial CC visit. No irregularities related to this study were identified in Zambia at any 
stage.  
The final sample size of ~650 participants (1:1 case: control ratio) provides ~80% study power to 
detect associations with odds ratios of ~1.75 or higher (or ~0.5 or lower), for explanatory variables 
with 15% prevalence among controls (α = 0.05).  
Multivariable logistic regression was used to estimate odds ratios, including community and gender 
in all models to account for the frequency-matched sampling strategy. Age category was also 
included as an a-priori potential confounding factor. Additional variables (related to demographic or 
behavioural characteristics but not opinions or perceptions) for which there was at least weak 
statistical evidence of association with HB-HTC acceptance were included potential confounding 
variables. Likelihood ratio tests (LRT) were performed to assess the statistical evidence for 
associations. Evidence of effect modification by gender and country was explored. For variables with 
3 or more response categories and potential for a dose-response relationship, test for trends were 
performed. 
The study was approved by the relevant in-country and international ethical review boards (Ethics 
committees of the University of Zambia, Stellenbosch University and London School of Hygiene and 
Tropical Medicine). 
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4.4 Results 
As shown in Figure 4.2a, of 910 non-acceptors of HB-HCT (cases) randomly selected to be contacted 
by CHiPs, 440 (48%) were found and agreed for their contact information to be passed on to the 
case-control field research assistants (RAs). Of them, 380 (86%) were consented into the study 
(Figure 4.2a) In South Africa, data were verifiable in 73 of the 140 (52%) cases initially recruited 
there. There were 313 cases in the final study sample. The proportions recruited among potential 
controls were similar as shown in Figure 4.2b with 329 controls in the final sample. Data from 642 
participants were included in the final analysis – 77% (495) from 8 communities in Zambia and 23% 
(147) from 5 communities in South Africa (Table-1). 
Demographic and household conditions and lifestyle, behavioural and health characteristics  
Cases and controls were well balanced by trial arm, community and gender, reflecting the sampling 
strategy of the study. Participants were distributed fairly evenly across age categories with slightly 
higher proportions in younger age groups (Table-1). The median age among cases was 32y (IQR: 23- 
43) and 30y (IQR: 22-40) among controls. The majority of cases and controls were married. While the 
proportion of participants with higher education was relatively low (12-13%) most had had 
secondary school education. Most participants were unemployed.   
Cases and controls were similarly distributed across almost all the characteristics examined. There 
were no differences by ethnicity or religion, nor in household conditions, sexual behaviour or health 
status (including mental health measured by WHO validated Self-Reported Questionnaire (10), 
circumcision status and history of pregnancies) (Table-1 and from data not shown).  
However, participants who had lived in the community for more than 3 years had twice the odds of 
declining HB-HCT than those who had been resident for less than 3 years (adjusted odds ratio 
(AOR):2.01,95% confidence interval(95%CI):1.25-3.22,p=0.003).  
Neither the number of other household members who were present when HB-HTC was offered to 
the household, nor the presence of the participant’s partner, were associated with acceptance of 
HB-HCT (Table-1).  
Perceptions of HIV-services affecting uptake of HB-HTC 
As shown in Table-2 most participants did not know the CHiP prior to the PopART home visit, and 
there was no association with uptake of HB-HTC. The majority had faith in the confidentiality of 
services provided by CHiPs, and there was no difference between cases and controls. However, 
when asked about whether they could talk openly to the CHiPs, participants who “strongly agreed” 
that they were comfortable talking openly to CHiPs (who provided HB-HTC) were less likely to have 
declined HB-HTC compared to those who “strongly disagreed/disagreed” (AOR: 0.34, 95%CI: 0.12-
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0.91, p=0.03). There is evidence of a trend suggesting that the more strongly a participant agreed 
that they could talk to the CHiP openly, the less likely they were to have declined HB-HCT (test-for-
trend p=0.003). Also, the more strongly participants agreed that providing treatment widely could 
reduce incidence of new infections, the less likely they were to have declined HB-HCT (test-for-trend 
p=0.03).  
Perceived advantages, disadvantages of HB-HTC (including stigmatizing attitudes which may affect 
uptake)  
When non-acceptors and acceptors were asked (identical) standardized questions about factors that 
encourage HIV-testing (regardless of whether they actually did), further associations emerged. 
Individuals who reported never previously testing for HIV, were less likely to have declined HB-HTC 
(AOR: 0.64, 95%CI: 0.43-0.95, p=0.03). Similarly, those who knew someone who had had an HIV test 
with the CHiPs (AOR:0.49,95%CI:0.31-0.77, p=0.002); thought they could get treatment without 
delay if HIV-positive (AOR:0.60,95%CI:0.43-0.85, p=0.004); accepted the CHiP’s advice that it was 
good to have an HIV test (AOR:0.33,95%CI:0.23-0.48, p<0.001); and considered testing at home as 
convenient (AOR:0.38,95%CI:0.27-0.54, p<0.001) – were less likely to have declined HB-HTC. 
Participants who indicated that their sexual behaviour put them at risk of HIV (as a reason to test) 
were also less likely to have declined HB-HTC (AOR: 0.61, 95%CI: 0.39-0.93, p=0.02).  
When exploring reasons against accepting HB-HTC, those who reported confidence in being HIV-
negative (so there was no need to test) (AOR: 1.61, 95%CI: 1.04-2.51, p=0.03) and reluctance to test 
again after recent testing (the definition of recency was not specified and left to the interpretation 
of the participant) (AOR: 1.69, 95%CI: 1.08-2.67, p=0.02), were more likely to decline HB-HCT.  
In contrast, other factors such as thinking that HIV is common or concerns about confidentiality of 
HIV-testing in the household, that might have influenced uptake of testing, were not found to be 
associated with acceptance (Table-3). There were no important differences between cases and 
controls in stigmatising attitudes that may affect uptake of HB-HTC (Table-3).  
Differences in association by gender and country  
There were few differences observed when stratifying associations by gender and country 
(Supplementary Table 1a and 1b). Men who stated that they feared an HIV-positive test result were 
more likely to have declined HB-HTC (AOR: 2.68, 95%CI: 1.33-5.38, p=0.005), whereas no such 
association was noted among women (AOR: 0.84, 95%CI: 0.39-1.80, p=0.65) (LRT for interaction with 
gender p-value=0.005). In Zambia, participants who had spent one or more nights away from the 
community in the last 3 months were less likely to have declined HB-HTC (AOR:0.63,95%CI:0.41-
0.96,p=0.03) while no evidence of difference was found in South Africa (AOR:1.33,95%CI:0.59- 
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2.97,p=0.49) (LRT for interaction with country p-value=0.05). There were also country differences in 
response to a question about whether lack of time due to work commitments was a reason to 
decline HB-HTC (LRT for interaction with country p-value=0.03). In South Africa, those who declined 
HB-HCT were much more likely to state this as a reason not to test than those who accepted, 
although the 95% CI was wide for the estimated adjusted odds ratio (AOR:4.73, 95%CI:1.02-21.98, 
p=0.03). There was no such association in Zambia (AOR: 0.95, 95%CI: 0.61-1.47, p=0.83), (LRT for 
interaction with country p-value=0.03) 
4.5 Discussion  
Our study provides evidence from large urban communities that were targeted to receive universal 
testing (and in Arm A communities, universal treatment as well) (Figure 4.1). UTT has the potential 
to influence acceptability and uptake of HIV-testing and only one other quantitative study to our 
knowledge has reported findings from a setting providing UTT. This study was on data from a much 
smaller trial than PopART, set in rural South Africa with 10 clusters and an average population size of 
approximately 1000 individuals/cluster), and only a few potential factors associated with the uptake 
of HB-HTC were described.(18)  While there are descriptive studies of acceptors of testing and HB-
HTC, relatively few studies have directly compared acceptors with non-acceptors of HB-HTC, and in-
depth quantitative data on reasons to decline are limited. (18-21) HB-HTC acceptance has been 
shown to be associated with age (greater than 25y) and female gender in Kenya,(19) and low socio-
economic position in a the setting of a small island in Lake Malawi.(20) Other data have shown no 
association between HB-HCT uptake and demographic or socio-economic position.(18) Prior 
knowledge of HIV status (known HIV-infected or believing one-self to be uninfected based on a 
previous HIV-negative test result), and not being ready to find out, have been found as reasons to 
decline HB-HTC in rural South Africa.(21) Others have reported little that is significantly different 
between those who accepted and those who did not accept HB-HTC.(18)  
In our study in 13 large urban communities in Zambia and South Africa, we found that among those 
who were encountered and offered HB-HTC, there were no fundamental differences based on 
demographic, lifestyle, behavioural or health characteristics, between those who accepted (controls) 
and those who declined HB-HCT (cases). Our data indicate that there were no specific subsets of the 
population who were systematically less likely to accept testing, once contacted, suggesting that HB-
HTC has the potential to be universally acceptable to those offered it. To achieve universal coverage, 
innovative means must be explored to ensure everyone in the community (or as high a proportion as 
possible) is contacted so that they can be offered HB-HTC.(22)  
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In contrast, cases and controls did seem to differ in perceptions held about issues related to HIV and 
HIV-services. Most participants gave favourable responses regarding HIV services, and those who 
held positive views about the CHiPs were less likely to have declined HB-HTC. There were several 
factors that encouraged testing at the individual level. Participants who had not tested for HIV 
previously were more likely to accept HB-HTC in contrast to those who had previously tested HIV-
negative or had tested recently and felt that repeat testing was not warranted. 
Participants who declined HB-HCT were less positive about treatment for HIV than those who 
accepted. Further, those who declined were more likely to hold the view that they were not at risk 
of HIV and it was therefore not a reason for them to test. Low-risk perception as a reason not to test 
was also observed by Naik et al.(23)  Yet when we explored self-reported sexual behaviour of 
participants there is no evidence that those who declined HB-HCT were at lower risk based on the 
number of partners in the last 12 months (Table-1), number of lifetime partners or age at sexual 
debut (data not shown).  
Other views that might have been assumed to encourage or discourage testing had no association 
with observed acceptance of HB-HTC. For example, concerns about confidentiality with testing in the 
home, or the presence of other household members during delivery of HB-HTC (including partner), 
were not associated with acceptance and so these factors did not appear to inhibit testing. Contrary 
to other studies (23), “not feeling ready to find out” his/her HIV status was not found to be 
associated with acceptance in our study. Having stigmatising attitudes about HB-HTC was also not 
seen to be an important barrier to uptake in our setting. 
We found surprisingly few differences between responses given by men and women. However, the 
data do suggest that among men, fear of an HIV-positive result was associated with HB-HTC non-
acceptance.  
Further research is needed to explain some study findings, including the association of longer 
duration lived in the community with non-acceptance, or the finding that greater mobility is 
associated with increased likelihood of acceptance in Zambia. Several of the communities studied 
have been exposed to HTC campaigns in the past. Individuals who have been resident for longer 
periods may have been tested before and therefore declined HB-HTC when offered by PopART 
CHiPs. In contrast, mobility is associated with higher sexual risk (24) and individuals who are mobile 
may be more inclined to accept HB-HTC if they feel at risk of HIV. Social science research is being 
conducted on a subset of the participants from this case-control study and in-depth interviews may 
provide more nuanced explanations. 
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Our study had some limitations to consider. To comply with ethical principles and good research 
practice, only individuals who were encountered and agreed to participate in the PopART 
intervention, and who were re-contacted and provided informed consent for the CC study, could be 
recruited as participants. Due to high mobility in the study communities, randomly selected 
individuals from the CHiP data-base were often difficult to trace, to ask permission for contact by the 
research team. As such, it may be that the study population is not representative of all community 
members and our results (like much of the published data from similar study settings) must be 
interpreted in the light of this limitation. 
Finally, in common with most research using self-reported data, reporting bias is possible. Social 
desirability may have played a part in the responses given, although we would not expect this to be 
differential based on whether an individual had accepted HB-HTC for most themes studied. We also 
minimised observer bias by keepings research assistants unaware of case/control status of 
participants until the end of the questionnaire. 
However, our study also had several strengths. There was no single or obvious hypothesis being 
tested, so respondents were unlikely to give responses in order to conform to (or contradict) such a 
hypothesis. In contrast to much of the existing literature on acceptability of HIV-testing, our study is 
specific to the context of attempting to provide universal testing and at large scale. Further, we 
directly compared those who accepted HB-HTC with those who did not to provide evidence of 
differences rather than simply describing individuals without comparators. Also, by frequency 
matching our study sample by gender we ensured an adequate sample of men who are often under-
represented in studies of HIV test uptake despite (or because of) the fact that they are more 
frequently non-engagers with HIV services. The response rates between cases and controls were 
similar indicating that there was no evidence of differential selection of potential participants by 
case/control status. Finally, the study covered an extensive range of themes. The null findings make 
an important contribution to identifying which areas may be less important when designing public 
health information to encourage HB-HCT. 
While firm evidence of causality cannot be inferred from this observational study, our study findings 
provide opportunities for tailoring services and public-health messaging to extend the reach of HB-
HTC, to those who may currently be avoiding it. Our first key recommendation in this light is to re-
inforce the importance of testing irrespective of self-held perceptions of risk of HIV, especially where 
universal knowledge of HIV status is sought. WHO guidelines do not recommend re-testing to cover 
a “window-period” (25) and it is reasonable not to re-test following a test in the last 3 months. 
However, if there is any potential for on-going exposure repeat and on-going testing (e.g., annually) 
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should be encouraged from a public-health point of view. The failure to re-test because of a past 
HIV-negative result may be complacent, especially in high prevalence settings. Data from PopART 
intervention delivery indicate high acceptability of HB-HTC provided by CHiPs.(26) Data from this 
study, highlight the benefits to be gained by maximising the acceptability of the cadre of staff 
delivering HB-HTC, and which may help us reach universality. Similarly, promoting the benefits of 
treatment may have benefits for uptake of testing.  Among men, fear of HIV seems to influence test 
uptake and efforts must be made to understand and mitigate it. We recommend that there should 
be investment in health promotion which de-mystifies HIV – through expansion of channels to target 
men (health promotion aligned with sporting events and activities, or tailored male-friendly services, 
for instance).  
Conclusion: 
This case-control study, which is nested within the largest HIV prevention trial to date, provides 
valuable insights into the acceptability of HB-HTC. HB-HTC has the potential to be universally 
acceptable to those who can be contacted and offered it. We have identified perceptions and 
opinions held by community members that could help tailor public health messaging with a view to 
achieving universal knowledge of HIV status in high prevalence settings. 
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Figure 4.1: PopART Trial Schema 
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Figure 4.2a: Case (non-acceptor) selection process and sampling fraction 
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Figure 4.2b: Control (acceptor) selection process and sampling fraction 
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Table 4.1: Demographic and household conditions, and lifestyle, behavioural and health characteristics of 
cases and controls  
  
Cases (Non-
acceptors)        
N (%) 
Controls 
(Acceptors)                                                            
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,     
95 %
Confidence 
Interval 
Adjusted 
Odds 
Ratio 3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Total 313  329          
Gender    
    
Male 153 (49) 150 (46)         
Female 160 (51) 179 (54)         
Demographic characteristics 
Age category   
    Ptrend 4 0.57 
18 – 24 years 95 (30) 110 (33) 1 0.16 1   0.34 
25 – 34 years 79 (25) 98 (30) 0.93 0.62-1.14 0.87 0.57-1.32 
35 – 44 years 73 (23) 54 (16) 1.55 0.98-2.45 1.35  0.84-2.15 
≥ 45 years 66 (21) 67 (20) 1.17 0.74-1.83 1.00  0.63-1.59 
Marital status   
     
Never married 104 (33) 106 (32) 1 0.63 1 0.56 
Currently married 162 (52) 178 (54) 0.89 0.62-1.27 0.78 0.50-1.23 
Previously married 5 47 (15) 45 (14) 1.08 0.65-1.81 0.85 0.46-1.58 
Educational attainment   
    Ptrend 4 0.21 
Primary (Grade 0-7) 86 (27) 94 (29) 1 0.81 1 0.62 
Junior secondary (Grade 8-9) 72 (23) 81 (25) 0.99 0.64-1.55 1.13 0.71-1.80 
Senior secondary (Grade 10-12) 115 (37) 114 (35) 1.12 0.74-1.71 1.32 0.83-2.10 
Higher education 40 (13) 40 (12) 1.28 0.72-2.29 1.38 0.75-2.51 
Employment        
None 165 (53) 186 (57) 1 0.36 1 0.52 
Casual/seasonal/occasional 43 (14) 44 (13) 1. 00 0.61-1.66 0.97 0.57-1.64 
Self employed  49 (16) 37 (11) 1.56 0.93-2.61 1.46 0.85-2.49 
Formal wage 56 (18) 62 (19) 0.97 0.63-1.51 1.00 0.63-1.60 
Household conditions 
SES (PCA6 of HH factors & assets7) 
      
Lower 152 (49) 170 (52) 1 0.10 1 0.15 
Higher 161 (51) 159 (48) 1.36 0.94-1.96 1.31 0.90-1.89 
Number  of other HH members present when CHiP offered HBT Ptrend 4 0.47 
0 113 (37) 122 (38) 1 0.90 1 0.73 
1 83 (27)  87 (27) 0.93 0.62-1.42 0.98 0.64-1.49 
≥ 2 107(35) 112 (35) 0.91 0.60-1.37 0.85 0.56-1.30 
Was partner present when participant offered CHiP HBT? 
N 237 (78) 249 (78) 1 0.53 1 0.47 
Y 66 (22) 72 (22) 0.87 0.56-1.34 0.84 0.52-1.35 
Lifestyle, behavioural and health factors 
Years lived in the community  
     
≤ 3 33 (11) 63 (19) 1 0.002 1 0.003 
≥ 4 278 (89) 261 (81) 2.09 1.31-3.32 2.01  1.25-3.22 
Any nights spent away from home in last 3m       
N 159 (58) 155 (52) 1 0.19 1 0.17 
Y 117 (42) 144 (48) 0.79 0.55-1.13 0.77 0.54-1.19 
Number of partners in last 12m  
     
0 64 (23) 70 (23) 1 0.87 1 0.79 
1 185 (65) 204 (67) 0.92 0.61-1.38 0.94 0.62-1.43 
≥ 2 35 (12) 31 (10) 1.09 0.59-2.01 1.15 0.61-1.43 
Audit Score       
Audit Score ≤ 7 242 (77) 260 (79) 1 0.74 1 0.56 
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Audit Score ≥ 8                                 71 (23) 69 (21) 1.07 0.71-1.61 1.13 0.75-1.72 
Unwell in last 12m  
     
N 208 (67) 224 (68) 1 0.74 1 0.59 
Y 104 (33) 105 (32) 1.06 0.75-1.50 1. 10 0.77-1.58 
Any form of violence (verbal/physical/sexual) from any partner in last 12m (among women) 
No 119 (74) 130 (73) 1 0.82 1 0.90 
At least once 41 (26) 49 (27) 0.94 0.56-1.57 0.98 0.57-1.67 
 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model including gender, community, age category and years lived in the community 
4. P value for test for trend 
5. Previously married = separated/divorced/widowed 
6. Principal components analysis  
7. HH factors detailed house structure, water, sanitation, electricity and cooking fuel used; assets listed were: 
working cell-phone, bicycle, motorcycle or scooter, car/bakkie, electricity to house, television set, fridge/freezer, 
radio, computer/laptop, CD or MP3 player, stereo/cassette/other music player, “none of the above” 
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Table 4.2: Participants’ perceptions of HIV service factors affecting uptake of testing 
 
Cases (Non-
acceptors)        
N (%) 
Controls 
(Acceptors)                                                            
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjusted 
Odds Ratio 3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
HIV service factors affecting uptake of testing  
Was the CHiP known to the participant prior to offer of HBT? 
N 265 (85) 272 (83) 1 0.61 1 0.49 
Y 48 (15) 57 (17) 0.88 0.56-1.40 0.85 0.54-1.35 
Do you think confidentiality will be maintained by the CHiP? 4 ptrend 5 0.16 
Strongly disagree/disagree 15 (5) 18 (5) 1 0.10 1 0.16 
Agree 98 (31) 82 (25) 1.49 0.69-3.22 1.42 0.65-3.10 
Strongly agree 200 (64) 229 (70) 0.95 0.46-2.00 0.91 0.43-1.94 
Was the CHiP someone you could talk to openly? 4 ptrend 5 0.003 
Strongly disagree/disagree 12 (4)  7 (2) 1 0.002 1 0.001 
Agree 92 (29) 70 (21) 0.81 0.29-2.24 0.70 0.25-1.94 
Strongly agree 209 (67) 252 (77) 0.40 0.15-1.07 0.34 0.12-0.91 
Providing treatment for as many HIV infected people as possible can help reduce new HIV infections happening in your 
community 4 
ptrend 5 0.03 
Strongly disagree 19 (6) 21 (6) 1 0.09 1 0.04 
Disagree 46 (15) 31 (9) 1.54 0.70-3.38 1.63 0.73-3.65 
Agree 91 (29) 89 (27) 1.14 0.55-2.35 1.11 0.54-2.31 
Strongly agree 156 (50) 188 (57) 0.82 0.42-1.61 0.78 0.39-1.52 
Group counselling for HH members (including offer of HIV test) in the home is acceptable 4 ptrend 5 0.93 
Strongly disagree 41 (13) 43 (13) 1 0.80 1 0.80 
Disagree 31 (10) 34 (10) 1.02 0.53-1.98 0.97 0.50-1.93 
Agree 86 (28) 83 (25) 1.20 0.68-2.13 1.21 0.68-2.16 
Strongly agree 154 (49) 169 (51) 0.97 0.58-1.61 0.98 0.58-1.63 
 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model including gender, community, age category and years lived in the community 
4. There were very few responses in the “strongly disagree” and “disagree” categories for these questions, 
responses are therefore grouped as shown to be more meaningful/increase power 
5. p-value for test for trend 
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Table 4.3: Participants’ perceptions of advantages and disadvantages of accepting of HB-HTC 
 
Cases (Non-
acceptors)        
N (%) 
Controls 
(Acceptors)                                                            
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjusted 
Odds Ratio 3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Individual level factors encouraging testing 
When offered a test by the PopART CHiP, did any of the following encourage you towards having an HIV test? 
I have never had an HIV test and wanted to learn my status 
N 247 (79) 237 (72) 1 0.03 1 0.03 
Y 65 (21) 92 (28) 0.65 0.44-0.96 0.64 0.43-0.95 
HIV is common in this community so I thought I should test to check my status  
N 217 (70) 223 (68) 1 0.46 1 0.37 
Y 95 (30) 106 (32) 0.87 0.60-1.27 0.84 0.57-1.23 
Convenience of having an HIV test at home encouraged me to test 
N 164 (53) 104 (32) 1 <0.001 1 0.001 
Y 148 (47) 225 (68) 0.39 0.28-0.55 0.38 0.27-0.54 
Many people I know had tested with a CHiP so I wanted to as well 
N 263 (84) 246 (75) 1 0.001 1 0.002 
Y 49 (16) 83 (25) 0.49 0.32-0.77 0.49 0.31-0.77 
Accepted CHiP advice that it was a good idea to test 
N 154 (49) 89 (27) 1 <0.001 1 <0.001 
Y 158 (51) 240 (73) 0.35 0.24-0.49 0.33 0.23-0.48 
Getting treatment without delay if I tested and was HIV-positive (encouraged me to test) 
N 149 (48) 119 (36) 1 0.004 1 0.004 
Y 163 (52) 210 (64) 0.61 0.44-0.86 0.60 0.43-0.85 
My sexual behaviour has put me at risk of HIV 
N 263 (84) 257 (78) 1 0.02 1 0.02 
Y 49 (16) 72 (22) 0.61 0.40-0.94 0.61 0.39-0.93 
Individual level factors discouraging testing 
When offered a test by the PopART CHiP, did any of the following discourage you from having an HIV test? 
I had difficulty with the time it would take - because of my livelihood/job  
N 226 (72) 247 (75) 1 0.42 1 0.52 
Y 86 (28) 82 (25) 1.18 0.79-1.75 1.14 0.76-1.71 
I was worried someone would find out I was having an HIV test  
N 305 (98) 313 (95) 1 0.08 1 0.11 
Y 7 (2) 16 (5) 0.45 0.18-1.12 0.48 0.19-1.22 
I did not want to find out my HIV status because I was afraid of a positive test result  
N 263 (84) 288 (88) 1 0.19 1 0.09 
Y 49 (16) 41 (12) 1.38 0.85-2.22 1.53 0.94-2.50 
I was confident I was HIV-negative and didn't need to test 
N 242 (78) 274 (83) 1 0.05 1 0.03 
Y 70 (22) 55 (17) 1.53 1.00-2.34 1.61 1.04-2.51 
I already had a test recently and did not want to test again 
N 254 (81) 287 (87 ) 1 0.03 1 0.02 
Y 58 (19) 42 (13) 1.63 1.05-2.53 1.69 1.08-2.67 
I am not ready to find out my HIV status 
N 267 (86) 289 (88) 1 0.15 1 0.12 
Y 45 (14) 40 (12) 1. 50 0.86-2.64 1.57 0.88-2.77 
I just did not want to find out my HIV status (no particular reason)  
N 279 (89) 298 (91) 1 0.40 1 0.40 
Y 33 (11) 31 (9) 1.32 0.70-2.48 1.32 0.69-2.50 
Stigmatising attitudes which may affect uptake of testing 
People are hesitant to take an HIV test due to fear of other people’s reaction if the test result is positive for HIV Ptrend 4 0.18 
Strongly disagree 69 (22) 72 (22) 1 0.10 1 0.10 
Disagree 54 (17) 49 (15) 1.03 0.57-1.86 0.96 0.52-1.76 
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Agree 99 (32) 116 (35) 1.28 0.77-2.13 1.20 0.71-2.02 
Strongly agree  90 (29) 92 (28) 0.73 0.45-1.18 0.68 0.42-1.12 
People sometimes talk badly about people who have had or who are thought to have had an HIV test Ptrend 4 0.79 
Strongly disagree 69 (22) 72 (22) 1 0.78 1 0.83 
Disagree 54 (17) 49 (15) 1.10 0.64-1.87 0.99 0.58-1.71 
Agree 99 (32) 116 (35) 0.86 0.53-1.39 0.83 0.51-1.35 
Strongly agree 90 (29) 92 (28) 1.02 0.62-1.67 0.98 0.59-1.62 
People may think that I have been immoral/irresponsible as the reason behind having an HIV test Ptrend 4 0.53 
Strongly disagree 129 (41) 146 (44) 1 0.60 1 0.53 
Disagree 69 (22) 77 (23) 0.96 0.62-1.48 0.90 0.57-1.40 
Agree 68 (22) 60 (18) 1.34 0.82-2.21 1.33 0.80-2.20 
Strongly agree 46 (15) 46 (14) 1.05 0.62-1.79 1.04 0.60-1.79 
People receive verbal abuse or insults because of having an HIV test Ptrend 4 0.90 
Strongly disagree 43 (14) 44 (13) 1 0.61 1 0.82 
Disagree 73 (23) 84 (26) 1.33 0.85-2.06 1.21 0.77-1.90 
Agree 78 (25) 65 (20) 1.03 0.65-1.62 1.02 0.64-1.62 
Strongly agree 118 (38)  136 (41) 1.04 0.61-1.77 0.97 0.56-1.69 
 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model including gender, community, age category and years lived in the community 
4. p value for test for trend 
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Supplementary Table 4.1a: Factors with effect modification by gender, of association with case/control status,  
 
Controls 
(Acceptors)                                                            
N (%) 
Cases 
(Non-
acceptors)        
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjusted 
Odds 
Ratio3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Controls 
(Acceptors)                                                            
N (%) 
Cases 
(Non-
acceptors)        
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjusted 
Odds 
Ratio3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
 Men Women 
Individual level factors affecting testing 
I did not want to find out my HIV status because I was afraid of a positive test result  peffect modification 4 0.02 
N 132 (88) 119 (78) 1 0.01 1 0.005 156 (87) 144 (90) 1 0.47 1 0.65 
Y 18 (12) 33 (22) 2.27 1.16-4.44 2.68 1.33-5.38 23 (13) 16 (10) 0.76 0.36-1.60 0.84 0.39-1.80 
I just did not want to find out my HIV status (no particular reason) peffect modification 4 0.05 
N 131 (86) 138 (92) 1 0.03 1 0.02 71 (97) 71 (96) 1 0.27 1 0.20 
Y 21 (14) 12 (8) 2.58 1.09-6.10 2.83 1.17-6.86 3 (2) 3 (4) 0.56 0.20-1.59 0.50 0.17-1.47 
People sometimes talk badly about people who have had or who are thought to have had an HIV test peffect modification 4 0.02 
Strongly disagree 32 (21) 32 (21) 1 0.39 1 0.43 37 (23) 40 (22) 1 0.05 1 0.04 
Disagree 25 (16) 20 (13) 1.06 0.47-2.37 1.00 0.44-2.26 29 (18) 29 (16) 1.04 0.50-2.16 0.94 0.44-1.98 
Agree 58 (38) 48 (32) 1.26 0.63-2.53 1.24 0.61-2.54 41 (26) 68 (38) 0.54 0.27-1.08  0.50 0.25-1.02 
Strongly agree 37 (24) 50(33) 0.72 0.34-1.50 0.71 0.34-1.51 53 (33) 42 (23) 1.28 0.65-2.52 1.25 0.62-2.52 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model including gender, community, age category and years lived in the community 
4. LRT p-value indicating evidence of effect modification by gender 
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Supplementary Table 4.1b: Factors with effect modification by country, of association with case/control status 
 
Controls 
(Acceptors)                                                            
N (%) 
Cases 
(Non-
acceptors)        
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjusted 
Odds 
Ratio3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Controls 
(Acceptors)                                                            
N (%) 
Cases 
(Non-
acceptors)        
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjusted 
Odds 
Ratio3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
 Zambia South Africa 
Demographic characteristics 
Any nights spent away from home in last 3m peffect modification 4 0.05 
N 110 (54) 100 (44) 1 0.03 1 0.03 49 (67) 55 (75) 1 0.26 1 0.49 
Y 93 (46) 126 (56) 0.64 0.43-0.97 0.63 0.41-0.96 24 (33) 18 (25) 1.53 0.72-3.29 1.33 0.59-2.97 
Individual level factors affecting testing 
I had difficulty with the time it would take - because of my livelihood/job peffect modification 4 0.03 
N 176 (69) 162 (68) 1 0.87 1 0.83 7 1 (96) 3 (4) 1 0.08 1 0.03 
Y 79 (31) 77 (32 1.04 0.68-1.58 0.95 0.62-1.47 64 (88) 9 (12) 3.22 0.79-1.321 4.73 1.02-21.98 
 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model including gender, community, age category and years lived in the community 
4. LRT p-value indicating evidence of effect modification by country 
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Chapter 5:  The cascade-of-care following community-based detection 
of HIV – a systematic review with 90-90-90 targets in sight 
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Outline of chapter 
This chapter presents a second systematic review which was carried out as part of this PhD to 
further understand the factors associated with the uptake of UTT. In order to achieve the goal of 
HIV-incidence reduction through UTT, a high proportion of individuals who are identified as PLWH 
have to link to care and initiate treatment in a timely fashion. A systematic review which explored 
the cascade of care following HIV diagnosis was done, and it was focused on the cascade following 
HTC in the community as home-based and mobile testing are the main interventions used to achieve 
universal testing. 
Presented below is the manuscript which is under consideration by the Journal of the International 
AIDS Society following re-submission after receiving peer reviewer comments. 
5.1 Abstract 
Introduction 
We aimed to establish how effective community-based HIV testing services (HTS), including home 
and mobile-based HIV testing services (HB-/M-HTS), are in improving care in sub-Saharan Africa 
(SSA), with a view to achieving the 90-90-90 targets. 
Methods 
We conducted a systematic review of published literature from 2006-16 which reported on the 
proportion of individuals who link-to-care and/or initiate ART after detection with HIV through 
community-based testing. A meta-analysis was deemed inappropriate due to heterogeneity in 
reporting. 
Results 
Twenty-two studies from 6 SSA countries were included in the final review – 12 HB-HTS, 8 M-HTS, 2 
combined HB-/M-HTS. Proportions linked-to-care over 1-10 months ranged from 14-96% for HB-HTS 
and 10-79% for M-HTS, with most studies reporting outcomes over short periods (3 months). There 
was variability in definitions of outcomes, numerators/denominators and observation periods. 
Outcomes varied between studies even for similar time-points since HTS. Previously diagnosed 
individuals appear more likely to link-to-care than those who reported being newly-diagnosed. 
Point-of-care (POC) CD4-counts at the time of HTS did not achieve higher proportions linking-to-care 
or initiating ART. Similarly, follow-up visits to HIV-positive individuals did not appear to enhance 
linkage to care overall.  
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Fewer studies reported ART-related outcomes following community-based testing especially 
retention on ART or viral suppression on treatment. Proportions initiating ART ranged from 23-85% 
(17 studies - 9 of them involving <50 individuals); 6-months after ART initiation, 76% were still on 
ART (one study); and viral suppression was 77-85% (two studies). 
Discussion and Conclusion 
This systematic review summarises the available data on linkage to care/ART initiation following 
community-based detection of HIV, to help researchers and policy makers evaluate findings. We 
have identified important methodological inconsistencies in the literature quantifying the cascade of 
care, which hamper comparisons. We recommend that standardised measures of reporting of steps 
on the cascade of care are needed, to measure progress against targets and compare across 
settings. 
In contrast to the benefits of POC CD4-counts in clinics, use in the community was not a facilitator 
for linkage to care or ART initiation. It appears that individuals diagnosed in the community need 
time before they are ready to link-to-care/initiate ART. The available evidence suggests that 
different approaches to community-based HTS including HB-HTS and M-HTS, are equally effective in 
achieving linkage to care and ART initiation. 
5.2 Introduction   
UNAIDS 90-90-90 targets aim to ensure that by 2020, 73% of people living with HIV (PLWH) are 
virally suppressed.(1) The benefits of early treatment for those who are infected, and for the 
prevention of onward transmission, are now firmly established.(2-4)   
Using out-of-facility, community-based approaches to increase knowledge of HIV status in sub-
Saharan Africa (SSA) towards achieving the first-90, now seems ever more attainable.(5-8) These 
approaches detect infected individuals earlier in the course of infection. The benefits may conversely 
pose challenges for timely linkage to care. Individuals who feel well may not be ready to access care 
at health facilities even when provided with a diagnosis. While community-HTS reduces barriers for 
testing, the challenges associated with health facilities remain and individuals identified by 
community-HTS may be less likely and/or take longer to link-to-care. 
Linkage to care should result ultimately in viral suppression among people living with HIV (PLWH). 
The 90-90-90 targets provide a standard against which performance can be measured. This 
systematic review examines published evidence from sub-Saharan Africa on linkage to care, 
initiation of ART and retention/viral suppression if reported, following out-of-facility community-
based detection of HIV, with the 90-90-90 targets in mind - in particular the second- and third-90s.  
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5.3 Methods 
We conducted a systematic review according to the criteria in PRISMA guidelines (Supplementary 
Material) and devised a pre-defined search protocol. Our primary objective was to determine what 
proportion of individuals, detected with HIV through community-based testing, link into HIV care 
and/or start ART. We use the term HIV detection to refer to HIV diagnosis through community-based 
HIV testing services (HTS) or self-report of known HIV-positive status at the time of HTS. 
Search strategy 
We summarised studies that described the cascade of care following HIV detection through 
community-based approaches (namely home-based HTS (HB-HTS) or mobile/outreach HTS (M-HTS) 
approaches which use mobile units or temporary structures), in SSA. We searched Pubmed, Embase 
and Global Health electronic databases. We developed a broad compound search strategy that 
combined terms for “home based”, “mobile”, “community”, “work-place”, “school-based”, “self-
testing” “HIV” and “voluntary counselling and testing” (Supplementary Material). We also manually 
searched the bibliographies of relevant articles. We screened studies published between January 
2006 and February 2016 irrespective of study design – examining data from the last decade to 
reflect the period during which community-based testing has become more widespread and to 
maximise relevance to current practice.  
Inclusion criteria for the review were studies which reported the proportion of individuals, detected 
with HIV through community-based testing, who link into HIV care and/or start ART, in SSA between 
January 2006 and February 2016 irrespective of study design. We excluded data on HIV testing in 
health-care facilities (HCFs) (or satellite sites of HCFs), or treatment initiation in the household, as 
our primary focus was on linkage to care to receive services (including ART initiation) at HCFs. We 
also excluded reports that pooled data from previously published studies to avoid duplication. 
Where there was substantial overlap of study subjects in more than one paper, we included the 
paper with the most complete information. Our search was limited to English language peer-
reviewed journal articles; with no age restrictions for participants. We excluded conference 
abstracts.  
Eligibility of articles was determined independently by two investigators (KS and OV). Using a 
standardised data-extraction form (KS and BH) independently extracted data on study characteristics 
and outcomes, with input from OV. Any disagreements were resolved by consensus.  Markers of 
study quality were examined and strengths and limitations of the studies are presented in Table 2. 
Studies were not excluded for quality reasons using formal criteria for reporting scientific data, not 
least because a large proportion of the available data came from operational delivery of HTC services 
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and authors presented data as were available from the programmes. Data from randomised 
controlled trials are, however, emphasised in the Discussion section.   
Ethical approval was not required as only published literature was included for review. 
Data synthesis and analysis 
If studies reported different approaches to testing (e.g. by study arm) we reported linkage outcomes 
by modality (e.g. M-HTS or HB-HTS) where possible. We calculated the proportion of individuals: i) 
linked-to-care and ii) initiated on ART and explored time to linkage to care and ART initiation. 
Further, we summarised retention on ART among those who initiated and extracted data on viral 
suppression, if studies reported this. 
A meta-analysis was considered but upon review of the data, not deemed appropriate for the 
following reasons: i) variability in definitions used for numerators and denominators when 
calculating proportions linked-to-care and initiated ART; ii) variability between studies in follow-up 
time and approaches for measuring time for linkage to care and treatment initiation; iii) wide 
variability in findings.  
5.4 Results 
Characteristics of included studies 
Our initial search yielded 2888 articles, of which 170 were reviewed as full-text articles and 20 were 
included in the final review (Supplementary Figure-1). From these 20 articles we present results of 
analyses based on 22 “studies” (Table-1) because one paper reported outcomes for HB- and M-HTS 
separately by modality, and a second reported results on random household HB-HTS and index TB 
patient household-member HB-HTS, as sub-groups. (9, 10)  The studies were from six countries:  
Kenya, Lesotho, Malawi, South Africa, Swaziland, and Uganda (9-28), mostly from rural areas, and 
were conducted between 2008 and 2015. Most studies offered HTS for adults (mostly aged ≥18 
years, but ≥13 years in one study), while 7 studies also offered HTS to children (mostly if they were 
orphaned or known to be HIV-exposed) (Supplementary Table-1). Regional adult HIV prevalence 
(obtained from UNAIDS national data if not reported by authors) ranged from 5-35%.  
Twelve studies reported on linkage to care after HIV detection through HB-HTS – most were door-to-
door services provided by lay counsellors; one was targeted HB-HTS for household contacts of TB 
patients(10); another was HB-HTS for randomly selected households(10); and one study used oral 
self-test kits which were distributed by trained volunteers from the community.(16) One of the door-
to-door HB-HTS studies was from a national HIV testing campaign.(15) Eight studies were on M-HTS 
approaches – which included use of mobile-vans, tents in busy community locations, shopping areas, 
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transport hubs, etc. The two remaining studies presented linkage outcomes from HB- and M-HTS in 
combination without stratifying linkage to care and ART outcomes by the approach of the HTS.(26, 
28) Three of the twenty-two studies provided HTS within a multi-disease intervention (one HB-HTS 
and two M-HTS studies).(9, 11)  
Nine studies estimated population size served by the testing intervention and fourteen reported the 
number encountered and offered testing. Proportions offered testing among the population served 
by the HTS ranged from 19-98% (Supplementary Table-1).  Proportions accepted testing among 
those offered testing ranged from 53% to ~100% in the twelve studies in which this could be 
calculated.  The proportion accepting HIV testing of the population served by the HTS ranged from 
17-91% (five home-based studies) while the only M-HTS study presenting the necessary data 
reported 25% coverage.    
HIV-positivity among those tested ranged from 4-30% in HB-HTS studies; 5-15% in M-HTS studies 
(Table-1). In two studies which reported on both HB- and M-HTS in the same setting, HB-HTS had a 
slightly lower proportion detected with HIV than M-HTS (3.5% vs 4.7%  and 3.6% vs 6.2%, 
respectively).(9, 28) Four studies excluded individuals who self-reported knowing they were HIV-
positive but the majority included previously known HIV-positive individuals among the number 
reported as detected by HTS - therefore proportions HIV-positive from those studies are not limited 
to newly detected individuals.   
As a result of losses from follow-up, data on proportions linked-to-care were limited to individuals 
who could be followed-up to identify linkage information (see Table-2). Twelve studies relied on 
individual self-report of linkage/ART initiation (three studies provided information on data which 
could be verified at clinics), eight studies used clinic records to obtain linkage and care outcomes, 
while two did not specify how outcomes were determined.  
Linkage to care outcomes  
Proportions linked-to-care 
Definitions used for linkage to care varied as did methods of outcome ascertainment. Some studies 
described the outcome simply as “linkage to care” while others specified definitions used including 
proxy markers such as “CD4-count measured” or “CD4-count result received”; or identifying 
registration at the HCF where PLWH were referred (Table-1). Some studies restricted the 
denominator to newly diagnosed individuals when calculating proportions linked-to-care while 
others included those previously known to be HIV-positive provided they were not already in 
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care/on ART (Table-1). Seven studies did not report HIV-positive individuals as newly diagnosed or 
previously known PLWH and may have included individuals already in care.  
Proportions linked-to-care ranged from 14-96% among HB-HTS studies and from 10-79% among M-
HTS studies over 1-10 months of observation, with no obvious differences by HTS approach (Figure-
1a). Labhardt et al compared outcomes after HB- and M-HTS in the same setting and found no 
difference in proportions linked-to-care (HB-HTS: 26% (10/39) vs M-HTS: 25% (19/75)). The data 
suggest (see Figure-1b) that linkage to care was higher when all PLWH not already on treatment 
(newly diagnosed and previously known HIV-positive) were examined, than among newly diagnosed 
PLWH alone. 
Linkage to care by duration of follow-up 
The periods of observation varied between studies and time available for observing linkage varied as 
a result. Studies ascertained linkage outcome by carrying out home-visits (occasionally in 
combination with telephone calls), once or at intervals after HTS; or consulted HCF records using a 
unique identifier to identify individuals who had been referred by HTS. The follow-up periods shown 
in Figure-2a represent the time between an individual being seen at HTS (when tested HIV-positive 
or self-reported HIV-positive status) and linkage-into-care. There was great variability in linkage to 
care between studies for similar time-points. The most commonly reported follow-up period for 
which linkage was reported was 3-months and proportions linked-to-care ranged from 7-85% 
(Figure-2a).  
The total study periods are shown in Table-2. Few studies reported outcomes beyond 6-months 
following HTS (Figure-2a).  Only two studies reported observed cumulative proportions linking-into-
care over more than one time-point and while both showed progressive increases with time, the 
relative increase was small.(14, 27) Six studies are not shown in Figure-2a because they did not 
report time taken for individuals to link. Some of these studies described overall proportions linked-
to-care at various periods of time following the HTS programme, but not the time interval between 
an individual’s HIV detection at HTS and linkage to care. Six studies presented cumulative probability 
of linkage to care curves over time, using time-to-event analyses.  Those estimates suggest that most 
linkage appears to occur in the first 3-months - with some studies showing incremental benefit up to 
12-months,(14, 15, 27) while others showed plateauing over time after an initial steep increase in 
the first 1-3 months.(18, 19, 25) 
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Approaches to facilitate linkage to care  
Several studies used field-worker follow-up as a means to encourage and monitor linkage to care. 
Follow-up visits to PLWH were employed by 7 HB-HTS studies and 1 M-HTS study (Table-1). One 
randomised controlled trial (RCT) with a factorial design (reporting linkage from HB- and M-HTs in 
combination), examined three approaches following detection of HIV - follow-up visits by a lay 
counsellor in one study arm and facilitation by a lay counsellor in the clinic in another study arm, 
both to enhance linkage to care, compared with a standard-of-care referral only arm.(26) Both 
approaches to improve linkage achieved high linkage to care with the clinic facilitation arm achieving 
a stronger effect than the lay counsellor home follow-up, when compared to the control (referral 
only) arm. Two studies used telephone calls to follow-up on PLWH detected through M-HTS.(20, 24) 
There is no clear evidence across all the studies that interventions to enhance linkage to care 
improved outcomes (Supplementary Figure-2a) 
Eleven studies provided CD4-counts at the time of HTS (using portable point-of-care (POC) 
technology or providing results within days of HTS if venous sampling was done for laboratory 
testing) (Supplementary Table-1). There is no clear evidence across studies that the proportion 
linked-to-care was higher if CD4-counts were provided at the time of HIV detection (Figure-1c). The 
above factorial design RCT also randomly allocated the clients from the 3 study arms described 
earlier to have either POC CD4-countor CD4-count sampling in the clinic. They found no benefit from 
POC CD4-count sampling over clinic testing on linkage to care, ART initiation or viral suppression.(26)   
Predictors of linkage to care  
Several studies reported factors associated with linkage to care. In eight studies (3 HB-HTS,4 M-HTS, 
1 combined HB-M-HTS) which reported on potential gender differences, five reported that fewer 
men linked-to-care than women(13-15, 17, 20) although one of those did not detect a statistically 
significant difference (17) and three other studies(11, 22, 28) found no association between gender 
and linkage to care. However, the trend was always for fewer men than women to link. Five studies 
found that older adults were more likely to link-to-care(13-15, 25, 28), while four observed no 
differences by age(11, 17, 22, 27). Parker et al was the only study to consider linkage in adolescents 
specifically (defined as 9-19 years), and while they observed that this group appeared to be more 
likely to link-to-care the association was of borderline statistical significance (adjusted odds ratio of 
2.5 (95% confidence interval: 1.0-6.0)).(28) Several other studies included people as young as 13-
years of age but considered them as adults. Three studies described the association of education 
with linkage to care, and no clear pattern was observed.(13, 14, 22) Marital status was also not 
predictive of linkage to care.(11, 13, 17, 22) 
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ART initiation outcomes 
Proportions initiating ART 
Proportions initiating ART among those eligible was reported in eight HB-HTS studies, two M-HTS 
studies and both combined HB-/M-HTS studies. As described above for linkage to care, the time 
available for ART initiation within the study periods varied (Table-2). The studies varied in ART 
eligibility criteria applied. Most studies had a CD4-count threshold of 350/cc3, while several had a 
threshold of 200-250/cc3 (Table-1). Ascertainment of CD4-count eligibility for ART was done at the 
time of HTS in some studies but only upon linkage to care and sampling at the clinic in other studies 
(Supplementary Table 1). 
Reported proportions initiating ART ranged from 23-85% in HB-HTS and combined HB-/M-HTS 
studies. The wide range is in part explained by the fact that the denominators varied. Most studies 
used HIV-positive individuals identified as eligible as the denominator while a minority used either 
all individuals identified as HIV-positive or those linked-to-care, and not already on ART (irrespective 
of CD4-count) (Table-1). Further, as shown in Supplementary Table-1 some studies identified ART 
eligibility in the community at the time (or within days) of HTS, while in others eligibility was only 
assessed once individuals had linked-to-care. Both M-HTS studies had very small samples of PLWH 
(less than 20 individuals referred for ART) to assess initiation of ART (Table 1).(11, 22) There were no 
notable differences in ART initiation based on HTS approach (Figure-1d); newly diagnosed vs all 
PLWH not on treatment (new and previously diagnosed) (Supplementary Figure-2b); and whether 
CD4-count results were provided during HTS (Supplementary Figure-2c). Among PLWH who self-
reported HIV-positive status after self-testing at home (and meeting ART eligibility criteria), 23% 
initiated ART.(16)   
ART initiation by duration of follow-up  
Eight studies reported ART initiation by time since HIV detection. There was no apparent trend and 
there was variability in the outcomes reported as seen in Figure-2b. Only two studies reported 
outcomes at more than one time-point, (14, 27) with one reporting cumulative outcomes based on 
time-to-event analysis estimates (27) (Figure-2b).  
Predictors of ART initiation 
Predictors of ART initiation were only examined in one study.(27) CD4-count was the only factor 
identified as predictive of ART initiation, with PLWH with CD4-counts <200/cc3 more likely to initiate 
ART than those with CD4-counts of 201-350/cc3. When we compared ART initiation by CD4-count 
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threshold across the studies in this review there were no distinct differences notable (data not 
shown). 
Retention on ART and viral suppression 
Retention on ART was reported by just one study. Macpherson et al reported that among those 
detected through self-testing at home, 6-months after ART initiation at the HCF, 76% (48/63) of 
participants were still on ART.(16) Three studies described viral suppression among participants on 
ART. One of them included patients who were already on ART before HB-HTS.(19) The remaining 
two studies both by Barnabas et al reported viral suppression (viral load < 1000 copies/ml) of 77% 
(59/77) among patients on ART for between 3-12 months in one study(27); and 85% (412/483)  of 
patients who initiated ART within 9-months of HIV detection in another study (with variable 
durations on ART).(26) 
5.5 Discussion 
 Community-level HIV testing has become established as a feasible and effective approach to 
increasing knowledge of HIV status in SSA(29). Others have published broad over-views of evidence 
following HTS (community and facility-based) and pooled outcomes, while acknowledging the 
limitations of summarising heterogeneous data.(5, 6) In our systematic review, we aimed to provide 
a more detailed scrutiny of the data on steps on the cascade of care - including examination of 
indicators used, measures of the numerators and denominators used to define linkage and 
treatment initiation, time-scales to observe outcomes etc. - with a specific focus on community-
based HTS in SSA. We aimed to establish how effective community-level HTS approaches are at 
getting PLWH into care, beyond knowledge of HIV status alone, with a view to achieving 90-90-90 
targets. 
Definitions used for linkage to care and periods of observation for linkage to care and ART initiation 
outcomes varied between studies. Data were limited to individuals who could be traced and the 
proportion of those identified HIV-positive at HTS in whom linkage and ART initiation outcomes 
could be ascertained was often low (Supplementary Table-2).  Most studies also relied on self-
reported outcomes.  
The above factors make summarising outcomes challenging and pooling of results potentially 
misleading. These important limitations in the data notwithstanding, we found that M-HTS and HB-
HTS were equally effective at achieving LTC. We did not find discernible differences in terms of ART 
initiation although data on ART initiation after M-HTS was limited. There is a suggestion of higher 
linkage to care among those previously diagnosed (who had not already started ART) compared to 
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newly diagnosed individuals. This fits with the idea that individuals need time to act on an HIV-
positive diagnosis. However, this group is heterogeneous and the barriers to link for those who have 
known their HIV status but not engaged with care compared to those already in care and have not 
started ART may be quite different. 
As described, only one study performed a randomised comparison of interventions to enhance 
linkage and they reported nuanced findings.(26) While clinic facilitation by a lay counsellor was more 
effective than lay-counsellor home follow-up at increasing linkage to care, it is was the latter which 
was more effective at increasing uptake of ART (Table-1). There were also no differences in viral 
suppression at 9-months between PLWH randomised to intervention arms vs standard of care 
(referral for care only). This highlights the importance of measuring all the key steps of the cascade 
of care, as improvements in linkage to care may not translate to better treatment uptake or 
outcomes once on treatment. Providing CD4-count results at the time of community-based HTS did 
not appear to influence linkage to care or ART initiation in our systematic review. The difference 
between our findings and other data which have shown benefits following POC CD4-counts, is that 
we were looking at whether it benefited linkage to care following use in the community rather than 
use of POC CD4-counts in clinics for patients who had already attended.(30)  
Studies reported that several patients were not initiated on ART (and told they were not eligible) 
despite being eligible.(28) (26) Transition to latest WHO guidelines of treatment for all PLWH will 
minimise decisions at the clinic level and reduce missed opportunities to offer/initiate treatment, 
provided that drugs are consistently available. Community delivery of ART for stable patients has to 
the potential to reduce the burden on HCFs and improve access for patients, thereby simplifying the 
cascade of care.(31) Macpherson et al examined home-initiation of ART following self-testing (in a 
randomised comparison with initiation of ART at the HCF which was included in this review).(16) 
They found higher proportions initiating ART in their home-initiation arm (although proportions 
retained on ART after 6 months were not different when compared with the facility-initiation arm). 
Several studies on community-based HTS did not meet the eligibility criteria for inclusion in our 
review because data on linkage to care or ART initiation were not reported. This excluded some 
work-place or school-based HTS programmes and there is only one study on a national testing 
campaign. Among eligible studies several of them stopped at reporting proportions linked-to-care 
without describing proportions initiating ART, especially M-HTS studies.  The scant reporting on viral 
suppression is probably related to low access to routine viral load testing in most SSA settings, but 
only one study included data on ART retention.  
 119 
 
The under-reporting within studies of multiple steps on the cascade alludes to the challenges in 
obtaining accurate data at the individual-level, for the continuum of care. In addition, it may indicate 
that health-care provider/researchers lack the resources to examine and report HIV care as a 
continuum, instead targeting efforts at individual steps in isolation. 
The limitations of this review have been described at length above. The strengths however include 
the fact that we limited our search to studies conducted in SSA over the last decade, thereby 
maximising relevance for current practice. The attention to detail when examining definitions used 
to measure outcomes also sheds light on the complexity of the data presented in current literature. 
We made the deliberate choice not to summarise data from studies in our review using meta-
analysis, given the heterogeneity in the data. Further, we provide a template of proposed standard 
indicators as a guide for data collection and reporting of community-based HTS programme 
performance on the cascade of care (Supplementary Figure-3). While not exhaustive, we hope that 
this will help minimise inconsistencies in future literature.  
The UNAIDS 90-90-90 targets are an important reminder of the multiple steps needed to provide 
comprehensive HIV care. With currently published data it was not possible to estimate current 
performance against 90-90-90 goals. The premise of the 90-90-90 targets is that the total number of 
PLWH in a given setting has to be known or, more realistically, estimated accurately and only then 
can the first proportion be calculated (to compare against the first-90). There is ambiguity in the 
term “sustained ART” (in the definition of the second-90) or what duration should be allowed for 
viral suppression to be achieved (to compare against the third-90). The other challenge is that the 
UNAIDS targets are “point” measures - at any point of time, 90% of HIV-positive individuals need to 
know their status, 90% of those who know their status need to be “on ART”, and 90% of the latter 
need to be virally suppressed. Data on time to link-to-care or initiate ART are therefore difficult to 
use to estimate the coverage against the UNAIDS targets, as they are not point measures. 
 This systematic review has identified the gaps and inconsistencies in the current literature 
quantifying the continuum of care. We found no differences in linkage to care or ART initiation by 
community testing approach but comparisons were hampered by the variability in reporting. We 
recommend that standardised measures of reporting of steps of the cascade of care are much 
needed in order to be able to measure progress against targets and across settings. 
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Author, 
Year 
Country, 
Rural/ 
Urban 
Testing approach  
Intervention(s) 
to enhance 
LTC1 
Proportion 
HIV+ (%) 
Number HIV+ 
Numerator 
for % LTC 
 
Denominator 
for % LTC 
 
Proportion 
 LTC 
% (n/N) 
Numerator 
for % 
initiated 
ART 
 
Denominator for 
%  
initiated ART 
 
Proportion 
initiated 
ART 
% (n/N) 
Newly 
identified 
HIV+ 
Known 
HIV+, 
not in 
care/ on 
ART 
HB-HTS 
Barnabas, 20142 
South 
Africa & 
Uganda, 
Rural & 
peri-
urban 
Door-to-door HB-
HTS study 
i, ii &iii  19.0 229 152 
n visiting an 
HIV clinic  
N newly 
diagnosed or 
known HIV+ 
not on ART  
96%  
(367/381) 
n initiated 
ART  
N  newly 
diagnosed or 
known HIV+ not 
on ART &  CD4 
<350/cc3 
76%  
(94/123) 
Dalal,  
2013 
Kenya, 
Rural + 
urban 
Door-to-door HB-
HTS 
implementation 
ii & iii 16.3 1839 NR 
n accessing 
patient 
support 
centre  
N newly 
diagnosed 
47%  
(454/958) 
n initiated 
ART 
N newly 
diagnosed adults 
& CD4 <250/cc3 
 
34% 
43/125 
Genberg, 2015 
Kenya, 
Rural,  
 
Door-to-door HB-
HTS 
implementation 
 
iv 11.0 1360 344 
n having 
clinical 
encounter 
with HIV care 
provider 
N newly 
diagnosed or 
known HIV+ 
not in care  
14%  
(243/1704) 
 
n initiated 
ART 
N newly 
diagnosed, 
eligible and LTC 
(ART eligibility 
NR) 
85%  
(78/92) 
N known HIV+ 
not on ART 
(ART eligibility 
NR) 
53% 
(18/34)  
Labhardt, 2014 
Lesotho, 
Rural 
Door-to-door HB-
HTS and multi-
disease services 
(within a cluster 
randomised trial) 
v 3.6 39 NR 
n linked to 
care 
N newly 
diagnosed 
26%  
(10/39) 
NR  NR NR 
MacKellar, 2016 
Swaziland, 
Rural + 
urban 
Door-to-door HB-
HTS  national 
campaign 
ii & vi NR 850 NR 
n received 
CD4 count 
result or 
WHO staged 
N newly 
diagnosed 
27%  
(209/788) 
NR NR NR 
Medley,  
2013 
Kenya, 
Rural 
Door-to-door HTS 
within 
demographic 
surveillance 
ii & iii 11.0 923 NR 
n currently 
attending to 
HIV clinical 
care 
N adults 
tested HIV+ 
42%  
(312/737) 
n on ART 
N adults tested 
HIV+ and LTC 
(ART eligibility 
NR) 
26%  
(80/312) 
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Author, 
Year 
Country, 
Rural/ 
Urban 
Testing approach  
Intervention(s) 
to enhance 
LTC1 
Proportion 
HIV+ (%) 
Number HIV+ 
Numerator 
for % LTC 
 
Denominator 
for % LTC 
 
Proportion 
 LTC 
% (n/N) 
Numerator 
for % 
initiated 
ART 
 
Denominator for 
%  
initiated ART 
 
Proportion 
initiated 
ART 
% (n/N) 
Newly 
identified 
HIV+ 
Known 
HIV+, 
not in 
care/ on 
ART 
Naik, 
2015 
South 
Africa, 
Rural 
Door-to-door HB-
HTS study 
ii 9.7 274 NR 
n linked to 
care 
N clients 
tested HIV+ 
not already in 
pre-ART or 
ART care  
76%  
(273/359) 
NR NR NR 
Tumwebaze, 20122 
Uganda, 
Rural & 
peri-
urban  
 
Door-to-door HB-
HTS study 
i & ii 9.8 77  36 
n visiting an 
HIV clinic  
N  newly 
diagnosed or 
known HIV+ 
but not on ART  
85% 
(96/113) 
n initiated 
ART  
N newly 
diagnosed  or 
known HIV-
positive not on 
ART & CD4 <250/ 
cc3 
71%  
(15/21)  
van Rooyen, 2014 
South 
Africa, 
Rural 
Door-to-door HB-
HTS study 
i & iii 30.0 73 64 
n visited HIV 
clinic  
N adults newly 
diagnosed or 
known HIV+ 
but not on ART  
96%  
(131/137) 
n initiated 
ART  
N newly 
diagnosed &CD4 
<350/cc3 and LTC 
54% 
(19/35) 
N known HIV+, 
not on ART & 
CD4 <350/cc3 
and LTC 
65% 
(17/26) 
MacPherson, 2014 
Malawi, 
Urban  
Study involving 
self-testing with 
oral test kits 
offered to 
household 
members 
(within a cluster 
randomised trial) 
v NR 278 NR NR NR NR 
n initiated 
ART  
N reporting HIV+ 
self-test result & 
CD4 <350/cc3 
and LTC 
23% 
(63/376) 
Shapiro,  
2012 
 
South 
Africa, 
urban 
Index case (TB 
patients) driven 
HB-HTS study  
ii for ART 
eligible/ iv for 
ART non-
eligible) 
14.6 NR NR NR NR NR 
n initiated 
ART 
N HIV+ 
household 
contacts of a TB 
index case & CD4 
<250/cc3 
41% 
(13/32) 
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Author, 
Year 
Country, 
Rural/ 
Urban 
Testing approach  
Intervention(s) 
to enhance 
LTC1 
Proportion 
HIV+ (%) 
Number HIV+ 
Numerator 
for % LTC 
 
Denominator 
for % LTC 
 
Proportion 
 LTC 
% (n/N) 
Numerator 
for % 
initiated 
ART 
 
Denominator for 
%  
initiated ART 
 
Proportion 
initiated 
ART 
% (n/N) 
Newly 
identified 
HIV+ 
Known 
HIV+, 
not in 
care/ on 
ART 
Shapiro,  
2012 
 
South 
Africa, 
urban 
Randomly selected 
household HB-HTS 
study  
As above 10.6 NR NR NR NR NR 
n initiated 
ART 
N HIV+ non- 
contact 
participants with 
CD4 <250/cc3 
53%  
(10/19) 
Community outreach and HB-HTS 
Barnabas, 2016 
 
South Africa 
& Uganda, 
Rural 
Door-to-door HB-
HTS  
& M-HTS using 
mobile testing  
(details NR) 
(LTC assessed 
within factorial 
design 
randomised 
controlled trial4) 
vii 15.0 992 333 
n visiting an 
HIV clinic  
 
N newly 
diagnosed & 
known HIV+ 
not on ART 
(Lay 
counsellor FU 
arm) 
93% 
(419/449) 
n initiated 
ART  
 
N newly 
diagnosed & 
known HIV+ 
not on ART 
(Lay counsellor 
FU arm) 
41% 
(185/449) 
 
N newly 
diagnosed & 
known HIV+ 
not on ART 
(Clinic 
facilitation 
arm) 
98% 
(421/431) 
N newly 
diagnosed & 
known HIV+ 
not on ART 
(Clinic 
facilitation 
arm) 
37% 
(161/431) 
N newly 
diagnosed & 
known HIV+ 
not on ART 
(Referral only 
arm) 
89% 
(378/423) 
N newly 
diagnosed & 
known HIV+ 
not on ART 
(Referral only 
arm) 
34% 
(142/423) 
Parker,  
2015 
Swaziland, 
Rural  
 
Door-to-door HB-
HTS 
implementation 
ii & vi 3.8 242 12 
n registered 
in pre-ART 
care 
N newly 
diagnosed 
34%  
(135/398) 
n initiated 
ART 
N newly 
diagnosed & 
CD4 <350/cc3 
and LTC  
52%  
(22/42) M-HTS with tents 
at community 
locations  
As above 
4.7 
 
96 
 
12 
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Author, 
Year 
Country, 
Rural/ 
Urban 
Testing approach  
Intervention(s) 
to enhance 
LTC1 
Proportion 
HIV+ (%) 
Number HIV+ 
Numerator 
for % LTC 
 
Denominator 
for % LTC 
 
Proportion 
 LTC 
% (n/N) 
Numerator 
for % 
initiated 
ART 
 
Denominator 
for %  
initiated ART 
 
Proportion 
initiated 
ART 
% (n/N) 
Newly 
identified 
HIV+ 
Known 
HIV+, 
not in 
care/ on 
ART 
Community outreach  
Bassett,  
 
2015 
South 
Africa, 
Urban 
M-HTS with 
mobile units at 
taxi stands, 
markets, and 
sporting grounds 
Phlebotomy for 
CD4-count 
done at time of 
M-HTS; v for 
clients who 
retrieved 
results  
 
10.0 455 455 
n retrieved 
CD4-count 
(within 90 
days) OR 
initiated ART 
literacy (at 
any time) 
 N newly 
diagnosed 
10%  
(45/455) 
NR NR NR 
Chamie,  
2012 
Uganda, 
Rural 
 
M-HTS multi-
disease 
campaign held at 
community 
locations  
 
i & iv 
7.8 82 28 
n attending 
at least one 
clinic 
appointment 
N newly 
diagnosed  
34% 
(25/64) 
n initiated 
ART 
N newly 
diagnosed & 
CD4 ≤100/cc3 
and LTC 
83%  
(5/6)  
Govindasamy,  
2013 
South 
Africa, 
Urban & 
peri-urban 
M-HTS provided 
five days per 
week at work 
sites (i.e. 
farms), outside 
various 
community 
locations 
i & ii 5.5 294 NR 
n attended 
HCF within 
≤1mth if 
CD4≤200/cc3;  
≤3mth if  
CD4 201-
350/cc3; 
≤6mth if 
CD4>350/cc3 
 
N newly 
diagnosed 
CD4≤200/cc3 
 38% 
(18/48)  
CD4 
200/cc3  
 
n on ART at 
1mth 
follow-up 
N newly 
diagnosed 
adults & CD4 
≤200/cc3and 
LTC 
83%  
(15/18) 
N newly 
diagnosed 
CD4           
201-350/cc3 
53% 
(44/83) 
CD4  
201-
350/cc3 
N newly 
diagnosed & 
CD4>350/cc3 
53% 
(77/145) 
Hatcher,  
2012 
Kenya, 
Urban  
 
M-HTS using 
tents in six 
community sites 
i & v NR 808  NR 
n  
linked to care 
N tested HIV+ 
and not  
in HIV care  
10m: 81% 
(393/483) 
NR NR NR 
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1.  i:POC CD4; ii: Written referral; iii: Lay counsellor follow-up (FU); iv: Verbal referral; v: Referred but mode of referral not reported; vi: Telephone reminder or call to FU; vii: Randomised comparison of 
POC CD4-count vs clinic CD4-count + Randomised comparison of lay counsellor FU vs  lay counsellor clinic facilitation vs referral only (mode of referral not reported) 
If follow-up (FU) visits were done, frequency of and intervals between FU are shown in Supplementary Table 1 
2. Incentives provided for study participation (not for linkage-to-care) 
3. Children whose biological mother was deceased or known to be HIV+  
4. We have not shown outcomes by POC CD4-count vs clinic CD4-count arms as outcomes were very similar  
 
Author, 
Year 
Country, 
Rural/ 
Urban 
Testing approach  
Intervention(s) 
to enhance 
LTC1 
Proportion 
HIV+ (%) 
Number HIV+ 
Numerator 
for % LTC 
 
Denominator 
for % LTC 
 
Proportion 
 LTC 
% (n/N) 
Numerator 
for % 
initiated 
ART 
 
Denominator 
for %  
initiated ART 
 
Proportion 
initiated 
ART 
% (n/N) 
Newly 
identified 
HIV+ 
Known 
HIV+, 
not in 
care/ on 
ART 
Kranzer, 20122 
South 
Africa, 
Urban 
M-HTS using a 
van parked at a 
township 
shopping centre 
or in front of a 
primary school 
 
iii or vi if 
CD4 <350/cc3 
10.9 102 NR 
n linked to 
care 
N  newly 
diagnosed & 
CD4  ≤350/cc3 
79%  
(26/33) 
NR NR NR 
Labhardt, 2014 
Lesotho, 
Rural 
Community 
gatherings in 
villages followed 
by M-HTS and 
multi-disease 
services (within a 
cluster 
randomised trial)  
v 7.5 75 NR 
n linked to 
care 
N newly 
diagnosed 
25%  
(19/75) 
NR NR NR 
Larson,  
2012 
South 
Africa, 
NR  
 
M-HTS using 
mobile units and 
tents/gazebos in 
taxi ranks/ 
shopping malls  
i (if nurse 
providing M-
HTS had 
equipment),  
v & vi 
NR NR NR 
n completed 
referral visit  
N tested HIV+   
54%  
(172/316) 
NR NR NR 
van Zyl,  
2015 
South Africa 
Rural + 
urban 
M-HTS (details 
NR) 
vi NR NR NR 
n tested HIV+  
and ART 
eligibility 
assessed. 
N tested HIV+  
51%  
(563/1096) 
NR NR NR 
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Table 5.2: Markers of study quality and additional characteristics 
 
Author, 
Year 
How was 
outcome 
determined? 
Did outcome 
exclude 
those already 
LTC 
(or on ART)? 
Period of 
Study for LTC 
(or ART 
initiation) 
% in whom 
outcome not 
ascertained 
among those 
testing HIV+ 
Reasons outcome not 
ascertained 
Who 
delivered 
HTS? 
Timing of interim 
follow-up visits 
Participant selection 
 
HBHTS 
Barnabas, 
2014 
Self-reported & 
review of clinic 
cards/medicati
ons with the 
individual 
Y 
(excluded 
individuals on 
ART) 
12m 
10% 
(n=60/635)i 
Moved (57%; n=34) 
Died (25%; n=15) 
Withdrew (18%; n=11) 
Lay 
counsellor 
1, 3, 6, 9m with 
voice and/or text 
message 
reminders of 
follow-up visits 
Individuals consenting to 
door-to-door offer of 
HBHTS 
Dalal, 
2013 
Self-reported Y 1m 
48% 
(n=881/1839) 
NR 
Trained 
counsellors 
1m post-HTS 
Individuals consenting to 
a household visit from 
HBHTS & accepting an 
offer of HBHTS 
Genberg, 
2015 
Health facility 
records 
Y 3m 
2% 
(n=33/1360) 
LTFU (91%; n=30) 
Died (9%; n=3) 
 
Trained 
counsellors 
NR 
Individuals consenting to 
door-to-door offer of 
HBHTS 
Labhardt, 
2014 
(HBHTS) 
Health facility 
records 
N 1m 0 NA 
Lay 
counsellor 
and nurse 
No FU visits 
Individuals consenting to 
door-to-door HBHTS 
MacKellar, 
2016 
Health facility 
records 
Y 26m NRii NR NR 
FU by telephone 
at 8w 
Individuals consenting to 
door-to-door offer of 
HBHTS 
Medley, 
2013 
Self-reported N 
2-4m post-
HBHTS 
32% 
(n=350/1087) 
 
Did not consent to FU visits 
(41%; n=144) 
Migrated 
(25%; n=89); 
Refused (20%; n=70); 
Died (6%; n=20); 
Missing/not at home (8%; 
n=27) 
Trained 
counsellors 
3 attempts to 
visit home by 
HIV-positive peer 
educators 
Individuals consenting to 
door-to-door offer of 
HBHTS 
Naik, 
2015 
Self-reported & 
health facility 
records 
Y 3m 
18% 
(n=79/438) 
LTFU completely or LTFU 
prior to 3mth (90%; n=71) 
Died (10%;  n=8) 
Lay 
counsellors 
“Periodic” home 
visits or phone 
calls 
Individuals consenting to 
door-to-door offer of 
HBHTS 
Tumwebaze, 
2012 
Self-reported 
 
N 3m 
2% 
(n=3/152) 
NR 
Trained 
HBHTS 
study staff 
1 & 2m 
Individuals consenting to 
door-to-door offer of 
HBHTS 
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van 
Rooyen, 
2013 
Self-reported & 
review of care 
documentation
/ medication 
with individual 
N 6m 
4% 
(n=5/137) 
Died (60%; n=3) 
Withdrew (40%; n=2) 
Lay 
counsellors 
or nurse 
assistants 
1, 3, & 6m 
Individuals consenting to 
door-to-door offer of 
HBHTS 
MacPherson, 
2014 
Health facility 
records 
Y 
(restricted to 
those not 
initiated on 
ART) 
6m 
(ART 
initiation) 
NA NA Self-testing No FU visits 
Individuals opting to self-
test (mostly at home) 
Shapiro 
(TB-
contacts), 
2012 
NR N 
2m 
(ART 
initiation) 
NR NR 
Nurse & lay 
counsellors 
NR 
HBHTS offered to 
household members of 
index TB patient 
Shapiro 
(Random 
HH), 
2012 
NR N 
2m 
(ART 
initiation) 
NR NR 
Nurse & lay 
counsellors 
NR 
HBHTS offered to 
household members of 
randomly selected 
households 
Community outreach & HBHTS 
Barnabas, 
2016 
Self-reported & 
review of clinic 
cards/medicati
ons with 
individual 
Y 
(excluded 
individuals on 
ART) 
9m 
3% 
(n=40/1325)iii 
Died (34%; n=8) 
Moved (18%; n=6) 
Withdrew (9%; n=3) 
Unknown (68%; n=23) 
Lay 
counsellors 
(Uganda); 
Lay 
counsellors 
& nurse 
teams (SA) 
1,3 and 6m for 
individuals 
randomised to 
lay counsellor FU 
Individuals consenting to 
door-to-door offer of 
HBHTS or self-selected 
through MHTS 
Parker, 
2015 
(HBHTS) Health facility 
records 
N 6m NR NR 
HTS 
counsellors 
NR 
 
Self-selection through 
MHTS 
Parker, 
2015 
(MHTS) 
Individuals consenting to 
door-to-door HBHTS 
Community outreach 
Bassett, 
2014 
Health facility 
records 
Y 3m NR NR 
Trained 
counsellors 
No FU visits 
Self-selection through 
MHTS 
Chamie, 
2012 
NR Y 3m 
22% 
(n=18/82) 
Implementation errors 
(72%; n=13) 
Trained 
counsellors 
NR 
Self-selection through 
MHTS 
Govinda-
samy, 
2013 
Self-reported Y 
Dependent 
on CD4 cell 
count – up to 
6m 
6% 
(n=18/294) 
 
Refused (n=4; 22%) 
Followed-up before follow-
up period (n=14; 78%) 
Nurse & 
counsellor 
supported 
Telephone call 
1w post-
diagnosis 
Self-selection into mobile 
HTS 
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1. By 12m FU, LTFU reported among all individuals, including individuals on ART. Denominator therefore includes N=254 known HIV+ & on ART 
2. Not reported (NR) as outcome not reported separately for those detected through HB-HTS 
3. Loss to follow-up is reported as individuals not followed-up at 9m; some of these individuals contributed to analysis of LTC and/or ART prior to being LTFU 
4. Not applicable (NA): Individuals defined as “not linked to care” regardless of whether or not the individual was contactable. Among individuals not LTC, reasons available for LTC N=442: 
Asked not to be called (14%; n=63); Deceased (0.2%; n=1); Called many times (56%; n=249) Incorrect information (18%; n=79); No telephone (11%; n=50) 
 
Hatcher, 
2012 
Self-reported Y 10m 
40% 
(n=325/808) 
Did not provide locator 
information (38%; n=124) 
Not located at 10m FU 
(42%; n=137) 
Did not consent to FU 
interview (15%; n=47) 
Reported that they already 
enrolled in care prior to 
MHTS 
(5%; n=17) 
Trained 
counsellors 
FU visits 
conducted but 
timing NR 
Self-selection through 
MHTS 
Labhardt, 
2014 
(MHTS) 
Health facility 
records 
N 1m 0 NA 
Lay 
counsellor 
and nurse 
No FU visits 
Self-selection through 
MHTS 
Kranzer, 
2012 
Self-reported Y 
1 & 3m 
(dependent 
on CD4 cell 
count at 
diagnosis) 
20% 
(n=8/41) 
(restricted to 
those with 
CD≤350) 
Unable to contact by 
telephone or home visits 
(100%; n=8) 
Nurse with 
counsellor 
support 
(who 
conducted 
HTS  NR) 
Up to 7 attempts 
to contact (phone 
or face-to-face) 
individuals with 
CD4 ≤200 at 4w 
& CD201-350 at 
12w post-HTS 
Individuals accepting an 
invitation to MHTS 
Larson, 
2012 
Self-reported N 2m 
38% 
(n=192/508) 
Could not be contacted by 
telephone 
(100%; n=192) 
Nurse 
Three attempts 
to contact 
individuals by 
phone 8w post-
HTS 
Self-selection through 
MHTS 
van Zyl, 
2015 
Self-reported N 1m NAiv NA NR 
Daily FU 
telephone calls 
Self-selection through 
MHTS 
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Figure 5.1: Forest plots showing LTC outcomes by (a) HTS approach; (b) by PLWH sub-
groups; (c) by when CD4-count result was available; and (d) ART initiation outcomes by 
HTS approach  
(a) Proportions linked-to-care (LTC) by HTS approach 
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(b) Proportions LTC by PLWH sub-groups  
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(c) Proportions LTC by when CD4-count result was available  
CD4-count result at time of HTS
Kranzer(2012)
Labhardt(2014)
Govindasamy(CD4<200)(2013)
Chamie(2012)
Labhardt(2014)
Govindasamy(CD4201-350)(2013)
Tumwebaze(2012)
van Rooyen(2013)
Govindasamy(CD4>350)(2013)
Larson(2012)
Barnabas(2014)
Hatcher(2012)
Barnabas(2016)(POC CD4-arm)
CD4-count result upon LTC at clinic
Naik(2015)
Parker(2015)
Bassett(2014)
Barnabas(2016)(Clinic CD4-arm)
MacKellar(2016)
Dalal(2013)
Genberg(2015)
Author
33
39
48
64
75
83
113
137
145
316
381
483
627
359
398
455
676
788
958
1704
HIVpositive
26
10
18
25
19
44
96
131
77
172
367
393
592
273
135
45
626
209
454
243
LTC
78.8 (61.1, 91.0)
25.6 (13.0, 42.1)
37.5 (24.0, 52.6)
39.1 (27.1, 52.1)
25.3 (16.0, 36.7)
53.0 (41.7, 64.1)
85.0 (77.0, 91.0)
95.6 (90.7, 98.4)
53.1 (44.6, 61.4)
54.4 (48.8, 60.0)
96.3 (93.9, 98.0)
81.4 (77.6, 84.7)
94.4 (92.3, 96.1)
76.0 (71.3, 80.4)
33.9 (29.3, 38.8)
9.9 (7.3, 13.0)
92.6 (90.4, 94.5)
26.5 (23.5, 29.8)
47.4 (44.2, 50.6)
14.3 (12.6, 16.0)
ES (95% CI)
  
0 10 20 30 40 50 60 70 80 90 100
 135 
 
(d) Proportions initiating ART by HTS approach  
 
*Three studies (Shapiro (Random HH), 2012 (HB-HTS study); Govindasamy, 2013 & Chamie, 2012 (both M-HTS studies)) 
with less than 20 in the denominator (HIV positive) are not shown above  
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Figure 5.2a-b: Time taken following HIV-detection at HTS for individuals – (a) to link-to-care, (b) to initiate ART 
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Supplementary Table 5.1: Additional study information 
Author, 
Year 
Primary objective 
Estimated 
population 
eligible for 
testing 
intervention 
Number 
offered 
testing 
(%) 1 
Number 
accepted 
testing (%) 2 
Adults or 
children 
offered HTC 
% of individuals 
accepting HTS 
that are male 3 
Median CD4-
count 
measured 
at diagnosis 
/cc3 (IQR) 
Median CD4-
count  
measured 
at LTC 
/cc3 (IQR) 
CD4-count 
result available 
when  
1. HIV detected 
(or within days) 
2. after LTC    
HB-HTS 
Barnabas, 
2014 
To assess linkage to local HIV clinics, ART 
initiation among individuals eligible by 
national guidelines and viral suppression 
at 12mths 
NR 3545 
3393  
(96%) 
Adults aged 
≥18y 
42%  
(n=1424/3393) 
456 
(288-628) 
NR 1 
Dalal, 
2013 
To assess acceptance of HB-HTS, HIV 
prevalence and treatment referral rates 
NR 24450 
19966  
(82%) 
Adults & 
children4 
45% 
(n=8889/19966) 
403 
(252–594) 
NR 2 
Genberg, 
2015 
Proportion with known HIV infection 
identified at HB-HTS who had ever 
engaged in care; time to and predictors of 
linkage to care (LTC) 
66723 
(Including 
children – 
ineligible in 
this study) 
32333 
Adults 
(≥13y) 
32269 
(~100%) 
Adults          
(≥13y) 
NR NR 
436 
(267-558) 
2 
Labhardt, 2014 
(HB-HTS) 
To compare HTS uptake, HIV prevalence 
and LTC within 1mth between HB-HTS and 
M-HTS 
6311 
1171 
(19%) 
1083  
(92%) 
Adults & 
children 
Men (≥12yrs): 
30% (n=247/812) 
438 (265-650) NR 1 
MacKellar, 
2016 
To evaluate compliance with new national 
linkage and retention standard 
operational procedures and enrolment in 
HIV care 
NR NR NR Adults  NR NR 
 
280  
(165–420) 
2 
Medley,  
2013 
To describe HB-HTS coverage and HIV 
prevalence, & characteristics associated 
with enrolment into HIV clinical care 
within two to four months after receiving 
an HIV diagnosis during HB-HTS among 
adult residents of a longitudinal Health 
and Demographic Surveillance System 
15933 
12035 
(76%) 
9895 
(82%) 
Adults & 
children4 
(≥13y) 
NR NR NR NR 
Naik,  
2015 
To determine what proportion of adults 
LTC after HB-HTS within 3mths & the 
factors associated with LTC 
NR NR NR 
Adults 
(≥14y) 
NR NR 
341  
(224-542) 
2 
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Tumwebaze, 
2012 
To evaluate HB-HTS combined with an 
electronic triage platform as a platform to 
facilitate LTC 
1941 
1587 
(82%) 
1558 
(98%) 
Adults 
(≥18y) 
47%  
(n=724/1558) 
479  
(330–715) 
NR 1 
van Rooyen, 
2014 
To assess whether HB-HTS with POC CD4 
& facilitated referrals to HIV care 
achieved: high HTS coverage; identified 
HIV-positive individuals unaware of their 
HIV status; reduced potential barriers to 
care engagement. & reduced 
infectiousness through high uptake of & 
adherence to ART 
739 
726 
(98%) 
671 
(92%) 
Adults 
(≥18yr) 
33%  
(n=222/671) 
435 
(301–591) 
NR 1 
Shapiro, 2012 
(non TB-
contact 
households) 
To determine the prevalence of 
undiagnosed TB & HIV in households of 
index TB-patients, to compare the yield of 
TB & HIV in TB-contact households with 
randomly selected non TB-contact 
households & determine the efficiency of 
targeting households 
of patients with TB for active case-finding 
interventions 
NR 
2843 
1568 
(55%) 
Adults & 
children4 
(excl <5y) 
NR 
381 
(236–567) 
NR 1 
Shapiro, 2012 
(TB-contact 
households) 
983 
521 
(53%) 
Adults & 
children4 
(excl <5y) 
383 
(285–561) 
NR 1 
MacPherson, 
2014 
To investigate whether offering optional 
home initiation of ART after HIVST might 
increase population level ART uptake 
compared with HIVST combined with 
facility-based initiation 
8466 
Unknown 
(Test kits 
made 
available for 
8466) 
Unknown 
(Participant 
choice to 
disclose) 
Adults 
(≥16y) 
NR NR 
187 
(100-256) 
2 
Community outreach and HB-HTS 
Barnabas, 
2016 
To assess whether community-based HTS 
with counsellor support and POC CD4 
increases uptake of ART compared to HB-
HTS 
NR 15700 
15332 
(98%) 
Adults 
(≥16y) 
43%  
(n=6533/15332) 
POC arm:  
486 
(344-653) 
Clinic arm & 
could recall 
CD4: 512 
(384-670) 
1 & 2  
(based on 
randomisation 
arm) 
Parker, 2015 
(HB-HTS) To evaluate the feasibility, yield & LTC of 
two strategies: HB-HTS and community-
based M-HTS 
12269 
7484 
(61%) 
7026 
(94%) 
Adults & 
children4 
(excl <5y) 
39%  
(n=3106/7026) 
NR 
NR 2 
Parker, 2015 
(M-HTS) 
18207 NR 2034 
Adults & 
children4 
(excl <5y) 
NR  2 
Community outreach 
Bassett, 
2014 
To evaluate yield and LTC from M-HTS 
compared to clinic based HTS in high 
prevalence South African township 
NR NR 4703 
Adults 
(≥15y) 
46% 
(2163/4703) 
416 
(287-587) 
NR 2 
 140 
 
 
 
 
Chamie, 
2012 
To test the feasibility and diagnostic yield 
of integrating NCD and other 
communicable disease services into a 
rapid, high through-put, community based 
HIV testing and referral campaign for all 
residents of a rural Ugandan parish; 
 and to determine rates and predictors of 
post-campaign LTC by disease 
6300 
(3150 adults) 
4343 
(2323 adults, 
2020children) 
2282 adults 
1826children 
Adults & 
children4 
NR 5 
Adults: 
415 
(281-568) 
NR 1 
Govindasamy, 
2013 
To determine the yield of newly-
diagnosed HIV, TB symptoms, diabetes & 
hypertension from a M-HTS unit, & assess 
CD4 testing, LTC & correlates of LTC & 
barriers to care 
NR 9806 NR 
Adults 
( ≥18y) 
NR 
Mean: 481 
(95% CI: 
458-505) 
NR 1 
Hatcher,  
2012 
To assess predictors of LTC among 
individuals testing HIV-positive after 
community-based HTS 
NR NR 10203 
Adults 
(≥18y) 
NR NR NR 1 
Kranzer,  
2012 
To compare yields of newly diagnosed HIV 
& advanced HIV between individuals 
attending M-HTS as participants in a 
population-based HIV seroprevalence 
survey & those accessing the service for 
routine HTS 
NR 
1300 
(number 
recruited 
i.e. given 
flyer about 
M-HTS) 
936 
(included in 
LTC 
analysis) 
Adults 
Recruited HTS: 
52% (n=491/936) 
Client-initiated 
HTS (not given 
flyer): 56% 
(n=488/877) 
Recruited HTS: 
385 
(267–602) 
Client-initiated 
HTS: 415 (309-
680) 
NR 1 
Labhardt, 2014 
(M-HTS) 
To compare HTS uptake, HIV prevalence 
and LTC within 1mth between HBHTS and 
M-HTS 
4909 
1392 
(28%) 
1207  
(87%) 
Adults & 
children4 
Men (≥12yrs): 
24% (n=236/994) 
400 (207-629) NR 1 
Larson,  
2012 
To assess the proportion of patients LTC 
within 8wks of M-HTS under routine 
conditions & the impact of 
including POC CD4 testing on the 
proportion of patients LTC within 
8wks of M-HTS 
NR NR NR 
Adults 
(≥18y) 
NR 
Among 
individuals 
offered POC 
CD4: 414 (251-
589) 
NR 1 
van Zyl,  
2015 
To determine LTC & time to LTC after M-
HTS combined with a call centre for 
facilitating LTC 
NR NR NR NR NR 370 (IQR NR) NR NR 
 141 
 
1. Percentage shown in brackets refers to proportion of population of offered testing among population served by HTS – if numerator and denominator reported in given study. 
2. Proportion accepted testing among those offered HTS – if numerator and denominator reported. 
3. Three studies also reported % of all men offered HTS who accepted testing: Dalal, 2013 - 80% (n=8889/11068); Labhardt, 2014 (HB-HTS) - 94%; (n=247/262); Labhardt, 2014 (M-HTS) 
- 97%; (n=236/243) 
4. Children whose biological mother was deceased or known to be HIV+  
5.  Authors did not report% of males accepted but reported % of male residents who attended (were offered HTS) = 52% men (vs 95% of women) 
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Supplementary Figure 5.1: Flow diagram of study selection process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Articles excluded as obviously 
irrelevant or conference 
abstract N = 1229 
Articles excluded for not reporting 
HIV testing (N = 936) or  
Linkage to care (N = 153) or facility-
based approach (N=400) 
Potential citations (published 
articles and conference papers 
after removal of duplicates) 
identified from search strategy 
(N = 2888) 
 
Articles excluded after screening by full-
text:  
 Health centre or VCT facility based 
testing (N = 87) 
 Linkage to care not reported - including 
1 home initiation of ART (N = 60) 
 Mostly data pre-2006 (N = 2) 
 Linkage to satellite of clinic (N=1) 
 
Full-texts articles retained and 
screened for eligibility 
(N = 170) 
Titles and abstracts retained 
for further evaluation  
(N =1659) 
 
1 additional article 
identified by manual 
search 
 
Articles included in 
the review (N=21)  
Articles for final data 
extraction (N=20)  
(22 studies described in  
20 articles) 
Articles with duplicate or 
overlap of study population            
(N = 1) 
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Supplementary Figure 5.2: Forest plots showing (a) LTC by method of follow-up (if any); 
(b) ART initiation outcomes by PLWH sub-groups; (c) ART initiation outcomes by when 
CD4-count result was available  
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van Rooyen(2013)
Govindasamy(CD4>350)(2013)
Naik(2015)
Barnabas(2016)(referral only arm)
Bassett(2014)
Hatcher(2012)
Genberg(2015)
Author
381
423
737
958
316
398
788
1096
431
33
48
64
75
83
113
137
145
359
449
455
483
1704
HIVpositive
367
378
312
454
172
135
209
563
421
26
18
25
19
44
96
131
77
273
419
45
393
243
LTC
96.3 (93.9, 98.0)
89.4 (86.0, 92.1)
42.3 (38.7, 46.0)
47.4 (44.2, 50.6)
54.4 (48.8, 60.0)
33.9 (29.3, 38.8)
26.5 (23.5, 29.8)
51.4 (48.4, 54.4)
97.7 (95.8, 98.9)
78.8 (61.1, 91.0)
37.5 (24.0, 52.6)
39.1 (27.1, 52.1)
25.3 (16.0, 36.7)
53.0 (41.7, 64.1)
85.0 (77.0, 91.0)
95.6 (90.7, 98.4)
53.1 (44.6, 61.4)
76.0 (71.3, 80.4)
93.3 (90.6, 95.4)
9.9 (7.3, 13.0)
81.4 (77.6, 84.7)
14.3 (12.6, 16.0)
ES (95% CI)
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(b) Proportions initiating ART by PLWH sub-groups  
 
 
 
  
New
Chamie(2012)
Govindasamy(2013)
van Rooyen(2013)
Parker(2015)
Genberg(2015)
Dalal(2013)
All PLWH not on ART (new and previously diagnosed)
Tumwebaze(2012)
van Rooyen(2013)
Genberg(2015)
Barnabas(2014)
Barnabas(2016)(referral only arm)
Barnabas(2016)(facilitation in clinic arm)
Barnabas(2016)(lay counsellor FU arm)
All PLWH (may include in care/on ART)
Shapiro(Random HH)(2012)
Shapiro(TB contacts)(2012)
Medley(2013)
PLWH self-report HIV after self-test
Macpherson(2014)
Author
6
18
35
42
92
126
21
26
34
123
423
431
449
19
32
312
376
HIVpositive
5
15
19
22
78
43
15
17
18
94
142
161
185
10
13
80
63
ART
ART eligible
ART eligible
ART eligible
ART eligible
ART eligible
ART eligible
ART eligible
ART eligible
ART eligible
ART eligible
Irrespective of ART Eligibility
Irrespective of ART Eligibility
Irrespective of ART Eligibility
ART eligible
ART eligible
Irrespective of ART Eligibility
ART eligible
ARTeligibility
83.3 (35.9, 99.6)
83.3 (58.6, 96.4)
54.3 (36.6, 71.2)
52.4 (36.4, 68.0)
84.8 (75.8, 91.4)
34.1 (25.9, 43.1)
71.4 (47.8, 88.7)
65.4 (44.3, 82.8)
52.9 (35.1, 70.2)
76.4 (67.9, 83.6)
33.6 (29.1, 38.3)
37.4 (32.8, 42.1)
41.2 (36.6, 45.9)
52.6 (28.9, 75.6)
40.6 (23.7, 59.4)
25.6 (20.9, 30.9)
16.8 (13.1, 20.9)
ES (95% CI)
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(c) Proportions initiating ART by when CD4-count result was available  
 
CD4-count result at time of HTS
Chamie(2012)
Govindasamy(2013)
Shapiro(Random HH)(2012)
Tumwebaze(2012)
Shapiro(TB contacts)(2012)
van Rooyen(2013)
Barnabas(2014)
Barnabas(2016)(POC CD4-arm)
CD4-count result upon LTC at clinic
Parker(2015)
Dalal(2013)
Genberg(2015)
Macpherson(2016)
Barnabas(2016)(Clinic CD4 arm)
Author
6
18
19
21
32
61
123
627
42
126
252
376
676
HIVpositive
5
15
10
15
13
36
94
245
22
43
192
63
243
ART
ART eligible
ART eligible
ART eligible
ART eligible
ART eligible
ART eligible
ART eligible
Irrespective of ART Eligibility
ART eligible
ART eligible
ART eligible
ART eligible
Irrespective of ART Eligibility
ARTeligibility
83.3 (35.9, 99.6)
83.3 (58.6, 96.4)
52.6 (28.9, 75.6)
71.4 (47.8, 88.7)
40.6 (23.7, 59.4)
59.0 (45.7, 71.4)
76.4 (67.9, 83.6)
39.1 (35.2, 43.0)
52.4 (36.4, 68.0)
34.1 (25.9, 43.1)
76.2 (70.4, 81.3)
16.8 (13.1, 20.9)
35.9 (32.3, 39.7)
ES (95% CI)
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Supplementary Figure 5.3: Proposed standard indicators for future reporting 
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Supporting Information 5.1: Search terms and PRISMA checklist 
 
Search Terms 
Search terms for “The cascade-of-care following community-based detection of HIV – 
a systematic review with 90-90-90 targets in sight” 
1. HIV 
HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR 
hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immune deficiency 
virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR 
((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR 
acquired immunodeficiency syndrome[tw] OR acquired immunodeficiency syndrome[tw] OR 
acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])) 
OR ”sexually transmitted diseases, viral“[MESH:NoExp] 
2. Home based  
 
Home-based or home based or homebased OR door to door OR door-to-door OR home care services OR homecare services 
OR homecare OR home care OR home-care OR home access OR home OR in-home OR domicile 
 
3. Community 
 
Community* OR community based OR community-based OR mobile*  
 
4. Work place 
 
Work place OR work-place OR workplace OR work OR occupation* 
 
5. School- based 
School-based OR school OR school* 
 
6. VCT  
 
Voluntary Counselling or voluntary Counselling or voluntary Testing or hiv testing or Vct or hbvct or hct 
 
7. Africa 
sub-Saharan Africa  OR south Africa  OR Africa South of the Sahara OR Lesotho  OR Swaziland  OR 
Namibia  OR Botswana  OR Zimbabwe  OR Mozambique  OR  Malawi  OR Zambia  OR Angola  OR 
Tanzania  OR Rwanda  OR Burundi  OR Democratic republic of Congo  OR Republic of Congo  OR 
Uganda  OR Kenya  OR Ethiopia  OR Somalia  OR Sudan  OR Central African republic  OR Cameroon  
OR Gabon  OR Guinea  OR Chad  OR Nigeria  OR Niger  OR Togo  OR Benin  OR Ghana  OR Burkina 
Faso  OR Cote d'ivoire   OR Ivory coast  OR Liberia  OR sierra Leone  OR Senegal  OR Gambia 
 
8. (1 AND 5) AND (2 OR 3 OR 4 OR 5)  
9. 8 AND 7  
10. Limit 7 to 01/01/2006 to 01/03/2016  
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PRISMA Checklist 
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Chapter 6: Predictors of timely linkage-to-ART within universal test 
and treat in the HPTN 071 (PopART) trial – findings from a nested 
case-control study 
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Outline of chapter 
The second of two case-control studies for this PhD was done to examine the factors associated with 
timely linkage to care and ART initiation during the first annual round of PopART. Presented below is 
the manuscript on the study which has been submitted to the Journal of International AIDS Society. 
6.1 Abstract 
Introduction 
This study examined factors associated with timely linkage-to-care and ART initiation (TLA) (i.e. 
within 6-months of referral) in the context of universal test and treat (UTT) within the intervention 
communities of the HPTN 071 (PopART) trial. 
Methods 
Of 7,572 individuals identified as PLWH (not on ART) during the first year of the PopART intervention 
provided by Community HIV-care Providers (CHiPs ) through door-to-door household visits, 
individuals who achieved TLA (controls) and those who did not (cases), stratified by gender and 
community, were randomly selected to be re-contacted for interview. Standardised questionnaires 
were administered to explore factors potentially associated with TLA, including demographic and 
behavioural characteristics, and participants’ opinions on HIV and related services. Odds ratios 
comparing cases and controls were estimated using multi-variable logistic regression. 
Results 
Data from 705 participants (333 cases/372 controls) were analysed. There were negligible 
differences between cases and controls by demographic characteristics including age, marital or 
socio-economic position. Prior familiarity with the CHiPs encouraged TLA (AOR of being a case: 0.58, 
95%CI: 0.39-0.86, p=0.006).  
Participants who found clinics overcrowded (AOR: 1.51, 95%CI: 1.08-2.12, p=0.006) or opening hours 
inconvenient (AOR: 1.63, 95%CI: 1.06-2.51, p=0.02) were less likely to achieve TLA, as were those 
expressing stronger feelings of shame about having HIV (ptrend=0.007). Expressing “not feeling 
ready” (AOR: 2.75, 95% CI: 1.89-4.01, p<0.001) and preferring to wait until they felt sick (AOR: 2.00, 
95% CI: 1.27-3.14, p=0.02) were similarly indicative of being a case. Worrying about being seen in 
the clinic or about how staff treated patients were not associated with TLA.  
While the association was not strong, we found that the greater the number of self-reported lifetime 
sexual partners the more likely participants were to achieve TLA (ptrend=0.06). There was some 
evidence that participants with HIV-positive partners on ART were less likely to be cases (AOR: 0.75, 
95% CI: 0.53-1.06, p=0.07) 
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Discussion 
The lack of socio-demographic differences between cases and controls is encouraging for a 
“universal” intervention that seeks to ensure high coverage across whole communities. Making 
clinics more “patient-friendly” could enhance treatment uptake further. The finding that those with 
higher risk behaviour are more actively engaging with UTT holds promise for treatment-as-
prevention.  
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6.2 Introduction 
The concept of universal test and treat (UTT) has been widely promoted for approximately the last 
decade and definitive evidence for the efficacy of treatment as prevention at the level of individual 
partnerships has been available since the results of the HPTN (HIV Prevention Trials Network) 052 
trial were announced in 2011.(1, 2) Other studies have since provided clear evidence on the benefit 
of early treatment for the health of the person living with HIV (PLWH).(3, 4) The World Health 
Organization (WHO) has revised its guidelines, to recommend that all PLWH be offered antiretroviral 
treatment (ART) irrespective of CD4 count, also known as “immediate treatment”.(5) 
The HPTN 071 (Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART)) 
trial has been underway in 21 communities in Zambia and South Africa to examine the impact of a 
combination prevention package including UTT on HIV-incidence at a community level. The trial 
consists of three arms as described elsewhere (6) and illustrated in Figure-1, and the full intervention 
arm (Arm A) has offered UTT from the launch of the trial in 2014.  
In order for UTT to have maximal impact in reducing community-level HIV-incidence, uptake of 
treatment would have to be wide-spread across subsets of the population with different socio-
demographic and behavioural characteristics.  There is evidence on factors associated with initiation 
of ART, usually among individuals who have already linked-to-care at least once since HIV diagnosis 
and from contexts where ART eligibility criteria applied. (7-12) More scarce are data from settings 
providing immediate treatment or UTT, with the latter not only making ART immediately available 
for all who have already presented to health-facilities, but first seeking to test everyone in the 
community (universal testing). (13)  Although a UTT approach substantially simplifies treatment by 
removing ART initiation criteria, providers must still negotiate all the steps along the cascade of care, 
to link clients to care following HIV detection in the community and achieve timely initiation of ART. 
It also involves attempting to initiate treatment in a timely fashion, in individuals who were 
diagnosed as part of a universal testing programme in the community, who may not otherwise have 
sought to find out their HIV status. While this helps achieve universal knowledge of HIV status and 
identify as many PLWH as possible, it may also pose challenges for treatment readiness – in addition 
to other potential barriers.  
The study described here examined the factors associated with the uptake of universal treatment, 
specifically timely linkage-to-care and initiation of treatment (which we will refer to as timely 
linkage-to-ART (TLA)) following door-to-door universal testing, during the first year of the PopART 
UTT intervention.  
 156 
 
6.3 Methods 
The nested case-control study was carried out in PopART Arm A communities which offered UTT - 
four in Zambia and three in South Africa (Figure-1). The study objectives were to identify differences 
between those who had not achieved TLA (cases) and those who had done so (controls). TLA was 
defined as linkage-to-care and initiation of ART within 6 months of referral by Community HIV-care 
Providers (CHiPs). 
CHiPs (lay counsellors employed and trained to work in their own communities), provided a door-to-
door community-based package of services (Figure-1) and captured the details of all individuals who 
consented to the PopART intervention on an electronic register.(6) During the initial CHiP home visit, 
HIV was detected through HIV testing and counselling (HTC) or by individuals self-reporting HIV-
positive status. All PLWH who were not on ART were offered referral to the local health-facility for 
linkage-to-ART. Follow-up home visits were conducted to ascertain linkage and ART initiation 
outcomes and recorded in the CHiP electronic register. 
Community members who were referred between January 2014-January 2015, during the first year 
of the PopART intervention and had had at least 6 months to achieve TLA (by July 2015) were eligible 
for the case-control study. Further, participants had to be ≥18 years old and be able and willing to 
provide informed consent.  
The data on TLA entered at a follow-up home visit by CHiPs, more than 6 months after referral (to 
allow time for TLA), were used as a starting point for random selection of study participants.  
Participants who had achieved TLA within 6 months of referral by CHiPs were eligible to be controls; 
individuals who had been followed up after 6 months but had not started ART at all or only started 
after 6 months were potential cases. Random samples of those who did not manage TLA (cases) 
were selected, stratified by community and gender, to have adequate representation of individuals 
from all the PopART intervention communities and from both genders.  An equal number of gender-
matched individuals per community, who did manage TLA (controls) were then randomly selected. 
A sample in excess of the number required for recruitment was selected in anticipation of difficulties 
in finding participants – given the mobility and migration in the study communities. Due to a wide 
range in community sizes, the numbers of individuals meeting the case and control definition varied 
across communities and some communities had fewer individuals than required by the study while 
others had much larger numbers. This meant that in the smaller communities everyone who had 
been referred was selected, rather than a random subset. 
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Verbal permission to allow case-control (CC) field research assistants (RAs) to approach participants 
was obtained by the CHiP staff who had previously referred individual community members for TLA. 
Written informed consent for study participation was then obtained by CC study RAs. RAs conducted 
electronically administered surveys with standardised questionnaires. Questionnaire themes were 
informed by current evidence in the literature and anecdotal local information on factors that may 
influence TLA. Participants’ case or control status was not given to RAs.  
The final sample size of ~700 participants (1:1 case: control ratio) provided just over 80% study 
power to detect associations with odds ratios of ~1.75 or higher (or ~0.5 or lower), for explanatory 
variables with 15% prevalence in controls (α = 0.05). Odds ratios were estimated using multivariable 
logistic regression and all models included community and gender to account for the frequency-
matched sampling strategy. Age category was then included as an a priori potentially confounding 
variable. Additional variables which showed at least weak evidence of association with TLA were 
included as appropriate. Likelihood ratio testing (LRT) was done to assess the statistical evidence of 
association. Evidence of interaction with gender and country was explored. For variables with three 
or more response categories and potential for a dose-response relationship, tests for trend were 
performed. 
The study was approved by the ethics committees of the University of Zambia, Stellenbosch 
University and London School of Hygiene and Tropical Medicine. 
6.4 Results 
Demographic, sexual behaviour and health-related characteristics 
During the first year of the PopART intervention 152,383 individuals consented to participate in the 
PopART intervention in the 7 arm A communities. Of these, 16,112 individuals (5,028 men and 
11,084 women) were identified as living with HIV (newly diagnosed or self-report of known HIV-
positive status) and 7,572 were referred to HIV care, among those not on ART at the time of referral. 
After allowing at least 6 months for TLA, 5,161 were documented as either having started ART within 
6 months after referral, or were followed up >6 months after referral and had not started ART. Of 
these, 2,444 individuals (781 men and 1,663 women) had linked-to-care and initiated ART within 6 
months of referral and 2,717 had not. 
Of the 2,717 potential cases who did not achieve TLA, 908 were randomly selected to be contacted 
by CHiPs, and 437 (48%) were found and agreed to be contacted by the CC field research assistants 
(RAs). Of them, 333 (76%) cases consented to participate in the study (Figure-2a). Of 812 potential 
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controls who achieved TLA and were randomly selected, 460 (57%) agreed to be contacted by the CC 
RAs and a slightly greater proportion were successfully recruited (372 (81%)) (Figure-2b).  
Data from 705 participants were included in the final analysis – 79% (555) from four communities in 
Zambia and 21% (150) from three communities in South Africa. There were fewer men (~40%) than 
women (~60%) in the study, but proportions were balanced by case/control status (Table-1). When 
compared with the randomly selected sample, there was a lower proportion of 18-24 year olds in 
the final study population (10% vs 18% of both cases and controls) and a higher proportion of ≥45 
year olds (22% vs 11% among cases, and 25% vs 15% among controls). 
Most participants were married, had had primary education only and were unemployed (2% of all 
participants were students). There were no differences by case/control status for any of these 
demographic characteristics, overall.  
The majority of participants reported 2-5 lifetime sexual partners and the number of partners was 
associated with case/control status. There is a suggestion of a trend that the greater the number of 
partners the more likely participants were to achieve TLA (with diminishing odds ratios (AORs) of 
being a case, ptrend=0.06) (Table-1).  
The HIV and ART status of the participant’s main partner (of the last 12 months) was associated with 
case/control status. Compared to those who did not report having a known HIV-positive partner, 
participants who had HIV-positive partners not on ART (although there were relatively few in that 
category) were twice as likely to be cases themselves (AOR:2.02,95% CI:1.11-3.66,p=0.02). 
Participants whose HIV-positive partners were on ART were less likely to be cases (OR: 0.70, 95% CI: 
0.50-0.98, p=0.04), but the evidence of association was weaker in the adjusted model (AOR: 0.75, 
95% CI: 0.53-1.06, p=0.07). 
Participants who had previously linked-to-care (prior to CHiP referral) and were still in care (but not 
on ART) when the initial CHiP home visit was conducted were less likely to be cases than those who 
had never previously linked, as might be expected (AOR: 0.60, 95% CI: 0.38-0.96, p=0.03). Although 
there were relatively few participants who reported that they had previously linked but had 
defaulted from care, when compared against those who had never linked there was no evidence of a 
difference (AOR: 0.79, 95% CI: 0.42-1.47, p=0.45) (Table-1). There was no relationship between 
latest CD4-count (self-reported at the time of the CC study by those who had had it done) and 
case/control status. However, not having had a CD4-count done or not knowing one’s result was 
predictive of being a case (AOR: 1.94, 95% CI: 1.18-3.21, p=0.009) when compared with those who 
had a CD4-count which was low (0-350/cc3). 
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Participants’ perceptions of HIV service factors which may affect TLA 
Cases and controls were asked (identical) standardized questions about factors that encourage TLA 
(regardless of whether TLA was achieved). Prior familiarity with the CHiP who delivered the 
intervention encouraged TLA (AOR of being a case: 0.58, 95% CI: 0.39-0.86, p=0.006) (Table-2). The 
majority of participants accepted HIV testing with the CHiP, and this appears to be associated with 
being a case, although not reaching statistical significance in the adjusted model (AOR:1.60,95% 
CI:0.95-2.70,p=0.07) when compared with individuals who self-reported HIV-positive status . 
Participants who reported time constraints due to work or housework as a factor which discouraged 
linkage-to-care were more likely to be cases (AOR:1.64,95% CI:1.14-2.38,p=0.02). When restricted to 
those who had not previously linked-to-care prior to the CHiP referral (N=603), a number of factors 
related to accessing the clinic, including inconvenient clinic opening hours (AOR:1.63,95% CI:1.06-
2.51,p=0.02); overcrowding in the clinic (AOR:1.51,95% CI:1.08-2.12,p=0.006); and distance/ time to 
travel to clinic (AOR:2.55,95% CI:1.14-5.69,p=0.009) were associated with being a case (although 
very few complained of the latter in the urban and peri-urban settings that characterize all our 
communities) (Table-2). Expressing “not feeling ready” (AOR: 2.75, 95% CI: 1.89-4.01, p<0.001) and 
preferring to wait until they felt sick (AOR: 2.00, 95% CI: 1.27-3.14, p=0.02) were similarly indicative 
of being a case. Neither being worried about being seen in the clinic or perceptions about how staff 
treated patients were associated with TLA (data not shown). 
Perceived advantages and disadvantages to the individual of achieving TLA (including stigmatizing 
attitudes) 
Participants who said that they would start ART for their own health, even without feeling unwell, 
were more likely to achieve TLA (AOR of being a case:0.53,95% CI:0.38-0.75,p<0.001) as were those 
who said they would comply with CHiPs/clinic staff’s advice to link-to-ART without delay (AOR of 
being a case:0.56,95% CI:0.34-0.91,p=0.02). There was weak evidence that knowing others who 
were well on ART (AOR: 0.74, 95% CI: 0.53-1.03, p=0.08) encouraged TLA. There was no strong 
association between case/control status and stating that protecting a partner from acquiring HIV 
was a factor which encouraged TLA (AOR: 0.81, 95% CI: 0.58-1.12, p=0.19) (Table-3). 
As was seen with “not feeling ready” to link to care (Table-2), “not feeling ready” to take ART was 
also associated with being a case (AOR: 2.25, 95% CI: 1.58-3.21, p<0.001). The idea of taking life-long 
treatment also appeared to be a deterrent to TLA (AOR: 1.44, 95% CI: 1.00-2.07, p=0.05) (Table-3). 
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Stigmatising attitudes were not generally seen to affect TLA (Table-3 and other data not shown). 
However, the more strongly participants agreed with a statement about feeling ashamed because 
they were HIV-positive, the more likely they were to be a case (test for trend p=0.007). 
Differences in association by gender and country 
There was no statistical evidence of differences in association by country but shown in 
Supplementary Table-1 are associations which were seen to differ by gender. While there was no 
association between education of participants overall and of women alone with case/control status, 
men who had secondary education appeared more likely to be cases than men with primary 
education (AOR: 2.50, 95% CI: 1.30-4.82, p=0.02). However, there was no clear trend seen across 
educational strata and it is possible that this association was a chance finding. Amongst men but not 
amongst women, being familiar with the CHiP prior to the initial PopART home visit was strongly 
associated with TLA (AOR of being a case among men: 0.29, 95% CI: 0.14-0.58, p<0.001). 
The majority of participants irrespective of gender or case/control status had disclosed their HIV 
status to someone. Amongst women, there was statistical evidence of disclosure encouraging TLA 
(AOR of being a case: 0.18, 95% CI: 0.09-0.36, p<0.001) while the association was weak among men. 
Men who had a high AUDIT (Alcohol Use Disorders Identification Test) score (≥ 8) which denoted 
hazardous and harmful alcohol use (14), and possible dependence, were more likely to be cases 
(AOR: 2.13, 95% CI: 1.20-3.81, p=0.009) than men with lower scores (≤ 7), while this was not the case 
among women who drank excessively.  
6.3 Discussion 
This study examined factors associated with the timely initiation of ART in high HIV prevalence 
settings in sub-Saharan Africa, in greater detail than any other published study we are aware of. It 
provides novel insights into TLA in the context of UTT, with participants identified with HIV during 
universal door-to-door home-based HIV testing. We have examined the combined outcome of TLA 
which requires linkage-to-care following HIV detection and referral in the community, and initiation 
of ART in the health facility, all within a relatively short period (6 months). The predictors of TLA we 
have examined may have influenced either linkage to care or ART initiation or both. Only one other 
study we are aware of has examined factors associated with “linkage-to-ART”. (15) Other studies 
have focused instead either on predictors of linkage-to-care or on predictors of initiation of ART 
among those already linked-to-care or diagnosed in health facilities. Yet, as community-based HIV 
testing becomes widespread in high HIV prevalence settings, combined with immediate eligibility for 
ART, we consider that it is pertinent to examine TLA - to effect meaningful change in ART coverage 
with a view to achieving the “second 90” of the UNAIDS 90-90-90 targets. (16) 
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Our study found no evidence of associations between demographic or socio-economic 
characteristics and TLA, similar to reported findings from other settings. (7, 10, 11, 13) This is 
encouraging for a “universal” intervention that seeks to ensure high coverage across the whole of 
the community. Having favourable views about the PopART CHiPs appears to facilitate TLA - with 
prior familiarity with the CHiPs (as fellow community members), feeling comfortable talking to the 
CHiPs and accepting their advice, all encouraging TLA. Few participants complained of healthcare 
worker factors as barriers to linking-to-care. Clinic infrastructure factors however were cited as 
disincentives (inconvenient clinic opening hours, over-crowding, etc.).  
While the evidence of associations was not strong we found that behavioural factors, including self-
reported sexual behaviour and HIV related behaviour (namely disclosure of HIV status) influenced 
TLA. Those reporting a greater number of lifetime sexual partners were more likely to succeed with 
TLA. This suggests that the self-acknowledged perception that one might be at risk of HIV, facilitated 
linkage and ART initiation. One possible explanation is that these individuals were more willing to 
acknowledge living with HIV and hence achieved TLA more readily. Consistent with this explanation 
is the finding that those who reported “not feeling ready” or who said they would only start 
treatment once they felt sick, were less likely to achieve TLA. The finding that those with higher risk 
behaviour are more actively engaging with UTT is encouraging for treatment as prevention. 
Corroborating the findings of the study by Boyer et al. on ART initiation (among those linked-to-care) 
in another UTT trial, we found that disclosure of HIV-status facilitated TLA. (13) Along a similar 
theme, participants who reported that they had an HIV-positive partner on ART were more likely to 
succeed with TLA themselves, while the opposite was true if they had an HIV-positive partner who 
was not ART. Our data also indicate that participants who reported that they had disclosed their HIV-
positive status were more likely to report a partner on ART than those who had not disclosed (36% 
vs 17%, respectively p<0.001). Protecting a partner from acquiring HIV as a reason to start ART was 
not associated with increased TLA (Table 3), and this may suggest that greater efforts to promote a 
“treatment for prevention” message are indicated. 
The high proportion of men overall who had high AUDIT scores is alarming (51%), although the 
prevalence in women (20%) is also substantial. The difference in association of alcohol excess with 
TLA by gender is interesting. Men with high AUDIT scores were more likely to be cases, and this 
suggests that provision of integrated alcohol reduction/treatment and HIV prevention/treatment 
programmes that target men should be explored. Among women, the evidence was of a weak 
association in the opposite direction. A possible explanation is that men with heavy alcohol 
consumption avoided engagement with treatment and care, while women who drank heavily may 
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have sought health-care/treatment as a way to compensate for “unhealthy” behaviour. Further, 
among women (but not men) a higher proportion of those who were heavy drinkers considered 
themselves at high risk of acquiring HIV infection compared to those who were non-heavy drinkers 
(59% vs 42%, p=0.005). This association among women is consistent with our finding above that high 
risk perception may encourage treatment engagement. 
Our data indicate that stigma overall is not a major barrier to TLA, but internalized stigma (i.e. taking 
on and believing to be true, the negative beliefs and attitudes about PLWH) may have an influence. 
This is said to be one of the most insidious aspects of stigma, as it somehow makes PLWH feel “less 
human”.(17) There is evidence to suggest that support groups can help mitigate this form of 
stigma.(18, 19)   
Our study had several limitations. Only participants who agreed for the study research team to 
contact them could be recruited into the study. This means that individuals who could not be 
contacted, or declined or avoided contact would not be represented in the study, nor would those 
who declined to consent once contacted. While this is common to many community-based survey 
studies, the representativeness of the study sample must be borne in mind as a limitation of the 
study. We did see evidence of differential selection of potential participants by case/control status 
with a higher proportion of randomly selected potential controls recruited than randomly selected 
potential cases (46% vs 37%). As described earlier there were also fewer men than women in the 
study sample despite frequency matching on gender when randomly selecting the sample. Young 
people were also somewhat under-represented in the final study sample. Both of these are likely 
due to the fact that the study was conducted in the household and men and younger people are less 
likely to be found at home than older people. Reporting bias and social desirability bias are both 
possibilities, in common with most research using self-reported data. However, given the wide range 
of themes explored by the questionnaire and the lack of an obvious single hypothesis, these biases 
are unlikely to be differential based on case or control status of the participant. Reverse causality 
must also be borne in mind given that the CC study was conducted a period of time after the referral 
for HIV care. Further, given the case-control design causality cannot be inferred from our findings 
and we are limited to observing associations. 
The strengths of this study have already been alluded to – including the breadth and depth of the 
themes explored, the novelty of examining TLA under UTT conditions and the focus on TLA as a 
combination of both timely linkage-to-care and ART initiation, given that community-based testing is 
becoming increasingly prevalent. In addition, we had a sizeable proportion of men (~40%) who are 
often under-represented. Our study was conducted in large urban and peri-urban communities and 
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this provides a good basis for generalizability for the majority of those living with HIV in sub-Saharan 
Africa. 
Further research is required to explain some of the results. For instance, even though familiarity with 
the CHiPs encouraged TLA, there is a suggestion in our data that having an HIV test with the CHiP 
was associated with being a case i.e. failure to achieve TLA. This is most likely due to the fact that 
those who tested with CHiPs were the ones receiving new diagnoses of HIV infection, and needing 
time to become comfortable with the idea of needing treatment, whereas those who did not test 
with CHiPs were the ones who already knew their HIV positive status and may have been more 
ready for TLA. However, this warrants further enquiry. 
In summary, our study findings suggest that the universal treatment intervention within PopART did 
not systematically exclude any subsets of the population and it has the potential to be universally 
acceptable. The finding that those who reported having an HIV-positive partner not on ART were less 
likely to achieve TLA points to the cumulative gains to be won by initiating individuals on ART – as it 
may have the added benefit that their partner would be encouraged to do so as well. As holding a 
favourable view of the CHiPs was associated with successful TLA, we recommend investment in the 
cadre of staff delivering services as a means to increase uptake. The concerns expressed by 
participants about health-facilities warrants both on-going improvement of infrastructure and 
innovative means to reduce the burden on clinics by providing care in the community for patients 
who are stable and comfortable with non-clinic based care. 
The findings that higher risk sexual behaviour may be associated with more timely linkage-to-ART 
holds great promise for the effectiveness of UTT in achieving reductions in HIV-incidence at the 
community level. Overall, we found few fundamental differences between those who linked-to-ART 
in a timely fashion and those who did not, but the differences we did uncover provide opportunities 
to achieve universal treatment coverage within the framework of universal test and treat. 
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Figure 6.1: PopART trial schema 
3 arm cluster-randomised trial with 21 communities 
Full PopART
intervention 
including
immediate ART 
irrespective of CD4 
count
Standard of care at 
current service 
provision levels 
including 
ART initiation 
according to current 
national guidelines
ART initiation 
according to current 
national guidelines
7 communities 
per arm (N=21)
Arm A Arm B Arm C
PopART intervention 
except
PopART intervention package
 Annual rounds of  Home Based Voluntary HIV Testing by Community HIV-care Providers (CHiPs)
 Health promotion, Active Referral and/or Retention in Care support by CHiPs for the following:
• Voluntary Medical Male Circumcision (VMMC) for HIV negative men
• Prevention of Mother to Child Transmission (PMCT) for HIV positive women
• HIV treatment and care for all HIV positive individuals
• Promotion of sexual health and TB services
• Condom provision
 ART irrespective of CD4-count or immune-status provided at the local health centre in Arm A 
~ 2,000 random sample 
from each community :
Population Cohort 
N = 42,000
Primary outcome:
HIV incidence at 36 months
12 in Zambia
9 in S. Africa
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Figure 6.2a – Case (did not achieve TLA i.e. did not initiate ART or initiated more than 6m after CHiP referral) selection process and 
sampling fraction 
CHiPs attempted contact with 908 individuals who did not achieve TLA, 
randomly selected from CHiP data-base from the first annual round of HBT in PopART
(Zambia: 628 / 280 SA1:)
RAs attempted contact with 437 (48%) potential cases to obtain informed 
consent to participate in CC study
(Zambia: 321 / SA: 116)
471 (52%) individuals could not be located 
or declined to be contacted by CC team
(Zambia: 307 / SA: 164)
333 (76%) cases in study sample
(Zambia: 258 / 75 SA: )
Usually 3 attempts made to locate 
individual if not initially found
Usually 3 attempts made to locate 
individual if not initially found
104 (24%) individuals could not be located, 
declined participation or were ineligible for the study
(Zambia: 63 / SA: 41)
1. SA = South Africa
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Figure 6.2b – Control (achieved TLA i.e. initiated ART within 6m of CHiP referral) selection process and sampling fraction 
CHiPs attempt contacted with 812 individuals who achieved TLA, 
randomly selected from CHiP data-base from the first annual round of HBT in PopART
(Zambia: 616 / SA1: 196)
RAs attempted contact with 460 (57%) potential controls to obtain 
informed consent to participate in CC study
(Zambia: 352 / SA: 108)
352 (43%) individuals could not be located or 
declined to be contacted by CC team
(Zambia: 264 / SA: 88)
372 (81%) controls in initial study sample
(Zambia: 297 / SA: 75)
Usually 3 attempts made to locate 
individual if not initially found
Usually 3 attempts made to locate 
individual if not initially found
88 (19%) individuals could not be located, 
declined participation or were ineligible for the study
(Zambia: 55 / SA: 33)
1. SA = South Africa
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Table 6.1: Demographic, sexual behaviour and health related characteristics of cases and controls 
 
Controls 
(Achieved 
TLA)                                                            
N (%) 
Cases       
(Did not 
achieve 
TLA)             
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Adjusted 
Odds 
Ratio 3 
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Total       
Gender 4 
Male 151 (41) 132 (40)     
Female 220 (59) 201 (60)     
Demographic and socio-economic characteristics 
Age category 
18 – 24 years 36 (10) 32 (10) 1 0.86 1 0. 60 
25 – 34 years 129 (35) 118 (35) 1.04 0.60-1.80 1.05 0.59-1.89 
35 – 44 years 115 (31) 110 (33) 1.08 0.61-1.89 1.08 0.60-1.95 
≥ 45 years 92 (25) 73 (22) 0.91 0.50-1.63 0.82 0.45-1.52 
Marital status 
Never married 48 (13) 55 (16) 1 0.48 1 0.27 
Currently married 215 (58) 184 (55) 0.75 0.46-1.21 0.77 0.45-1.32 
Previously married 5 109 (29) 94 (28) 0.75 0.44-1.28 0.63 0.35-1.12 
Educational attainment  Ptrend 6 0.11 
Primary (Grade 0-7) 183 (49) 153 (46) 1 0.76 1 0.21 
Junior secondary (Grade 8-9) 94 (25) 84 (25) 1.09 0.75-1.58 1.15 0.77-1.72 
Senior secondary (Grade 10-12) or higher 
education 
94 (25) 96 (29) 1.22 0.83-1.78 1.45 0.96-2.19 
Employment 
None 181 (49) 166 (50) 1 0.42 1 0.41 
Casual/seasonal/occasional 61 (16) 60 (18) 1.12 0.71-1.75 1. 18 0.74-1.89 
Self employed 67 (18) 64 (19) 1.12 0.73-1.73 1.22 0.77-1.92 
Formal wage 63 (17) 43 (13) 0.75 0.47-1.19 0.79 0.49-1.29 
SES (PCA7 of HH factors & assets 8) 
Lower 181 (49) 176 (53) 1 0.27 1 0.43 
Higher 191 (51) 157 (47) 0.84 0.61-1.15 0.87 0.63-1.22 
Sexual behaviour 
No of lifetime sexual partners  Ptrend 6 0.06 
1 33 (9) 47 (14) 1 0.02 1 0.04 
2 - 5 221 (60) 192 (58) 0.57 0.34-0.93 0.55 0.33-0.92 
6 - 9 49 (13) 48 (14) 0.59 0.30-1.13 0.56 0.28-1.10 
≥ 10 68 (18) 45 (14) 0. 40 0.21-0.75 0.38 0.19-0.74 
Self-assessment of sexual risk (“My sexual behaviour (incl. partner(s) I have had), has put me at risk of getting HIV”) 
Low 180 (49) 181 (55) 1 0.08 1 0.13 
High 191 (51) 151 (45) 0.75 0.55-1.03 0.77 0.55-1.08 
HIV and health factors 
Has HIV status been disclosed to anyone 
N 38 (10) 74 (22) 1 <0.001 1 <0.001 
Y 334 (90) 259 (78) 0.39 0.25-0.59 0.39 0.25-0.60 
HIV & ART status of spouse/main partner 9 (in last 12m)  
No sexual partner in last 12m / partner HIV status 
not known or reported HIV negative 
214 (58) 204 (61) 1 0.002 1 0.005 
HIV positive partner - not on ART 20 (5) 37 (11) 1.96 1.10-3.49 2.02 1.11-3.66 
HIV positive partner - on ART 138 (37) 92 (28) 0. 70 0.50-0.98 0.72 0.51-1.03 
Had participant linked to care prior to referral by CHiP 
Not linked prior to CHiP 280 (75) 274 (82) 1 0.04 1 0.09 
Linked prior to CHiP but not in care when referred 29 (8) 21 (6) 0. 70 0.38-1.28 0.79 0.42-1.47 
Linked prior to CHiP and in care when referred (not 
self-reported on ART) 
63 (17) 38 (11) 0.59 0.38-0.92 0.60 0.38-0.96 
Most recent CD4-count 
0-350 60 (16) 34 (10) 1 <0.001 1 <0.001 
351-500 44 (12) 18 (5) 0.72 0.36-1.46 0.69 0.33-1.43 
≥501 53 (14) 34 (10) 1.17 0.63-2.16 1.17 0.62-2.20 
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Not done / don’t know CD4-count 215 (58) 247 (74) 2.21 1.37-3.58 1.94 1.18-3.21 
Health in last 12m 
Not been unwell 269 (72) 225 (68) 1 0.33 1 0.18 
Unwell, not hospitalised 63 (17) 71 (21) 1.35 0.91-2.04 1.46 0.97-2.21 
Unwell and hospitalised 40 (11) 37 (11) 1.07 0.66-1.74 1.19 0.72-1.99 
AUDIT score        
Audit Score ≤ 7 253 (68) 226 (68) 1 0.85 1 0.73 
Audit Score ≥ 8 119 (32) 107 (32) 1.03 0.73-1.45 1.07 0.74-1.54 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model a priori including gender, community, age category as well as demographic/behavioural factors 
which were associated with case/control status (i.e. whether CHiP was known to participant prior to PopART to home-
visit, whether HIV status has been disclosed, whether partner is HIV positive and on ART, and lifetime number of sexual 
partners) 
4. One participant (control) with missing gender data 
5. Previously married = separated/divorced/widowed 
6. p-value for test for tend 
7. Principal components analysis  
8. HH factors detailed house structure, water, sanitation, electricity and cooking fuel used; assets listed were: working cell-
phone, bicycle, motorcycle or scooter, car/bakkie, electricity to house, television set, fridge/freezer, radio, 
computer/laptop, CD or MP3 player, stereo/cassette/other music player, “none of the above” 
9. Participant’s own definition of “main partner” 
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Table 6.2: Participants perceptions of HIV service factors which may affect initiation of timely 
treatment  
 
Controls 
(Achieved 
TLA)                                                            
N (%) 
Cases    
(Did not 
achieve 
TLA)           
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjusted 
Odds 
Ratio3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
CHiP related factors  
Was the CHiP previously known to participant (prior to PopART home-visit) 
N 259 (70) 253 (76) 1 0.05 1 0.006 
Y 113 (30) 80 (24) 0.70 0.48-1.01 0.58 0.39-0.86 
Did participant have an HIV test with CHiP 4  
N 47 (13) 27 (8) 1 0.05 1 0.07 
Y 325 (87) 306 (92) 1.63 0.99-2.71 1.60 0.95-2.70 
Was the CHiP someone you could talk to openly? 5 ptrend 6 0.01 
Strongly disagree/Disagree 7 (2) 14 (4) 1 0.02 1 0.04 
Agree 66 (18) 80 (24) 0.59 0.22-1.58 0.64 0.23-1.81 
Strongly agree 299 (80) 239 (72) 0.37 0.14-0.97 0.41 0.15-1.13 
Factors specifically affecting linkage to care   
Time constraints affecting linkage to care 
Already in care/ time not a constraint for LTC 289 (78) 231 (69) 1 0.02 1 0.02 
Time constraints due to livelihood/housework 
or both 
82 (22) 102 (31) 1.62 1.14-2.30 1.64 1.14-2.38 
Among those never previously registered for care prior to CHiP referral (N=603), did the following affect linkage to care? 
“Clinic is only open when I am at work” 
N 262 (85) 231 (78) 1 0.03 1 0.02 
Y 46 (15) 64 (22) 1.63 1.06-2.51 1.63 1.06-2.51 
“Clinic is too crowded” 
N 181 (59) 144 (49) 1 0.12 1 0.006 
Y 127 (41) 151 (51) 1.50 1.07-2.11 1.51 1.08-2.12 
“I could not go to the clinic because it is too 
far away/ because of the time it would take 
to travel there”   
    
N 299 (97) 273 (93) 1 0.02 1 0.03 
Y 9 (3) 22 (7) 2.52 1.13-5.61 2.55 1.14-5.69 
“I am not ready to go the clinic for HIV care” 
N 249 (81) 183 (62) 1 <0.001 1 <0.001 
Y 59 (19) 112 (38) 2.68 1.84-3.89 2.75 1.89-4.01 
“I will only go if/when I feel sick” 
N 270 (88) 232 (79) 1 0.003 1 0.02 
Y 38 (12) 63 (21) 1.96 1.26-3.07 2.00 1.27-3.14 
 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model a priori including gender, community, age category as well as demographic/behavioural factors 
which were associated with case/control status (i.e. whether CHiP was known to participant prior to PopART to home-
visit, whether HIV status has been disclosed, whether partner is HIV positive and on ART, and lifetime number of sexual 
partners) 
4. Participants who did not have a test with CHiPs were those who self-reported known HIV-positive status, while those 
who had an HIV test with CHiPs were likely to be previously undiagnosed. 
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Table 6.3: Participants’ perceptions of advantages and disadvantages of initiation of timely 
treatment 
 
Controls 
(Achieved 
TLA)                                                           
N (%) 
Cases  
(Did not 
achieve 
TLA) 
  N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Adjust
ed 
Odds 
Ratio3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Individual level factors encouraging initiation of timely treatment (“Did any of the following encourage you start ART?”) 
“For my health - even though I don’t feel unwell” 
N 96 (26) 127 (38) 1 <0.001 1 <0.001 
Y 275 (74) 206 (62) 0.54 0.39-0.75 0.53 0.38-0.75 
Recommended by HCW (CHiP/clinic staff) 
N 35 (9 ) 55 (17) 1 0.005 1 0.02 
Y 336 (91) 278 (83) 0.52 0.33-0.82 0.56 0.34-0.91 
To protect partner from getting HIV 
N 189 (51) 188 (56) 1 0.11 1 0.19 
Y 182 (49) 145 (44) 0.78 0.58-1.06 0.81 0.58-1.12 
“I know someone/others who are well on ART and want to be on it too” 
N 142 (38) 155 (47) 1 0.01 1 0.08 
Y 229 (62) 178 (53) 0.67 0.48-0.92 0.74 0.53-1.03 
Individual level factors discouraging initiation of timely treatment (“Did any of the following discourage you from starting 
ART?”) 
“I was worried someone would find out about my HIV because of taking treatment/going to the clinic” 
N 278 (75) 232 (70) 1 0.1 1 0.15 
Y 93 (25) 101 (30) 1.33 0.95-1.86 1.30 0.91-1.87 
“I was/am not ready to take ART” 
N 285 (77) 196 (59) 1 <0.001 1 <0.001 
Y 86 (23) 137 (41) 2.42 1.73-3.38 2.25 1.58-3.21 
“I don't think the treatment works so there is no point in starting”   
N 333 (90)  285 (86) 1 0.12 1 0.16 
Y 38 (10) 48 (14) 1.44 0.91-2.29 1.42 0.87-2.30 
“I don't like the idea of taking life-long treatment”  
N 288 (78) 234 (70) 1 0.03 1 0.05 
Y 83 (22) 99 (30) 1.48 1.04-2.09 1.44 1.00-2.07 
Stigmatising attitudes which may affect initiation of timely treatment  
“People living with or thought to be living with HIV are verbally insulted, harassed and/or threatened” ptrend 5 0.27 
Strongly disagree 46 (12) 34 (10) 1 0.17 1 0.08 
Disagree 76 (20) 83 (25) 1.47 0.85-2.53 1.64 0.92-2.92 
Agree 137 (37) 133 (40) 1.28 0.76-2.15 1. 30 0.76-2.23 
Strongly agree 113 (30) 83 (25) 0.95 0.55-1.63 0.95 0.54-1.66 
“I have felt ashamed because of my HIV status” ptrend 5 0.007 
Strongly disagree 118 (32) 86 (26) 1 0.02 1 0.05 
Disagree 139 (37) 106 (32) 1. 10 0.74-1.64 1. 20 0.78-1.84 
Agree 59 (16) 74 (22) 1.83 1.12-2.98 1.82 1.10-3.03 
Strongly agree 56 (15) 67 (20) 1. 70 1.06-2.72 1.71 1.05-2.79 
“I have been excluded from social gatherings or activities because I have HIV” ptrend 5 0.16 
Strongly disagree 162 (44) 134 (40) 1 0.73 1 0.30 
Disagree 187 (50) 177 (53) 1.14 0.82-1.59 1.31 0.94-1.89 
Strongly agree/ agree 23 (6) 22 (7) 1.13 0.59-2.16 1. 40 0.71-2.76 
 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model a priori including gender, community, age category as well as demographic/behavioural factors 
which were associated with case/control status (i.e. whether CHiP was known to participant prior to PopART to home-
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visit, whether HIV status has been disclosed, whether partner is HIV positive and on ART, and lifetime number of sexual 
partners) 
4. There were very few responses in the “strongly agree” and “agree” categories for this question, responses are therefore 
grouped as shown to be more meaningful/increase power 
5. p-value for test for trend 
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 Supplementary Table 6.1: Factors with effect modification by gender, of association with case/control status 
  
 
Controls 
(Achieved 
TLA)                                                            
N (%) 
Cases    
(Did not 
achieve 
TLA)          
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjusted 
Odds 
Ratio3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Controls 
(Achieved 
TLA)                                                            
N (%) 
Cases   
(Did not 
achieve 
TLA)  
N (%) 
Odds 
Ratio 1
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjusted 
Odds 
Ratio3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
 Men Women 
Demographic, sexual behaviour and health related characteristics of cases and controls 
Educational attainment pem 4 0.005 
Primary (Grade 0-7) 70 (46) 45 (34) 1 0.06 1 0.02 113 (51) 108 (54) 1 0.30 1 0.21 
Junior secondary 
(Grade 8-9) 
 36 (24) 45 (34) 2.04 1.13-3.67 2.50 1.30-4.82 58 (26) 39 (19) 0.74 0.45-1.23 0.71 0.41-1.24 
Senior secondary 
(Grade 10-12) or higher 
education  
45 (30) 42 (32) 1.41 0.79-2.52 1.81 0.94-3.50 49 (22) 54 (27) 1.16 0.68-1.97 1.21 0.68-2.17 
Was the CHiP known to the participant prior to offer of HBT? pem 4 0.006 
N 106 (70) 112 (85) 1 0.006 1 <0.001 153 (69) 141 (70) 1 0.68 1 0.38 
Y 45 (30) 20 (15) 0.41 0.22-0.77 0.29 0.14-0.58 68 (31) 60 (30) 0.90 0.57-1.44 0.80 0.49-1.32 
Have you disclosed your HIV status to anyone? pem 4 0.002 
N 24 (16) 27 (20) 1 0.27 1 0.35 14 (6) 47 (23) 1 <0.001 1 <0.001 
Y 127 (84) 105 (78) 0.70 0.38-1.31 0.72 0.37-1.43 207 (94) 154 (77) 0.20 0.11-0.39 0.18 0.09-0.36 
AUDIT Score pem 4 0.02 
Audit Score 7 or lower 82 (54) 58 (44) 1 0.05 1 0.009 171 (77) 168 (84) 1 0.07 1 0.08 
Audit Score 8 or higher 
(hazardous and harmful 
alcohol use; possible 
dependence) 
69 (46) 74 (56) 1.64 1.00-2.70 2.13 1.20-3.81 50 (23) 33 (16) 0.63 0.38-1.04 0.61 0.35-1.06 
Participants perceptions of HIV service factors which may affect initiation of timely treatment 
Time constraints affecting linkage to care pem 4 0.03 
Already in care/ time 
not a constraint for LTC 
96 (64) 82 (62) 1 0.91 1 0.86 193 (87) 149 (74) 1 <0.001 1 0.001 
Time constraints due to 
livelihood/housework 
or both 
54 (36) 50 (38) 1.02 0.63-1.69 1.05 0.61-1.81 28 (13) 52 (26) 2.43 1.44-4.10 2.47 1.41-4.34 
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Participants’ perceptions of advantages and disadvantages of initiation of timely treatment 
I have felt ashamed because of my HIV status pem 4 0.02 
Strongly disagree 47 (31) 30 (23) 1 0.002 1 <0.001 71 (32) 56 (28) 1 0.22 1 0.20 
Disagree 61 (40) 44 (33) 1.48 0.75-2.91 2.03 0.93-4.42 78 (35) 62 (31) 0.96 0.58-1.61 1.02 0.58-1.77 
Agree  17 (11) 35 (27) 4.84 2.06-11.39 6.57 2.59-16.67 42 (19) 39 (19) 1.08 0.58-2.02 0.98 0.50-1.91 
Strongly agree 26 (17) 23 (17) 1.93 0.87-4.25 2.05 0.86-4.86 30 (14) 44 (22) 1.72 0.94-3.14 1.81 0.96-3.41 
People sometimes talk badly about me because I am living with HIV pem 4 0.02 
Strongly disagree 27 (18) 33 (25) 1 0.10 1 0.16 56 (25) 45 (22) 1 0.19 1 0.17 
Disagree 67 (44) 58 (44) 0.67 0.34-130 0.78 0.37-1.64 74 (33) 86 (43) 1.39 0.82-2.35 1.77 0.99-3.17 
Agree 36 (24) 33 (25) 0.70 0.33-1.49 0.72 0.32-1.61 63 (29) 46 (23) 0.82 0.44-1.51 1.11 0.57-2.14 
Strongly agree 21 (14) 8 (6) 0.28 0.10-3.05 0.30 0.10-0.89 28 (13)  24 (12) 0.93 0.46-1.86 1.31 0.62-2.75 
 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model a priori including gender, community, age category as well as demographic/behavioural factors which were associated with case/control status (i.e. whether CHiP was 
known to participant prior to PopART to home-visit, whether HIV status has been disclosed, whether partner is HIV positive and on ART, and lifetime number of sexual partners) 
4. P value for effect modification by gender 
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Chapter 7: Discussion 
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Outline of chapter 
This chapter will summarise and synthesise the findings of the four preceding chapters, with 
emphasis on the two case-control studies and discuss the implications of the PhD as a whole. 
Strengths and limitations will be examined and lessons learned will be presented. Recommendations 
will be made for further research. Finally, policy implications will be discussed. 
 Although this is a Discussion chapter, additional tables will be presented where necessary. Some 
data were not shown in the manuscripts which were written for publication of the studies (due to 
word limits and feasibility of what could be included in Tables), but are nonetheless of interest. They 
will therefore be presented in this chapter. 
7.1 Research findings  
The research undertaken for this PhD has explored the key steps in the cascade of HIV care, 
specifically applied to the context of the PopART trial. However, the findings of the nested studies 
should be broadly generalizable to many urban and peri-urban settings in sub-Saharan Africa where 
UTT may be delivered. 
7.1.1 Home Based-HIV Testing and Counselling 
The systematic review and meta-analysis on the uptake of HB-HTC systematically evaluated the 
published literature on the acceptability of HB-HTC as measured by HIV test uptake among those 
offered it at the household in sub-Saharan Africa between 2000 and 2012. The finding that 83% of 
those offered HB-HTC accepted it, at a time when PopART was still in the planning stages, was highly 
promising for the prospect of using HB-HTC as the main component to achieve universal testing in 
PopART. Evidence on the acceptability of HB-HTC has continued to emerge since then and has 
supported our results.(1-3)  
The finding in our systematic review on HB-HTC that there were no significant differences between 
men and women in uptake among those offered HB-HTC highlights an important issue around the 
difference between uptake and coverage. Coverage measures acceptance out of all those estimated 
to be present (or living in the community for example), while if uptake is examined, the denominator 
is limited to those met and offered testing. This is important to bear in mind when examining data 
on HIV testing, so that uptake is not interpreted as equivalent to coverage. Uptake could be high but 
coverage would be low if not enough of a given population is encountered by service providers. 
Evidence indicates that there are fewer men found at home than women and HB-HTC providers may 
therefore encounter less men. (4, 5) Once contacted however, men are not notably less likely to 
accept HIV-testing.(4, 5) The challenge for achieving universal coverage, among men and women 
alike, lies in maximising the number of men contacted through HB-HTC. Weekend and evening 
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provision has been shown to increase the number of men encountered. (6, 7) This suggests that with 
innovative means to contact men, HB-HTC has the potential to have universal reach. 
Having established that HB-HTC is broadly well accepted we wanted to establish if there were sub-
sets of the population with particular demographic characteristics, behaviours or those holding 
certain views and beliefs that were being excluded / were not accepting HB-HTC despite being 
offered it at their doorstep (or because it was at their doorstep). Case-control study 1 was done to 
examine this question. By comparing a sub-set of the population who had been contacted and 
accepted HB-HTC (controls) with those who declined HB-HTC (cases) when offered it by the PopART 
CHiPs, we were able to explore differences in the two groups.  
As described in Chapter 4, there were no fundamental differences in terms of demographic or 
behavioural characteristics between those who declined and those who accepted HB-HTC. The CC1 
study sample was frequency matched by gender and community to ensure adequate representation 
of those groups. As such, rather than identify if there were any differences in uptake by gender 
(other PopART data on uptake of HB-HCT answer that) (4), we were able to explore differences 
between those who declined and those who accepted HB-HTC after accounting for gender. We were 
also able to examine if associations differed by the gender of the participant. Few other studies have 
been able to do this, with most having considerably fewer men in the study sample. (1, 8) 
We observed no clear associations with case/control status according to age category. The 
association of HB-HTC uptake with age is conflicting, with some data indicating that older age groups 
are more likely to accept. (8) Age was therefore included as a potential confounding factor in the 
final multi-variable model given that it is generally recognised as an important determinant of 
engagement with health services. 
Acceptors and non-acceptors of HB-HTC were similar in terms of educational attainment, 
employment and socio-economic position. Similarly, there were no differences by health status, 
health seeking behaviour or sexual behaviour and influences such as presence of other household 
members when offered HBT (Chapter 4, Table 4.1 and Table 7.1 below).  
As described in Chapter 4, Table 4.1, most participants had lived in the community for 4 or more 
years, and this was associated with twice the odds of being a case i.e. having declined HB-HTC. This 
may be due to the fact that those who had lived in the community for some time were more likely to 
have been exposed to HIV-testing campaigns in the past and been tested before. Our data suggest 
that it was those who had never tested previously who were more likely to test (Chapter 4, Table 
4.1). However in our study, those who had lived in the community for longer were neither more nor 
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less likely to self-report as not having previously tested (8% of those who had lived in the community 
for ≥4 years had not tested previously vs 5% of those who had lived in the community for ≤3 years; 
X2 p=0.26).  
An alternative explanation might have been that those who were resident in the community for 
longer were more likely to be in stable partnerships and therefore considered themselves less at risk 
of HIV and declined HB-HTC as a result. Again, there is no suggestion of that in our data (no 
differences of lifetime number of sexual partners or self-perception of high risk sexual behaviour, by 
duration lived in community (Table 7.2)). Or it may be that participants who had lived in the 
community for 4 or more years were more traditional in their attitudes and therefore were more 
likely to have declined HB-HTC (after adjusting for age), although this is merely speculative.  
There were differences observed by case/control status, with regard to perceptions about HIV care, 
treatment or service providers (Chapter 4, Table 4.3). Individuals who expressed favourable opinions 
about the CHiPs, about the convenience of testing at home and about accessing treatment without 
delay after diagnosis were more likely to accept HB-HTC. Participants who said that they knew 
people who had tested with the CHiPs were also less likely to decline HB-HCT and this likely ties in 
with a positive disposition towards the CHiPs, which encouraged testing. This suggests that the 
opinions shared between community members about HB-HCT provided by the CHiPs were positive 
rather than negative, therefore encouraging uptake of testing among those who knew others who 
had accepted CHiPs HB-HCT.  
Participants who said that they were confident that they were HIV-negative or reported having 
recently tested (and were presumably also HIV-negative given that those who self-reported living 
with HIV were not routinely offered the HB-HCT intervention and would therefore not be part of the 
study sample), were more likely to decline HB-HCT. The fact that those who were previously test-
naïve found HB-HCT acceptable when offered by the CHiPs is encouraging as it suggests HB-HCT is 
effective at increasing knowledge of HIV-status. As was described in Chapter 4, stigma and concerns 
about confidentiality were not associated with test uptake in our study. The implications of all these 
findings are discussed in section 7.4 below. 
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Table 7.1 Health seeking behaviour, circumcision (among men) and pregnancy (among 
women) status of cases and controls in CC1 
 
Cases (Non-
acceptors)        
N (%) 
Controls 
(Acceptors)                                                            
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Adjusted 
Odds 
Ratio 3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
Hospitalised in last 12m       
N 291 (93) 309 (94) 1 0.65 1 0.54 
Y 21 (7) 20 (6) 1.16 0.61-2.22 1.23 0.64-2.36 
Ever circumcised (among men) 
N 94 (62) 85 (57)  1 0.52 1 0.59 
Y 58 (38) 64 (43) 0.84 0.50-1.42 0.86 0.51-1.47 
Ever pregnant (among women)       
N 29 (18) 31 (17) 1 0.76 1 0.79 
Y  279 (82) 148 (83) 0.91 0.50-1.65 0.98 0.49-1.98 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model including gender, community, age category and years lived in the community 
4. P value for test for trend 
Table 7.2 Sexual behaviour of CC1 participants by duration lived in the community 
Years lived in the community 
≤3 
N (%) 
≥4 
N (%) 
No of lifetime sexual partners 
1 29 (32) 136 (28) 
2 16 (18) 98 (20) 
3 24 (27) 148 (30) 
≥ 5 21 (23) 112 (23) 
My sexual behaviour has put me at risk of HIV 
N 78 (81) 436 (81) 
Y 18 (19) 102 (19) 
 
7.1.2 Timely linkage-to-care and ART initiation without delay 
Our systematic review on the cascade-of-care following community-based detection of HIV 
described in Chapter 5 established that there is considerable variability in the existing literature 
when it comes to measures of reporting linkage-to-care and ART initiation and in outcomes 
reported, even for similar time periods. Nonetheless, the evidence from some of the studies with 
high proportions LTC and/or initiated ART following home or other community location-based HTC 
suggests that it is possible to achieve favourable outcomes. (9-11)  
We also found evidence to suggest that individuals who had been diagnosed previously were more 
likely to link-to-care than those who reported being newly diagnosed. This could be because those 
who had been previously diagnosed had previously linked-to-care and even if they had defaulted 
from care, were less daunted by the prospect of linking again. Alternatively, it may that PLWH need 
time to come to terms with an HIV diagnosis and once there is greater acceptance of living with HIV, 
 182 
 
individuals feel able to engage with services. PopART intervention data and evidence from the ANRS 
TasP trial which indicate that there is incremental linkage-to-care over time since referral support 
this idea. (4, 5) 
Our systematic review did not find any benefit from using point-of-care CD4-count testing with 
regard to linkage-to-care/ART initiation outcomes following home or other community location-
based HTC. This is in contrast to studies based in facilities, where CD4-count testing provided an 
incentive for individuals who test HIV positive to register for HIV care. (12) However, these findings 
have to be interpreted with caution given the variability in the measures used in the studies which 
reported on LTC/ART initiation following community-based HTC which met inclusion criteria for the 
systematic review. Nonetheless, from the available evidence we did not find differences between 
different modes of community-based HTC e.g. mobile vs home-based testing, for instance.    
In Case-control study 2 we focused on timely linkage-to-care and ART initiation within 6 months 
(referred to as timely linkage-to-ART), irrespective of CD4-count or immune-status. The study was 
done in PopART Arm A communities where universal test and treat was provided, to compare those 
who had achieved TLA (controls) with those who had not (cases). Just as in CC1, CC2 was designed so 
that participants from all relevant communities and both genders would be represented in the 
study. And as with CC1, CC2 found no differences in terms of demographic characteristics between 
those who achieved TLA and those who did not.  
However, there were some behavioural characteristics related to self-reported sexual behaviour and 
disclosure of HIV which were predictive of case/control status. As previously seen (Chapter 6, Table 
6.1) there is a suggestion that the more lifetime sexual partners participants reported, the more 
likely they were to achieve TLA (reduced odds ratios of being a case). This might be due to the fact 
that those who had had a greater number of sexual partners were more accepting of living with HIV 
(as opposed to being in disbelief/denial about their diagnosis if they considered themselves at low 
risk of getting HIV, for example).  
Disclosure of HIV status was seen to encourage TLA and our data suggest a similar encouraging 
effect from having an HIV-positive partner on ART (the latter however not reaching statistical 
significance in the multi-variable adjusted model). In contrast, reporting an HIV-positive partner who 
was not known to be on ART meant that the individual was twice as likely to have failed to achieve 
TLA, compared to the baseline group consisting of individuals who did not report having an HIV-
positive partner (i.e. partner reportedly HIV-negative or status unknown, or no partner in last 12 
months). Collectively, these findings could suggest that participants who had come to terms with 
 183 
 
their HIV diagnosis and were in relationships where openness about HIV related matters prevailed, 
had an advantage with regards to achieving TLA.  
As was seen in CC1, participants who reported favourable views about the CHiPs – for instance 
strongly agreeing that the CHiP was someone they could talk to openly - were more like to achieve 
TLA (Chapter 6, Table 6.2). We also saw that participants who were in favour of treatment 
(encouraged to start treatment “for my own health even though I don’t feel unwell” or “I know 
someone/others who are well on ART and want to be on it too”) were more likely to achieve TLA 
whereas those with more negative views (“I was/am not ready to take ART” or “I don’t like the idea 
of lifelong treatment”) were more likely to fail to achieve TLA (Chapter 6, Table 6.3). Encouragingly, 
knowing others on treatment and previously knowing the CHiP were predictive of achieving TLA.  
As has been demonstrated by others, participants who reported time constraints were more likely to 
fail to achieve to TLA (Chapter 6, Table 6.2). (13) Similarly, among those who had never previously 
registered for care, time-related constraints to accessing the clinics were seen to be barriers to TLA. 
Further, clinic infra-structure factors including opening hours and crowding in the clinic were 
predictive of failure to achieve TLA. Of note, health care worker (HCW) factors (being treated badly 
by HCWs or inadvertent disclosure by HCW) - were not associated with TLA (Table 7.3). In fact, 
participants who said the recommendation of a HCW to start ART was an encouraging factor for TLA, 
were more likely to succeed with timely initiation (Chapter 6, Table 6.3). 
Table 7.3: Health care worker related perceptions held by participants 
 
Controls 
(Acceptors)                                                            
N (%) 
Cases 
(Non-
acceptors)        
N (%) 
Odds 
Ratio 1 
LRT 2              
p-value,      
95 % 
Confidence 
Interval 
Adjust- 
ed 
Odds 
Ratio3  
LRT 2              
p-value,     
95 % 
Confidence 
Interval 
I think people get treated badly by clinic staff if they are HIV+ve 
N 272 (88) 254 (86) 1 0.48 1 0.19 
Y 36 (12) 41 (14) 1.19 0.73-1.95 1.41 0.84-2.37 
“A health worker may disclose to others without my permission that I am on treatment for HIV (if I am on 
treatment)” 
ptrend 5 0.15 
Strongly disagree 182 (49) 163 (49) 1 0.28 1 0.23 
Disagree 169 (45) 141 (42) 0.93 0.68-1.27 0.99 0.70-1.39 
Strongly agree/ agree 21 (6) 29 (9) 1.52 0.83-2.78 1.7 0.90-3.20 
1. A priori adjusted for gender and community to reflect sampling strategy 
2. Likelihood ratio test 
3. Multivariable model a priori including gender, community, age category as well as demographic/behavioural 
factors which were associated with case/control status (i.e. whether CHiP was known to participant prior to 
PopART to home-visit, whether HIV status has been disclosed, whether partner is HIV positive and on ART, and 
lifetime number of sexual partners) 
4. There were very few responses in the “strongly agree” and “agree” categories for this question, responses are 
therefore grouped as shown to be more meaningful/increase power 
5. p-value for test for trend 
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As for uptake of HB-HTC, stigmatising attitudes do not appear to be major determinants for 
engagement with services. The implications of the findings from CC2 are discussed in section 7.4 
below.  
7.2 Limitations and strengths of research conducted for PhD 
7.2.1 Potential limitations of study design and procedures and findings 
7.2.1.2 Study design  
During the planning stages of PopART and the nested case-control studies, it was anticipated that 
non-uptake of the HB-HTC and the timely treatment interventions would be infrequent. As such, a 
case-control design was chosen with the assumption that the “non-engagers” (with the unsuccessful 
outcome) would befit being the cases, and a sample of controls who accepted  the interventions (i.e. 
with the successful outcome) could be chosen to represent the population from which the cases 
arose, for comparison.  
As PopART intervention data has emerged, it has become clear that initiation of timely treatment - 
within 6 months for example - has not been as successful as initially hoped. (4) PLWH initiate 
treatment and increasingly so with time since referral, but achieving timely linkage and treatment 
initiation has been a challenge. As such, for CC2 in some communities there were fewer controls 
(achieved TLA) than cases (delayed ART initiation or not started at all – at the time of random 
selection for CC2). The frequency matching was therefore not always 1 case: 1 control per 
community. However, at the analysis stage odds ratios were adjusted for community and any 
imbalances would therefore be accounted for. 
The case-control design meant that specific individuals who were randomly selected for having a 
specific outcome (case or control) had to be traced in order to ask permission for study participation. 
As already described in Chapter 4 and 6 for CC1 and CC2 respectively, tracing of named individuals 
who were previously encountered in the community by the CHiPs at the time of intervention 
delivery was not always possible. Despite prior knowledge of the communities, the extent of 
mobility and frequency of turnover of addresses was greater than expected. Given the importance in 
case-control studies of selecting individuals with known outcomes and in specified proportions for 
the required case: control ratio, the difficulty in tracing community members became a key 
challenge for both studies.  
 
 185 
 
Related to the above observation in PopART intervention data that PLWH took longer than we had 
initially hoped to start ART, the case/control definition in CC2 had to be modified as described in 
Chapter 6. Initially, treatment initiation irrespective of CD4-count within 3 months was hoped for to 
maximise the impact of treatment as prevention by minimising the duration of uncontrolled 
viraemia in a given PLWH who was not yet on treatment. However, the time-period had to be 
extended to 6 months to allow more individuals to meet the control criteria of initiating treatment 
within a given (relatively short) period. PopART intervention data indicate that 42% of PLWH who 
were referred by CHiPs had initiated ART by six months, representing the vast majority of those who 
did so within the first year. Therefore, on balance 6 months was chosen as the most meaningful time 
period to use as a cut-off for the definition of “timely” initiation of ART. A shorter time would be 
applicable to too few individuals and a longer period would not have the full benefit of treatment as 
prevention.   
7.2.1.3 Recruitment of cases and selection bias 
The CC studies sought to explore reasons for non-uptake of PopART interventions and it is possible 
that a substantial proportion of those individuals who declined HB-HTC / did not achieve TLA, also 
declined study participation.  As shown in Chapter 4 and 6, there were losses of individuals initially 
identified as potential candidates for the study. This could mean that the individuals who were 
encountered were not necessarily representative of all those who were offered interventions. In CC1 
there was no evidence of differential recruitment based on outcome as shown in Chapter 4, Figure 2. 
In CC2, individuals who were not traceable for follow-up with a resultant “unknown” ART uptake 
status were not eligible to participate in the study. As a result, there may be a selection bias related 
to who was eligible for study participation, especially as it is reasonable to assume that household 
members who were absent at multiple follow-up attempts, may also have been more likely not to 
have initiated timely ART. Among those eligible, the failure to locate individuals and/or the refusal to 
participate in the case-control study (i.e. response rates) were differentially associated with success 
of achieving TLA – a lower proportion of randomly selected potential cases were located and 
recruited than among potential controls (Chapter 6, Figure 2). While undesirable, this limitation in 
CC2 was somewhat inevitable given the study question and the necessary pre-requisite of 
individuals’ willingness and consent to participate.  
The most important short-coming of the case-control studies was that only community members 
who had accepted the intervention when offered by CHiPs i.e. agreed to have their identification 
details recorded and partook in the CHiP household visit (which included the offer of HB-HTC and 
referral for HIV care for those identified as HIV-positive), could be eligible for random selection into 
the case-control studies. This means that those who refused outright to have any form of 
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engagement with the CHiPs are not represented in the case-control studies at all. There is a 
reasonable chance that those individuals are systematically different from those who accepted the 
intervention. Therefore, the case-control study findings can only be generalised to the latter group 
and not all community members. However, that was the goal from the outset i.e. to explore the 
factors associated with uptake of interventions among those who were offered them. Furthermore, 
estimates suggest that it is a relatively small proportion of community members (especially among 
women) who did not participate in the intervention. Data from the first year of PopART in Zambia 
indicate that among women, 90% of those enumerated consented to the PopART intervention and 
while the proportion among men was smaller at 77%, it was still the majority of men in the 
community. (4) 
7.2.1.4 Information bias 
Information bias in both CC studies may have resulted either from the respondents (recall or 
reporting (e.g. social desirability) bias) or from the researcher (observation bias). Recall could have 
been a problem in both studies given that the CC studies were conducted towards the end of the 
intervention annual round for feasibility reasons. It is therefore possible that participants’ responses 
were representative of their situation/views/perspectives at the time of the study but that these 
were changed from the time of the intervention. For example, in CC1 factors associated with 
acceptance of HB-HTC at the time of offer by CHiPs were the focus of the study, yet the participants’ 
responses may have been reflective of factors at the time of the CC study conduct instead. For some 
participants who were included in the intervention at the start of the annual round, the CC study 
would have been conducted approximately a year later. For the majority however, there would have 
been a shorter time lag between being offered HB-HTC and taking part in the study. Also, given the 
importance of giving everyone who participated in the intervention during the first year an equal 
probability of being included in the study, the random selection and therefore the study had to 
occur after completion of the first annual round of the intervention (or as close to it as possible). 
The questionnaires were dependent on self-report and would inevitably have been influenced by 
individual subjectivity. For instance, how participants responded to the question about the number 
of years lived in the community may have been inconsistent if for example, there were periods of 
out-migration or having returned to a village of origin for an extended period to care for a relative, 
as often happens in these communities. Depending on the participant’s interpretation of the 
question, they may have given the duration as the entire time since first moving into the community, 
or alternatively may consider their most recent return to the community as the starting point to 
calculate duration.  
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Another factor to consider was the fact that both cases and controls were asked identical questions 
– in order to allow comparisons between the two groups, even though some questions would have 
involved hypothetical scenarios for some participants. This is a nuanced concept which may have 
been difficult for some participants to grasp. For example, cases in CC1 (who would have declined 
HB-HTC), were asked about reasons which may have encouraged them to accept. This was done to 
allow comparison with controls who did accept HB-HTC, regarding factors associated with 
motivation to test. It is possible that those who declined simply said “No” when asked about any 
factor which encouraged uptake. As seen in chapter 4, Table 4.3 and chapter 6, Table 6.3, this does 
not appear to be an overwhelming concern but it remains a potential consideration. 
Social desirability bias is a concern when interpreting self-reported data. However, given that there 
were no a priori hypotheses about the associations of the exposure variables and the outcomes, it is 
not expected that any bias would have been differential and the conclusions drawn as a result were 
more likely to under-estimate rather than over-estimate associations.  
Further, field researchers were kept blind to case vs control status of study participants until the end 
of the questionnaire to minimise the observer bias which could have arisen from prior knowledge of 
whether a given participant was an acceptor or non-acceptor of the intervention.  
7.2.1.5 Reverse causality 
Given the case-control design and the fact that the outcome had occurred before the study was 
conducted, reverse causality is the other potential limitation when interpreting certain factors in 
both studies. To illustrate the point using CC2 and a question related to whether participants were 
worried that a HCW may disclose their HIV status without their permission – participants who had 
achieved TLA may have formed their opinions about HCWs after attending the clinic. Positive views 
expressed about them may be reflective of the experience in the clinics after achieving the outcome. 
In other words, in this example the “predictor” we were examining arose after the outcome. 
Therefore, to conclude that the positive views about health care workers encouraged those PLWH to 
link to care and start ART would be wrong. This is one of the key reasons that the findings of our 
studies are limited to observations of association and causality cannot be inferred. Reverse causality 
applies more to certain factors such as opinions and perceptions, which are changeable and have 
less objective measures, than others such as demographic characteristics. 
7.2.2 Strengths of research conducted  
The research conducted to contribute to this PhD also had several strengths. The case-control 
studies are nested within the largest HIV prevention trial to date in two high HIV prevalence 
countries in sub-Saharan Africa. The communities represented in the studies have an average total 
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population size of approximately 55,000 individuals (ranging from 20,000 to 150,000). All the 
PopART study sites are urban or semi-urban and this is a key strength given that in sub-Saharan 
Africa prevalence of HIV in urban settings is twice that of rural areas and a growing proportion of 
people live in urban areas. (14) This, along with the fact that the populations studied come from 
more than one country, add to the generalisability of the findings. 
Despite the limitations described above, the fact that the case-control study populations were 
randomly selected from communities which were randomly allocated to receive the universal testing 
and universal treatment intervention is a further advantage. There is only one other quantitative 
study exploring a limited number of factors associated with uptake of HB-HTC (1) and one on the 
factors associated with ART initiation (15) in the context of UTT. We examined a wide range of 
themes to a level of depth that others have not in existing published literature – especially when the 
background context of universal test and treat is considered.   
The study samples were also of substantial size with over six and seven hundred participants (CC1 
and CC2, respectively). Despite falling short of the originally intended sample sizes (described in 
Chapter 2, Section 2.5) we still had approximately 80% study power to detect associations with odds 
ratios of ~1.75 or higher (or ~0.5 or lower), for explanatory variables with 15% prevalence among 
controls (α = 0.05).  At this level, important differences which would have a population level impact 
would be detected by the studies, even if weaker associations of less common factors may have 
been missed. 
In addition to the research conducted for the CC studies, the findings of two systematic reviews 
done as part of the PhD make important contributions to the understanding of HB-HTC and TLA in 
sub-Saharan Africa. The systematic review and meta-analysis on HB-HTC which was published in 
2012 has promoted the acceptability of home-based testing as a means to increasing knowledge of 
HIV status in high prevalence settings. The second systematic review on the cascade of care after HIV 
diagnosis in the community (which is under review for publication) provides detailed scrutiny of the 
published literature and highlights the importance of consistency in reported data if we are to 
measure progress against UNAIDS 90-90-90 targets. 
7.3 Lessons learned from PhD process 
The period since embarking on the PhD has been a time of intensive learning and reflection. The first 
lesson learned was the need for flexibility and patience when conducting research. Given that the 
nested case-control studies were nested within a very large trial such as PopART there were a 
number of delays incurred by the main trial which affected sub-studies. The reasons ranged from 
delays in obtaining approvals from local regulatory authorities and greater than anticipated time 
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required to conduct training of field staff. The result was that the main trial started up to a year later 
than initially anticipated. This had a direct impact on when the case-control studies could start. 
Subsequent changes to PopART staffing arrangements also meant that new staff had to be recruited 
to work on the case-control studies, which required further preparation and training. 
The next major lesson learned arose from the data irregularity issue in South Africa, described in 
Chapter 2, Section 2.4.2. The episode was challenging in terms of the ethical considerations of what 
would be the best course of action to take. The greatest dilemma was in terms of seeking to retain 
data which were provided by participants in good faith and collected correctly, versus ensuring that 
data which were compromised were appropriately excluded. Further, the event exposed some of 
the difficulties which arise from collaborations with partner institutions which may have different 
perspectives and priorities.  
The key lessons learned from the episode for better research practice in future included the 
following. Frequent but open communication with field staff is required to understand challenges 
they face. In this case, staff were fearful to report that a number of participants who were randomly 
selected to be approached for case-control study participation were in reality impossible to find - 
given the feedback from neighbours or other household members that no one fitting the names/age 
of the participants sought were ever known at the given addresses. This could have resulted in 
extreme frustration for the case-control study staff who then felt that fabricating data on non-
existent individuals was the preferred course of action, rather than being seen to be ineffective at 
recruiting participants. There were implications for those staff in terms of future employment in the 
PopART trial (upon the completion of the case-control studies) which may have acted as perverse 
incentives for data fabrication.  
Understanding the obstacles staff are facing can improve how we support and manage them and 
what we expect of them. Greater anticipation of potential difficulties may have enabled clearer 
guidance for field level researchers and managers, so that they could have been better prepared in 
turn. Another vital lesson learned is the value of using electronic data-capture without which there 
would have been far fewer checks available to be able to explore and investigate irregularities in the 
data. As a result of careful monitoring of the data in “real-time”, I was able to detect the 
irregularities which arose in South Africa during CC1. The main trial has also learned from the 
experience and systems of data monitoring have been instituted as a result, with “red flags” raised 
when performance becomes implausibly high, for instance. 
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Insights have also been gained into the subtleties of questionnaire design, in particular the need to 
balance questions which are detailed enough to elicit important information against excessive detail 
which leads to participant and/or field researcher fatigue and resultant meaningless responses being 
recorded. Given the challenges faced in participant recruitment posed by the mobility and frequent 
in- / out-migration of community members, another lesson learned is the importance of having 
enough background information about study settings and the social dynamics at play before studies 
are planned, if possible. 
7.4 Research in context, implications of the findings and recommendations 
for the future 
The research for this PhD set out to establish whether the PopART UTT intervention would be 
acceptable across communities. It was conducted within the context of universal testing (CC1 on HB-
HTC) and universal test and treat (CC2 on TLA) and indicates that the interventions do not 
systematically exclude any subsets of the population. Our research provides supportive evidence for 
the potential to achieve universal coverage, in similar urban high-HIV prevalence settings in sub-
Saharan Africa. 
The importance of making the distinction between uptake of HB-HTC and coverage has been 
highlighted earlier. We have shown that HB-HTC is highly acceptable and does not exclude 
individuals by demographic or behavioural characteristics. The key to achieving universal access to 
testing using HB-HTC, will however, require innovative means to ensure that those who may not 
spend as much time at home (e.g.. men and young people in general) have the opportunity to be 
offered HB-HTC. Weekend and evening provision of services is one solution (6,7) but there may be 
limits to what is feasible. Concerns about staff safety (with respect to going door-to-door in the 
evenings), employment law (weekend working may be problematic in some settings) and recruiting 
staff to work unsociable hours (including the cost of paying out-of-hours salary rates), may all be 
obstacles.  
We have examined HB-HTC delivered by lay health workers, but the use of self-testing in the home 
with the subsequent support of lay health workers in the community to help interpret results and 
facilitate TLA has also been explored. (16) More research is needed on whether it may be the answer 
to reaching those who are less frequently encountered at home by staff going door-to-door. Iwuji et 
al from the ANRS TasP trial have suggested that supplementing HB-HTC with mobile-HTC in 
community locations may be the answer to help reach those who are missed or who chose not to 
participate in HB-HTC interventions, in order to reach universal coverage. (1) The SEARCH trial for 
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instance, is using multi-disease health campaigns in the community in combination with HB-HTC to 
maximise their coverage. (6) 
HIV testing is the gateway to HIV care for PLWH and can help HIV-negative individuals to remain so. 
(17) It appears from our research that HB-HTC is effective in reaching those who had not previously 
tested for HIV, which is key to increasing knowledge of HIV status. However, an individual’s HIV 
status may change over time and therefore on-going knowledge of HIV-status is essential. This 
requires repeat testing at regular intervals. Data from CC1 indicate that individuals weigh-up their 
own risk when deciding whether an HIV test is relevant for them. Those who believe that they are 
likely to be HIV-negative appear to decline (or perhaps defer) testing on the basis that there is “no 
need” to test for their circumstances. This finding was also reported by Iwuji et al from the ANRS 
TasP trial.(1) WHO no longer recommends repeat testing to cover a window-period (18) and for a 
given individual it is logical that an HIV-negative result would indicate there is no need for further 
testing if sexual partnership circumstances remain unchanged, assuming they are in a sero-
concordant HIV-negative relationship. Interestingly, those who agreed with the statement “My 
sexual behaviour has put me at risk of HIV” were more likely to accept HB-HTC. Interpreted together 
with the finding above about those who considered themselves likely to be HIV negative, it seems 
that community members are doing their own risk assessments about the added value of accepting 
HIV testing for their own perceived circumstances. This seems a perfectly reasonable position – 
provided the assessment of risk is based on an accurate picture of potential exposure to HIV.  
However, from a public health perspective an HIV-negative result may be false re-assurance given 
that HIV transmission is embedded not only within individual sexual partnerships but sexual 
networks. Any given individual may be unwittingly exposed to (new) risk if their partner’s 
circumstances change or are not what they believe them to be. With this in mind it seems important 
from a public health point of view that repeat on-going testing at fairly regular intervals (e.g. 
annually) is recommended in settings where HIV-prevalence is high. In order to achieve this, 
individual community members will have to be convinced that having an HIV test which is freely 
available and convenient is worth accepting irrespective of perceived risk. Self-testing using oral test 
kits could have a particular role for this. 
Evidence from CC2 suggests that those who perceive that their sexual behaviour has put them at risk 
of HIV were more likely to achieve TLA. More research is needed on how to effectively tailor public-
health messaging to address the issue of self-risk assessment and engagement with services, not 
least because the issues to be considered involve intimate relationships and they touch on sensitive 
societal norms and values relating to sexual behaviour. Social science research on the interplay 
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between perceived sexual risk and decision making pathways about accessing care could help 
enhance engagement with HIV prevention services and make an important contribution towards 
achieving universal coverage.   
Data from more than one HIV prevention trial which are seeking to reduce HIV incidence using 
treatment as prevention indicate that linkage to care is the current most important barrier to 
universal treatment. (4, 19) As discussed in Chapter 6, factors which were seen to affect TLA in CC2 
could have done so by influencing either or both, linkage to care and/or ART initiation. We observed 
that the CHiPs had a positive influence with respect to encouraging engagement with services. While 
social desirability bias may have influenced how commonly our study participants reported a 
positive view of the CHiPs, it seems unlikely it would have been differentially associated with 
case/control status. The association of a positive view of the CHiPs with engagement with services 
(uptake of HB-HTC or achieving TLA) therefore, seems significant. Evidence from other studies which 
have used lay health workers to enhance linkage to care have also seen benefits to outcomes.(9-11)  
Our findings from CC1 indicate that knowing someone else who accepted HB-HTC from CHiPs was 
associated with acceptance of HB-HTC. This suggests that the more coverage is achieved the greater 
uptake could become. Similarly, the data from CC2 suggest that we have reason to be optimistic that 
the acceptability of the universal treatment intervention in PopART (as defined by TLA) will improve 
over time. This is evidenced by the fact that knowing others on treatment and previously knowing 
the CHiP were predictive of achieving TLA. Relatedly, we also found that not only is disclosure of HIV-
positive status associated with TLA as has been seen by others (15), but also that participants who 
reported that they had an HIV-positive partner on ART were more likely to succeed with TLA 
themselves. Overall, this is promising for future years of PopART implementation as it could mean 
that positive momentum will build over time as more of the community become familiar with the 
PopART interventions and services provided by CHiPs. 
It has long been acknowledged that health-facilities pose a barrier to linkage to care and ART 
initiation. (13) Our research findings help unpick the underlying factors which contribute to this. 
While clinic infra-structure factors (over-crowding, clinic opening hours etc.) were barriers to TLA, a 
positive view of health care workers seems to encourage TLA (Chapter 6, Tables 6.2 and 6.3). This 
information is helpful when looking at which components pose barriers to linkage to care to make 
improvements in delivery of ART. Community ART clinics and community groups for drug refills 
which are led by HCWs in the community, make the most of the benefits of HCWs but remove the 
barriers posed by needing to attend clinics. (20) The potential role of CHiP led community models of 
ART delivery within PopART is being explored in an ancillary study. 
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Currently, community health workers hold a relatively low status in the hierarchy of health care 
workers. Our findings support the idea that we should invest in the CHiPs and similar lay health 
workers as a cadre of staff. Training and support on areas related to motivational interviewing or 
similar counselling skills should be considered to capitalise on their apparent ability not only to 
deliver the HB-HTC but to increase uptake and encourage TLA, seen in our studies.  
We did however also find that protecting a partner from acquiring HIV as a reason to start ART was 
not associated with increased TLA (Chapter 6, Table 6.3), and this suggests that greater efforts to 
promote a “treatment for prevention” message are indicated.  
Both CC studies found that stigma was not an important barrier to uptake of PopART interventions, 
suggesting progress in attitudes related to HIV given that over the years the opposite has been 
reported. (13) Similarly, fear of lack of confidentiality of testing for HIV at home was not a barrier to 
uptake of HB-HTC. Taken together, these findings reflect the advances which have been made in 
addressing HIV in SSA. 
7.5 Conclusion 
In conclusion, the research done for this PhD adds to current knowledge on the cascade of care in 
the context of UTT. While there are limitations to consider, the data provide in-depth information on 
the factors associated with the uptake of key interventions in the PopART model of UTT, therefore 
fulfilling the aim of the PhD. The findings of few differences by demographic and behavioural 
characteristics between those who accepted and those who did not accept PopART interventions 
suggest acceptability across population sub-groups. This holds great promise for reaching universal 
coverage. The association of favourable views of the CHiP cadre of staff with acceptance of 
interventions further suggests that the PopART model which uses CHiPs to deliver the HB-HTC 
intervention and facilitate linkage, is worth replicating in future implementation of UTT. We have 
also identified that self-perception of high risk sexual behaviour is facilitatory for uptake of 
interventions. Importantly, if individuals who engage in high risk sexual behaviour embrace 
interventions the prospect for treatment as prevention is optimistic. 
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Appendix 1 PopART Trial Schema   
Source: PopART Trial Protocol Version 1.0(1) 
 
 
 
21 Community Clusters 
12 in Zambia / 9 in South Africa 
Average of approx. 55,000 individuals in each cluster 
 
 
Arm B 
Clusters: 4 Zambia / 3 South Africa 
 
Intervention 
Combination prevention including: 
•Universal household-based testing 
•active linkage to care  
•ART eligibility according to national 
guidelines 
 
Research/Evaluation 
Population Cohort B 
One adult from each of 2,500 randomly-
selected households in each cluster 
 
 
 
Arm C 
Clusters: 4 Zambia / 3 South Africa 
 
Standard of Care 
Control Arm: 
•Existing prevention & testing services 
and referral for care 
•ART eligibility according to national 
guidelines 
 
Research/Evaluation 
Population Cohort C 
One adult from each of 2,500 randomly-
selected households in each cluster 
 
Arm A 
Clusters: 4 Zambia / 3 South Africa 
 
Intervention 
Combination prevention including:  
•universal household-based testing 
•active linkage to care 
•immediate ART eligibility 
 
 
Research/Evaluation 
Population Cohort A 
One adult from each of 2,500 randomly-
selected households in each cluster 
  
  
Primary Outcome Measure 
•HIV incidence measured over 3 years in Population Cohort 
Randomisation 
Secondary Outcome Measures 
•Population Cohort: HIV incidence measured over 1st , 2nd , and 3rd years, HSV-2 incidence, sexual risk behavior+,  
community VL*, viral suppression (ART patients)* , drug resistance (ART patients with detectable VL)*   
•Population Cohort and Health Center Data: ART Adherence, HIV disease progression and death, ART toxicity, HIV stigma 
•Health Center Data: TB notification and mortality rates 
•Population Cohort, Health Center Data, CHiPs Data: uptake of PMTCT, uptake of male circumcision, ART screening and 
uptake, uptake of HIV testing and retesting, time between diagnosis and initiation of care 
 
* Subject to funding for these assays. 
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Appendix 2: Information Sheet and Verbal Consent for Consideration 
of Case-control Study 1 (Zambia) 
Information Sheet and Verbal Consent for Consideration of Case-control Study 1 (Zambia) 
Factors associated with the uptake and non-uptake of Home-Based Voluntary HIV testing during 
the first annual round of the PopART * interventions - Case-control Study 1 
*Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A cluster-randomized trial 
of the impact of a combination prevention package on population-level HIV incidence in Zambia and South 
Africa 
Introduction 
This information sheet is about a study that is trying to identify why some people take-up home-
based voluntary HIV testing offered by the PopART trial and why other people choose not to take-up 
this service. This study is called the case-control study 1 in PopART. 
What is the purpose of the Case-control Study 1? 
The case-control study 1 aims to understand the views and behaviours of community members who 
either accepted or did not accept the home-based voluntary HIV testing which was offered by CHiPs 
at peoples’ homes. These questionnaires will let the researchers understand how the community feels 
about PopART trial activities. 
What will happen during this study? 
In each community, around 60 people will be asked whether they are willing to be interviewed by 
study researchers who will complete questionnaires based on answers participants give. You have 
been randomly selected – meaning you have not been singled out for any reason but the number on 
your CHiPs card was picked randomly from a list to be one of the people from your community who 
we would invite to participate in the study. If you participate in this study, you will undergo an 
interview with the researcher.   
Where and who is conducting this study?  
This study is being carried out in two countries, Zambia and South Africa, for a period of about1-2 
months in 2014/2015. It will be done in 14 communities, 8 of which are in Zambia and 6 in South 
Africa. Researchers from the Zambia AIDS Related Tuberculosis Project and the Desmond Tutu TB 
Centre at Stellenbosch University, South Africa, and the London School of Hygiene and Tropical 
Medicine, UK will conduct the study.  This study is being funded by the U.S. National Institutes of 
Health, the Office of the United States Global AIDS Coordinator, and the Bill and Melinda Gates 
Foundation.  
What are you being asked? 
At this point I am asking you for your permission to pass on your name, address, date of birth and 
gender to the researchers conducting the case-control Study 1 so that they can approach you. If you 
agree, the research team will be made aware that you participated in the CHiPs programme. I will 
not pass on any other information about what you have told me as part of the CHiPs programme.  
Then one of the researchers will come to find you and explain fully what the study involves. If you do 
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not agree now, I will not pass on any information, the research team will not approach you, and you 
will still receive all the services that are available to other community members here.  
If you do agree for me to pass on your details to the research team, a researcher will explain the 
study to you. Once you fully understand what the study involves you will be asked for your written 
consent to participate in the study. At that time, you can decline to participate in the study if you 
decide not to proceed for any reason.  If you decline, you will still receive all the services that are 
available to other community members here. 
What are the possible risks or discomforts? 
You may become embarrassed, worried or anxious when talking about your HIV status and discussing 
sexual risk behaviour and other topics.  The researchers are trained to treat participants with respect, 
maintain confidentiality and to help you deal with any feelings or questions you have. You may feel 
that being part of this study could lead to you feeling stigmatized or separated from your community.  
What are the potential benefits? 
The benefit of agreeing to allow us to pass on your information to the research staff and for the 
research staff to come speak with you is the opportunity to participate in the study (if you agree).  If 
you enrol in the study, you will be able express your opinions and represent views about yourself, your 
community and the PopART trial. This information will be anonymised and not be linked directly back 
to you. It will however help the research team understand how to improve HIV related services in the 
future. In addition, knowledge gained from this study may help reduce the spread of HIV in the future 
and promote better health for you and your family as well as helping with acknowledgement and 
acceptance of HIV as a community-wide health problem. 
Persons to Contact for Problems or Questions  
If you have any questions about this research study, your rights, or if you feel that you have 
experienced a research-related injury, contact:  
Investigator of Record Name: Dr Helen Ayles  
Research Site Address: ZAMBART Project, School of Medicine, Ridgeway campus, Po Box 50697, 
Lusaka  
Daytime telephone number(s): +260 211 254710  
If you have any questions or concerns about your rights or want to discuss a problem, get 
information or offer input, you may contact:  
Independent Review Board/Ethics Committee: UNZA Biomedical Research Ethics Committee  
Address of Independent Review Board: School of Medicine, Ridgeway campus, Po Box 50110, 
Lusaka  
Daytime Telephone Number: +260-211-256067  
Verbal Consent  
Now I would like to find out if you have understood this information and if you agree to me passing 
on your name, address, date of birth and gender to the Case-Control Study 1 researchers along with 
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the fact that you participated in the CHiPs programme, so that they can approach you to explain 
and obtain full informed consent to participate in the study. 
[CHiP records in a log/electronic device the decision by the participant(s)] 
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Appendix 3: Information Sheet and Informed Consent Case-control 
Study 1 (Zambia) 
INFORMATION SHEET AND INFORMED CONSENT FORM FOR  
CASE-CONTROL STUDY 1:  
 
PARTICIPANT INFORMATION AND CONSENT FORM 
 
Title of Research Study: Factors associated with the uptake and non-uptake of 
Home-Based Voluntary HIV testing during the first annual 
round of the PopART * interventions (Case-control Study 1) 
(*Population Effects of Antiretroviral Therapy to Reduce 
HIV Transmission (PopART): A cluster-randomized trial of 
the impact of a combination prevention package on 
population-level HIV incidence in Zambia and South Africa) 
 
Protocol #: HPTN 071, Version 1.0, 26 October 2012 
DAIDS ID: 11865 
 
Sponsor: National Institute of Allergy and Infectious Diseases 
National Institute of Mental Health  
(U.S. National Institutes of Health) 
Office of the United States Global AIDS Coordinator 
Bill and Melinda Gates Foundation  
 
Investigator of Record: Professor Nulda Beyers 
 
Research Site Address (es):   
 
Site: Delft South Clinic 
Address: Cr Main Rd & Boyce St 
Site: Bloekombos Clinic 
Address: Sam Nokasela Avenue 
Site: Ikwhezi clinic  
Address: Simon Street Nomzame 
Site: Town 2 Clinic (outreach) 
Address: c/o Zibonele and Manyano 
Street 
Site: Kuyasa Clinic 
Address: Ntlazana Street, Khayelitsha 
Site: Luvuyo Clinic 
Address: Hlela Road, Makaza 
Site: Dalevale Clinic (outreach) 
Address: Symphony Avenue,  
Site: Cloetesville Clinic 
Address: Tennant Street  
Site: Wellington Clinic (outreach)  
Address: Wellington Municipality 
 
Daytime telephone number(s): 021 983 9114 
 
24-hour contact number(s):  083 572 1470 
 Participant Information and Consent Form 
Please ask the study investigator or the study staff to explain any words or procedures that you do 
not clearly understand. 
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The PopART trial is looking at ways to reduce HIV incidence in your community. Information about 
the trial is supplied in the document which you may already have received from the Community HIV-
care Providers (CHiPs) who have been visiting households in this community (Provide CHiPs 
Information sheet (see separate document) if needed – document which would have already been 
provided to all community members at the time of providing the intervention). The purpose of this 
form is to give you information about a research study you are being asked to join. The study is 
trying to identify why some people take-up home-based voluntary HIV testing offered by the PopART 
trial and why other people choose not to take-up this service.  If you sign this form, you will be giving 
your permission to take part in the study.  The form describes the purpose, procedures, benefits, 
and risks of the research study.  You should take part in the study only if you want to do so.  You may 
choose not to join the research project or withdraw from this study at any time. Choosing not to 
take part in this research will not in any way affect the health care or benefits that you or your family 
will receive.  Please read this t Information and Consent Form and ask as many questions as needed.  
You should not sign this form if you have any questions that have not been answered to your 
satisfaction. 
 
This study is being funded by the U.S. National Institutes of Health, the Office of the United States 
Global AIDS Coordinator, and the Bill and Melinda Gates Foundation 
 
Your participation is voluntary 
You do not have to take part in this study.  If you decide today to take part in this research project, 
you may refuse to take part in any portion of the study or stop at any time without reducing or 
affecting any care that you receive at the health centers in your community.   
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Purpose of the PopART Research in the Communities 
The HPTN 071 or PopART trial is testing a program to try to reduce HIV infection in a community like 
yours.  Twenty one communities that include about 600,000 adults are included in this research 
(about 400,000 adults in twelve Zambian communities and 200,000 adults in nine South African 
communities, all located in the Western Cape).  
 
In some communities, the level of care that people are used to will stay the same, in terms of HIV 
testing, and care of those who have HIV.  
 
In other communities, to make HIV testing easier, CHiPs will go to all homes and will offer to do an 
HIV test on those wishing to have a test. (In South Africa children over the age of twelve can choose 
to have an HIV test without getting permission from their parents or guardians although it is better 
to first get consent from parents or guardians). For anyone infected with HIV, they will be offered to 
start taking drugs to treat HIV according to the standard treatment guidelines that are in place in the 
Western Cape.  The health workers will visit every home again once a year for up to three more 
years to repeat the HIV testing and to refer people to care.   
 
In other communities, CHiPs will go to all houses offering HIV testing, as was just described.  In these 
communities if someone over the age of 18 tests HIV positive however, they will be offered to start 
taking medicines to treat HIV right away.  The CHiPs will visit every home again once a year for up to 
three more years to repeat the HIV testing and to refer people to care.  Children under the age of 18 
who test HIV positive will be offered care according to the standard treatment guidelines used in the 
Western Cape. 
 
At the end of the trial, the researchers will see if offering HIV tests in each household and offering 
people the chance to start HIV treatment right away has reduced the number of people with HIV 
infection in the community. They will also see if starting ART early has any negative effects on 
people’s health.  
 
Your community is one of the communities participating in this research.  If health care workers are 
visiting homes in your community, you will notice that they provide some other information and 
services to people, but the most important thing is the testing and HIV treatment they offer. 
 
What is the purpose of the Case-control study? 
In each community, around 60 people will be asked to participate in additional activities such as 
completing questionnaires.  These questionnaires will let the researchers understand how the 
community feels about the program.  You have been selected to be one of the 60 people from your 
community who we are asking to participate in these additional activities to represent the views and 
behaviours of community members who either accepted or did not accept the home-based voluntary 
HIV testing which was offered by the PopART CHiP workers at peoples’ homes.  That is why you are 
being asked to read this document.  
 
What will happen during this study? 
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If you participate in this study, you will undergo an interview with the researcher who has presented 
this information to you. We will ask you questions about a number of topics including you and your 
sexual practices, HIV testing, male circumcision, and how you and others feel about HIV. 
  
The PopART CHiPs keep records of all their clients.  We would like to look at your records to help us 
better understand how the study activities in the community are being taken up over time and how 
they are affecting the health of people diagnosed with HIV.  In addition, and for the same reasons, we 
would like to access the routine patient records kept at the health center for HIV-infected patients.  If 
you agree to participate in this study, we will ask you for your permission to look at your records from 
the household and, if applicable, at the health center.  
What are the possible risks or discomforts? 
You may become embarrassed, worried or anxious when talking about your HIV status and 
discussing sexual risk behavior and other topics.  A trained staff member will help you deal with any 
feelings or questions you have. You may feel that being part of this study could lead to you feeling 
stigmatized or separated from our community  
 
What are the potential benefits? 
During the study, you will be able express your opinions and represent views about yourself, your 
community and the PopART trial. This information will be coded and not be linked directly back to 
you. It will however help us understand how to improve HIV related services in the future.  In 
addition, knowledge gained from this study may help reduce the spread of HIV in the future and 
promote better health for you and your family as well as helping with acknowledgement and 
acceptance of HIV as a community-wide health problem. 
 
Our research staff will provide you with advice on any services that may be of help to you, if we 
identify problems that you are experiencing. 
 
Are there any alternatives to participation? 
If you decide not to participate in this study, you will still receive all the services that are available to 
other community members here. 
 
How will my confidentiality and privacy be protected? 
We cannot guarantee absolute confidentiality.  However, we will do everything possible to protect 
your confidentiality if you join this study. We do this by giving you a study number and any 
information will be labeled with this number only, so only the research staff will be able to link this 
number to your name. Your personal information (name, address, phone number) will be protected 
by the research staff. This information will not be used in any publication of information about this 
study. 
 
To protect your privacy, you will meet with the researcher in a private area where others cannot 
overhear conversations with you.   
 
People who may review your records include: [insert name of site IRB/EC], local regulatory agencies, 
US National Institutes of Health (NIH), study staff, and study monitors.  Institutional Review Boards 
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(IRBs) or Ethics Committees (ECs) are committees that watch over the safety and rights of research 
participants. 
 
What happens if I am injured by participating in this study? 
It is very unlikely that you could be injured as a result of participating in this study.  However, if you 
are injured while participating in this study, you will be given immediate treatment for your injuries.  
You will not] have to pay for this care.  Stellenbosch University does have is a/ insurance cover for 
serious research related injury compensation. You will not be giving up any of your legal rights by 
signing this Participant Information and Consent Form. 
 
What are some reasons why I may be withdrawn from this activity without my consent? 
You may be withdrawn from the study without your consent for the following reasons: 
 
 The research study, or this part of the study, is stopped or canceled 
 The study staff feels that completing the study or this part of the study would be harmful to 
you or others 
 
The study will be conducted according to the international Declaration of Helsinki and other 
applicable international ethical codes for research on human participants. 
 
This study has been approved by a research ethics committee from Stellenbosch University 
 
Persons to Contact for Problems or Questions 
If you have any questions about your participation in this research study, your rights as a research 
subject, or if you feel that you have experienced a research-related injury, contact: 
 
 
 Dr Peter Bock, Co-Investigator, Desmond Tutu TB Centre, Department of Paediatrics and 
Child Health, Faculty of Health Sciences, University of Stellenbosch. Telephone: 021 
9389062. Email: peterb@sun.ac.za 
 
 Principal Investigator: Nulda Beyers, Desmond Tutu TB Centre, Department of Paediatrics 
and Child Health, Faculty of Health Sciences, University of Stellenbosch. Telephone: 021 938 
9114. Email:nb@sun.ac.za 
 
 Mr Franklin Weber, HREC coordinator, Health Research Committee 1, Stellenbosch 
University Health Research Ethics Committee, Tygerberg Campus. Telephone: 021 938 9657.  
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PARTICPANTS STATEMENT OF CONSENT 
 
Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A cluster-
randomized trial of the impact of a combination prevention package on population-level HIV 
incidence in Zambia and South Africa 
 
 I have been given sufficient time to consider whether to take part in this study. 
 My taking part in this research study is voluntary.  I may decide not to take part or to 
withdraw from the research study at any time without penalty or loss of benefits or 
treatment to which I am entitled. 
 The research study may be stopped at any time without my consent. 
 I have had an opportunity to ask my study investigator questions about this research study.  
My questions so far have been answered to my satisfaction. 
 I have been told how long I may be in the research study. 
 I have been informed of the procedures that may be performed during the research study. 
 I have been told what the possible risks and benefits are from taking part in this research 
study.  I may not benefit if I take part in this research study. 
 I do not give up my legal rights by signing this form. 
 I have been told that before any study related procedures being performed, I will be asked 
to voluntarily sign this Participant Information and Consent Form. 
 I will receive a signed and dated copy of this Information and Consent Form. 
 
If you have either read or have heard the information in this Participant Information and Consent 
Form, if all of your questions have been answered, and if you agree to take part in the study, please 
print and sign your name and write the date on the line below. 
 
 
Access of Data from PopART Community Health Worker Records 
_____ My initials indicate that I agree to allow my data from the PopART Community Health Worker 
Records to be accessed and used for this study.  
_____ I do not agree to allow my data from the PopART Community Health Worker Records to be 
accessed and used for this study. 
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Access of Data from Heath Center 
 
_____ My initials indicate that I agree to allow my records at the health center to be accessed and 
used for this study.   
 
_____  I do not agree to allow my health care records to be accessed and used for this study. 
 
 
 
 
I voluntarily agree to take part in this research study. 
 
 
----------------------------   --------------------------------- 
Subject’s Name (print)   Subject’s Signature and Date 
 
 
 
 
I certify that the information provided was given in a language that was understandable to the 
subject. 
   
 
------------------------------   -------------------------------------- 
Name of Study Staff    Study Staff Signature and Date 
Conducting Consent Discussion (print) 
 
 
 
-------------------------------   -------------------------------------- 
 
Witness’ Name (print)    Witness’ Signature and Date 
(As appropriate) Date 
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Appendix 4: CC1 questionnaire 
Case- Control Study 1 Questionnaire 
 Item / Question Display Response Options Skip Pattern Rationale for Q 
Comments (for phrasing 
of Qs or issues for 
training of RAs) 
Attempt_1 
Record the results of your 
attempt to locate the 
randomly-selected household 
member for interview.   
Attempt 1:  [dd][mm][yy], Has 
the participant been met?; 
Attempt 2; [dd][mm][yy] Has 
the participant been met?; 
Attempt 3; [dd][mm][yy]Has 
the participant been met?; … 
"add more" 
1. Yes- Individual participant is 
available; 2. No, participant is 
not available. I will make 
further attempts to contact; 3. 
No, this is my final attempt to 
contact the participant. 
If 1, go to 
"Language"; if 3 , 
go to "Attempt 2" 
    
Attempt_2 
Record the outcome of the 
final attempt to reach the 
participant. 
1. Individual absent (expected 
to return to community); 
2.Individual moved out from 
community; 3.Individual 
deceased; 4.Individual 
incapacitated/in hospital; 
5.Individual incarcerated; 6. 
Other 
End of survey, go 
to "home screen" 
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Lang 
Select appropriate language 
for the participant survey 
Zambia: English only; English + 
Bemba; English + Nyanja; 
English + Lozi; English + Tonga. 
South Africa: English only; 
English + Afrikaans; English + 
Xhosa; None 
If "none" end of 
survey, go to 
Ineligible_0 
    
Agree_1 
Thank you for taking the time 
to speak with me about a study 
on services provided by the 
PopART trial. I have been given 
your name and address by a 
PopART CHiP who has said you 
agreed to talk him/her about 
what services PopART was 
offering and also that you 
agreed that I could come to  
talk to you about another 
study. Please note, they did 
not pass on any other 
information about what you 
told them or any medical 
information about you. Can I 
proceed? 
Yes; No 
If yes, go to 
"Details"; if no 
continue 
Note 1, this refers 
to the fact that 
CHiP had 
previosuly asked 
permission and ppt 
agreed - ie not 
cold-calling. Note 
2: For ppts who 
still don't 
remember who 
CHiP are, PopART 
leaflet will be 
provided to 
refresh ppt's 
memory. Note 3: 
The RA will be kept 
blind to ppt test 
uptake (and Case v 
Control) status - up 
until the end of 
this study (see 
HIV_test section)  
to minimise 
interviewer bias. 
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Agree_2 
What was  the main reason the 
participant did not agree?  
Time constraints;  
Confidentiality concerns; 
Spouse did not agree; Changed 
his/her mind; Does not want to 
(unspecified reason);No 
response; Other 
Go to "Declined 
Study 
Participation" 
(Dec_01) 
    
Agree_3 
Can I come back at another 
time that might be more 
suitable? 
Yes; No 
If no go to 
"Declined Study 
Participation" 
(Dec_01) 
    
Agree_4 Record when to return Time and date field     
Must be within 2 week 
window 
Details 
I need to check some details 
before deciding whether it is 
suitable for us to continue with 
the study. Can I proceed?  
        
Inclusion_DoB What is your date of birth? Date; Don't know       
Inclusion_Age What is your age? XX 
If <18y (but 
shouldn't be as 
pre-checked from 
CHiPs EDC before 
random selection 
as potential ppt), 
continue but 
ineligible so Skip to 
Ineligible_0 before 
Consent Qs 
    
Dem_Gen (Record ppt's gender) Male; Female       
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Dem_Disab_1 
Do you have any disabilities? 
(RA to choose all that apply 
from): 
No, No Disability; Sight 
(blind/severe visual 
impairment; Hearing 
(deaf/profoundly hard of  
hearing); Communication 
(speech impairment); Physical 
(needs wheelchair/ 
crutches/stick); Mental 
disability; Other 
Mark all that apply. If  
"no, no disability" 
continue; if yes go to 
Excl_HIV_res 
    
Excl_Disab 
Does the disability prevent 
participation in the study? 
Yes; No 
If yes, continue but 
ineligible so Skip to 
Ineligible_0 before 
Consent Qs 
  
RA judgement - this Q 
will put some people into 
Ineligible therefore is an 
exclusion Q. RA training 
to only exclude eg if ppt 
is non-verbal/ no mental 
capacity. Criteria will be 
defined and provided at 
RA training. 
Excl_HIV 
research 
Are you currently involved in 
any other HIV research study 
?” 
Yes; No   
RA to probe and 
verify eg not 
referring to 
PopART 
intervention itself 
Note, not an exclusion 
but want to record it. 
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Excl_PC 
Are you currently involved in 
the Population Cohort of the 
PopART study? 
Yes; No 
If yes, continue but 
ineligible so Skip to 
Ineligible_0 before 
Consent Qs 
  
RA to probe and 
ascertain (ie not 
intervention but PC). 
Participation in other CC 
is also Excl criterion but 
we would exclude this 
overlap at the time of 
selection of potential 
candidates from EDC 
register. 
Excl_staff 
Are you or any member of your 
HH working as staff on the 
PopART trial? 
Yes; No 
If yes go to 
ineligibility text; if 
no continue. 
    
Consent_1 
I would like to take some time 
to explain the research that we 
are carrying out in this study - 
a study about  services 
provided by the PopART trial. 
At the end of that you can 
decide whether you would like 
to participate and continue 
with answering specific 
questions for the study. Before 
we begin, do you have any 
questions? 
        
Consent_2 
Obtain consent (as per 
language on consent form) 
        
Consent_3 
Did the individual give consent 
to participate in the study ?  
Yes; No 
If yes, continue; if 
no go to "Consent 
_6" 
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Consent_4 Is the participant literate? Yes; No 
If yes, go to 
Consent_7 
Only to determine 
if witness is 
required (eligible 
to participate 
either way). 
Use literacy tool 
Consent_5 Who acted as a witness? 
1.Family member;2 
Neighbour;3 Health care ;4. 
Other 
Go to Consent_7   
ie this Q only for those 
illiterate 
Consent_6 
What was  the main reason the 
participant did not consent?  
Time constraints;  
Confidentiality concerns; 
Spouse did not agree; No 
witness available/refused 
witness; Did not want to 
(unspecified reason); Other 
Go to "Declined 
Study 
Participation" 
(Dec_01) 
  Pilot reasons 
Consent_7 
Did the participant give 
consent to access further 
records from CHiPs EDC and 
routine health centre records?  
Yes; No   
Ppt can decline 
this part and still 
be in CC study. 
Only if consented to CC 
study.  
Ineligible_0 
Thank you very much for your 
cooperation. The information 
you provided is very helpful 
and we appreciate your time 
and assistance. Unfortunately, 
you do not meet our specific 
eligibility criteria for this 
particular study. This does not 
affect any of the services 
available to you in this 
community or elsewhere - 
whether as part of PopART or 
otherwise. Thank you again for 
your willingness to participate 
in this study.  Do you have any 
final questions or comments 
that you would like to share 
with me? 
  go to End_01     
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Declined_0 
Thank you for your time. Your 
decision not to participate in 
this particular study does not 
affect any of the services 
available to you in this 
community or elsewhere - 
whether as part of PopART or 
otherwise.  Do you have any 
final questions or comments 
that you would like to share 
with me? 
  go to End_01     
Intro 
Thank you for agreeing to take 
part in this study. I would like 
to ask you a few questions. 
Your answers in this study are 
completely confidential. This 
means that they will not be 
shared with anyone outside of 
the study team (including the 
CHiPs) in a way that can be 
connected to you. No one will 
know what particular answers 
you give. The answers you give 
do not affect any of the 
services available to you in this 
community or elsewhere - 
whether as part of PopART or 
otherwise. Some of these 
questions may be 
uncomfortable for you. Please 
remember that you don't have 
to answer any questions that 
you don't want to and we can 
stop  the interview at any time. 
If I ask about something that 
makes you feel uncomfortable, 
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just let me know and we can 
consider skipping the question. 
Our discussion will last just 
over an hour. 
Dem_Edu 
What is the highest grade of 
education that you have 
completed? Please choose one 
from: 
None; Grade 1; Grade 2; Grade 
3; Grade 4; Grade 5; Grade 6; 
Grade 7; Grade 8; Grade 9; 
Grade 10; Grade 11; Grade 12; 
College/University; other 
      
Dem_Nation What is your nationality? 
list of all African countries; 
other 
If not South Africa 
or Zambia, go to 
"Dem_relig_1"  
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Dem_Ethnic 
What is your ethnic group? 
Please choose one from: 
If Zambia- drop down  Bemba, 
Tonga , Chewa, Lozi, Nsenga, 
Tumbuka, Ngoni, Lala, Kaonde, 
Lunda, Luvale, Lenje, Ila, Bisa, 
Ushi, Chishinga, Ng’umbo, 
Lamba, Mbunda, Lungu, 
Mambwe, Namwanga, Seng, 
other If SA – drop down Xhosa, 
Zulu, Venda, Sotho, Tsonga, 
Tswana, Fengu, Afrikaner, Cape 
Coloured, Indian South 
Africans, Pakistani South 
Africans, other 
      
Dem_Relig_1 
What is your religion? Please 
choose one from: 
Christian; Islam; Baha’i faith; 
Buddhism; Hinduism; Judaism; 
Animist; Traditionalist; No 
religion ; Other 
If not Christian, go 
to "Dem_Marr" 
This Q is being 
asked as it has 
relevance wrt to 
uptake of our 
services / 
competing services 
offered by faith 
healers etc. Also, 
we may see a 
particular group 
associated with 
non-uptake which 
might indicate 
need for better 
engagement with 
that group's 
religous leaders 
etc. 
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Dem_Relig_2 
What is your denomination? 
Please choose one from: 
Roman Catholic ; Anglican ; 
Seventh-Day Adventist; Baptist; 
Pentecostal; Salvation Army; 
Lutheran; Evangelical church; 
United Methodist/African 
Methodist; Jehovah’s witness; 
New Apostolic church (NAC); 
Apostolic faith Mission (AFM); 
Zion Christian Church 
(ZCC)Other 
  As above.   
Dem_Marr_1 
Are you currently married or 
living as married? 
Yes; No 
If yes, go to 
"Dem_Child_1" 
  
Yes if any of 
Traditional/legal/western 
according to country 
norms - training issue 
Dem_Marr_2 
Have you ever been married? 
Please choose one from: 
never married; 
divorced/separated; widowed; 
No Answer 
      
Dem_Child_1 
To how many children are you 
a parent or guardian? 
# (includes 0)     
All alive.Includes step-
children; 
nieces/nephews which 
ppt cares for (self-
defined) 
Dem_Work_1 Are you currently working? Yes; No 
If no, go to 
"Dem_Work_3" 
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Dem_Work_2 
In your main job what type of 
work do you do? Please choose 
one from: 
Occasional  employment; 
Seasonal employment; Casual 
employment; Formal wage 
employment, full-time; Formal 
wage employment, part time; 
Self-employed in agriculture; 
Self-employed making money, 
full-time; Self-employed making 
money, part-time; Other 
Go to 
"Dem_Work_4" 
    
Dem_Work_3 
What is the reason why you 
are not working? Please 
choose one from: 
Waiting to continue agricultural 
work; Unemployed (looking for 
work);Unemployed (waiting to 
start new work);Unable to work 
(permanently sick or 
injured);Student; 
Housewife/homemaker (not 
looking for work);Other, not 
looking for work 
      
Dem_Work_4 
Describe the work that you do 
or did in your most recent job. 
If you have more than one 
profession, choose the one you 
spend the most time doing. 
Please choose one from: 
Farmer (own land);Farm work 
on employers land; Domestic  
;Work in bar, hotel, guest 
house; Fishing; Mining; Working 
in shop; Informal Selling; 
Commercial sex work; 
Transport (trucker, taxi 
driver);Factory ; Guard (security 
company);Police/soldier; 
Clerical and office work; 
Government ; Teacher; health 
care ; Other Professional; Other 
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Dem_Comm 
How long have you lived in this 
community? 
XX in years, months, weeks or 
days 
    Best guess/estimate 
Dem_Abs_1 
In the last 3 months, how 
many nights did you spend 
away from home? 
# nights If 0, go to HH_1   
RA training - "night 
spent" away = slept away 
Dem_Abs_2 
In the last 3 months, how 
many nights did you spend 
outside this community 
[community name]? 
# nights If 0, go to HH_1   as above 
Dem_Abs_3 
What was the main reason you 
spent time outside this 
community - on the last 
occasion when you were 
away? Please choose one 
from: 
work or business; visiting 
family/leisure/holiday; other 
    
only if ppt was away in 
last 3 months ie ≥1 for Q 
above; train RA to ask 
ppt to pick most 
appropriate (eg ppt may 
have work and visit 
family - pick main one 
based on greatest time 
spent). 
Dem_Abs_4 
How often do you usually 
spend time away from this 
community for the above 
reason? Please choose one 
from: 
>once ever 3 months; once 
every 3 months; once every 6 
months; once every year; once 
every >1year 
    
once = one episode (not 
one night/day) 
Dem_Abs_5 
In the last year, how many 
nights did you spend outside 
this community [community 
name]? 
# nights     
Include last 3 months + 
other nights away in last 
year (less complicated) 
Dem_Abs_6 
What was the main reason you 
spent time outside this 
community over the last year? 
Please choose one from: 
work or business; visiting 
family/leisure/holiday; other 
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Dem_Abs_7 
How often do you usually 
spend time away from this 
community for the above 
reason?  
>once ever 3 months; once 
every 3 months; once every 6 
months; once every year; once 
every >1year 
      
HH_1 Total Household Members #      Including ppt 
HH_2 Are you the Head of HH? Yes; No 
If yes go to 
Econ_Hous_1 
    
HH_3 
How are you related to the 
Head of HH. Is he/she your ...? 
Please choose one from: 
Husband; father; father-in-law; 
brother, brother-in-law; son, 
son-in-law; grandfather; uncle; 
nephew; Wife; mother; mother-
in-law; sister; sister-in-law; 
daughter; daughter-in-law; 
grandmother; aunt; niece; 
cousin; friend; landlord; other 
      
Econ_Hous_1 
Which of the following best 
describes the main type of 
building that this household 
occupies? Please choose one 
from: 
single unit/brick structure on its 
own stand; cluster/multi-unit; 
traditional hut/structure made 
from traditional material; flat in 
block of flats; servant quarters; 
caravan/tent; hostel; shack; 
other 
      
Econ_Hous_2 
What is the main type of 
flooring for this household? 
Please choose one from: 
Dirt/earth; Wood/plank; 
Parquet; Lino; Cement; Tile; 
Other 
      
Econ_Hous_3 
How many living and sleeping 
rooms are there in this housing 
unit? Please choose one from: 
XX rooms       
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Econ_Hous_4 
What is the main source of 
drinking water for this 
household? Please choose one 
from: 
Piped indoors; Stand pipe/tap 
within plot; communal tap; 
borehole; Protected well; 
Unprotected/shallow well 
river/dam/lake/pan; 
bowser/tanker; other 
      
Econ_Hous_5 
What is the main source of 
energy used for cooking? 
Please choose one from: 
No cooking done in household; 
Electricity (mains);Electricity 
(individual solar); Gas; Paraffin; 
Charcoal; Wood; Other 
      
Econ_Hous_6 
What is the main toilet facility 
used in your household? 
Please choose one from: 
Own flush toilet; Shared  flush 
toilet; own pit latrine; Shared 
pit latrine; Own VIP latrine; 
Shared VIP latrine; Pail/bucket; 
Communal chemical latrine; 
Bush; Other 
      
Econ_Ass 
Does any member of your 
household have access to the 
following items in good 
working order? Please choose 
all that apply from: 
Working Cellphone; bicycle; 
motorcycle or scooter; 
car/bakkie; Electricity to house; 
TV; Fridge/freezer; Radio; 
Computer/Laptop; CD or MP3 
player; stereo/cassette /other 
music player; 
    Select all that apply 
Econ_Inc_2 
Do you or anyone in your 
household receive any 
government grants? 
Yes; No       
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Econ_Contr 
Do you make decisions about 
how money is spent in your 
household? Please choose one 
from: 
Yes (someone else's approval 
needed); Yes (no one else's 
approval needed); No 
  
There is evidence 
that suggests 
women who have 
some financial 
autonomy, are 
more likely to 
take-up and 
follow-up with 
PMCT care, so I am 
interested in 
exploring similar 
for test uptake   
CHiP_exp_0 
I would now like to ask you 
some Qs about your 
experience with the CHiP  who 
came to your house to offer 
you services related to 
PopART. The information you 
give us will help the PopART 
team learn what they are doing 
well and what could be done 
better.  Your answers in this 
study are completely 
confidential, will not be shared 
with CHiPs and the answers 
you give do not affect any of 
the services available to you 
(including the services 
provided by the CHiPs). Also, I 
don't know whether you had a 
test with the PopART CHiP and 
it makes no difference to these 
next questions.Do you have 
any questions before we 
begin? 
      
Note, in trainings it will 
be highlighted that it is 
important that RA is seen 
as separate from CHiPs. 
One is research the other 
intervention 
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CHiP_exp_1 
This question is regarding the 
CHiP(s) who came to see you. 
Did you previously know the 
individual(s) BEFORE you first 
met them as a CHiP? 
Yes; No     
(If more than 1 CHiP - 
any of them); rely on 
ppts own definition of 
"know" someone 
CHiP_exp_2 
Did you know which 
community they come from 
when you first met them as a 
CHiP? 
Yes; No 
If yes, continue, if no 
go to CHiP_exp_4 
    
CHiP_exp_3 
Do they come from this 
community (XX community 
name)? 
        
CHiP_exp_4 
Please choose one from the 
following about whether you 
think confidentiality will be 
maintained after your 
encounter(s) with the ChiP? 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
  
  
Training point - 
confidentiality still 
maintained if result 
discussed with ppt's 
permission/ for pt 
management. But breach 
of confidentiality if any 
client details discussed 
with other community 
members etc. 
CHiP_exp_5 
Please choose one from the 
following about whether you 
think that in general, the CHiP  
treated you with respect? 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
CHiP_exp_6 
Please choose one from the 
following about whether you 
think that in general, the CHiP  
was someone you could talk to 
and answer questions openly? 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
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CHiP 
test_peer_0 
For the next 4 Qs, please think 
about the first time when you 
met the CHiP and they offered 
you an HIV test. 
    
Note the CC study 
will be done upto 
9m after the first 
encounter. We are 
trying to get at 
how the ppt felt at 
the time of 
deciding whether 
to take up testing. 
From CHiP EDC we 
will know time-line 
of when offer was 
first made and if 
multiple offers 
were made before 
test was accepted 
among controls. 
Recall bias is a 
valid concern but 
we will try our 
best! 
Ensure these next Qs are 
related to first encounter 
as CHiP (eg for those 
who knew the CHiP 
worker previously) 
CHiP 
test_peer_1 
At that first time when you 
met the CHiP and they offered 
you an HIV test, did you 
already know beforehand, 
people who had accepted HIV 
testing by CHiPs? 
Yes; No 
If no go to CHiP 
test_peer_3 
Focus on testing of 
a peer by CHiP as 
the key peer 
influence on the 
ppt's own uptake 
of CHiP HBT ie not 
looking at other 
test uptake.  
RA training - "already 
know" should not 
incluide those who are 
being offered testing at 
the same time as ppt  
CHiP 
test_peer_2 
Who was it you knew, who had 
accepted HIV testing by the 
CHiP? Please choose all that 
apply: 
Sexual partner; Household 
member(s) (not including sexual 
partner); 
friend(s)/neighbour(s)/colleague(s); 
other 
    
RA training to avoid 
double-counting (sexual 
partner and HH member) 
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CHiP 
test_peer_3 
How many other HH members 
(not including yourself) were 
present you were first offered 
HIV testing by CHiPs? 
XX If 0, go to Sex_0     
CHiP 
test_peer_4 
How many HH members (not 
including yourself) accepted 
testing when offered HIV 
testing by CHiPs at that time? 
XX       
CHiP 
test_peer_5 
Was your partner present 
when you were offered testing 
at home by the CHiPs?  
Yes; No       
Sex_0 
Now I would like to ask you 
some questions about your 
recent sexual activity. I know 
these questions are sensitive 
and want to remind you that 
your answers are completely 
confidential. Scientists are 
interested to know about 
patterns of sexual behaviours 
in the community and this 
information will not be linked 
to you as an individual.  If 
anyone comes near us I will 
change the topic of 
conversation. If we should 
come to any questions that 
you don’t want to answer, just 
let me know and we can 
decide if we should skip the 
question. Do you have any 
questions before we continue? 
        
Sex_1 
Have you ever had sex 
(meaning penetrative 
intercourse)? 
Yes; No       
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Sex_2 
How old were you when you 
had sex for the first time? If 
you can’t recall the exact age, 
please give a best guess. 
XX years       
Sex_3 
In your lifetime how many 
different people have you had 
sex with (including your 
husband/wife)? If you can’t 
recall the exact number, please 
give a best guess. 
XXX sexual partners       
Sex_4 
Have you had sex in the past 
12 months? 
Yes; No If  No go to Stigma_0     
Sex_00 
At this point, let me say that I 
understand that some of the 
Qs I ask you may seem 
inappropriate for your 
situation. Please know that I 
am asking them as part of 
standard list of questions 
which I have to ask everyone 
and I appreciate your patience 
and honesty when answering 
them, remembering that your 
answers will be kept 
confidential. 
        
Sex_5 
In the past 12 months, how 
many different people have 
you had sex with (including 
your husband/wife)? If you 
can’t recall the exact number, 
please give a best guess. 
XXX people   
If 1 partner go to 
Part_one_0; 2 
partners go to 
Part_two_0; ≥ 3 go 
to Part_three_0 (if 
0 partners this Q 
would be skipped 
see - Sex_4 skip 
pattern) 
  
Sex_6 
..., do any live outside of 
[community name]? 
Yes; No; Don’t now       
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Part_one_0 
I would like to ask more 
questions about the partner 
with whom you have had sex 
most recently. In order to ask 
the questions we will call this 
partner - Partner 1. Can I 
proceed? 
  Go to Part_one_1     
Part_two_0 
I would like to ask more 
questions about the 2 partners 
with whom you have had sex 
most recently. In order to ask 
the questions we will list these 
2 partners by number and then 
I will ask the same set of 
questions about each partner 
in turn.  We will start with the 
partner you have had sex with 
most recently - who we will 
refer to as Partner 1. Can I 
proceed?  
  
Go to Part_one_1 
(which will be 
followed by same 
loop questions for 
Part_two) 
    
Part_three_0 
I would like to ask more 
questions about the 3 partners 
with whom you have had sex 
most recently. In order to ask 
the questions we will list these 
3 partners by number and then 
I will ask the same set of 
questions about each partner 
in turn.  We will start with the 
partner you have had sex with 
most recently - who we will 
refer to as Partner 1. Can I 
proceed? 
  
Go to Part_one_1 
(which will be 
followed by same 
loop questions for 
Part_two; then 
Part_three) 
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Part_one_1 
What was your relationship 
with "this partner 1" the  last 
time you had sex? Please 
choose one from: 
Husband/wife (i.e. married or living 
as married); Boyfriend/ Girlfriend; 
Casual partner known to you 
before having sex; One-time 
partner who was unknown to you 
before having sex; Other 
      
Part_one_2 
Where was  "this partner 1" 
living the last time you had 
sex? 
Same house; Same community 
[insert name of this community]; 
Outside  [insert name of this 
community]; Don’t Know 
      
Part_one_3 
How old is "this partner 1" ? If 
you don't know for sure, 
please give a best guess. 
XX years       
Part_one_4 
When did you first have sex 
with "this partner 1"?  (Best 
guess) 
MM/YYYY        
Part_one_5 
How long ago did you last have 
sex with  "this partner 1" ? If 
you are not sure, please give a 
best guess.  
xxx days; Use calendar and help 
work out number of days. 
      
Part_one_6 
The last  time you had sex with  
"this partner 1" , did you/your 
partner use a condom?  
Yes; No; Don’t remember 
If Yes, continue; If 
Don’t remember or 
No answer go to 
Part_one_11 
  
Can be male or female 
condom 
Part_one_7 
Did you drink alcohol before 
the last time you had sex with  
"this partner 1" ? 
Yes; No; Don’t remember       
Part_one_8 
The last time you had sex with  
"this partner 1" , did you give 
or were you given money or a 
gift in order to have sex? It 
could be money (eg rent or 
fees for something), food, 
soap, transport, or clothing. 
Yes, I Received money/gift; Yes, I 
gave money/gift; No, I did not give 
or receive money/gift 
If yes, skip to 
Part_one_14 OR if 
Part_one_1 response 
is husband/wife, skip 
to Part_one_14 
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Part_one_9 
What is the HIV status of "this 
partner 1" ? 
Positive; Negative; Don't know 
If Negative or Don't 
know, go to 
Part1_16 
    
Part_one_10 
Do you know if  "this partner 
1"  is taking ART? 
Yes, he/she is taking; No, he/she is 
not taking; Don’t know 
      
Part_one_11 
Over the past 12 months, 
during your relationship with  
"this partner 1" , do you know 
or suspect that this partner 
was having sex with someone 
else? 
Yes – I know with another spouse; 
Yes – I know with another partner 
or partners; Yes - I believe there 
was another partner or partners; 
No, I know this partner did not 
have other partners; Don’t know 
      
      
If Sex_5=2 or 
Sex_5=3, proceed 
with partner loop Qs 
for each partner 
(max 3) 
  
Programme loop Qs to 
repeat according to 
answer in Sex_5 
HIV self_risk_1   
Very high; somewhat high; 
somewhat low; very low 
    
Training - to ensure 
prompting that if partner 
perceived to be high risk, 
this will be a "yes" for 
the ppt too (even if eg 
ppt is monogamous) 
Stigma_0 
I am going to ask you about 
issues relevant to HIV and 
taking an HIV test.  Using your 
own opinions and thinking 
about this community 
[community name], please tell 
me how strongly you agree or 
disagree to the following 
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statements. Do you have any 
questions before we begin? 
Stigma_1 
I fear that I could contract HIV 
if I come into contact with the 
saliva of a person living with 
HIV 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_2 
I would be ashamed if 
someone in my family had an 
HIV test 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
    
Training point - Q is 
about taking a test ie not 
about HIV +ve result 
Stigma_3 
People are hesitant to take an 
HIV test due to fear of other 
people’s reaction if the test 
result is positive for HIV. 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_4 
People sometimes talk badly 
about people who have had or 
who are thought to have had 
an HIV test.  
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_5 
I would not buy fresh 
vegetables from a vendor if I 
knew that this person had had 
an HIV test 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_6 
People may think that I have 
been immoral/irresponsible as 
the reason behind having an 
HIV test 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_7 
People receive verbal abuse or 
insults because of having an 
HIV test 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
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Stigma_8 
People fear other people’s 
reaction if the test result is 
positive for HIV 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_9 
People are ashamed if the test 
result is positive for HIV 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Health_0 
I will now ask you questions 
about whether you have been 
unwell in the last 12? months. 
Do you have any questions 
before we begin? 
        
Health_1 
During the past 12 months 
have you been unwell to the 
extent that you needed to seek 
advice about it? 
Yes; No       
Health_2 
If yes, approximately how 
many times in the last 12 
months? 
# (if not sure, best guess)       
Health_3 
During the past 12 months 
which of the following did you 
go to for health 
care/treatment - please choose 
all that apply from: 
Traditional/faith healer; Health 
worker at a health facility; 
Pharmacy or other drug vendor; 
other 
    All that apply 
Health_4 
In general, which of these 
would you consult first for a 
health related problem (if 
anyone)? Please choose one 
from: 
Traditional/faith healer; Health 
worker at a health facility; 
Pharmacy or other drug vendor 
    Only one 
Health_5 
During the past 12 months, 
have you had to stay overnight 
in hospital for any illnesses? 
Yes; No 
If no, go to 
Health_8 
    
Health_6 
During the past 12 months, 
how many times have you 
been hospitalised? 
# times       
Health_7 
During the past 12 months, 
what was the total duration of 
hospitalisation? 
# days       
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Health_8 
During the past 12 months, 
have you paid for private 
health care? 
Yes; No     
Private health - may 
include HIV testing/ 
treatment/admission. 
Circum_0 
Now I would like to ask you 
about male circumcision. As a 
reminder, by male 
circumcision, I mean removal 
of the foreskin of the penis. I 
understand these Qs can be 
sensitive. The reason that I am 
about to ask them is so 
scientists can understand 
circumcision practices in this 
community, because medical 
male circumcision has been 
shown to be associated with 
HIV transmission. I would be 
grateful if you could answer as 
honestly as possible 
remembering that your 
answers are confidential. 
Before we begin, do you have 
any questions?  
  
Only if 
Dem_Gen:Male 
    
Circum_1 Are you circumcised? Yes; No; not sure; 
If  No, not sure, No 
answer go to 
SRQ_0 
    
Circum_2 
At what age were you 
circumcised? 
< 5years of age; XX years       
Circum_3 When were you circumcised? MM/YYYY    
This is to identify if 
MC was after 
PopART start 
If VMMC done - use 
circumcision "certificate"  
or other proof if 
available; if not - ppt self-
report 
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Circum_4 
What was the main reason 
why you were circumcised? 
Tradition or religious; To 
protect myself against HIV; 
Hygiene; Other medical reason; 
Other; Don’t know 
If Don’t know or 
No answer go to 
Circum_06 
    
Preg_0 
I will now ask you questions 
about pregnancy and antenatal 
care. Do you have any 
questions before we begin? 
  
Only if 
Dem_Gen:Female 
    
Preg_1 
How many times have you 
given birth? Include both live 
births and stillbirths. Multiple 
births, such as twins, count as 
1 birth. 
# times If #:0 go to SRQ_0     
Preg_2 When was the last birth? MM/YYYY  
If last birth < 12m 
ago continue, if 
>12m go to SRQ_0 
    
Preg_3 
Did you go for antenatal care 
during this pregnancy? 
Yes; No       
Preg_4 
Were you tested for HIV during 
this pregnancy?  
Yes; No; Don't know 
If yes go to Preg_5; 
If no, go to Preg_6; 
If Don't know go to 
SRQ_0 
    
Preg_5 When was that? 
MM:YYYY (if not sure, best 
guess) 
Go to Preg_7     
Preg_6 
Why were you not tested for 
HIV during this pregnancy? 
Did not agree to testing; Not 
offered / did not attend a clinic 
where testing is available; 
Husband/partner refused; 
Already knew I was HIV 
positive; other 
Go to SRQ_0+D148     
Preg_7 
If you feel comfortable, were 
you given ART for you to take 
to protect your baby? 
Yes;No; Don’t know; Not yet 
received; Already on ART 
before attending ANC 
      
 236 
 
SRQ_0 
The following questions are 
related to certain pains and 
problems, that may have 
bothered you in the last 
30days. If you think the 
question applies to you and 
you had the problem described 
in the last 30days, answer YES. 
On the other hand, if the 
question does not apply to you 
and you did not have the 
problem in the last 30days, 
answer NO.If you are unsure 
please give the best answer 
you can. To remind you again, 
all your reponses are 
confidential. 
      
Yes =1 and score of 6 or 
greater = suggestive of 
mental disorder 
SRQ_1 Do you often have headaches? Yes; No       
SRQ_2 Is your apetite poor? Yes; No     
Poor apetite = low 
interest in food 
SRQ_3 Do you sleep badly? Yes; No       
SRQ_4 Do you cry more than usual? Yes; No       
SRQ_5 
Do you find it difficult to enjoy 
your daily activities? 
Yes; No       
SRQ_6 
Do you find it difficult to make 
decisions? 
Yes; No       
SRQ_7 Is your daily work suffering? Yes; No       
SRQ_8 
Are you unable to play a useful 
part in life? 
Yes; No       
SRQ_9 
Has the thought of ending your 
life been on your mind? 
Yes; No       
SRQ_10 Do you feel tired all the time? Yes; No     
 - for reasons that cannot 
be explained 
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Alcohol_0 
I will now ask you questions 
about drinking alcohol and 
drug use. I know these 
questions are sensitive and 
want to remind you that your 
answers are completely 
confidential. Do you have any 
questions before we begin? 
        
Alcohol_1 
How often do you have a drink 
containing alcohol? 
(0) Never  ; (1) Monthly or less; 
(2) 2 to 4 times a month; (3) 2 
to 3 times a week; (4) 4 or more 
times a week REVERSE ORDER 
OF OPTIONS 
If zero go to Alc_9   
Training - reassure ppts 
that Alc_9 and 10 are std 
and still asked of 
everyone even if score 
here is zero. 
Alcohol_2 
How many drinks containing 
alcohol do you have on a 
typical day when you are 
drinking? 
(0) 1 or 2; (1) 3 or 4; (2) 5 or 6; 
(3) 7, 8, or 9; (4) 10 or more 
      
Alcohol_3 
How often do you have six or 
more drinks on one occasion? 
(0) Never; (1) Less than 
monthly; (2) Monthly; (3) 
Weekly; (4) Daily or almost 
daily 
Skip to Alc_9 if 
Total Score for 
Questions 2 and 3 
= 0 
    
Alcohol_4 
How often during the last 12 
months have you found that 
you were not able to stop 
drinking once you had started? 
(0) Never; (1) Less than 
monthly; (2) Monthly; (3) 
Weekly; (4) Daily or almost 
daily 
      
Alcohol_5 
How often during the last 12 
months have you failed to do 
what was normally expected 
from you because of drinking? 
(0) Never; (1) Less than 
monthly; (2) Monthly; (3) 
Weekly; (4) Daily or almost 
daily 
      
Alcohol_6 
How often during the last 12 
months have you needed a 
first drink in the morning to get 
yourself going after a heavy 
drinking session? 
(0) Never; (1) Less than 
monthly; (2) Monthly; (3) 
Weekly; (4) Daily or almost 
daily 
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Alcohol_7 
How often during the last 12 
months have you had a feeling 
of guilt or remorse after 
drinking? 
(0) Never; (1) Less than 
monthly; (2) Monthly; (3) 
Weekly; (4) Daily or almost 
daily 
      
Alcohol_8 
How often during the last 12 
months have you been unable 
to remember what happened 
the night before because you 
had been drinking? 
(0) Never; (1) Less than 
monthly; (2) Monthly; (3) 
Weekly; (4) Daily or almost 
daily 
      
Alcohol_9 
Have you or someone else 
been injured as a result of your 
drinking? 
(0) No ; (2) Yes, but not in the 
last year; (4) Yes, during the last 
year 
      
Alcohol_10 
Has a relative or friend or a 
doctor or another health  been 
concerned about your drinking 
or suggested you cut down? 
(0) No ; (2) Yes, but not in the 
last year; (4) Yes, during the last 
year 
      
Alcohol_11 
Among people of similar age 
and sex as you in this 
community during an average 
month, how common do you 
think it is for them to have six 
or more drinks on one 
occasion?  
Very common; somewhat 
common; somewhat 
uncommon; very uncommon 
      
Drugs_1 
In your lifetime  have you ever 
used any drugs recreationally?  
Yes; No 
If no or refused – If 
Dem_Gen:Female 
go to IPV_0; if  
Dem_Gen:Male go 
to IPV_7  
    
Drugs_2 
In the last 12 months, have you 
used drugs recreationally? 
Yes; No 
If no or refused – If 
Dem_Gen:Female 
go to IPV_0; if  
Dem_Gen:Male go 
to IPV_7  
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Drugs_3 
In the last 12 months, which 
drugs have you used? 
Cannabis/Marijuana; 
Cocaine/Crack; Khat/Miraa; 
Ecstasy/Disco biscuit; Heroin; 
Amphetamine/Speed;Tik; 
Nyamba ( any drug mixed with 
ART and smoked); 
Glue/solvents/petrol 
sniffing;Other 
If 
Dem_Gen:Female 
go to IPV_0; if  
Dem_Gen:Male go 
to IPV_7 
    
IPV_0 
I would now like to ask you 
some questions about your 
relationship(s) and how any 
partner during the last 12 
months treated you. If anyone 
comes near us I will change the 
topic of conversation. I would 
again like to assure you that 
your answers will be kept 
confidential. If we should come 
to any questions that you don’t 
want to answer, just let me 
know and we can decide if we 
need to skip the question. Do 
you have any questions before 
I begin?  
    
There could be 
different ways of 
addressing the 
issue of GBV - but 
on balance we 
have gone with 
any partner of last 
12m and Qs 
related specifically 
to IPV ie not 
overall violence 
women may be 
subjected to in the 
community (so 
does not include 
rape by a stranger 
etc).I think this is 
the most pertinent 
to explore wrt asso 
with uptake of 
testing. Qs are 
largely based on 
DHS questions. 
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IPV_1 
In the last 12 months, how 
often has a partner verbally 
insulted you or humiliated you 
in front of other people, or 
intimidated or threatened to 
hurt you? 
Often; A few times; Once; 
Never 
If no go to IPV_3   
Training to emphasise 
this Q is about non-
physical/sexual abuse 
rather verbal/ other 
intimidation. 
IPV_2 
When was the last time any of 
the above happened? 
MM:YYYY     Approximate 
IPV_3 
In the last 12 months, how 
often has a partner physically 
hurt you eg slapped, kicked, 
pushed, punched, beaten or 
otherwise physically hurt you? 
Often; A few times; Once; 
Never 
If no go to IPV_5     
IPV_4 
When was the last time any of 
the above happened? 
MM:YYYY     Approximate 
IPV_5 
In the last 12 months, how 
often has a partner made you 
have sexual activities when you 
did not want to? 
Often; A few times; Once; 
Never 
If no go to IPV_7   
Check best language to 
use - would prefer to 
avoid too strong a word 
as women will be less 
inclined to say yes (eg 
avoiding "rape" or 
"forced"). Other 
thoughts? 
IPV_6 
When were you last made to  
have sexual activities when you 
did not want to? 
MM:YYYY     Approximate 
IPV_7 
In this community how 
common do you think it is for 
people to believe a husband is 
justified in physically hurting 
his wife if he has a reason? 
Very common; somewhat 
common; somewhat 
uncommon; very uncommon 
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IPV_8 
In this community how 
common do you think it is for 
people to believe a husband is 
justified in making his wife 
have sexual activities with him 
if he wants to? 
Very common; somewhat 
common; somewhat 
uncommon; very uncommon 
      
IPV_!! 
If experience of IPV - I'm sorry 
to hear about what has 
happened to you. If you wish 
we can provide information on 
what help might be available 
for you, before I leave. 
      
Programme prompt at 
end of survey to provide 
further information. 
Percep_0 
I am going to provide you with 
some statements about HIv 
testing and about the PopART 
trial and would like you to 
choose the most appropriate 
response. As before, your 
answers will not be shared 
with anyone outside of the 
study team (including the 
CHiPs) in a way that can be 
connected to you.  The 
answers you give do not affect 
any of the services available to 
you in this community or 
elsewhere - whether as part of 
PopART or otherwise. Can I 
proceed?  
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Percep_1 
The activities promoted by the 
PopART trial can increase the 
number of people having an 
HIV test in your community 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
  
If ppts unclear 
about the activities 
- RAs can illustrate 
using study 
inforamtion sheets 
which ppts are 
routinely given by 
CHiPs in PopART 
intervention 
communities 
  
Percep_2 
The activities promoted by the 
PopART trial can increase the 
number of people having 
treatment for HIV in your 
community 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Percep_3 
Maximising the number of HIV 
infected individuals on 
treatment can help reduce the 
amount of new HIV infections 
arising in your community 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Percep_4 
Condoms are not required to 
prevent HIV transmission if 
infected individuals are on 
treatment   
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Percep_5 
What do you think about the 
PopART trial being delivered in 
your community 
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
If Strongly agree or 
Agree, go to 
Percep_7 
    
Percep_6 
Which of these is the most 
important explanation for why 
you disagree with the PopART 
trial being delivered in your 
community? Please choose all 
that apply from: 
The CHiPs workers ask too 
many questions; the CHiPs 
workers pressure people to test 
for HIV or to talk to them; HIV 
testing/talking about HIV at 
home is not a good idea; doing 
research in my community is 
not a good idea; other 
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Percep_7 
What do you think about 
talking to household members 
together in a group about HIV 
testing (including offering HIV 
testing) at home?  
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
    
Training - this is about 
group pre-test cuoneling 
and offer of testing (not 
necessarily including 
testing itself) 
Percep_8 
What do you think about 
talking to couples together 
about HIV testing (including 
offering HIV testing) at home?  
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
      
Percep_9 
What do you think about 
providing household members 
results of HIV testing together 
at home?  
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
  ie full disclosure   
Percep_10 
What do you think 
about providing couples results 
of HIV testing together at 
home?  
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
  ie full disclosure   
PrevT_1 
Have you ever been tested for 
HIV? 
Yes; No 
If  No, go to 
FavCHT_0 
    
PrevT_2 
How many times have you had 
an HIV test? If you do not 
remember the number of 
times, give a best guess. 
#  of times        
PrevT_3 
The last time you were tested 
for HIV, where were you 
tested? 
Government hospital or clinic 
(includes ANC, TB, etc.); 
Private/church/mission hospital or 
clinic; Stand-alone HIV testing 
centre; Mobile testing site(caravan, 
tent, etc.; Work place; Home with 
CHiP; Home not with CHiP; Other 
place 
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PrevT_4 
When was the last time you 
were tested for HIV? If you 
don't know the exact date, give 
a best guess. 
MM:YYYY       
PrevT_5 
Have your disclosed the result 
of you last HIV test with 
anyone? (not including me) 
Yes; No       
  
Different factors may influence 
someone's choice on whether 
to take up HIV testing. The 
following sets of questions are 
about the factors which may 
have encouraged or 
discouraged you from testing 
with the CHiP. Consider these 
questions about pros and cons 
for you regardless of your final 
decision ie whether you tested 
with the CHiP or not. 
      
RA training Q is about 
pros/cons around HIV 
testing when offered by 
CHiP not just any HIV 
testing 
FavCHT_0 
When offered a test by the 
PopART CHiP, did any of the 
following encourage you 
towards having an HIV test?  
        
FavCHT_1 
I have never had an HIV test 
and wanted to learn my status 
Yes; No       
FavCHT_2 
I recently tested HIV negative 
and wanted to re-check 
Yes; No       
FavCHT_3 
I just believed I was HIV 
negative and wanted to check 
Yes; No       
FavCHT_4 
I knew a current/previous 
sexual partner was/is HIV 
positive so I wanted to know 
my status 
Yes; No       
FavCHT_5 
I suspected (not confirmed) I 
had an HIV positive partner so I 
wanted to know my status  
Yes; No       
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FavCHT_6 
I was sick and suspected it was 
because of HIV 
Yes; No       
FavCHT_7 
HIV is very common in this 
community so I thought I might 
be positive 
Yes; No       
FavCHT_8 
I thought my current/past 
sexual behaviour put me at 
high risk of getting HIV 
Yes; No       
FavCHT_9 
Many people I know had 
tested with a CHiP so I wanted 
to as well 
Yes; No       
FavCHT_10 
I wanted to be able to get 
treatment without delay if I 
tested and was HIV-positive 
Yes; No       
FavCHT_11 
I accepted the advice of the 
CHiP  that it was a good idea to 
test 
Yes; No       
FavCHT_12 
I accepted as I had no special 
reason to decline 
Yes; No       
FavCHT_13 
Would there be some other 
reason we have not already 
taked about? 
Yes; No       
AgCHT_0 
When offered a test by the 
PopART CHiP, did any of the 
following discourage you from 
having an HIV test?  
        
AgCHT_1 
I had difficulty with the time it 
would take - because of my 
livelihood/job 
Yes; No       
AgCHT_2 
I had difficulty with the time it 
would take - because of 
housework 
Yes; No       
AgCHT_3 
I was worried that someone I 
did not want to know, would 
find out that I was having an 
HIV test 
Yes; No 
If no, go to 
AgCHT_5 
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AgCHT_4 
Who was it that you did not 
want knowing that you were 
having an HIV test? Please 
choose all that apply: 
Sexual partner; Household 
member(s) (not including sexual 
partner); 
friend(s)/neighbour(s)/colleague(s); 
other 
      
AgCHT_5 
I was worried that someone I 
did not want to know, would 
find out if I tested HIV-positive 
Yes; No 
If no, go to 
AgCHT_7 
    
AgCHT_6 
Who was it that you did not 
want knowing that you were 
having an HIV test? Please 
choose all that apply: 
Sexual partner; Household 
member(s) (not including sexual 
partner); 
friend(s)/neighbour(s)/colleague(s); 
other 
      
AgCHT_7 
I did not want to find out my 
HIV status because I was afraid 
of a positive test result 
Yes; No       
AgCHT_8 
I was confident I was HIV-
negative and didn't need to 
test 
Yes; No       
AgCHT_9 
I believed I was HIV-positive 
and didn't need to test to find 
out 
Yes; No       
AgCHT_10 
I already had a test recently 
and did not want to test again 
Yes; No       
AgCHT_11 
I was not comfortable having 
an HIV test at home 
Yes; No       
AgCHT_12 
I didn't want to have an HIV 
test done by the particular 
CHiP who offered it to me 
Yes; No       
AgCHT_13 I don't think I am at risk of HIV Yes; No       
AgCHT_14 
I am not ready to find out my 
HIV status 
Yes; No       
AgCHT_15 
I just did not want to find out 
my HIV status (no particular 
reason) 
Yes; No       
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AgCHT_16 
Was there some other reason 
we have not already covered? 
Yes; No       
CHT_1 
Did you accept the test when 
offered by the PopART CHiP ? 
Yes; No If yes, go to CHT_3 
Note this is saved 
until the end to 
minimise 
interviewer bias as 
to whether a ppt is 
a case or control 
  
CHT_2 
In your own words why did you 
decide not to test with a 
PopART CHiP? 
  Go to Result_1   
RA to select most 
suitable from drop-down 
menu - same list as 
AgCHT 
CHT_3 
In your own words what was 
your main reason for testing 
with a PopART CHiP? 
      
RA to select most 
suitable from drop-down 
menu - same list as 
FavCHT 
Result_1 
If you feel comfortable, would 
you mind telling me what the 
result of your last HIV test 
was?  
HIV-negative; HIV-positive; Not 
comfortable/Don't know 
Skip Q if 
PrevT_1=No 
  
Note, for Cases (declined 
CHiP test) this will relate 
to any other HIV test; 
Programme to skip this Q 
if earlier response was - 
never had a test before. 
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Further research 
participation 
permission 
If you are interested, we would 
like to enter your name on a 
list from which you may be 
selected to participate in 
further research. Would you be 
interested in being included in 
such a list? If so, we will enter 
your name, address, date of 
birth and gender on a list and a 
researcher will come to explain 
the next study to you. Once 
you fully understand what the 
study involves you will be 
asked for your written consent 
to participate in the study. At 
that time, you can decline to 
participate in the study if you 
decide not to proceed for any 
reason.  If you decline at any 
stage, you will still receive all 
the services that are available 
to other community members 
here.  Would you be interested 
in being included in such a list? 
Yes;No       
Concl_0 
Thank you very much for your 
cooperation. The information 
you provided is very helpful 
and we appreciate your time 
and assistance.    Do you have 
any final questions or 
comments that you would like 
to share with me? 
  Go to End_01     
IPV 
For participants with 
experience of IPV - provide 
contact information of police 
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and NGOs working on IPV 
support 
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Appendix 5: Information Sheet and Verbal Consent for Consideration 
of Case-control Study 2 (South Africa) 
 
Consideration for Case-control Study 2  -  
Information Sheet and Verbal Consent by CHiPs (South Africa) 
 
Introduction 
This information sheet is about a study that is trying to identify why some people start antiretroviral 
treatment (ART) without delay after being referred by the PopART Community HIV-care Providers 
(CHiPs) and why other people choose not to or delay starting treatment. This study is called the 
Case-Control Study 2 in PopART. 
What is the purpose of the Case-Control study 2? 
The Case-control study 2 aims to understand the views and behaviours of community members who  
started ART without delay, after being referred by the PopART CHiPs compared with those who 
delayed starting treatment, or not at all. These questionnaires will let the researchers understand how 
the community feels about the treatment being offered in PopART Arm A communities which your 
community ……………… (community name), is a part of. 
 
What will happen during this study? 
In each community, approximately 120 people will be asked whether they are willing to be interviewed 
by study researchers who will complete questionnaires based on answers participants give. You have 
been randomly selected – meaning you have not been singled out for any reason but the number on 
your CHiPs card was picked randomly from a list to be one of the people from your community who 
we would invite to participate in the study. If you participate in this study, you will undergo an 
interview with the researcher. 
 
Where and who is conducting this study?  
This study is being carried out in two countries, Zambia and South Africa, for a period of about 5 
years from 2012 to 2017. It will be done in 21 communities, 12 of which are in Zambia and 9 in South 
Africa. Researchers from the Zambia AIDS Related Tuberculosis Project and the Desmond Tutu TB 
Centre at Stellenbosch University, South Africa, will work closely together with colleagues from 
different institutions including the Ministry of Health (Zambia) and the Department of Health (South 
Africa). This study is being funded by the U.S. National Institutes of Health, the Office of the United 
States Global AIDS Coordinator, and the Bill and Melinda Gates Foundation.  
What are you being asked to do? 
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At this point I am asking you for your permission to pass on your name, address, date of birth and 
gender to the researchers conducting the Case-control Study 2 so that they can approach you. The 
research team will be made aware that you were referred for HIV care at the clinic by the CHiPs. I 
will not pass on any other information about what you have told me as part of the CHiPs 
programme. If you agree, one of the researchers will come to find you at home and explain fully 
what the study involves. If you do not agree now, I will not pass on any information and you will still 
receive all the services that are available to other community members here.  
If you do agree for me to pass on your details to the research team, a researcher will come to explain 
the study to you. Once you fully understand what the study involves you will be asked for your 
written consent to participate in the study. At that time, you can decline to participate in the study if 
you decide not to proceed for any reason.  If you decline, you will still receive all the services that are 
available to other community members here. 
What are the possible risks or discomforts? 
You may become embarrassed, worried or anxious when talking about your HIV status and discussing 
sexual risk behavior and other topics.  The researchers are trained to treat participants with respect, 
maintain confidentiality and to help you deal with any feelings or questions you have. You may feel 
that being part of this study could lead to you feeling stigmatized or separated from your community.  
 
What are the potential benefits? 
During the study, you will be able express your opinions and represent views about yourself, your 
community and the PopART trial. When producing results your information will be anonymised and 
not be linked directly back to you. The results will however help the research team understand how 
to improve HIV related services in the future. In addition, knowledge gained from this study may help 
reduce the spread of HIV in the future and promote better health for you and your family as well as 
helping with acknowledgement and acceptance of HIV as a community-wide health problem. 
 
Persons to Contact for Problems or Questions  
If you have any questions about this research study, your rights, or if you feel that you have  
experienced a research-related injury, contact:  
Investigator of Record Name: Professor Nulda Beyers and Dr Peter Bock  
Research Site Address: Desmond Tutu TB Centre, Department of Paediatrics and Child  
Health, Faculty of Health Sciences, University of Stellenbosch  
Daytime telephone number(s): +27 21 983 9114 and +27 21 938 9062  
Health Research Committee: Health Research Committee 1, Stellenbosch University Health  
Research Ethics Committee, Tygerberg Campus, Stellenbosch University  
Daytime Telephone Number: +27 21 938 9657  
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Verbal Consent  
Now I would like to find out if you have understood this information and if you agree to me passing 
on your name, address, date of birth and gender to the Case-Control Study 2 researchers along with 
the fact that were referred for HIV care at the clinic by the CHiPs so that they can approach you to 
explain and obtain full informed consent to participate in the study. 
[CHiP records in a log the decision by the participant(s)] 
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Appendix 6: Information Sheet and Informed Consent Case-control 
Study 2 (South Africa) 
INFORMATION SHEET AND INFORMED CONSENT FORM FOR  
CASE-CONTROL STUDY 2:  
 
PARTICIPANT INFORMATION AND CONSENT FORM 
 
Title of Research Study: Factors associated with the uptake and non-uptake of 
immediate antiretroviral treatment during the first annual 
round of the PopART * interventions  
(*Population Effects of Antiretroviral Therapy to Reduce 
HIV Transmission (PopART): A cluster-randomized trial of 
the impact of a combination prevention package on 
population-level HIV incidence in Zambia and South Africa) 
 
Protocol #: HPTN 071, Version 1.0, 26 October 2012 
DAIDS ID: 11865 
 
Sponsor: National Institute of Allergy and Infectious Diseases 
National Institute of Mental Health  
(U.S. National Institutes of Health) 
Office of the United States Global AIDS Coordinator 
Bill and Melinda Gates Foundation  
 
Investigator of Record: Professor Nulda Beyers 
 
Research Site Address (es):   
 
Site: Delft South Clinic 
Address: Cr Main Rd & Boyce St 
Site: Bloekombos Clinic 
Address: Sam Nokasela Avenue 
Site: Ikwhezi clinic  
Address: Simon Street Nomzame 
Site: Town 2 Clinic (outreach) 
Address: c/o Zibonele and Manyano 
Street 
Site: Kuyasa Clinic 
Address: Ntlazana Street, Khayelitsha 
Site: Luvuyo Clinic 
Address: Hlela Road, Makaza 
Site: Dalevale Clinic (outreach) 
Address: Symphony Avenue,  
Site: Cloetesville Clinic 
Address: Tennant Street  
Site: Wellington Clinic (outreach)  
Address: Wellington Municipality 
 
Daytime telephone number(s): 021 983 9114 
 
24-hour contact number(s):  083 572 1470 
 Participant Information and Consent Form 
Please ask the study investigator or the study staff to explain any words or procedures that you do 
not clearly understand. 
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The PopART trial is looking at ways to reduce HIV incidence in your community. Information about 
the trial is supplied in the document which you may already have received from the Community HIV-
care Providers who have been visiting households in this community (Provide CHiPs Information 
sheet  – see separate document). The purpose of this form is to give you information about a 
research study you are being asked to join. The study is trying to identify why some people start 
antiretroviral treatment soon after being recommended it by PopART community health workers 
and why other people choose not to start or delay starting treatment.  If you sign this form, you will 
be giving your permission to take part in the study.  The form describes the purpose, procedures, 
benefits, and risks of the research study.  You should take part in the study only if you want to do so.  
You may choose not to join the research project or withdraw from this study at any time. Choosing 
not to take part in this research will not in any way affect the health care or benefits that you or your 
family will receive.  Please read this t Information and Consent Form and ask as many questions as 
needed.  You should not sign this form if you have any questions that have not been answered to 
your satisfaction. 
 
This study is being funded by the U.S. National Institutes of Health, the Office of the United States 
Global AIDS Coordinator, and the Bill and Melinda Gates Foundation 
 
Your participation is voluntary 
You do not have to take part in this study.  If you decide today to take part in this research project, 
you may refuse to take part in any portion of the study or stop at any time without reducing or 
affecting any care that you receive at the health centers in your community.   
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Purpose of the PopART Research in the Communities 
The HPTN 071 or PopART trial is testing a program to try to reduce HIV infection in a community like 
yours.  Twenty one communities that include about 600,000 adults are included in this research 
(about 400,000 adults in twelve Zambian communities and 200,000 adults in nine South African 
communities, all located in the Western Cape).  
 
In some communities, the level of care that people are used to will stay the same, in terms of HIV 
testing, and care of those who have HIV.  
 
In other communities, to make HIV testing easier, community health care workers will go to all 
homes and will offer to do an HIV test on those wishing to have a test. (In South Africa children over 
the age of twelve can choose to have an HIV test without getting permission from their parents or 
guardians although it is better to first get consent from parents or guardians). For anyone infected 
with HIV, they will be offered to start taking drugs to treat HIV according to the standard treatment 
guidelines that are in place in the Western Cape.  The health workers will visit every home again 
once a year for up to three more years to repeat the HIV testing and to refer people to care.   
 
In other communities, health care workers will go to all houses offering HIV testing, as was just 
described.  In these communities if someone over the age of 18 tests HIV positive however, they will 
be offered to start taking medicines to treat HIV right away.  The health workers will visit every 
home again once a year for up to three more years to repeat the HIV testing and to refer people to 
care.  Children under the age of 18 who test HIV positive will be offered care according to the 
standard treatment guidelines used in the Western Cape. 
 
At the end of the trial, the researchers will see if offering HIV tests in each household and offering 
people the chance to start HIV treatment right away has reduced the number of people with HIV 
infection in the community. They will also see if starting ART early has any negative effects on 
people’s health.  
 
Your community is one of the communities participating in this research.  If health care workers are 
visiting homes in your community, you will notice that they provide some other information and 
services to people, but the most important thing is the testing and HIV treatment they offer. 
 
What is the purpose of the Case-Control study? 
In each community, around 120 people will be asked to participate in additional activities such as 
completing questionnaires.  These questionnaires will let the researchers understand how the 
community feels about the program.  You have been selected to be one of the people from your 
community who we are asking to participate in these additional activities to represent the views and 
behaviours of community members who either did or did not initiate antiretroviral treatment within 
3 months of being recommended it by PopART community health workers.  That is why you are being 
asked to read this document.  
 
What will happen during this study? 
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If you participate in this study, you will undergo an interview with the researcher who has presented 
this information to you. We will ask you questions about a number of topics including you and your 
sexual practices, HIV testing, male circumcision, and how you and others feel about HIV. 
  
The PopART community health care workers and staff at the health center keep records of all their 
clients and patients as part of their normal procedures.  We would like to look at these records 
collected at the household, and medical records for any study participant who is HIV infected. Doing 
so will help us better understand how the study activities in the community are being taken up over 
time and how they are affecting the health of people diagnosed with HIV.  If you agree to participate 
in this study, we will ask you for your permission to look at your records from the household and at 
the health center.  
What are the possible risks or discomforts? 
You may become embarrassed, worried or anxious when talking about your HIV status and 
discussing sexual risk behavior and other topics.  A trained staff member will help you deal with any 
feelings or questions you have. You may feel that being part of this study could lead to you feeling 
stigmatized or separated from our community  
 
 
What are the potential benefits? 
During the study, you will be able express your opinions and represent views about yourself, your 
community and the PopART trial. This information will be coded and not be linked directly back to 
you.  It will however, help us understand how to improve HIV related services in the future.  In 
addition, knowledge gained from this study may help reduce the spread of HIV in the future and 
promote better health for you and your family as well as helping with acknowledgement and 
acceptance of HIV as a community-wide health problem. 
 
Our research staff will provide you with advice on any services that may be of help to you, if we 
identify problems that you are experiencing. 
 
Are there any alternatives to participation? 
If you decide not to participate in this study, we will refer you to other places where you can receive 
an HIV test. If it is offered in your community, you can also receive testing from a health worker 
visiting your home during the study period. 
 
How will my confidentiality and privacy be protected? 
We cannot guarantee absolute confidentiality.  However, we will do everything possible to protect 
your confidentiality if you join this study. We do this by giving you a study number and any 
information will be labeled with this number only, so only the research staff will be able to link this 
number to your name. Your personal information (name, address, phone number) will be protected 
by the research staff. This information will not be used in any publication of information about this 
study. 
 
To protect your privacy, you will meet with the researcher in a private area where others cannot 
overhear conversations with you.   
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People who may review your records include: [insert name of site IRB/EC], local regulatory agencies, 
US National Institutes of Health (NIH), study staff, and study monitors.  Institutional Review Boards 
(IRBs) or Ethics Committees (ECs) are committees that watch over the safety and rights of research 
participants. 
 
What happens if I am injured by participating in this study? 
It is very unlikely that you could be injured as a result of participating in this study.  However, if you 
are injured while participating in this study, you will be given immediate treatment for your injuries.  
You will not] have to pay for this care.  Stellenbosch University does have is a/ insurance cover for 
serious research related injury compensation. You will not be giving up any of your legal rights by 
signing this Participant Information and Consent Form. 
 
What are some reasons why I may be withdrawn from this activity without my consent? 
You may be withdrawn from the study without your consent for the following reasons: 
 
 The research study, or this part of the study, is stopped or canceled 
 The study staff feels that completing the study or this part of the study would be harmful to 
you or others 
 
The study will be conducted according to the international Declaration of Helsinki and other 
applicable international ethical codes for research on human participants. 
 
This study has been approved by a research ethics committee from Stellenbosch University 
 
Persons to Contact for Problems or Questions 
If you have any questions about your participation in this research study, your rights as a research 
subject, or if you feel that you have experienced a research-related injury, contact: 
 
 
 Dr Peter Bock, Co-Investigator, Desmond Tutu TB Centre, Department of Paediatrics and 
Child Health, Faculty of Health Sciences, University of Stellenbosch. Telephone: 021 
9389062. Email: peterb@sun.ac.za 
 
 Principal Investigator: Nulda Beyers, Desmond Tutu TB Centre, Department of Paediatrics 
and Child Health, Faculty of Health Sciences, University of Stellenbosch. Telephone: 021 938 
9114. Email:nb@sun.ac.za 
 
 Mr Franklin Weber, HREC coordinator, Health Research Committee 1, Stellenbosch 
University Health Research Ethics Committee, Tygerberg Campus. Telephone: 021 938 9657.  
  
 258 
 
PARTICPANTS STATEMENT OF CONSENT 
 
Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A cluster-
randomized trial of the impact of a combination prevention package on population-level HIV 
incidence in Zambia and South Africa 
 
 I have been given sufficient time to consider whether to take part in this study. 
 My taking part in this research study is voluntary.  I may decide not to take part or to 
withdraw from the research study at any time without penalty or loss of benefits or 
treatment to which I am entitled. 
 The research study may be stopped at any time without my consent. 
 I have had an opportunity to ask my study investigator questions about this research study.  
My questions so far have been answered to my satisfaction. 
 I have been told how long I may be in the research study. 
 I have been informed of the procedures that may be performed during the research study. 
 I have been told what the possible risks and benefits are from taking part in this research 
study.  I may not benefit if I take part in this research study. 
 I do not give up my legal rights by signing this form. 
 I have been told that before any study related procedures being performed, I will be asked 
to voluntarily sign this Participant Information and Consent Form. 
 I will receive a signed and dated copy of this Information and Consent Form. 
 
If you have either read or have heard the information in this Participant Information and Consent 
Form, if all of your questions have been answered, and if you agree to take part in the study, please 
print and sign your name and write the date on the line below. 
 
 
Access of Data from PopART Community Health Worker Records 
_____ My initials indicate that I agree to allow my data from the PopART Community Health Worker 
Records to be accessed and used for this study.  
_____ I do not agree to allow my data from the PopART Community Health Worker Records to be 
accessed and used for this study. 
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Access of Data from Heath Center 
 
_____ My initials indicate that I agree to allow my records at the health center to be accessed and 
used for this study.   
 
_____  I do not agree to allow my health care records to be accessed and used for this study. 
 
 
 
 
I voluntarily agree to take part in this research study. 
 
 
----------------------------   --------------------------------- 
Subject’s Name (print)   Subject’s Signature and Date 
 
 
 
 
I certify that the information provided was given in a language that was understandable to the 
subject. 
   
 
------------------------------   -------------------------------------- 
Name of Study Staff    Study Staff Signature and Date 
Conducting Consent Discussion (print) 
 
 
 
-------------------------------   -------------------------------------- 
 
Witness’ Name (print)    Witness’ Signature and Date 
(As appropriate) Date 
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Appendix 7: CC2 questionnaire  
 Item / Question Display Response Options Skip Pattern Rationale for Q 
Comments (for phrasing 
of Qs or issues for 
training of RAs) 
Attempt_1 
Record the results of your attempt 
to locate the randomly-selected 
household member for interview.   
Attempt 1:  [dd][mm][yy], Has the 
participant been met?; Attempt 2; 
[dd][mm][yy] Has the participant 
been met?; Attempt 3; 
[dd][mm][yy]Has the participant 
been met?; … "add more" 
1. Yes- Individual participant is 
available; 2. No, participant is not 
available. I will make further 
attempts to contact; 3. No, this is 
my final attempt to contact the 
participant. 
If 1, go to 
"Language"; if 3 , go 
to "Attempt 2" 
    
Attempt_2 
Record the outcome of the final 
attempt to reach the participant. 
1. Individual absent (expected to 
return to community); 2.Individual 
moved out from community; 
3.Individual deceased; 4.Individual 
incapacitated/in hospital; 
5.Individual incarcerated; 6. Other 
End of survey, go to 
"home screen" 
    
Lang 
Select appropriate language for 
the participant survey 
Zambia: English only; English + 
Bemba; English + Nyanja; English + 
Lozi; English + Tonga. South Africa: 
English only; English + Afrikaans; 
English + Xhosa; None 
If "none" end of 
survey, go to 
Ineligible_0 
    
 261 
 
Agree_1 
Thank you for taking the time to 
speak with me about a study on 
services provided by the PopART 
trial. I have been given your name 
and address by a PopART CHiP 
who has said you agreed to talk 
him/her about what services 
PopART was offering and that you 
were referred to the clinic for HIV 
care. I was also informed that you 
agreed that I could come to  talk 
to you about another study. 
Please note, they did not pass on 
any other information about what 
you told them or any medical 
information about you. Can I 
proceed? 
Yes; No 
If yes, go to 
"Details"; if no 
continue 
Note 1: this refers 
to the fact that 
CHiP had 
previosuly asked 
permission and ppt 
agreed - ie not 
cold-calling. Note 
2: For ppts who still 
don't remember 
who CHiP are, 
PopART leaflet will 
be provided to 
refresh ppt's 
memory. Note 3: 
the RA will be kept 
blind to ppt 
treatment status 
(and Case v Control 
status) - up until as 
late into the survey 
as possible to 
minimise 
interviewer bias. 
  
Agree_2 
What was  the main reason the 
participant did not agree?  
Time constraints;  Confidentiality 
concerns; Spouse did not agree; 
Changed his/her mind; Does not 
want to (unspecified reason);No 
response; Other 
Go to "Declined 
Study Participation" 
(Dec_01) 
    
Agree_3 
Can I come back at another time 
that might be more suitable? 
Yes; No 
If no go to "Declined 
Study Participation" 
(Dec_01) 
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Agree_4 Record when to return Time and date field     
Must be within 2 week 
window 
Details 
I need to check some details 
before deciding that you meet the 
criteria for the study.  
        
Inclusion_DoB What is your date of birth? Date; Don't know       
Inclusion_Age What is your age? XX 
If <18y (but 
shouldn't be as pre-
checked from CHiPs 
EDC before random 
selection as 
potential ppt), 
continue but 
ineligible so Skip to 
Ineligible_0 before 
Consent Qs 
    
Dem_Gen (Record ppt's gender) Male; Female       
Dem_Disab_1 Do you have any disabilities? 
No, No Disability; Sight 
(blind/severe visual impairment; 
Hearing (deaf/profoundly hard of  
hearing); Communication (speech 
impairment); Physical (needs 
wheelchair/ crutches/stick); Mental 
disability; Other 
Mark all that apply. 
If  "no, no disability" 
continue; if yes go 
to Excl_HIV_res 
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Excl_Disab_1 
Does the disability prevent 
participation in the study? 
Yes; No 
If yes, continue but 
ineligible so Skip to 
Ineligible_0 before 
Consent Qs 
  
RA judgement - this Q 
will put some people into 
Ineligible therefore is an 
exclusion Q. RA training 
to only exclude eg if ppt 
is non-verbal/ no mental 
capacity. Criteria will be 
defined and provided at 
RA training. 
Excl_HIV 
research 
Are you currently involved in any 
other HIV research study?” 
Yes; No   
RA to probe and 
verify eg not 
referring to 
PopART 
intervention itself 
Note, not an exclusion 
but want to record it. 
Excl_PC 
Are you currently involved in the 
Population Cohort of the PopART 
study ?” 
Yes; No 
If yes, continue but 
ineligible so Skip to 
Ineligible_0 before 
Consent Qs 
  
RA to probe and 
ascertain (ie not 
intervention but PC). 
Participation in other CC 
is also Excl criterion but 
we would exclude this 
overlap at the time of 
selection of potential 
candidates from EDC 
register 
Excl_staff 
Are you or any member of your 
HH working as staff on the 
PopART trial? 
Yes; No 
If yes go to 
Ineligible_0; if no 
continue. 
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Consent_1 
I would like to take some time to 
explain the research that we are 
carrying out in this study - a study 
about  services provided by the 
PopART trial. At the end of that 
you can decide whether you 
would like to participate and 
continue with answering specific 
questions for the study. Before we 
begin, do you have any questions? 
        
Consent_2 
Obtain consent (as per language 
on consent form) 
        
Consent_3 
Did the individual give consent to 
participate in the study ?  
Yes; No 
If yes, continue; if 
no go to "Consent 
_6" 
    
Consent_4 Is the participant literate? Yes; No 
If yes, go to 
Consent_7 
  Use literacy tool 
Consent_5 Who acted as a witness? 
1.Family member;2 Neighbour;3 
Health care ;4. Other 
Go to Consent_7   
ie this Q only for those 
illiterate 
Consent_6 
What was  the main reason the 
participant did not consent?  
Time constraints;  Confidentiality 
concerns; Spouse did not agree; No 
witness available/refused witness; 
Did not want to (unspecified 
reason); Other 
Go to "Declined 
Study Participation" 
(Dec_01) 
  Pilot reasons 
Consent_7 
Did the participant give consent to 
access further records from CHiPs 
EDC and routine health centre 
records?  
Yes; No   
Ppt can decline this 
part and still be in 
the main CC study 
if consented above 
(see wording in IC 
form). 
Only if consented to CC 
study.  
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Ineligible_0 
Thank you very much for your 
cooperation. The information you 
provided is very helpful and we 
appreciate your time and 
assistance. Unfortunately, you do 
not meet our specific eligibility 
criteria for this particular study. 
This does not affect any of the 
services available to you in this 
community or elsewhere - 
whether as part of PopART or 
otherwise. Thank you again for 
your willingness to participate in 
this study.  Do you have any final 
questions or comments that you 
would like to share with me? 
  go to End_01     
Declined_0 
Thank you for your time. Your 
decision not to participate does 
not affect any of the services 
available to you in this community 
or elsewhere.  Do you have any 
final questions or comments that 
you would like to share with me? 
  go to End_01     
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Intro 
Thank you for agreeing to take 
part in this study. I would like to 
ask you a few questions. Your 
answers in this study are 
completely confidential. This 
means that they will not be 
shared with anyone outside of the 
study team (including the CHiPs) 
in a way that can be connected to 
you. No one will know what 
particular answers you give. The 
answers you give do not affect 
any of the services available to 
you in this community or 
elsewhere - whether as part of 
PopART or otherwise. Some of 
these questions may be 
uncomfortable for you. Please 
remember that you don't have to 
answer any questions that you 
don't want to and we can stop  
the interview at any time. If I ask 
about something that makes you 
feel uncomfortable, just let me 
know and we can consider 
skipping the question. Our 
discussion will last just over an 
hour. 
        
Dem_Edu 
What is the highest grade of 
education that you have 
completed? Please choose one 
from: 
None; Grade 1; Grade 2; Grade 3; 
Grade 4; Grade 5; Grade 6; Grade 
7; Grade 8; Grade 9; Grade 10; 
Grade 11; Grade 12; 
College/University; other 
      
 267 
 
Dem_Nation What is your nationality? list of all African countries; other 
If not South Africa 
or Zambia, go to 
"Dem_relig_1"  
    
Dem_Ethnic 
What is your ethnic group? Please 
choose one from: 
If Zambia- drop down  Bemba, 
Tonga , Chewa, Lozi, Nsenga, 
Tumbuka, Ngoni, Lala, Kaonde, 
Lunda, Luvale, Lenje, Ila, Bisa, Ushi, 
Chishinga, Ng’umbo, Lamba, 
Mbunda, Lungu, Mambwe, 
Namwanga, Seng, other If SA – 
drop down Xhosa, Zulu, Venda, 
Sotho, Tsonga, Tswana, Fengu, 
Afrikaner, Cape Coloured, Indian 
South Africans, Pakistani South 
Africans, other 
      
Dem_Relig_1 
What is your religion? Please 
choose one from: 
Christian; Islam; Baha’i faith; 
Buddhism; Hinduism; Judaism; 
Animist; Traditionalist; No religion ; 
Other 
If not Christian, go 
to "Dem_Marr" 
This Q is being 
asked as it has 
relevance wrt to 
uptake of our 
services / 
competing services 
offered by faith 
healers etc. Also, 
we may see a 
particular group 
associated with 
non-uptake which 
might indicate 
need for better 
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engagement with 
that group's 
religous leaders 
etc. 
Dem_Relig_2 
What is your denomination? 
Please choose one from: 
Roman Catholic ; Anglican ; 
Seventh-Day Adventist; Baptist; 
Pentecostal; Salvation Army; 
Lutheran; Evangelical church; 
United Methodist/African 
Methodist; Jehovah’s witness; New 
Apostolic church (NAC); Apostolic 
faith Mission (AFM); Zion Christian 
Church (ZCC)Other 
      
Dem_Marr_1 
Are you currently married or living 
as married? 
Yes; No 
If yes, go to 
"Dem_Child_1" 
  
Yes if any of 
Traditional/legal/western 
according to country 
norms - training issue 
Dem_Marr_2 
Have you ever been married? 
Please choose one from: 
never married; 
divorced/separated; widowed; No 
Answer 
      
Dem_Child_1 
To how many children are you a 
parent or guardian? 
# (includes 0)       
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Dem_Work_1 Are you currently working? Yes; No 
If no, go to 
"Dem_Work_3" 
    
Dem_Work_2 
In your main job what type of 
work do you do? Please choose 
one from: 
Occasional  employment; Seasonal 
employment; Casual employment; 
Formal wage employment, full-
time; Formal wage employment, 
part time; Self-employed in 
agriculture; Self-employed making 
money, full-time; Self-employed 
making money, part-time; Other 
Go to 
"Dem_Work_4" 
    
Dem_Work_3 
What is the reason why you are 
not working? Please choose one 
from: 
Waiting to continue agricultural 
work; Unemployed (looking for 
work);Unemployed (waiting to 
start new work);Unable to work 
(permanently sick or 
injured);Student; 
Housewife/homemaker (not 
looking for work); Other; not 
looking for work 
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Dem_Work_4 
Describe the work that you do or 
did in your most recent job. If you 
have more than one profession, 
choose the one you spend the 
most time doing. Please choose 
one from: 
Farmer (own land);Farm work on 
employers land; Domestic  ;Work in 
bar, hotel, guest house; Fishing; 
Mining; Working in shop; Informal 
Selling; Commercial sex work; 
Transport (trucker, taxi 
driver);Factory ; Guard (security 
company);Police/soldier; Clerical 
and office work; Government ; 
Teacher; health care ; Other 
Professional; Other 
      
Dem_Comm 
How long have you lived in this 
community? 
XX in years, months, weeks or days     Best guess/estimate 
Dem_Abs_1 
In the last 3 months, how many 
nights did you spend away from 
home? 
# nights 
If 0, go to 
Dem_Abs_5 
  
RA training - "night 
spent" away = slept away 
Dem_Abs_2 
In the last 3 months, how many 
nights did you spend outside this 
community [community name]? 
# nights 
If 0, go to 
Dem_Abs_5 
  as above 
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Dem_Abs_3 
What was the main reason you 
spent time outside this 
community - on the last occasion 
when you were away? Please 
choose from: 
work or business; visiting 
family/leisure/holiday; other 
    
only if ppt was away in 
last 3 months ie ≥1 for Q 
above; train RA to ask 
ppt to pick most 
appropriate (eg ppt may 
have work and visit 
family - pick main one 
based on greatest time 
spent). 
Dem_Abs_4 
How often do you usually spend 
time away from this community 
for the above reason? Please 
choose one from: 
>once ever 3 months; once every 3 
months; once every 6 months; 
once every year; once every >1year 
    
once = one episode (not 
one night/day) 
Dem_Abs_5 
In the last year, how many nights 
did you spend outside this 
community [community name]? 
# nights     
Include last 3 months + 
other nights away in last 
year (at analysis, we can 
seperate out what was 
beyond 3months) 
Dem_Abs_6 
What was the main reason you 
spent time outside this 
community over the last year? 
Please choose from: 
work or business; visiting 
family/leisure/holiday; other 
      
Dem_Abs_7 
How often do you usually spend 
time away from this community 
for the above reason? Please 
choose from: 
>once ever 3 months; once every 3 
months; once every 6 months; 
once every year; once every >1year 
      
HH_1 Total Household Members #      Including ppt 
HH_2 Are you the Head of HH? Yes; No 
If yes go to 
Econ_Hous_1 
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HH_3 
How are you related to the Head 
of HH. Is he/she your ...? Please 
choose one from: 
Husband; father; father-in-law; 
brother, brother-in-law; son, son-
in-law; grandfather; uncle; 
nephew; Wife; mother; mother-in-
law; sister; sister-in-law; daughter; 
daughter-in-law; grandmother; 
aunt; niece; cousin; friend; 
landlord; other 
      
Econ_Hous_1 
Which of the following best 
describes the main type of 
building that this household 
occupies? Please choose one 
from: 
single unit/brick structure on its 
own stand; cluster/multi-unit; 
traditional hut/structure made 
from traditional material; flat in 
block of flats; servant quarters; 
caravan/tent; hostel; shack; other 
      
Econ_Hous_2 
What is the main type of flooring 
for this household? Please choose 
one from: 
Dirt/earth; Wood/plank; Parquet; 
Lino; Cement; Tile; Other 
      
Econ_Hous_3 
How many living and sleeping 
rooms are there in this housing 
unit? 
XX rooms       
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Econ_Hous_4 
What is the main source of 
drinking water for this household? 
Please choose one from: 
Piped indoors; Stand pipe/tap 
within plot; communal tap; 
borehole; Protected well; 
Unprotected/shallow well 
river/dam/lake/pan; 
bowser/tanker; other 
      
Econ_Hous_5 
What is the main source of energy 
used for cooking? Please choose 
one from: 
No cooking done in household; 
Electricity (mains);Electricity 
(individual solar); Gas; Paraffin; 
Charcoal; Wood; Other 
      
Econ_Hous_6 
What is the main toilet facility 
used in your household? Please 
choose one from: 
Own flush toilet; Shared  flush 
toilet; own pit latrine; Shared pit 
latrine; Own VIP latrine; Shared VIP 
latrine; Pail/bucket; Communal 
chemical latrine; Bush; Other 
      
Econ_Ass 
Does any member of your 
household have access to the 
following items in good working 
order? Please choose all that 
apply from: 
Working Cellphone; bicycle; 
motorcycle or scooter; car/bakkie; 
Electricity to house; TV; 
Fridge/freezer; Radio; 
Computer/Laptop; CD or MP3 
player; stereo/cassette /other 
music player; 
  
  Select all that apply 
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Econ_Inc_2 
Do you or anyone in your 
household receive any 
government grants? 
Yes; No 
 
    
Econ_Contr 
Do you make decisions about how 
money is spent in your 
household? Please choose one 
from: 
Yes (someone else's approval 
needed); Yes (no one else's 
approval needed); No 
  
There is evidence 
that suggests 
women who have 
some financial 
autonomy, are 
more likely to take-
up and follow-up 
with PMCT care, so 
we are interested 
in exploring similar 
for treatment 
uptake   
CHiP_exp_0 
I would now like to ask you some 
Qs about your experience with 
the CHiP  who came to your house 
to offer you services related to 
PopART. The information you give 
us will help the PopART team 
learn what they are doing well 
and what could be done better. 
Your answers in this study are 
completely confidential, will not 
be shared with CHiPs and the 
answers you give do not affect 
any of the services available to 
you (including the services 
provided by the CHiPs). No one 
will know what particular answers 
you give (including the CHiPs). Do 
you have any questions before we 
begin? 
      
Note, in trainings it will 
be highlighted that it is 
important that RA is seen 
as separate from CHiPs. 
One is research the other 
intervention 
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CHiP_exp_1 
This question is regarding the 
CHiP(s) who came to see you. Did 
you previously know the 
individual(s) BEFORE you first met 
them as a CHiP? 
Yes; No     
(If more than 1 CHiP - 
any of them); rely on 
ppts own definition of 
"know" someone 
CHiP_exp_2 
Did you know which community 
they come from when you first 
met them as a CHiP? 
Yes; No 
If yes, continue; if 
no go to 
CHiP_exp_4 
    
CHiP_exp_3 
Do they come from this 
community (XX community 
name)? 
        
CHiP_exp_4 
Please choose one from the 
following about whether you 
think confidentiality will be 
maintained after your 
encounter(s) with the ChiP? 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
  
  
Training point - 
confidentiality still 
maintained if result 
discussed with ppt's 
permission/ for pt 
management. But breach 
of confidentiality if any 
client details discussed 
with other community 
members etc. 
CHiP_exp_5 
Please choose one from the 
following about whether you 
think that in general, the CHiP  
treated you with respect? 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
CHiP_exp_6 
Please choose one from the 
following about whether you 
think that in general, the CHiP  
was someone you could talk to 
and answer questions openly? 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
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ART_peer_0 
For the next 2 Qs, please think 
about the first time when the 
CHiP referred you for HIV care at 
the clinic. 
    
Note the CC study 
will be done upto 
9m after the first 
encounter. We are 
trying to get at how 
the ppt felt at the 
time of deciding 
whether to take up 
testing. From CHiP 
EDC we will know 
time-line of when 
offer was first 
made and if 
multiple offers 
were made before 
test was accepted 
among controls. 
Recall bias is a valid 
concern but we will 
try our best! 
Train RAs to ensure these 
next Qs are related to 
first referral by CHiP ie 
not follow-up /repeated 
visits. Responses from 
ppt to be based on their 
impressions (best guess) 
about their peers. 
ART_peer_1 
At that first time, did you already 
know people who had been on 
ART? 
Yes; No 
If no go to 
HIV_stat_0 
    
ART_peer_2 
Who was it you knew, who had 
been on ART? Please choose all 
that apply from: 
Sexual partner; Household 
member(s) (not including sexual 
partner); 
friend(s)/neighbour(s)/colleague(s); 
other 
    
RA training to avoid 
double-counting (sexual 
partner and HH member) 
HIV_stat_0 
I would now like to ask you some 
questions about your HIV status. 
Can I proceed? 
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HIV_stat_1 
When was your first positive HIV 
test result?  Please give the month 
and year.  If you can’t recall 
exactly, please give a best guess. 
MM:YYYY      
Note, these ppts should 
all be known HIV+ve in 
this study. Note, in 
Agree_1 already 
acknowledged that been 
referred for HIV services 
HIV_stat_2 
Have you disclosed your HIV 
status to anyone, except to me for 
the purpose of this study? 
Yes; No 
If no or no answer 
go to Sex_0 
    
HIV_stat_3 
To whom did you disclose your 
HIV status? 
husband/wife /Sexual partner; 
Family Member; 
Friend/neighbour/colleague; 
Religious leader/; Health care ; 
Other 
      
Sex_0 
Now I would like to ask you some 
questions about your recent 
sexual activity. I know these 
questions are sensitive and want 
to remind you that your answers 
are completely confidential. 
Scientists are interested to know 
about patterns of sexual 
behaviours in the community and 
this information will not be linked 
to you as an individual.  If anyone 
comes near us I will change the 
topic of conversation. If we should 
come to any questions that you 
don’t want to answer, just let me 
know and we can decide if we 
should skip the question. Do you 
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have any questions before we 
continue? 
Sex_1 
Have you ever had sex (meaning 
penetrative intercourse)? 
Yes; No       
Sex_2 
How old were you when you had 
sex for the first time? If you can’t 
recall the exact age, please give a 
best guess. 
XX years       
Sex_3 
In your lifetime how many 
different people have you had sex 
with (including your 
husband/wife)? If you can’t recall 
the exact number, please give a 
best guess. 
XXX sexual partners       
Sex_4 
Have you had sex in the past 12 
months? 
Yes; No 
If  No go to 
Stigma_0 
    
Sex_00 
At this point, let me say that I 
understand that some of the Qs I 
ask you may seem inappropriate 
for your situation. Please know 
that I am asking them as part of 
standard list of questions which I 
have to ask everyone and I 
appreciate your patience and 
honesty when answering them, 
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remembering that your answers 
will be kept confidential. 
Sex_5 
In the past 12 months, how many 
different people have you had sex 
with (including your 
husband/wife)? If you can’t recall 
the exact number, please give a 
best guess. 
XXX people 
If 1 partner go to 
Part_one_0; 2 
partners go to 
Part_two_0; ≥ 3 
go to 
Part_three_0 (if 0 
partners this Q 
would be skipped 
see - Sex_4 skip 
pattern)  
  
Sex_6 
..., do any live outside of 
[community name]? 
Yes; No; Don’t now       
Part_one_0 
I would like to ask more questions 
about the partner with whom you 
have had sex most recently. In 
order to ask the questions we will 
call this partner - Partner 1. Can I 
proceed? 
  Go to Part_one_1     
Part_two_0 
I would like to ask more questions 
about the 2 partners with whom 
you have had sex most recently. In 
order to ask the questions we will 
list these 2 partners by number 
and then I will ask the same set of 
questions about each partner in 
turn.  We will start with the 
partner you have had sex with 
  
Go to Part_one_1 
(which will be 
followed by same 
loop questions for 
Part_two) 
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most recently - who we will refer 
to as Partner 1. Can I proceed?  
Part_three_0 
I would like to ask more questions 
about the 3 partners with whom 
you have had sex most recently. In 
order to ask the questions we will 
list these 3 partners by number 
and then I will ask the same set of 
questions about each partner in 
turn.  We will start with the 
partner you have had sex with 
most recently - who we will refer 
to as Partner 1. Can I proceed? 
  
Go to Part_one_1 
(which will be 
followed by same 
loop questions for 
Part_two; then 
Part_three) 
    
Part_one_1 
What was your relationship with 
"this partner 1" the  last time you 
had sex? Please choose one from: 
Husband/wife (i.e. married or living 
as married); Boyfriend/ Girlfriend; 
Casual partner known to you 
before having sex; One-time 
partner who was unknown to you 
before having sex; Other 
      
Part_one_2 
Where was  "this partner 1" living 
the last time you had sex? 
Same house; Same community 
[insert name of this community]; 
Outside  [insert name of this 
community]; Don’t Know 
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Part_one_3 
How old is "this partner 1" ? If you 
don't know for sure, please give a 
best guess. 
XX years       
Part_one_4 
When did you first have sex with 
"this partner 1"?  (Best guess) 
MM/YYYY        
Part_one_5 
How long ago did you last have 
sex with  "this partner 1" ? If you 
are not sure, please give a best 
guess.  
xxx days; Use calendar and help 
work out number of days. 
      
Part_one_6 
The last  time you had sex with  
"this partner 1" , did you/your 
partner use a condom?  
Yes; No; Don’t remember 
If Yes, continue; If 
Don’t remember or 
No answer go to 
Part_one_11 
  
Can be male or female 
condom 
Part_one_7 
Did you drink alcohol before the 
last time you had sex with  "this 
partner 1" ? 
Yes; No; Don’t remember       
Part_one_8 
The last time you had sex with  
"this partner 1" , did you give or 
were you given money or a gift in 
order to have sex? It could be 
money (eg rent or fees for 
something), food, soap, transport, 
or clothing. 
Yes, I Received money/gift; Yes, I 
gave money/gift; No, I did not give 
or receive money/gift 
If yes, skip to 
Part_one_14 OR if 
Part_one_1 
response is 
husband/wife, skip 
to Part_one_14 
    
Part_one_9 
What is the HIV status of "this 
partner 1" ? 
Positive; Negative; Don't know 
If Negative or Don't 
know, go to 
Part1_16 
    
Part_one_10 
Do you know if  "this partner 1"  is 
taking ART? 
Yes, he/she is taking; No, he/she is 
not taking; Don’t know 
      
 282 
 
Part_one_11 
Over the past 12 months, during 
your relationship with  "this 
partner 1" , do you know or 
suspect that this partner was 
having sex with someone else? 
Yes – I know with another spouse; 
Yes – I know with another partner 
or partners; Yes - I believe there 
was another partner or partners; 
No, I know this partner did not 
have other partners; Don’t know 
      
      
If Sex_5=2 or 
Sex_5=3, proceed 
with partner loop 
Qs for each partner 
(max 3) 
  
Programme loop 
Q+F102s to repeat 
according to answer in 
Sex_5 
HIV self_risk_1 
If you consider your behaviour 
(current or past) with respect to 
getting HIV (including anything 
entirely due to a sexual partner 
you are/were with) - would you 
consider that you have been at 
high risk of HIV?  
Very high; somewhat high; 
somewhat low; very low 
    
Training - to ensure 
prompting that if partner 
perceived to be high risk, 
this will be a "yes" for 
the ppt too (even if eg 
ppt is monogamous) 
Stigma_0 
Different people feel differently 
about people  living with HIV.  I 
am going to ask you about issues 
relevant to HIV and people living 
with HIV.  Some of these 
questions will ask for your opinion 
on how you think people with HIV 
are treated.  Using your own 
opinions and thinking about this 
community [community name], 
please tell me how strongly you 
agree or disagree to the following 
statements. Do you have any 
questions before we begin? 
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Stigma_1 
People think that having HIV is 
shameful and they don't want to 
be associated with me 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_2 
People sometimes talk badly 
about people living with or 
thought to be living with HIV to 
others.  
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_3 
People living with or thought to 
be living with HIV are verbally 
insulted, harassed and/or 
threatened 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_4 
I have felt ashamed because of my 
HIV status 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_5 I blame myself for getting HIV 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_6 
I think less of myself because of 
my HIV status 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_7 
People sometimes talk badly 
about me because I am living with 
HIV.  
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_8 
I have been excluded from social 
gatherings or activities because I 
have HIV 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_9 
People have disclosed my HIV 
status to others wihtout my 
permission 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_10 
People may think that I have been 
immoral/irresponsible as the 
reason behind why I have HIV 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Stigma_11 
I confronted, challenged, or 
educated someone who was 
stigmatising and/or discriminating 
against me 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
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Stigma_12 
A health worker may disclose to 
others without my permission 
that I am on treatment for HIV (if I 
am on treatment) 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Health_0 
I will now ask you questions about 
whether you have been unwell in 
the last 12 months. Do you have 
any questions before we begin? 
        
Health_1 
During the past 12 months have 
you been unwell to the extent 
that you needed to seek advice 
about it? 
Yes; No       
Health_2 
If yes, approximately how many 
times in the last 12 months? 
# (if not sure, best guess)       
Health_3 
During the past 12 months which 
of the following did you go to for 
health care/treatment - please 
choose all that apply from: 
Traditional/faith healer; Health 
worker at a health facility; 
Pharmacy or other drug vendor; 
other 
    All that apply 
Health_4 
In general, which of these would 
you consult first for a health 
related problem (if anyone)? 
Please choose one from: 
Traditional/faith healer; Health 
worker at a health facility; 
Pharmacy or other drug vendor 
    Only one 
Health_5 
During the past 12 months, have 
you had to stay overnight in 
hospital for any illnesses? 
Yes; No 
If no, go to 
Health_8 
    
Health_6 
During the past 12 months, how 
many times have you been 
hospitalised? 
# times       
Health_7 
During the past 12 months, what 
was the total duration of 
hospitalisation? 
# days       
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Health_8 
During the past 12 months, have 
you paid for private health care? 
Yes; No     
Private health - may 
include HIV testing/ 
treatment/admission. 
Circum_0 
Now I would like to ask you about 
male circumcision. As a reminder, 
by male circumcision, I mean 
removal of the foreskin of the 
penis. I understand these Qs can 
be sensitive. The reason that I am 
about to ask them is so scientists 
can understand circumcision 
practices in this community, 
because medical male 
circumcision has been shown to 
be associated with HIV 
transmission. I would be grateful 
if you could answer as honestly as 
possible remembering that your 
answers are confidential. Before 
we begin, do you have any 
questions?  
  
Only if 
Dem_Gen:Male 
    
Circum_1 Are you circumcised? Yes; No; not sure; 
If  No, Not sure, go 
to SRQ_0 
    
Circum_2 
At what age were you 
circumcised? 
< 5years of age;XX years       
Circum_3 When were you circumcised? MM/YYYY      
If VMMC done - use 
circumcision "certificate"  
or other proof if 
available; if not - ppt self-
report 
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Circum_4 
What was the main reason why 
you were circumcised? 
Tradition or religious; To protect 
myself against HIV; Hygiene; Other 
medical reason; Other; Don’t know 
If Don’t know or No 
answer go to 
Circum_06 
    
Preg_0 
I will now ask you questions about 
pregnancy and antenatal care. Do 
you have any questions before we 
begin? 
  
Only if 
Dem_Gen:Female 
    
Preg_1 
How many times have you given 
birth? Include both live births and 
stillbirths. Multiple births, such as 
twins, count as 1 birth. 
# times If #:0 go to SRQ_0     
Preg_2 When was the last birth? MM/YYYY  
If last birth < 12m 
ago continue, if 
>12m go to SRQ_0 
    
Preg_3 
Did you go for antenatal care 
during this pregnancy? 
Yes; No       
Preg_4 
Were you tested for HIV during 
this pregnancy?  
Yes; No; Don't know 
If yes go to Preg_5; 
If no, go to Preg_6; 
If Don't know go to 
SRQ_0 
    
Preg_5 When was that? MM:YYYY (if not sure, best guess) Go to Preg_7     
Preg_6 
Why were you not tested for HIV 
during this pregnancy? 
Did not agree to testing; Not 
offered / did not attend a clinic 
where testing is available; 
Husband/partner refused; Already 
knew I was HIV positive; other 
Go to SRQ_0     
 287 
 
Preg_7 
Were you given ART for you to 
take to protect your baby? 
Yes;No; Don’t know; Not yet 
received; Already on ART before 
attending ANC 
      
SRQ_0 
The following questions are 
related to certain pains and 
problems, that may have 
bothered you in the last 30days. If 
you think the question applies to 
you and you had the problem 
described in the last 30days, 
answer YES. On the other hand, if 
the question does not apply to 
you and you did not have the 
problem in the last 30days, 
answer NO. If you are unsure 
please give the best answer you 
can. To remind you again, all your 
reponses are confidential. 
      
Yes =1 and score of 6 or 
greater = suggestive of 
mental disorder 
SRQ_1 Do you often have headaches? Yes; No       
SRQ_2 Is your apetite poor? Yes; No     
Poor apetite = low 
interest in food 
SRQ_3 Do you sleep badly? Yes; No       
SRQ_4 Do you cry more than usual? Yes; No       
SRQ_5 
Do you find it difficult to enjoy 
your daily activities? 
Yes; No       
SRQ_6 
Do you find it difficult to make 
decisions? 
Yes; No       
SRQ_7 Is your daily work suffering? Yes; No       
SRQ_8 
Are you unable to play a useful 
part in life? 
Yes; No       
SRQ_9 
Has the thought of ending your 
life been on your mind? 
Yes; No       
SRQ_10 Do you feel tired all the time? Yes; No     
 - for reasons that cannot 
be explained 
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Alcohol_0 
I will now ask you questions about 
drinking alcohol and drug use. I 
know these questions are 
sensitive and want to remind you 
that your answers are completely 
confidential. Do you have any 
questions before we begin? 
        
Alcohol_1 
How often do you have a drink 
containing alcohol? 
(0) Never  ; (1) Monthly or less; (2) 
2 to 4 times a month; (3) 2 to 3 
times a week; (4) 4 or more times a 
week REVERSE ORDER OF OPTIONS 
If zero go to Alc_9   
Training - reassure ppts 
that Alc_9 and 10 are std 
and still asked of 
everyone even if score 
here is zero. 
Alcohol_2 
How many drinks containing 
alcohol do you have on a typical 
day when you are drinking? 
(0) 1 or 2; (1) 3 or 4; (2) 5 or 6; (3) 
7, 8, or 9; (4) 10 or more 
      
Alcohol_3 
How often do you have six or 
more drinks on one occasion? 
(0) Never; (1) Less than monthly; 
(2) Monthly; (3) Weekly; (4) Daily 
or almost daily 
Skip to Alc_9 if Total 
Score for Questions 
2 and 3 = 0 
    
Alcohol_4 
How often during the last 12 
months have you found that you 
were not able to stop drinking 
once you had started? 
(0) Never; (1) Less than monthly; 
(2) Monthly; (3) Weekly; (4) Daily 
or almost daily 
      
Alcohol_5 
How often during the last 12 
months have you failed to do 
what was normally expected from 
you because of drinking? 
(0) Never; (1) Less than monthly; 
(2) Monthly; (3) Weekly; (4) Daily 
or almost daily 
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Alcohol_6 
How often during the last 12 
months have you needed a first 
drink in the morning to get 
yourself going after a heavy 
drinking session? 
(0) Never; (1) Less than monthly; 
(2) Monthly; (3) Weekly; (4) Daily 
or almost daily 
      
Alcohol_7 
How often during the last 12 
months have you had a feeling of 
guilt or remorse after drinking? 
(0) Never; (1) Less than monthly; 
(2) Monthly; (3) Weekly; (4) Daily 
or almost daily 
      
Alcohol_8 
How often during the last 12 
months have you been unable to 
remember what happened the 
night before because you had 
been drinking? 
(0) Never; (1) Less than monthly; 
(2) Monthly; (3) Weekly; (4) Daily 
or almost daily 
      
Alcohol_9 
Have you or someone else been 
injured as a result of your 
drinking? 
(0) No ; (2) Yes, but not in the last 
year; (4) Yes, during the last year 
      
Alcohol_10 
Has a relative or friend or a doctor 
or another health  been 
concerned about your drinking or 
suggested you cut down? 
(0) No ; (2) Yes, but not in the last 
year; (4) Yes, during the last year 
      
Alcohol_11 
Among people of similar age and 
sex as you in this community 
during an average month, how 
common do you think it is for 
them to have six or more drinks 
on one occasion?  
Very common; somewhat 
common; somewhat uncommon; 
very uncommon 
      
Drugs_1 
In your lifetime  have you ever 
used any drugs recreationally?  
Yes; No 
If no or refused – If 
Dem_Gen:Female 
go to IPV_0; if  
Dem_Gen:Male go 
to IPV_7  
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Drugs_2 
In the last 12 months, have you 
used drugs recreationally? 
Yes; No 
If no or refused – If 
Dem_Gen:Female 
go to IPV_0; if  
Dem_Gen:Male go 
to IPV_7  
    
Drugs_3 
In the last 12 months, which drugs 
have you used? 
Cannabis/Marijuana; 
Cocaine/Crack; Khat/Miraa; 
Ecstasy/Disco biscuit; Heroin; 
Amphetamine/Speed;Tik; Nyamba 
(any drug mixed with ART and 
smoked); Glue/solvents/petrol 
sniffing;Other 
If Dem_Gen:Female 
go to IPV_0; if  
Dem_Gen:Male go 
to IPV_7 
    
IPV_0 
I would now like to ask you some 
questions about your 
relationship(s) and how any 
partner during the last 12 months 
treated you. If anyone comes near 
us I will change the topic of 
conversation. I would again like to 
assure you that your answers will 
be kept confidential. If we should 
come to any questions that you 
don’t want to answer, just let me 
know and we can decide if we 
need to skip the question. Do you 
have any questions before I 
begin?  
    
There could be 
different ways of 
addressing the 
issue of GBV - but 
on balance we 
have gone with any 
partner of last 12m 
and Qs related 
specifically to IPV ie 
not overall violence 
women may be 
subjected to in the 
community (so 
does not include 
rape by a stranger 
etc).I think this is 
the most pertinent 
to explore wrt asso 
with uptake of 
testing. Qs are 
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largely based on 
DHS questions. 
IPV_1 
In the last 12 months, how often 
has a partner verbally insulted you 
or humiliated you in front of other 
people, or intimidated or 
threatened to hurt you? 
Often; A few times; Once; Never If no go to IPV_3   
Training to emphasise 
this Q is about non-
physical/sexual abuse 
rather verbal/ other 
intimidation. 
IPV_2 
When was the last time any of the 
above happened? 
MM:YYYY   Approximate 
 
IPV_3 
In the last 12 months, how often 
has a partner physically hurt you 
eg slapped, kicked, pushed, 
punched, beaten or otherwise 
physically hurt you? 
Often; A few times; Once; Never If no go to IPV_5     
IPV_4 
When was the last time any of the 
above happened? 
MM:YYYY   Approximate 
 
IPV_5 
In the last 12 months, how often 
has a partner made you have 
Often; A few times; Once; Never If no go to IPV_7     
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sexual activities when you did not 
want to? 
IPV_6 
When were you last made to  
have sexual activities when you 
did not want to? 
MM:YYYY   Approximate 
 
IPV_7 
In this community how common 
do you think it is for people to 
believe a husband is justified in 
physically hurting his wife if he 
has a reason 
Very common; somewhat 
common; somewhat uncommon; 
very uncommon 
      
IPV_8 
In this community how common 
do you think it is for people to 
believe a husband is justified in 
making his wife have sexual 
activities with him if he wants to 
Very common; somewhat 
common; somewhat uncommon; 
very uncommon 
      
IPV_!! 
If experience of IPV - I'm sorry to 
hear about what has happened to 
you. If you wish we can provide 
information on what help might 
be available for you, before I 
leave. 
      
Programme prompt at 
end of survey to provide 
further information. 
Percep_0 
I am going to provide you with 
some statements about HIV 
testing and about the PopART trial 
and would like you to choose the 
most appropriate response. As 
before, your answers will not be 
shared with anyone outside of the 
study team (including the CHiPs) 
in a way that can be connected to 
you.  The answers you give do not 
affect any of the services available 
to you in this community or 
elsewhere - whether as part of 
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PopART or otherwise. Can I 
proceed?  
Percep_1 
The activities promoted by the 
PopART trial can increase the 
number of people having an HIV 
test in your community 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
  
If ppts unclear 
about the activities 
- RAs can illustrate 
using study 
inforamtion sheets 
which ppts are 
routinely given by 
CHiPs in PopART 
intervention 
communities. 
  
Percep_2 
The activities promoted by the 
PopART trial can increase the 
number of people having 
treatment for HIV in your 
community 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Percep_3 
Maximising the number of HIV 
infected individuals on treatment 
can help reduce the amount of 
new HIV infections arising in your 
community 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Percep_4 
Condoms are not required to 
prevent HIV transmission if 
infected individuals are on 
treatment   
Strongly agree; Agree; Disagree; 
Strongly Disagree 
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Percep_5 
What do you think about the 
PopART trial being delivered in 
your community 
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
If Strongly agree 
or Agree, go to 
Percep_7 
    
Percep_6 
Which of these is the most 
important explanation for why 
you disagree with the PopART trial 
being delivered in your 
community? Please choose all 
that apply from: 
The CHiPs workers ask too 
many questions; the CHiPs 
workers pressure people to test 
for HIV or to talk to them; HIV 
testing/talking about HIV at 
home is not a good idea; doing 
research in my community is 
not a good idea; other 
      
Percep_7 
What do you think about offering 
households members HIV testing 
together at home?  
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
      
Percep_8 
What do you think about offering 
couples HIV testing together at 
home?  
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
      
Percep_9 
What do you think about 
providing household members 
results of HIV testing together at 
home?  
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
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Percep_10 
What do you think 
about providing household 
members results of HIV testing 
together at home?  
Strongly agree with it; Agree 
with it; Disagree with it; 
Strongly Disagree with it 
      
HIV care_0 
Now we have some questions 
about HIV testing and treatment. 
We will also talk about the first 
time that the CHiP advised you to 
attend the clinic (CHiP referral) 
and also about whether you 
enrolled for HIV care. As before, 
your answers will be kept 
completely confidential and will 
not be shared with anyone 
outside of the study team 
(including the CHiPs or clinic staff) 
in a way that can be connected to 
you. The answers you give do not 
affect any of the services available 
to you in this community or 
elsewhere - whether as part of 
PopART or otherwise. 
        
Test_1 
Did you have a test with a PopART 
CHiP? 
Yes; No   
Note, clients may 
have tested before 
CHiPs and self-
report +ve status to 
CHiPs 
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Test_2 
The last time you were tested for 
HIV, where were you tested? 
Please select one from: 
Government hospital or clinic 
(includes ANC, TB, etc.); 
Private/church/mission hospital or 
clinic; Stand-alone HIV testing 
centre; Mobile testing site(caravan, 
tent, etc.; Work place; Home with 
CHiP; Home not with CHiP; Other 
place 
      
Test_3 
When was the last time you were 
tested for HIV? If you don't know 
the exact date, give a best guess. 
MM:YYYY       
Test_4 
Have your disclosed the result of 
you last HIV test with anyone? 
(not including me) 
Yes; No       
Reg_1 
Have you ever registered for HIV 
related medical care? 
Yes; No 
If no go to PoCH-
R_0 
registered= 
enrolled=HIV care 
number/ID given  
Reg_2 
Do you have your HIV care 
number? 
Record number preferably from 
card; Card not available; Did not 
agree 
      
Reg_3 
When did you first register for HIV 
care? 
MM:YYYY Provide option to 
indicate if proof seen vs verbal 
report only 
    
Use clinic card or other 
proof if available 
Reg_4 Which clinic did you register at? XX       
Reg_5 
When you were referred by a 
CHiP had you already registered 
for HIV care at some point before 
that? 
Yes; No 
If no go to PoCH-
R_0 
  
RA training - emphasise 
before CHiP 
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PreCH-R_1 
Thinking of that period of HIV care 
before being referred by a CHiP - 
had you discontinued / 
interrupted from care at any 
time? 
Yes; No 
Continue either 
response 
Discontinued / 
interrupted = not 
attended for 
allocated appt.  
 
PreCH-R_2 
At the time when you were 
referred by a CHiP - were you 
actively in HIV care? 
Yes; No 
If yes, go to PoCH-
R_8; if no, continue 
Actively in HIV care 
=  attending for 
given 
appointments  
PoCH-R_0 
Now thinking of the period after 
you were referred by a CHiP... 
  
Use as stem for 
PoCH-R_0 Qs  
    
PoCH-R_1 Did you go to the clinic? Yes; No 
If no, go to PoCH-
R_5; if yes, continue    
    
PoCH-R_2 
Did you register for care after 
referral by a CHiP? 
Yes; No 
If yes, go to PoCH-
R_5; if no, continue 
    
PoCH-R_3 
Did you go but leave the clinic 
without registering? 
Yes; No 
If no go to PoCH-
R_5  
    
PoCH-R_4 
After going to the clinic what was 
the reason you left without being 
registered - please choose one 
from: 
I was given another date to return 
by clinic staff; I was sent away by 
clinic staff without a date to return; 
I decided to leave; other 
  
I decided to leave = 
of own accord 
 
  
Different factors may influence 
someone's choice on whether to 
attend/register for HIV care. The 
following sets of questions are 
about the factors which may have 
encouraged or discouraged you 
from attending/registering. 
Consider these questions about 
pros and cons for you regardless 
of your final decision ie whether 
      
RA training Q is about 
pros/cons around 
registeration for care 
after referral by CHiP  
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you finally regsitered for care or 
not. 
PoCH-R_5 
When referred by the PopART 
CHiP, did any of the following 
encourage you to attend/register 
for HIV care?  
        
PoCH-R_5_1 
I had difficulty with the time it 
would take - because of my 
livelihood/job 
Yes; No       
PoCH-R_5_2 
I had difficulty with the time it 
would take - because of 
housework 
Yes; No       
PoCH-R_5_3 
I could not go to the clinic because 
it is too far away/time it would 
take to travel there 
Yes; No       
PoCH-R_5_4 
I could not go to the clinic because 
of transport costs to get there 
Yes; No       
PoCH-R_5_5 
I could not go to the clinic because 
it is only open during hours when I 
am at work 
Yes; No       
PoCH-R_5_6 
I think people get treated badly by 
clinic staff if they are HIV+ve 
Yes; No       
PoCH-R_5_7 The clinic is too crowded  Yes; No       
PoCH-R_5_8 
People have to wait for a long 
time in the clinic 
Yes; No       
PoCH-R_5_9 
The clinic is a place for those who 
are weak/women/children, and 
not for me 
Yes; No       
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PoCH-R_5_10 
I am not ready to go to the clinic 
for HIV care 
Yes; No       
PoCH-R_5_11 I will only go if/when I feel sick Yes; No       
  
Thinking about registration for 
HIV care after you were referred 
by CHiPs... 
  
use as stem for 
PoCH-R_6-8 
    
PoCH-R_6 
When did you register for HIV 
care? 
MM:YYYY Provide option to 
indicate if proof seen vs verbal 
report 
 
  
Use clinic card or other 
proof if available 
PoCH-R_7 Which clinic did you register at? free text       
PoCH-R_8 
Have you discontinued / 
interrupted from care since 
registering for care? 
Yes; No       
Care_1 Are you currently in HIV care? Yes; No       
Care_2 
When did you last attend the 
clinic for HIV care? 
MM:YYYY        
Care_3 
For this most recent outpatient 
medical care visit, how long did it 
take you to get to the clinic? 
        
Care_4 
How long did you spend in the 
clinic in total at your last visit? 
< 1 hour, ≥1-2h; ≥2-3h; ≥3-4h; ≥4h   
  
  
Care_5 
Have you had a CD4 count blood 
test? 
Yes; No; Don't know 
If no or don't know, 
go to Care_7 
  
RA to provide std 
explanantion of CD4 
count if ppt not familiar. 
Care_6 
What was the result of you last 
CD4 count? If can't remember 
exactly, please give your best 
guess. 
XXX; Don't know Provide option to 
indicate if proof seen vs verbal 
report 
    
Use clinic card or other 
proof if available 
Care_7 
At your last visit, was the time you 
had to spend in the clinic 
acceptable? Please choose one 
from the followin:g 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
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Care_8 
In general, did the clinic staff 
treated with you respect? Please 
choose one from the following 
Strongly agree; Agree; Disagree; 
Strongly Disagree 
      
Care_9 
In general, were you worried 
about someone you know seeing 
you in the clinic? 
Yes; No       
EvART_1 
Has a health care worker 
recommended that you start 
antiretroviral therapy or ART ? 
Yes; No; Don't know       
EvART_2 Have you ever taken any ART?  Yes; No; Don't know 
If no go to 
FavART_2_0 
    
EvART_3 
When did you first start taking 
ART?  
MM:YYYY (verify with ART card) 
Provide option to indicate if proof 
seen vs verbal report 
      
EvART_4 
Did you first start taking ART 
before or after referral by a CHiP? 
Before; after 
If after, go to PoCH-
ART 
  
RA training - emphasis on 
FIRST ART 
PreCH-ART_0 
Thinking about any ART taken 
before you were referred by a 
CHiP...  
  
Use as stem for 
each PreCH-ART Q 
    
PreCH-ART_1 Did you ever stop taking ART? Yes; No 
If no, go to Ineligible 
after confirming 
ART started before 
CHiPS and never 
stopped ie was 
already on ART (and 
on it) when saw 
CHiP ie ineligible for 
CC2 
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PreCH-ART_2 Why did you stop taking ART?  
Doctor told me I didn't need them; 
Traditional Healer / Religious 
Leader told me I didn't need them; 
Husband/Wife asked me to stop; I 
ran out of pills/ didn’t fill 
prescription; Out of stock at the 
clinic/pharmacy; I feel well/ I don't 
think I need them/ I am cured ;Too 
many pills; They don't work; They 
make me sick; Too 
difficult/expensive to get to facility 
to collect them; I was only taking 
them during pregnancy/ to protect 
my baby ( PMTCT intermittent);I 
felt ashamed to take them/I didn’t 
want anyone to know; Other; 
      
PreCH-ART_3 
Were you taking ART at the time 
when you were first seen by a 
CHiPs? 
Yes; No 
If yes, go to 
FavART_2 
    
PoCH-ART_0 
Now thinking of the period after 
you were seen by  by a CHiP... 
  
Use as stem for Qs 
on PoCH-ART, 
FavART and AgART 
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PoCH-ART_1 
Did you first start or re-start ART 
after referral by a CHiP? 
Yes; No  
If no go to 
FavART_2_0 
  
First start or re-start 
depending on responses 
to above 
PoCH-ART_2 
When did you start/re-start taking 
ART?  
MM:YYYY (verify with ART card) 
Provide option to indicate if proof 
seen vs verbal report only 
      
PoCH-ART_3 
Did you start/re-start ART within 3 
months of being referred by a 
CHiP? 
Yes; No       
FavART_1 
In your own words what was you 
main reason for starting/re-
starting ART after being referred 
by a CHiP?  
      
RA to select most 
suitable from drop-down 
menu - same list as 
FavART 
  
Different factors may influence 
someone's choice on whether to 
start treatment. The following 
sets of questions are about the 
factors which may have 
encouraged or discouraged you 
from starting. Consider these 
questions about pros and cons for 
you regardless of your final 
decision ie whether you finally 
started ART or not. 
        
FavART_2_0 
Did any of the following 
encourage you to start ART?  
        
FavART_2_1 
For my own health even though I 
did not feel unwell before starting 
Yes; No       
FavART_2_2 
For my own health because I was 
feeling unwell before starting 
Yes; No       
FavART_2_3 
To protect my partner from 
getting HIV from me 
Yes; No       
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FavART_2_4 
Recommended by health are 
worker (including CHiPs)/ clinic 
staff 
Yes; No       
FavART_2_5 
To protect my baby from getting 
HIV infection while I was 
pregnant/breast-feeding 
Yes; No (women only)     
FavART_2_6 
I know someone/others who are 
well on ART and want to be on it 
too 
Yes; No       
AgART_1 
In your own words what was you 
main reason for not starting ART?  
      
RA to select most 
suitable from drop-down 
menu - same list as 
AgART 
AgART_2_0 
Did any of the following 
discourage you from starting ART?  
Yes; No   
Note, there is 
deliberately some 
overlap with 
reasons for not 
going to clinic - but 
they're not the 
same Qs 
  
AgART_2_1 
I could not or did not want to go 
to the clinic 
Yes; No       
AgART_2_2 
Going to the clinic for treatment is 
too time-consuming 
Yes; No       
AgART_2_3 
I was worried someone would find 
out about my HIV because of 
taking treatment/going to the 
clinic 
Yes; No       
AgART_2_4 
Who was it that you did not want 
finding out about your HIV 
because of taking 
treatment/going to the clinic? 
Please choose all that apply: 
Sexual partner; Household 
member(s) (not including sexual 
partner); 
friend(s)/neighbour(s)/colleague(s); 
other 
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AgART_2_5 
I was/am not ready to take 
treatment 
Yes; No       
AgART_2_6 
I didn't think the treatment works 
so there was no point in starting it 
Yes; No       
AgART_2_7 
I think people get worse (or die) 
because of the treatment 
Yes; No       
AgART_2_8 
I didn't like the idea of taking life-
long treatment 
Yes; No       
AgART_2_9 
I think I would have to make too 
many life-style changesto take 
ART (eg how I eat/ how much 
alcohol I drink / how much I go 
out socially etc) 
Yes; No       
CuART_1 Are you currently taking ART?   Yes; No 
If no or no answer, 
go to CuART_3 
Current = ART 
taken in the last 7d  
  
CuART_2 
In the past 7 days, did you miss 
taking any of your ART pills? 
Yes; No       
CuART_3 
Have you ever hidden your ART 
pills so that others couldn’t  see 
them? 
Yes; No       
CuART_4 
In the past 12 months, have you 
ever stopped taking ART? 
Yes; No 
If No or No answer, 
go to Concl_0 
    
CuART_5 
When did you stop taking 
antiretroviral therapy? If you have 
stopped taking ART on more than 
one occasion, please tell me the 
most recent time you stopped 
taking ART.  
MM:YYYY; If month not known just 
enter year.  
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CuART_6 
Why did you stop taking ART (at 
the most recent time you 
stopped)?  
Doctor told me I didn't need them; 
Traditional Healer / Religious 
Leader told me I didn't need them; 
Husband/Wife asked me to stop; I 
ran out of pills/ didn’t fill 
prescription; Out of stock at the 
clinic/pharmacy; I feel well/ I don't 
think I need them/ I am cured ;Too 
many pills; They don't work; They 
make me sick; Too 
difficult/expensive to get to facility 
to collect them; I was only taking 
them during pregnancy/ to protect 
my baby ( PMTCT intermittent);I 
felt ashamed to take them/I didn’t 
want anyone to know; Other; 
      
Concl_0 
Thank you very much for your 
cooperation. The information you 
provided is very helpful and we 
appreciate your time and 
assistance.    Do you have any final 
questions or comments that you 
would like to share with me? 
  Go to End_01     
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Further research 
participation 
permission 
If you are interested, we would 
like to enter your name on a list 
from which you may be selected 
to participate in further research. 
Would you be interested in being 
included in such a list? If so, we 
will enter your name, address, 
date of birth and gender on a list 
and a researcher will come to 
explain the next study to you. 
Once you fully understand what 
the study involves you will be 
asked for your written consent to 
participate in the study. At that 
time, you can decline to 
participate in the study if you 
decide not to proceed for any 
reason.  If you decline at any 
stage, you will still receive all the 
services that are available to other 
community members here.  
Would you be interested in being 
included in such a list? 
Yes;No       
IPV 
For participants with experience 
of IPV - provide contact 
information of police and NGOs 
working on IPV support 
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Appendix 8: Link to South Africa Case-control Study 1 Critical Incident 
Report 1  
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Appendix 9: Link to South Africa Case-control Study 1 Critical Incident 
Report 2 
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Appendix 10: Link to US Department of Health and Human Sciences 
and HIV Prevention Trials Network Office of Research Integrity Final 
Report 
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Appendix 11: South Africa Case-control Study 1 Data Verification 
Questionnaire 
 
Factors associated with the uptake and non-uptake of Home-Based Voluntary HIV testing 
and Counseling during the first annual round of the PopART interventions  
(Case-Control study 1) 
 
We are conducting a review of processes during one of our studies – the Case Control Study 
(1). During the study, the Research Assistants asked selected community members a 
number of questions to try to identify differences between people who accepted HIV testing 
offered by the PopART CHiPs, and those who chose not to accept testing. 
We appreciate you taking time to talk to us and very much value your contribution.  We are 
making a follow-up visit to participants who were selected for the study to monitor the 
quality of the information which has been collected. We do this in order to ensure that we 
conduct high quality research and that only accurate information is included in the study. 
I/we would therefore like to ask you a few questions and this will take no more than 15 
minutes of your time.  Do you have any questions before I/we begin? 
 
Q1 What is your name? Free text  
Q2 Did you participate in the Case-control study (1)?  Yes; No; Not sure  
Q3 
Is this your signature? (show copy of consent form 
we have on record at DTTC) 
Yes; No  
Q4 What is your age (in years)? _ _ y  
Q5 
What is the highest grade of education that you 
have completed? Please choose one from: 
None; Grade 1; Grade 2; 
Grade 3; Grade 4; Grade 5; 
Grade 6; Grade 7; Grade 8; 
Grade 9; Grade 10; Grade 
11; Grade 12; 
College/University; other 
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Q6 
When did you complete the above level of 
education? 
Month; Year  
Q7 What is your religion? Please choose one from: 
Christian; Islam; Baha’i faith; 
Buddhism; Hinduism; 
Judaism; Animist; 
Traditionalist; No religion ; 
Other 
 
Q8 How long have you lived in this community? 
XX in years, months, weeks 
or days  
 
Now I would like to ask you about male 
circumcision. As a reminder, by male circumcision, 
I mean removal of the foreskin of the penis. I 
understand that the question is sensitive. I would 
be grateful if you could answer as honestly as 
possible - your answers are confidential. Do you 
have any questions?  
  Only if Male 
Q9Ma Are you circumcised? Yes: No; Not sure; Only if male  
Q10M When were you circumcised? Month; Year  
 
I will now ask you questions about pregnancy and 
antenatal care.  
  Only if Female 
Q9F 
How many times have you given birth? Include 
both live births and stillbirths. Multiple births, such 
as twins, count as 1 birth. 
# times  
Q10F When did you last give birth? Month; Year  
 
Thank you for answering our questions. We have 3 more questions we would like to ask you with 
regard to your experience with participating in a study, and we would also like to ask about any 
additional feedback you have for us. 
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Q11 
How did you experience the case-control study and 
procedure? 
Free text  
Q12 How does it feel to be a research participant?  Free text  
Q13 
How were you treated as a research participant by 
the research team? 
 
Free text 
 
Q14 Do you have any additional comments? Free text  
 
We would like to thank you again for helping us collect this valuable information. Is there 
anything you would like to tell me/us or ask me before I/we leave? 
 
Data collected by – 
 
Name: 
 
Signature: 
 
Date: 
 
 
 
i By 12m FU, LTFU reported among all individuals, including individuals on ART. Denominator therefore 
includes N=254 known HIV+ & on ART 
ii Not reported (NR) as outcome not reported separately for those detected through HB-HTS 
iii Loss to follow-up is reported as individuals not followed-up at 9m; some of these individuals contributed to 
analysis of LTC and/or ART prior to being LTFU 
iv Not applicable (NA): Individuals defined as “not linked to care” regardless of whether or not the individual 
was contactable. Among individuals not LTC, reasons available for N=442: Asked not to be called (14%; n=63); 
Deceased (0.2%; n=1); Called many times (56%; n=249) Incorrect information (18%; n=79); No telephone (11%; 
n=50) 
                                                          
